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Resumo 
 
O Capítulo 1 descreve o enquadramento deste trabalho identificando as 
doenças pré-natais relevantes e os métodos de diagnóstico actualmente 
disponíveis. É depois apresentada a metodologia seguida, assim como uma 
breve introdução dos princípios dos métodos analíticos e estatísticos 
aplicados. O capítulo é concluído com uma descrição do estado da arte na 
área de metabolómica em investigação pré-natal, identificando o mérito desta 
inovadora estratégia para a identificação de marcadores robustos de doenças 
pré-natais. A relevância deste trabalho torna-se clara através do escasso uso 
de urina materna e do recém-nascido em trabalhos anteriores. O Capítulo 2 
descreve os procedimentos experimentais utilizados neste trabalho, incluindo 
condições de amostragem, recolha e preparação das amostras, protocolos de 
aquisição e de tratamento dos dados. 
A caracterização da composição da urina materna, através de espectroscopia 
de Ressonância Magnética Nuclear (RMN) de protão é apresentada no 
Capítulo 3. Define-se o perfil metabólico urinário característico para cada 
trimestre de gravidez, tendo sido encontrado um conjunto de 21 metabolitos 
descritivo das alterações metabólicas ocorridas ao longo da gravidez. 8 
metabolitos foram encontrados a variar com a gravidez, pela primeira vez, 
tendo sido confirmadas variações metabólicas conhecidas. É ainda estudado o 
efeito do não-jejum (usado neste trabalho) como possível factor de confusão. 
O Capítulo 4 apresenta o estudo metabolómico de urina materna do 2º 
trimestre para o diagnóstico de doenças fetais e previsão de complicações 
mais tarde desenvolvidas. Este estudo compreende a aplicação de um método 
de selecção de variáveis desenvolvido no âmbito desta tese. Observou-se que 
as malformações fetais (e, especificamente, do sistema nervoso central, SNC) 
e as cromossomopatias (e, especificamente, a trissomia 21, T21) são 
acompanhadas por alterações nos metabolismos energético, dos aminoácidos, 
lípidos e nucleótidos, enquanto que as cromossomopatias mostraram ser 
acompanhadas por uma desregulação adicional dos metabolismos dos 
açúcares, ciclo da ureia e/ou biossíntese da creatinina. A validação dos 
modelos multivariados revelou taxas de classificação (CR) de 84% para 
malformações (87%, SNC) e 85% para CD (94%, T21). Para o parto pré-termo, 
pré-eclampsia (PE) e restrição de crescimento intrauterino (RCIU) observaram-
se perfis que podem ajudar à previsão precoce, com CR 84% para pretermo 
(11-20 semanas de gestação, g.w. pré-diagnóstico), 94% para PE (18-24 g.w. 
pré-diagnóstico) e 94% para RCIU (2-22 g.w. pré-diagnóstico). Este capítulo 
inclui resultados obtidos por cromatografia líquida de ultra eficiência acoplada 
a espectrometria de massa (UPLC-MS) para pré-pretermo e correlação com os 
dados de RMN. Um possível composto marcador foi detectado mas a sua 
identificação não foi possível. 
O Capítulo 5 descreve o estudo metabolómico por RMN da diabetes mellitus 
gestacional (DMG), estabelecendo-se um perfil metabólico potencialmente 
preditivo da doença (CR 83%, 2-21 g.w. pré-diagnóstico). Verificou-se ainda 
que o espectro de RMN contém informação sobre o fenótipo individual, capaz 
de prever a necessidade futura de tratamento com insulina (CR 94%). 
No Capítulo 6 demonstra-se o impacto do tipo de parto (CR 88%) e género do 
bebé (CR 76%) no perfil da urina do recém-nascido. Verificou-se ainda que a 
prematuridade, depressão respiratória, crescimento grande para a idade 
gestacional e malformações induzem perturbações metabólicas relevantes (CR 
82-92%), assim como algumas doenças maternas como a DMG (CR 82%) e 
doenças psiquiátricas (91% CR). 
Finalmente, no Capítulo 7 apresentam-se as principais conclusões deste 
trabalho, enfatizando o potencial da metabolómica de urina materna e do bebé 
para o acompanhamento da gravidez e previsão de doenças, visando o 
desenvolvimento de novos métodos de diagnóstico precoce e não-invasivo. 
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Abstract 
 
Chapter 1 introduces the scope of the work by identifying the clinically relevant 
prenatal disorders and presently available diagnostic methods. The 
methodology followed in this work is presented, along with a brief account of 
the principles of the analytical and statistical tools employed. A thorough 
description of the state of the art of metabolomics in prenatal research 
concludes the chapter, highlighting the merit of this novel strategy to identify 
robust disease biomarkers. The scarce use of maternal and newborn urine in 
previous reports enlightens the relevance of this work. Chapter 2 presents a 
description of all the experimental details involved in the work performed, 
comprising sampling, sample collection and preparation issues, data 
acquisition protocols and data analysis procedures.  
The proton Nuclear Magnetic Resonance (NMR) characterization of maternal 
urine composition in healthy pregnancies is presented in Chapter 3. The urinary 
metabolic profile characteristic of each pregnancy trimester was defined and a 
21-metabolite signature found descriptive of the metabolic adaptations 
occurring throughout pregnancy. 8 metabolites were found, for the first time to 
our knowledge, to vary in connection to pregnancy, while known metabolic 
effects were confirmed. This chapter includes a study of the effects of non-
fasting (used in this work) as a possible confounder.  
Chapter 4 describes the metabolomic study of 2
nd
 trimester maternal urine for 
the diagnosis of fetal disorders and prediction of later-developing 
complications. This was achieved by applying a novel variable selection 
method developed in the context of this work. It was found that fetal 
malformations (FM) (and, specifically those of the central nervous system, 
CNS) and chromosomal disorders (CD) (and, specifically, trisomy 21, T21) are 
accompanied by changes in energy, amino acids, lipids and nucleotides 
metabolic pathways, with CD causing a further deregulation in sugars 
metabolism, urea cycle and/or creatinine biosynthesis. Multivariate analysis 
models´ validation revealed classification rates (CR) of 84% for FM (87%, CNS) 
and 85% for CD (94%, T21). For later-diagnosed preterm delivery (PTD), 
preeclampsia (PE) and intrauterine growth restriction (IUGR), it is found that 
urinary NMR profiles have early predictive value, with CRs ranging from 84% 
for PTD (11-20 gestational weeks, g.w., prior to diagnosis), 94% for PE (18-24 
g.w. pre-diagnosis) and 94% for IUGR (2-22 g.w. pre-diagnosis). This chapter 
includes results obtained for an ultraperformance liquid chromatography-mass 
spectrometry (UPLC-MS) study of pre-PTD samples and correlation with NMR 
data. One possible marker was detected, although its identification was not 
possible. 
Chapter 5 relates to the NMR metabolomic study of gestational diabetes 
mellitus (GDM), establishing a potentially predictive urinary metabolic profile for 
GDM, 2-21 g.w. prior to diagnosis (CR 83%). Furthermore, the NMR spectrum 
was shown to carry information on individual phenotypes, able to predict future 
insulin treatment requirement (CR 94%). 
Chapter 6 describes results that demonstrate the impact of delivery mode (CR 
88%) and gender (CR 76%) on newborn urinary profile. It was also found that 
newborn prematurity, respiratory depression, large for gestational age growth 
and malformations induce relevant metabolic perturbations (CR 82-92%), as 
well as maternal conditions, namely GDM (CR 82%) and maternal psychiatric 
disorders (CR 91%).  
Finally, the main conclusions of this thesis are presented in Chapter 7, 
highlighting the value of maternal or newborn urine metabolomics for 
pregnancy monitoring and disease prediction, towards the development of new 
early and non-invasive diagnostic methods.  
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MAS Meconium aspiration syndrome 
Mat. Maternal 
MBB Maternity Bissaya Barreto 
MCADD Medium chain acyl-coenzyme A dehydrogenase deficiency 
MIR Mid-infrared spectroscopy 
MLEV-17 Malcolm Levitt- 17 sequence 
MLPA Multiplex Ligation Probe dependent Amplification 
MRS Magnetic resonances spectroscopy 
MS  Mass spectrometry 
MVA Multivariate analysis 
Mw Molecular weight 
NA Not available 
  
NaAD Nicotinic acid adenine nucleotide 
NAD
+
 Nicotinamide adenine dinucleotide 
NaDP Nicotinicotinamide dinucleotide phosphate 
NaMN Nicotinic acid mono nucleotide 
NLM Non-linear mapping 
NMND N-methylnicotinamide 
NMR Nuclear magnetic resonance 
NP Non-pregnant 
NS Number of scans 
nS-HR-MS Nanospray high resolution mass spectrometry 
NTD Neural tube defect 
OGTT  Oral glucose tolerance test 
OPLS-DA Orthogonal Partial Least Squares-Discriminant Analysis 
OSC Orthogonal signal correction 
p p-value 
PAG Phenylacetylglutamine 
PAPP-A Pregnancy associated plasma protein-A 
PC Principal Component 
PCA Principal Component Analysis 
p-CS p-cresol sulphate 
pcvSE Covairance’s standard error obtained by cross validation 
PE Preeclampsia 
PG Plasma glucose 
PI Phosphatidylinositol 
PKU Phenylketonuria 
PLS-DA Partial Least Squares-Discriminant Analysis 
pPROM Preterm premature ruptures of the membranes 
PQN Probabilistic quotient normalization 
PROM Premature rupture of the mebranes 
PTD Preterm delivery 
q  Quartet 
Q
2
 Goodness of prediction or prediction power 
QC Quality control 
Q-TOF Quadropole time-of-flight 
r Correlation coefficient 
R
2
x Variation explained by the X matrix 
R
2
y Variation explained by the Y matrix 
RDS Respiratory  distress syndrome 
RF Random forest 
RF Random forest 
RG Receiver gain 
ROC Receiver operating characteristic 
  
RSPA Recursive segment-wise peak alignment 
RT Retention time 
s Singlet 
S/N Signal to noise ratio 
Sens Sensitivity 
SGA Small for gestational age 
SHY Statistical Heterospectroscopy 
SI Size of real spectrum 
SIMCA Soft Independent Modeling of Class Analogy 
SOM Self-organizing maps 
Spec Specificity 
SVM-RFE Support Vector Machines-recursive feature elimination 
SW Spectral window 
t Triplet 
T18 Trisomy 18 
T1DM Type 1 Diabetes Mellitus 
T21 Trisomy 21 
T2DM Type 2 Diabetes Mellitus 
TCA Tricarboxylic acid  
TD Size of FID 
THF Tetrahydrofolate 
TIC Total ion chromatogram 
TMA Trimethylamine 
TMAO Trimethylamine-N-oxide 
TN True negative 
TOCSY Total Correlation Spectroscopy 
TOF Time-of-flight 
TP  True positive 
TPR True positive rate 
TSP 3-trimethylsilylpropionic acid 
UA University of Aveiro 
uE3 Unconjugated estriol 
Ui Unassigned resonance i 
UPCA Unsupervised unfold principal component analysis 
UPLC Ultraperformance liquid chromatography 
UV Unit variance 
VAST Variable stability scaling 
VD Vaginal delivery 
VIP Variable importance for the projection 
VIPcvSE VIP’s standard error obtained by cross validation 
VLBW Very low birthweight 
VLDL Very low density lipoproteins 
  
WDW Type of window function 
Ypr[class] Y predicted value reflective of sample class 
β-hCG β-human chorionic gonadotropin 
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1. Introduction 
1.1 Healthy pregnancy and fetal development 
Fetal development 
Normal pregnancy has the duration of 38 to 40 gestational weeks (g.w.) and is 
divided into three trimesters, each of these periods characterized by specific hallmarks of 
fetal development (Moore et al., 2008). The first trimester (1
st
 T) corresponds to the period 
from fertilization to the 12
th
 g.w. and it is during this period that organogenesis takes place 
and organ systems are most vulnerable. After fertilization the oocyte is formed and, by the 
end of the 2
nd
 week, where implantation is completed. From that week onwards rapid 
anatomic development occurs and, by the 4
th
 g.w., the complex vascular network of the 
placenta is formed enabling maternal-embryonic exchanges of gases, nutrients and 
metabolic wastes (Moore et al., 2008, Atzori et al., 2011, Kliegman et al., 2011). 
Following this phase, the 4
th
 to 8
th
 g.w. are the most critical period in fetal development, as 
it is during this time that the main external and internal fetal structures begin to form  
(Moore et al., 2008). Between week 9 to 12, primary ossification of the skeleton appears, 
limbs are partially formed, of the spleen produces red blood cells and urine production and 
discharge by the urethra into the amniotic fluid is initiated.  
The following trimester (2
nd
 T) corresponds to the period from the 12
th
 to 26
th
 g.w. 
and it is during this time that rapid growth and fetal organ maturation occurs. By the 24
th
 
g.w. the lungs begin to secrete surfactant to the developing alveoli, a necessary 
requirement for breathing after birth. The third trimester (3
rd
 T) starts on the 26
th
 g.w. and 
extends to the end of gestation, enhanced fetal growth occurring during this period. The 
fetus becomes able to synthesize its own body fat and fetal maturation is complete by week 
37 (Moore et al., 2008). 
A representation of the most critical periods in fetal development is shown in 
Figure 1.1 highlighting the sensitive periods for adverse fetal development, and a timeline 
of development of specific anomalies and common sites of action of teratogens (Kliegman 
et al., 2011). Through this figure it becomes clear that the most critical period in fetal 
development goes from the 3
rd
 to 16
th
 g.w. and that, during this period, major congenital 
anomalies can affect the central nervous system (CNS), heart, limbs, ears, eyes, teeth, 
palate and external genitalia.  
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Figure 1.1: Representation of the critical periods in prenatal fetal development (adapted from 
(Kliegman et al., 2011)). 
  
Main maternal adaptations to pregnancy 
During pregnancy, the mother undergoes profound physiological, endocrine and 
metabolic adaptations to 1) ensure the necessary requirements for the adequate growth and 
development of the fetus, 2) provide the fetus energy substrates required after birth, 3) 
ensure maternal needs to cope with the enhanced physiological demands of pregnancy and 
4) provide the mother with sufficient energy stores and substrates necessary for labor and 
lactation (Hadden and McLaughlin, 2009). Maternal physiology is adjusted to support the 
requirements for fetal homeostasis and growth without compromising maternal well-being. 
These changes affect maternal cardiovascular, respiratory, renal and endocrine systems. 
Briefly, during pregnancy there is increased water and calcium retention, increased total 
blood volume to about 40%, increased cardiac output and heart rate. The respiratory 
changes are a consequence of the mechanical effect of the enlarging uterus that elevates the 
diaphragm position, of increased total oxygen consumption, mainly in the uterus and its 
contents, and of respiratory stimulant effects of progesterone, an important pregnancy 
hormone. Significant anatomic changes in the urinary collecting system occur due to 
progesterone action and enlarging uterus. Renal blood flow and glomerular filtration rate 
increase about 40% until mid-gestation due to increased maternal plasma volume. 
Endocrine adaptations include changes in insulin secretion, thyroid and adrenal hormone. 
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In pregnancy, insulin response to glucose stimulation is enhanced, and from early 
pregnancy until mid-gestation, fasting insulin levels are increased while reducing glucose 
levels. During this period, the anabolic effects of insulin are potentiated leading to 
inhibition of lipolysis, and gluconeogenesis whilst glycogen synthesis and storage in the 
liver is enhanced. Later in pregnancy, insulin resistance develops leading to impaired 
glucose tolerance possibly due to humoral factors such as increased human placental 
lactogen, cortisol and progesterone (Hacker et al., 2004). 
 
The placenta  
The placenta and umbilical cord form a transport system for substances passing 
between mother and fetus (Moore et al., 2008). The placenta plays a key role in 
maintaining the exquisite symbiosis between mother and fetus, as it is through this feto-
maternal organ that all nutrient, gases and waste exchanges occur. The placenta is essential 
for protection, nutrition, respiration, excretion and hormone production, which are essential 
for maintaining pregnancy and promoting fetal development. Glycogen, cholesterol and 
fatty acids synthesis takes place in the placenta, which serves as nutrients and energy for 
the fetus, as well as pregnancy hormones human chorionic gonadotropin (hCG), 
progesterone and estrogen. The placenta also transports oxygen to the fetus and removes 
carbon dioxide and carbon monoxide from the fetus. In addition, it transports glucose, 
amino acids, vitamins, hormones, electrolytes and maternal antibodies while removing 
waste products such as urea and uric acid. It is also through the placenta that drugs, drug 
metabolites and infectious agents that may pose a teratogen risk (such as cytomegalovirus 
and Toxoplasma gondii) are transported (Hacker et al., 2004, Moore et al., 2008) . 
 
Preparation for extrauterine life 
Fetal adaptation to the extrauterine life begins before the onset of labor and its 
particularly challenged in premature newborns due to incomplete anatomic development 
and biochemical maturation (Moore et al., 2008). Several days before labor, the fetal 
thyroid hormone dynamic is changed enabling the conversion of fetal thyroxine (T4) to 
triiodothyronine (T3), a metabolically more active form of the hormone and necessary for 
neonatal thermogenesis. Fetal breathing is also diminished with the onset of labor to 
decrease pulmonary fluid dynamics, an important step for respiration onset after delivery 
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and retention of surfactant in the lungs. The stress that labor imposes on the fetus also 
increases the release of catecholamines, responsible for glucose mobilization, lung fluid 
absorption, alterations in the perfusion of organs systems and possibly the onset of 
respiration (Hacker et al., 2004). Shortly after birth, the overall status of the newborn is 
given by the Apgar score, a scoring system that allows the systematic assessment of the 
newborn’s condition and immediate needs (Hacker et al., 2004, Moore et al., 2008). Apgar 
scores are assigned 1, 5 and 10 minutes after birth and are calculated by the sum of scores 
summarized in Table 1.1 for each minute. A normal score is considered 7 or higher in the 
1
st
 minute and 9 or higher in the 5
th
 and 10
th
 minutes (Hacker et al., 2004). 
 
Table 1.1: Apgar scoring for determining the newborns status (Hacker et al., 2004).
 
a
response to foot sole stimulation. 
Sign 
Score 
0 1 2 
Heart rate Absent <100 beats/min >100 beats/min 
Respiratory effort Absent Slow, weak cry Good, strong cry 
Muscle tone Limp Some flexion of 
extremities 
Active motion 
Reflex irritability
a
  None Grimace Strong cry 
Color Pale, blue Pink body, blue 
extremities 
Completely pink 
 
1.2 Prenatal disorders and diagnostic procedures: availability and needs 
In spite of the remarkable adaptations that pregnant women undergo to ensure the 
healthy course of pregnancy and adequate fetal development, disruptions in this delicate 
maternal-fetal symbiosis may occur, which pose significant risk for the mother, fetus and 
newborn. Thus, adequate prenatal care and pregnancy monitoring are necessary to allow 
early intervention and improve fetal and maternal outcomes. Pregnancy disorders may 
affect mother, fetus or both, the main pathologies being summarized in Table 1.2, 
presented in alphabetical order, along with their prevalences, i.e. the percentage of 
pregnancies affected by each condition.  
 
The work described in this thesis entailed the study of prenatal disorders with 
higher prevalences (due to the corresponding higher number of samples available), namely 
fetal malformations (FM), chromosomal disorders (CD), intrauterine growth restriction 
(IUGR), preeclampsia (PE), preterm delivery (PTD), gestational diabetes mellitus (GDM) 
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and premature rupture of the membranes (PROM). For other relevant disorders such as 
small for gestational age (SGA), fetal bleeding, intrauterine fetal demise (IUFD), placental 
abruption, placenta previa, oligohydramnios, polyhydramnios and uterine rupture, it was 
not possible to gather sufficient samples. A brief overview of each of these conditions (i.e. 
pathophysiology, diagnostic procedures and management) is presented throughout this 
section, in decreasing order of impact to the mother, fetus and/or newborn. 
 
Table 1.2: Main prenatal disorders and corresponding prevalence. ADA: American Diabetes 
Association. 
Prenatal disorder Prevalence Reference 
Chromosomal disorders (CD) 0.5% of all live births (Hacker et al., 2004). 
Fetal bleeding 0.1-0.8% of all pregnancies (Hacker et al., 2004) 
Fetal Malformations (FM) 3-4% of all live births (Bacino, 2012) 
Gestational Diabetes Mellitus 
(GDM) 
1-14% of all pregnancies (ADA, 2004) 
Intrauterine fetal demise (IUFD) 1% of all pregnancies (Hacker et al., 2004) 
Intrauterine growth restriction 
(IUGR) 
7-15% of all pregnancies (Cetin and Alvino, 2009) 
Oligohydramnios 1-5% of all pregnancies (Kliegman et al., 2011) 
Placental abruption 0.5-1.5% of all pregnancies (Hacker et al., 2004) 
Placental previa 0.5 of all pregnancies (Hacker et al., 2004) 
Polyhydramnios 1-3% of all pregnancies (Kliegman et al., 2011) 
Post-term pregnancy 6-12% of all pregnancies (Hacker et al., 2004) 
Preeclampsia (PE) 5-8% of all live births (Calhoun et al., 2011) 
Premature rupture of the 
membranes (PROM) 
8-10% of all pregnancies (Stuart et al., 2005) 
Preterm delivery (PTD) 9.6% of all live births (Gracie et al., 2011) 
Small for gestational age (SGA) < 10% of all live births (Horgan et al., 2010) 
Uterine rupture 0.5 % of all pregnancies (Hacker et al., 2004) 
 
1.2.1 Fetal Malformations 
Fetal malformations (FM), also referred to as congenital anatomic anomalies, 
congenital malformations or birth defects, are fetal anatomic anomalies that develop during 
the fetal period and are present at birth. Malformations may be single or multiple, of 
varying severity (minor or major), affecting organs, tissues and limbs (Moore et al., 2008). 
Some examples of fetal anomalies, involving the central nervous system, face, heart, lung, 
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abdominal wall, gastrointestinal tract, urinary system and skeletal, are summarized in 
Table 1.3. 
 
Table 1.3: List of common fetal malformations (adapted from (Hacker et al., 2004). 
Affected organ or system Malformation type 
Central nervous system  Hydrocephaly, anenchephaly, spina bifida 
Face Cleft lip and/or palate 
Heart Atrial septal defect, ventricular septal defect, tetralogy of 
Fallot, transposition of great vessels, arrythmias 
Lung Congenital cystic adenomatoid malformations, lung 
sequestration, diaphragmatic hernia 
Abdominal Wall Gastrochisis, omphalocele 
Gastrointestinal Tract Bowel atresia or obstruction 
Urinary System Renal agenesis, polycystic kidney disease, hydronephrosis, 
posterior urethral valves 
Skeletal Skeletal dysplasia 
 
Fetal malformations affect 3-4% of all live births, the most common type being 
malformations of the brain (10/1000 births), followed by malformations of the heart 
(8/1000 births), kidney (4/1000 births) and limbs (2/1000 births) (Moore et al., 2008). The 
majority of malformations (about 50-60%) are of unknown etiology although some can be 
attributed to chromosomal disorders (described in detail in section 1.2.2), mutant genes, 
environmental agents (such as viruses or drugs) or multifactorial (genetic or environmental 
factors). Malformations originating from environmental factors account for 7-10% of 
malformations, with several teratogen effects of certain drugs and viruses being 
recognized. Thalidomide is an example of a teratogen drug, an anti-nausea drug used in the 
past, and now known to have caused  abnormal development of limbs, namely meromelia 
(partial absence) and amelia (complete absence), facial anomalies, cardiac and kidney 
defects, while viral agents such as cytomegalovirus (CMV) causes microcephaly (small 
brain and skull), hepatosplenomegaly (enlarged liver and spleen), hydrocephaly (enlarged 
head), cerebral palsy (abnormal brain development causing impairment or total loss of 
motor function) and periventricular calcification in the brain. A summary list of 
malformations caused by thalidomide, CMV and other environmental agents is shown in 
Table 1.4. 
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Table 1.4: Some fetal malformations caused by environmental agents. FAS: fetal alcohol 
syndrome, IUGR: intrauterine growth restriction, CNS: central nervous system, NTD: neural tube 
defects, adapted from (Hacker et al., 2004). 
Drugs Common congenital anomalies 
Alcohol FAS, IUGR, mental retardation, microcephaly, ocular anomalies, joint 
abnormalities, short palpebral fissures 
Cocaine IUGR, prematurity, microcephaly, cerebral infarction, urogenital anomalies, 
neurobehavioral disturbances 
Methotrexate 
(anti-cancer) 
Multiple anomalies, especially skeletal, involving the face, cranium, limbs, 
and vertebral column 
Phenytoin (anti-
convulsants) 
Fetal hydantoin syndrome: IUGR, microcephaly, mental retardation, ridged 
frontal suture, inner epicanthal folds, eyelid ptosis, broad depressed nasal 
bridge, phalangeal hypoplasia 
Thalidomide  
(anti-nausea) 
Abnormal development of limbs, e.g., meromelia (partial absence) and amelia 
(complete absence), facial anomalies, systemic anomalies, e.g., cardiac and 
kidney defects 
Valproic acid (anti-
convulsant) 
Craniofacial anomalies, NTDs, often hydrocephalus, heart and skeletal 
defects 
Warfarin (anti-
coagulant) 
Nasal hypoplasia, stippled epiphyses, hypoplastic phalanges, eye 
anomalies, mental retardation 
Infection agents 
Cytomegalovirus 
(CMV) 
Microcephaly, chorioretinitis, sensorineural hearing loss, delayed 
psychomotor/mental development, hepatosplenomegaly, hydrocephaly, 
cerebral palsy, brain (periventricular) calcification 
Human parvovirus 
B19 
Eye defects, degenerative changes in fetal tissues 
Rubella virus IUGR, postnatal growth retardation, cardiac and great vessel abnormalities, 
microcephaly, sensorineural deafness, cataract, microphthalmos, glaucoma, 
pigmented retinopathy, mental retardation, newborn bleeding, 
hepatosplenomegaly, osteopathy, tooth defects 
Toxoplasma gondii Microcephaly, mental retardation, microphthalmia, hydrocephaly, 
chorioretinitis, cerebral calcifications, hearing loss, neurologic disturbances 
Varicella virus Cutaneous scars (dermatome distribution), neurologic anomalies, 
hydrocephaly, cataracts, microphthalmia, Horner syndrome, optic atrophy, 
nystagmus, chorioretinitis, microcephaly, mental retardation, skeletal 
anomalies (hypoplasia of limbs, fingers, and toes, etc.), urogenital anomalies 
 
Diagnosis of fetal malformations 
Ultrasound 
The diagnosis of a malformation is carried out by ultrasound after the 16
th
 weeks of 
gestation. In the 2
nd
 T of gestation, the detection rates of these anomalies vary from 17 to 
74%, depending on the population and the operator skill. In spite of the low sensitivity of 
the procedure (which corresponds to a low positive detection rate, i.e. low number of 
malformations correctly classified), it is very useful in detecting normal fetuses, with 
Chapter 1  
36 
specificity (true negative detection rate, i.e. the number of normal cases correctly 
classified) being around 100% (Hacker et al., 2004). 
 
Amniocentesis 
Amniocentesis consists of removing amniotic fluid through the transabdominal 
insertion of a needle under ultrasound guidance. It is performed at 16-20 g.w. and has an 
associated 0.5% risk of pregnancy loss (Hacker et al., 2004). In cases of equivocal or non-
diagnostic fetal ultrasonic imaging, the determination of elevated alpha feto-protein (AFP, 
a fetal serum protein) levels in amniotic fluid allows the detection of neural tube defects, 
which in normal circumstances should be detectable only in trace amounts (Hacker et al., 
2004). Amniocentesis is also used in 3
rd
 T to determine the risk of fetal lung maturity 
through the measurement of pulmonary phospholipids, used as lung surfactants, which 
enter the amniotic fluid from fetal lungs. Lung surfactants line lung alveoli diminishing the 
surface tension, thus lowering the pressure required to open alveoli and breath (Kliegman 
et al., 2011). The presence of phosphatidylglycerol and a ratio of lecithin (or 
phosphatidylcholine) to sphingomielin higher than 2.0 are indicators of normal lung 
surfactants levels, thus minimal risk of respiratory distress in the neonate (Hacker et al., 
2004). 
 
1.2.2 Chromosomal Disorders 
A normal human karyotype has 22 pairs of chromosomes, named autosomes, and a 
pair of sex chromosomes, i.e. females have two X chromosomes and males have one X and 
on Y chromosome. An example of a human male karyotype comprising 22 pairs of 
autosome chromosomes and an XY pair of sex chromosomes is shown in Figure 1.2. 
Chromosomal disorders (CD) are named numerical, in case there is loss or excess of 
chromosomes, or structural, if they involve rearrangements with or without loss or gain of 
the genetic material. CD affect 0.5% of all live births but it is estimated to affect 50% 
spontaneous abortions (Hacker et al., 2004). Depending on the type of the CD, the affected 
chromosome and if it is balanced or unbalanced, the resulting phenotype (i.e. the 
individuals observable trait) is of variable severity.  
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Figure 1.2: Human karyotype of a male subject (22 pairs of autosome chromosomes plus sex 
chromosomes pair XY). Adapted from (Kliegman et al., 2011). 
 
Numerical Chromosomal Disorders 
Numerical CD, or aneuploidy, result from nondisjunction during gametogenesis, 
i.e. the failure of a chromosomal pair or pair of chromatids to disjoin during meiosis or 
mitosis (Moore et al., 2008). These abnormalities can be monosomies, if there is only one 
chromosome of a given pair e.g. Turner’ syndrome (45,X), trisomies, when there are three 
chromosomes of a given pair e.g. Down’s syndrome (47,XX+21 or 47,XY+21), 
mosaicism, as is the case of two or more cell lines containing different number of 
chromossomes, tetrasomies, if there are four or five sex chromossomes and triploidies, 
when there is a complete extra set of chromosomes (Moore et al., 2008).  
Numerical disorders are unbalanced, since there is either gain or loss of the total 
genetic material, thus having a significant implication in the carrier’s phenotype, affecting 
mental skills and/or causing anatomic defects with varying severity. Down syndrome (or 
trisomy 21, T21) is the most common numerical chromosomal disorder and subjects 
affected by this condition suffer from mental deficiency, brachycephaly, flat nasal bridge, 
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upward slant to palpebral fissures, protruding tongue, simian crease, clinodactyly of fifth 
digit, congenital heart defects and gastrointestinal tract abnormalities. A detailed list of 
some numerical disorders along with the corresponding karyotype, prevalence and 
phenotype is summarized in Table 1.5. 
 
Table 1.5: List of types of chromosomal disorders, karyotypes, prevalence and phenotype adapted 
from (Moore et al., 2008) and “Chromosome abnormalities” in www.genome.welcome.ac.uk. 
Karyotype, syndrome and 
prevalence 
Phenotype 
45, X  
Turner Syndrome 
2/10 000 female live births 
Low height, sexual immaturity, short and thick neck, lymphoma, 
large thorax and cardiac anomalies. 
47,XX+21 or 47,XY+21 
Down Syndrome 
15/10 000 births 
Mental deficiency, brachycephaly, flat nasal bridge, upward slant 
to palpebral fissures, protruding tongue, simian crease, 
clinodactyly of fifth digit, congenital heart defects, 
gastrointestinal tract abnormalities. 
47,XX+18 or 47,XY+18 
Edward Syndrome 
3/10 000 births 
Mental deficiency, growth retardation, prominent occiput, short 
sternum, ventricular septal defect, micrognathia, low-set 
malformed ears, flexed digits, hypoplastic nails, rocker-bottom 
feet. 
47,XX+13 or 47,XY+13 
Patau Syndrome 
2/10 000 live births 
Mental deficiency, severe central nervous system malformations, 
sloping forehead, malformed ears, scalp defects, microphthalmia, 
bilateral cleft lip and/or palate, polydactyly, posterior prominence 
of the heels. 
47, XXY 
Klinefelter Syndrome 
2/10 000 male live births 
Small testes, hyalinization of seminiferous tubules, 
aspermatogenesis, often tall with disproportionately long lower 
limbs. Intelligence is less than in normal siblings. Approximately 
40% of these males have gynecomastia. 
47, XXX 
10/10 000 female live births 
Normal appearance, usually fertile, 15-25% are mildly mentally 
retarded. 
47, XYY 
10/10 000 male live births 
Normal appearance, usually tall, often exhibit aggressive 
behavior. 
 
Structural Chromosomal Disorders 
Structural CD can be balanced, if they involve rearrangements without loss or gain 
of the genetic material (e.g. translocations, inversions and insertions) or unbalanced if there 
is gain or loss of genetic material (e.g. deletions, duplications, ring chromosomes and 
isochromosomes (Moore et al., 2008). A diagram of the formation of these chromosome 
structural abnormalities is shown in Figure 1.3.  
Translocations occur when a part of a chromosome is transferred to the 
nonhomologous chromosome, as shown in Figure 1.3a while if the two nonhomologous 
chromosomes exchange parts it is called reciprocal translocation. Translocations are 
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commonly balanced thus do not necessarily cause an abnormal phenotype. Chromosome 
deletion occurs when there is a chromosome break with partial loss (Figure 1.3b), a 
specific type of deletions being ring chromosomes, when both ends of the chromosome are 
lost and rejoined forming a ring-shape chromosome (Figure 1.3c). Chromosome 
duplications refer to the duplication of part of a chromosome, and they can occur within a 
chromosome, attached to a chromosome or as a separate fragment (Figure 1.3d). Inversions 
are chromosomal aberrations where a segment of the chromosome is inverted as shown in 
Figure 1.3e. Inversions can be paracentric, if only one arm of the chromosome is involved, 
or pericentric, if the both arms and the centromere are involved. If the centromere division 
occurs transversely instead of longitudinally, i.e. with loss of one arm and duplication of 
the other arm, it is called isochromosome (Figure 1.3f), this being the most common type 
of structural abnormality of the X chromosome (Moore et al., 2008).  
 
 
Figure 1.3: Diagrams illustrating various structural chromosomal abnormalities: a) reciprocal 
translocation, b) terminal deletion, c) ring chromosome, d) duplication, e) Paracentric inversion, f) 
Isochromosome, g) Robertsonian translocation. Arrows indicate how the structural abnormalities 
are produced. Adapted from (Moore et al., 2008). 
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Specific chromosome deletions and duplications are associated with certain 
syndromes that pose significant phenotypic implications. An interesting example is Prader-
Willi and Angelmans syndromes, which are caused by the loss of the critical region 
envolving bands 1 to 3 of the proximal region of the long arm chromosome 15  
del15(q12q13)  If the deletion occurs in the paternal chromosome the offspring will have 
Prader-Willi syndrome, whilst if it occurs in the maternal chromosome the offspring will 
have Angelmans syndrome, characterized by microcephaly, macrosomia, ataxia, excessive 
laughter, seizures, severe mental retardation (Moore et al., 2008). These and other 
syndromes are summarized in Table 1.6 along with the related chromosome abnormality, 
prevalence (when available) and phenotype. 
 
Table 1.6: Examples of genetic syndromes, chromosomal abnormality, prevalence (when available) 
and phenotype. q: long arms and p: short arm of a chromosome. Adapted from (Struthers et al., 
2002, Tharapel et al., 2002, Clayton-Smith and Laan, 2003, Moore et al., 2008, Shprintzen, 2008, 
Morris, 2010, Weksberg et al., 2010). 
Syndrome, chromosome 
abnormality and prevalence 
Phenotype 
Prader-Willi Syndrome 
del15q12 (most cases) 
1/16 000 live births 
Hypotonia, hypogonadism, obesity with hyperphagia, distinct 
face, short stature, small hands and feet, mild developmental 
delay. Paternal origin. 
Angelman’s Syndrome 
del15q12 (most cases) 
1/10 000-40 000 live births 
Microcephaly, macrosomia, ataxia, excessive laughter, seizures, 
severe mental retardation. Maternal origin. 
Miller-Dieker Syndrome 
del17p13.3 (most cases) 
Type I lissencephaly, dysmorphic face, seizures, severe 
developmental delay, cardiac anomalies. 
DiGeorge Syndrome 
del22q11 (some cases) 
1/4000 live births 
Thymic hypoplasia, parathyroid hypoplasia, conotruncal cardiac 
defects, facial dysmorphism. 
Velocardiofacial Syndrome 
del22q11 (most cases) 
1/2 000 live births 
Palatal defects, hypoplastic alae nasi, long nose, conotruncal 
cardiac defects, speech delay, learning disorder, schizophrenia-
like disorder. 
Smith-Magenis Syndrome 
del17p11.2 
1/25000-50000 live births 
Brachycephaly, broad nasal bridge, prominent jaw, short broad 
hands, speech delay, mental retardation. 
Williams Syndrome 
del17q11.23 (most cases) 
1/7 500 live births 
Short stature, hypercalcemia, cardiac anomalies, especially 
supravalvular aortic stenosis, characteristic elfin-like face, 
mental retardation. 
Beckwith-Wiedemann 
Syndrome 
dup11p15 (some cases) 
1/13 700 live births 
Macrosomia, macroglossia, omphalocele (some cases), 
hypoglycemia, hemihypertrophy, transverse ear lobes. 
 
 
Introduction 
41 
Diagnosis of chromosomal disorders 
The probability of carrying a fetus affected by an aneuploidy significantly increases 
with maternal age, the estimated risk of having a child with trisomy 21, 18 and 13 of 1 in 
1000, 1 in 2500 and 1 in 8000 respectively at age 20 whilst at age 35 the risk increases to 1 
in 250, 1 in 600 and 1 in 1800 (Nicolaides, 2011). Conversely, for other chromosomal 
disorders such as Turner syndrome (45,X), abnormalities in sex chormosomes (47,XXX, 
47,XXY and 47,XYY), and triploidies (defined as an entire extra set of chromosomes, i.e. 
69,XXX or 69,XXY or 69,XYY) have no connection with maternal age (Nicolaides, 
2011). Until recently, the gold standard for detecting fetal chromosomal disorders was 
amniocentesis performed at the 2
nd
 T. Recently, non-invasive tests performed at the 1
st
 T, 
allow the earlier suspicion of CD through the measurement of maternal serum biomarkers, 
alpha-fetoprotein (AFP), free β-human chorionic gonadotropin (β-hCG), inhibin A, 
unconjugated estriol (uE3) and pregnancy associated plasma protein-A (PAPP-A), 
combined with ultrasound measurement of the nuchal translucency (Hourrier et al., 2010). 
Definitive confirmation, in the 1
st
 T, requires chorionic villus sampling (CVS) or 
amniocentesis in the 2
nd
 T of pregnancy. These diagnostic procedures will be described in 
more detail below. 
 
Amniocentesis, Chorionic villus sampling (CVS) and Cordocentesis 
After retrieving amniotic fluid through amniocentesis, amniotic cells require 
approximately 2 weeks of culture before fetal karyotyping can be performed, although 
fluorescent insitu hybridization (FISH) and Multiplex Ligation Probe dependent 
Amplification (MLPA) can give preliminary results for specific chromosome 
abnormalities, i.e. in chromosome 21, 13 and 18 within 24-48 hours (Scott et al., 2003, 
Hacker et al., 2004). Other genetic disorders, such as Prader-Willi syndrome, Angelman 
syndrome, DiGeorge syndrome and Wiliam syndrome, and also cystic fibrosis, Tay-Sachs 
disease, can be diagnosed via amniocentesis by amplifying fetal DNA in amniocytes using 
a polymerase chain reaction (Hacker et al., 2004). CVS consists of removing a small 
sample of chorionic villi transabdominally or transcervically under ultrasound guidance 
with an associated fetal loss rate inferior to 1% (Hacker et al., 2004). Chorionic villi are 
branches emerging from the chorion, on the fetal portion of the placenta that maximizes 
the contact surface with maternal blood, as shown in Figure 1.4 (Moore et al., 2008). CVS 
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is usually performed from the 9
th
 to 12
th
 gestational weeks (before amniocentesis could be 
performed), enabling earlier diagnosis, although with diagnostic precision somewhat 
inferior to that of amniocentesis due to 1% risk of mosaicism caused by placental 
contamination (Scott et al., 2003, Hacker et al., 2004). Fetal karyotyping is performed after 
tissue culture and results are obtainable in 6 to 8 days (Hacker et al., 2004). 
 
Figure 1.4: Graphic representation of a gravid utero at the 4
th
 week of gestation showing fetal 
membranes and embryo, adapted from (Moore et al., 2008).  
 
Cordocentesis, or fetal blood sampling, consists of transabdominally removing fetal 
blood directly from the umbilical vein under ultrasound guidance. The procedure is 
performed after the 17
th
 g.w. and has an associated pregnancy loss rate of 1%. Because 
fetal leucocytes are more rapidly cultured than amniocytes, fetal karyotyping is faster 
through than amniocentesis, the result being available in 3 days (Scott et al., 2003, Hacker 
et al., 2004).  
 
Maternal serum markers 
In the presence of a fetal aneuploidy some feto-placental products levels, such as 
alpha-fetoprotein (AFP), free β-hCG, inhibin A, uE3 and PAPP-A are changed in maternal 
serum (Nicolaides, 2011). The measurement of these maternal serum markers has a 
detection rate for T21 (Down syndrome) at the 2
nd
 trimester of pregnancy that varies from 
60 to 65% when combined with AFP and free β-hCG with maternal age, 65-70% with the 
addition of uE3, and 70-75% with the addition of inhibin A, at a false positive rate of 5% 
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(Nicolaides, 2011). In the 1
st
 T, T21 may be detected by the measurement of maternal 
serum AFP and free β-hCG in combination with ultrasound, as fetuses with trisomy 21 
have increased nuchal translucency, absence of the nasal bone, increased impedance to 
flow in ductus venous and tricuspid regurgitation (Hacker et al., 2004). When combining 
nuchal translucency with maternal age, and maternal serum free β-hCG and PAPP-A, 
named triple test, the detection rate for trisomy 21 increases to 93-96%, with a 2.5% false 
positive rate (Nicolaides, 2011). Other chromosomal disorders, such as trisomy 18 and 13 
are associated with decreased maternal serum free β-hCG and PAPP-A, whilst 
abnormalities in sex chromosome are associated with decreased PAPP-A and normal free 
β-hCG (Nicolaides, 2011). 
 
1.2.3 Intrauterine Growth Restriction 
Intrauterine growth restriction (IUGR) is defined as fetal growth below the 5
th
 
percentile being growth restricted fetuses at higher risk of meconium aspiration, asphyxia, 
polycythemia, hypoglycemia and mental retardation. IUGR differs from small for 
gestational age (or SGA) as the latter refers to cases with fetal growth below a given 
reference range whilst in IUGR fetal growth potential is restricted by a pathological 
process in utero (Scott et al., 2003, Hacker et al., 2004). The condition affects 7 to 15% of 
all pregnancies (Cetin and Alvino, 2009), the origin of the disorder being maternal, 
placental or fetal, although a combination of these is frequently found in IUGR affected 
pregnancies (Hacker et al., 2004). Some causes of IUGR include poor nutritional intake, 
smoking, drug abuse, alcoholism, cyanotic heart disease and pulmonary insufficiency, 
whilst other conditions that lead to inadequate placental transfer of nutrients can also cause 
IUGR e.g. hypertension, chronic renal disease and pregnancy-induced hypertension, or 
situations leading to inadequate substrates levels in the fetal compartment, such as 
intrauterine infection (toxoplasmosis, CMV, rubella and herpes simplex) and congenital 
malformations (Hacker et al., 2004). IUGR can be symmetric, in case the head and body 
are equally restricted and the head to abdominal ratio is normal, although at an inferior 
growth rate, or asymmetric, usually developed in late pregnancy, if brain growth is 
preferred over other organs resulting in a head size proportionally larger than the 
abdominal size (Hacker et al., 2004). 
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Diagnosis of IUGR 
IUGR is diagnosed by ultrasound, being 50-90% of all cases detectable through this 
method (Hacker et al., 2004). The assessment of several sonographic parameters is used to 
diagnose IUGR, i.e. biparietal diameter, head circumference, head to abdominal 
circumference ratio, femoral length, femoral length to abdominal circumference ratio, 
amniotic fluid volume, calculated fetal weight and abdominal circumference, the latter 
being the single most effective predictor of fetal weight as it is reduced in both symmetric 
and asymmetric IUGR (Hacker et al., 2004). Apart from the anatomic changes in IUGR 
fetuses, abnormalities in the placental vascular tree are known to cause variations in fetal 
circulation that can be detected through Doppler velocimetry of the umbilical artery (Scott 
et al., 2003). 
 
1.2.4 Preeclampsia 
Preeclampsia (PE) is defined by the new onset of the triad hypertension, proteinuria 
and generalized edema (Scott et al., 2003, Hacker et al., 2004), usually after the 20
th
 week 
of gestation, and affects 5-8% of all live births (Calhoun et al., 2011). It usually affects 
nulliparas although in multiparas with twins and chronic hypertension are at increased risk 
of developing this condition (Hacker et al., 2004). PE may be present in mild or severe 
forms, depending on the severity of hypertension and proteinuria and the degree of other 
organs involvement (Scott et al., 2003, Hacker et al., 2004). A variant of severe PE is the 
Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) syndrome, more common 
in multiparous women, older than 25 and prior to 36 g.w.. Another form of severe PE 
includes the occurrence of seizures unrelated to other causes (Scott et al., 2003, Hacker et 
al., 2004). The condition poses significant risk for the mother, such as development of 
disseminated intravascular coagulation, intracranial hemorrhage, renal failure, retinal 
detachment, pulmonary edema, liver rupture, placental abruption and death, whilst 
neonatal outcome depends to gestational age at delivery (Scott et al., 2003). PE is 
characterized by vasospasm, hemoconcentration and ischemic changes in the placental, 
kidney, liver and brain, with several causative mechanisms having been suggested, i.e. 
placental, immunologic, endocrine, nutritional, infectious agents and genetic predisposition 
origins, the exact etiology remaining unclear (Scott et al., 2003, Hacker et al., 2004).  
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Diagnosis and Management of PE 
PE diagnosis is mainly based on the development of hypertension, i.e. systolic 
blood pressure higher than 140 mm Hg and diastolic blood pressure higher than 90 mm 
Hg, in a woman with previous normal blood pressure, and 24 hour urine proteinuria higher 
than 300 mg. The condition is often accompanied or preceded by generalized edema, 
mainly in the lower extremities but also in the face, hands or lungs (Scott et al., 2003, 
Hacker et al., 2004). Delivery is the only definitive resolution, thus PE management 
depends on the gestational age at diagnosis and must be a compromise between preventing 
maternal complication and minimizing neonatal morbidity arising from prematurity (Scott 
et al., 2003, Hacker et al., 2004). Currently, there are no predictive or preventive methods 
for PE and, given the disorders’ significant impact for mother and newborn, the 
development of reliable methods are of paramount importance (Scott et al., 2003). 
 
1.2.5 Preterm Delivery 
Preterm delivery (PTD), or preterm labor, is defined as birth occurring between 20
th
 
and 37
th
 gestational weeks. PTD occurs in 9.6% of all live births and it is associated with 
50 to 70% of neonatal morbidity and mortality (Hacker et al., 2004). PTD can be classified 
into three subtypes, spontaneous PTD or idiopathic, preterm premature ruptures of the 
membranes (PPROM or pPROM) or induced labor due to medical indication. The 
possibility of identifying women at risk of a preterm delivery in order to allow the effective 
intervention and/or prevention of PTD or to decrease neonatal morbidity and mortality is a 
goal with utmost relevance. Although some findings have been associated with the risk of 
developing PTD although no reliable predictive method is yet available. Cervico-vaginal 
infections, such as bacterial vaginosis, and short cervical length have been associated with 
the occurrence of PTD. Cervical length is measured by transvaginal ultrasound and women 
with cervical length inferior to 2.5 cm at 24-28 g.w. have a 3- to 5-fold higher risk of PTD. 
At the same time of gestation, the presence of fetal fibronectin, a protein produced in fetal 
membranes, in the cervix and vagina predicts more than half of the spontaneous preterm 
births before the 28 g.w., while its absence is associated with low risk of PTD (Hacker et 
al., 2004). Salivary estriol, a fetal product increased prior to spontaneous birth, has also 
Chapter 1  
46 
been tested for prediction of PTD although with low sensitivity and specificity and high 
false positive rates (71%, 77% and 23%, respectively) (Scott et al., 2003). 
 
Diagnosis and Management of PTD 
The diagnosis of PTD follows two criteria: a) uterine contractions (>4 per 20 
minutes or 8 per 60 minutes) and cervical dilation (2 cm in a nullipara, a woman who has 
never given birth, or 3 cm in a multipara, a woman who has given birth) and cervical 
effacement (cervical thinning expressed in percentage) higher than 80% or b) uterine 
contractions and cervical change, the latter being the most well accepted criteria although 
vulnerable to bias. After PTD diagnosis, women are given adequate hydration and bed rest 
and uterine contractions cease in approximately 20% of the cases. When the previous 
attempt is not successful uterine tocolytic therapy (anti contraction medications) is 
initiated, namely with magnesium sulphate, nifedipine and prostaglandin synthetase 
inhibitors as well as antibiotics to prevent intra-amniotic and fetal infections. Furthermore 
corticoid therapy, specifically bethamethasone, is given to promote fetal lung maturation, 
reducing the incidence of respiratory distress syndrome (or RDS) and mortality in the 
newborn (Hacker et al., 2004). 
 
1.2.6 Gestational Diabetes Mellitus 
Gestational diabetes Mellitus (GDM) is defined as the development of carbohydrate 
intolerance with onset or first recognition during pregnancy. The condition varies in terms 
of severity and is known to affect 1 to 14% of all pregnancies (ADA, 2004, Hod et al., 
2008). In terms of pathophysiology, GDM is similar to that of Type 2 Diabetes Mellitus 
(T2DM) as it involves pancreatic beta-cell dysfunction leading to impaired insulin 
secretion and, subsequently, increased insulin resistance (ADA, 2004, Hod et al., 2008, 
Creasy et al., 2009). The occurrence of GDM often increases the risk of adverse pregnancy 
outcomes, such as fetal macrosomia, neonatal hypoglycemia, perinatal mortality, jaundice, 
polycythemia, hypocalcemia, development of maternal hypertensive disorders, need for 
cesarian delivery and, in more severe cases, fetal demise in the last 4-8 weeks of gestation 
(ADA, 2004, Hod et al., 2008). GDM may also pose long-term complications for the 
mother and child such as post-natal maternal T2DM and increased risk of obesity, glucose 
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intolerance, T2DM and cardiovascular disease in the offspring (ADA, 2004, Hod et al., 
2008). In GDM-affected pregnancies, maternal metabolism is perturbed, increased insulin 
resistance and β-cell dysfunction being known to cause deregulation in carbohydrates, 
lipids and amino acids metabolism (Hod et al., 2008). Decreased insulin secretion leads to 
decreased glucose uptake by insulin-dependent tissues causing maternal hyperglycemia. 
Because glucose transfer to the fetus is concentration-dependent, maternal hyperglycemia 
leads to increased placental transfer of glucose and subsequently fetal hyperglycemia and 
hyperinsulinism, a condition leading to the development of macrosomia. As fetal 
hyperinsulinism remains after delivery, the sudden disruption of umbilical cord glucose 
supply to the newborn increases the risk of neonatal hypoglycemia, a condition that can 
lead to brain damage in the newborn (Hod et al., 2008). GDM is associated with increased 
levels of triglycerides and cholesterol, further increasing the hyperlipidemia condition 
occurring in pregnancy, and also increasing the risk of fetal macrosomia. The origin of 
hyperlipidemia has been associated with hormonal dysfunction, and GDM has been found 
to increase placental lipids fluxes and enhanced fatty acids consumption by the fetus in 
GDM affected pregnancies (Hod et al., 2008, Herrera and Ortega-Senovilla, 2010). GDM 
is also associated with increased oxidative stress, characterized by placental endothelial 
dysfunction, increased formation of reactive species and decreased anti-oxidant defenses 
whereas macrosomic infants from GDM mothers have lower antioxidant defenses, and 
higher products of oxidation reactions (Hod et al., 2008, Herrera and Ortega-Senovilla, 
2010).  
 
Diagnosis and Management of GDM 
GDM screening is usually performed at 24-28 g.w. initially by a 50 g glucose 
challenge followed by the measurement of plasma glucose (PG) after 1 hour named 
O’Sullivan test. If PG is higher than 140 mg/dL (7.8 mmol/L) a subsequent 100 g or 75 g 
oral glucose tolerance test (OGTT) should be performed, the latter being the current 
recommendation by the American Diabetes Association- ADA (Scott et al., 2003, Hacker 
et al., 2004, ADA, 2013). After the glucose challenge plasma glucose (PG) is measured at 
fasting (FPG) and after 1 and 2 hours, for the 75 g challenge and at fasting and after 1, 2 
and 3 hours, for the 100 g challenge. GDM is then diagnosed if two or more values are 
above the cutoffs for the 75 g challenge or if three or more values are above the cutoff for 
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the 100 g challenge. The cutoff values for O’Sullivan, and OGTT with 75 g and 100 g are 
summarized in Table 1.7. 
 
Table 1.7: Criteria for the diagnosis of GDM for O’Sullivan, 100 g oral glucose tolerance test 
(OGTT) and 75 g OGTT, adapted from (Hod et al., 2008). 
 O’Sullivan 50 g test 100 g OGTT 75 g OGTT 
 mg/dL mmol/dL mg/dL mmol/dL mg/dL mmol/dL 
Fasting — — 95 5.3 95 5.3 
1 hour 140 7.8 180 10.0 180 10.0 
2 hours — — 155 8.6 155 8.6 
3 hours — — 140 7.8 — — 
 
GDM management aims to achieve euglycemia (normal blood glycemic levels) 
through diet, insulin therapy and exercise, in order to decrease the occurrence of GDM 
complications. In the dietary intervention caloric intake is calculated with basis on the ideal 
body weight and is normally efficient for the management of GDM patients with normal 
fasting PG (FPG). Patients with FPG higher than 105 mg/dL or 2 hour post prandial PG 
higher than 120 mg/dL need to complement the dietary intervention with insulin therapy. 
Other oral hypoglycemic agents are not recommended in pregnancy as they can cross the 
placenta and pose risk of teratogenesis and neonatal hypoglycemia. Furthermore, GDM 
patients are encouraged to exercise for about half an hour after meals (Hacker et al., 2004). 
 
1.2.7 Premature Rupture of the Membranes 
Premature rupture of the membranes (PROM) is defined as the spontaneous rupture 
of membranes prior to the onset of labor at any stage of gestation. It is the most common 
pregnancy disorder, affecting 8-10% (Stuart et al., 2005) of all pregnancies and 30% of 
preterm deliveries (Scott et al., 2003). The etiology of PROM remains unclear although 
some conditions such as cervical incompetence, polyhydramnios (increased amniotic 
fluid), cervical and vagina infections, abnormal membrane physiology and nutritional 
deficiency are thought to contribute to its occurrence (Scott et al., 2003, Hacker et al., 
2004). The occurrence of PROM at term is associated with increased risk of maternal and 
neonatal sepsis and the need for neonatal resuscitation after delivery (Stuart et al., 2005).  
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Diagnosis and Management of PROM 
The diagnosis of PROM is based on vaginal loss of amniotic fluid, confirmed by 
testing for the presence of amniotic fluid with nitrazine papers which turns blue in the 
presence of alkaline amniotic fluid or by microscopic observation of arborization or 
“ferning” of dried amniotic fluid. These methods have high accuracy (93% and 96% for 
nitrazine and microscopic evaluation respectively) although high false positive rates are 
common due to contaminations with blood, semen, alkaline urine, bacterial vaginosis, 
thricomoniasis (Scott et al., 2003, Hacker et al., 2004). As the amniotic sac serves as a 
barrier against infection, PROM poses higher risk of infection and sepsis. Thus, PROM 
management depends on the gestational age at the time of membrane rupture. If PROM 
occurs after 36
th
 weeks of gestation, labor should be induced after 6-12 hours in the 
absence of spontaneous contractions are absent. If PROM occurs prior to the 36
th
 
gestational week infection vs. prematurity must be weighted as the risk of infection 
increases with the duration of membrane rupture. Antibiotic therapy is recommended if 
chorioamnionitis, or intraamniotic infection, is confirmed and labor must be induced once 
antibiotics are started, whilst in the absence of infection tocolytic therapy can be useful in 
prolonging pregnancy (Scott et al., 2003, Hacker et al., 2004). 
In spite of the plethora of diagnostic procedures used for prenatal care, there is a 
continuous need to improve currently available methods, and to do this by developing 
reliable non-invasive tests that pose no harm to the mother and developing fetus. 
Moreover, there is a recognized lack of predictive methods for disorders developed in late 
pregnancy such as IUGR, PE, PTD and GDM, conditions associated with significant 
complications for mother, fetus and newborn. Thus, metabolomics emerges as valuable 
methodology to identify potential markers in connection with pregnancy disorders. The 
basic concepts underlying a metabolomic study are presented in the following section.  
 
1.3 Metabolomics: envisaging new clinical strategies in prenatal health 
The terms metabolomic and metabonomic are often used interchangeably, in spite of slight 
differences in their history and definitions. Metabolomics is defined as the comprehensive 
measurement and quantification of all metabolites in a living system (Fiehn, 2002), whilst 
metabonomics has been defined as “the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
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genetic modification”, thus including the concept of metabolome perturbation and need for 
advanced statistical methods to detects the perturbation effects  (Nicholson et al., 1999). 
Metabolomics is one of the “omics” techniques together with genomics, transcriptomics 
and proteomics that study the genome (DNA), the transcriptome (RNA) and proteome 
(proteins), respectively. The term genomics encompasses the study of the set of genes 
describing an organism, the genome, whilst transcriptomics reflects the study of changes in 
gene expression which are then translated into proteins, thus emerging proteomics as the 
study of proteins in a living system (Figure 1.5). However, the complex interaction 
between genes and environment, such as lifestyle and diet, induce changes in biochemical 
processes which can be difficult to detect with proteomics or transcriptomics. On the other 
hand, such interactions are known to influence the metabolome very significantly. Indeed, 
it has been realized that small molecules, or metabolites (low molecular weight 
compounds, Mw<1500 Da), involved in biological processes provide a great deal of 
 
 
Figure 1.5:Schematic representation of the “Omic” technologies showing information flow from 
genomics to transcriptomics, proteomics and metabolomics (adapted from  (Dunn et al., 2011, 
Roux et al., 2011)). 
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information of the whole organism and its interactions with both internal and external 
perturbations (Lindon et al., 2007, Roux et al., 2011). 
 
The value of metabolomics has been well recognized in the field of molecular 
toxicology, pharmacology and disease research (Lindon et al., 2004, Lindon et al., 2006, 
Lindon et al., 2007, Coen et al., 2008, Duarte et al., 2013). These studies are pursued 
through the analysis of biofluids, such as urine, blood, cerebrospinal fluid, amniotic fluid, 
saliva, or intact tissues, tissue extracts, cell cultures or in vitro cell systems (Lindon et al., 
2000, Lindon et al., 2007).  In the context of disease research, the mostly used biofluids are 
urine and blood plasma since they are easily collectable and hence can easily be used for 
disease diagnosis and monitoring but also for clinical trials and drug therapy monitoring 
(Lindon et al., 2004, Lindon et al., 2007). Some of the diseases more extensively studied 
through metabolomics comprise cancer (Madsen et al., 2009, Rocha et al., 2010, DeFeo et 
al., 2011, Duarte and Gil, 2012), diabetes (Salek et al., 2007, Makinen et al., 2008, Madsen 
et al., 2009, Friedrich, 2012), cardiovascular diseases (Madsen et al., 2009, Griffin et al., 
2011, Wurtz et al., 2011, Senn et al., 2012), neurological diseases(Sussulini et al., 2009, 
Lutz and Cozzone, 2011, Cai et al., 2012, Hassan-Smith et al., 2012, Xu et al., 2012, 
Zheng et al., 2013), respiratory diseases (Slupsky et al., 2009, Saude et al., 2011), 
gastroenterological diseases (Bernini et al., 2011, Schicho et al., 2012)  among others 
(Madsen et al., 2009, Emwas et al., 2013). In disease research, the application of 
metabolomic has evolved towards the use of large-scale epidemiological data to unveil not 
only the disease-related profiles but also the profile associated with disease risk factors, for 
instance high blood pressure as a major risk of coronary heart disease and stroke (Holmes 
et al., 2008). The potential of metabolomics has also been tested for disease prediction, for 
instance type 1 and type 2 diabetes mellitus (Oresic et al., 2008, Wang et al., 2011) and 
disease prognosis (Makinen et al., 2008, Nicholson et al., 2012). Another emerging 
concept is that of pharmacometabolomics which aims to predict the effect of drug 
administration prior to dosing, towards the implementation of personalized medicine 
procedures (Nicholson et al., 2011, Nicholson et al., 2012). This hypothesis has been 
tested to predict acetaminophen (a common analgesic) metabolism (Clayton et al., 2009), 
to predict anti-diabetic drugs response (Qiu et al., 2008), and the metabolic effects of 
chemotherapy agents (Keun et al., 2009). 
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A general scheme of a metabolomic study based on NMR and MS is shown in 
Figure 1.6, showing a typical workflow from data acquisition to MVA, possible 
identification of biomarkers of the condition being studied, which can be ultimately used to 
elaborate a biological outcome. Metabolomic studies are strongly based in Nuclear 
Magnetic Resonance (NMR) and Mass Spectrometry (MS) techniques, their principles 
being described in the following section 1.4, although Infrared (IR) spectroscopy has also 
been used occasionally.  NMR and MS are suitable for the study of biofluids since they 
provide large amounts of potential information on composition of complex mixtures, in 
one single run. The use of proton (
1
H) NMR is advantageous due to its robustness, 
accuracy and reproducibility and it is well recognized for the study of complex mixtures.  
 
 
Figure 1.6: General scheme of a metabolomic study using NMR and MS methods. 
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However, NMR lacks sensitivity which may be complemented through the use of MS 
platforms, the latter technique requiring a pre-separation step, usually liquid 
chromatography (LC), gas chromatography (GC), or more recently ultraperformance LC 
(UPLC) (Lindon et al., 2000, Lindon et al., 2004, Lenz and Wilson, 2007, Lindon et al., 
2007, Coen et al., 2008, Lindon and Nicholson, 2008). Both NMR and MS methods 
generate complex datasets that require subsequent multivariate analysis (MVA, as 
described in section 1.5), to maximize information recovery and possibly biomarker 
identification (Cloarec et al., 2005, Trygg et al., 2007, Madsen et al., 2009).  
 
1.4 Principles of Nuclear Magnetic Resonance (NMR) spectroscopy and 
Mass Spectrometry (MS) 
1.4.1 NMR Spectroscopy 
Proton NMR is based on the magnetic property (or magnetic momentum, μ), 
originating from their rotating movement, known as spin, and associated to an angular 
momentum P and a spin quantum number I. Only the nuclei corresponding to non-zero 
values of I (which takes integer or half-integer values) are detectable by NMR (Lindon et 
al., 2000). For instance,
1
H, 
13
C, 
15
N, 
9
F, 
31
P have I=1/2,  
2
H, 
14
N that have I=1 or 
17
O 
which has I=5/2, are detectable by NMR spectroscopy whilst  
12
C and 
16
O that have I=0 are 
not NMR active. For the nuclei with I≠0, the associated magnetic moment μ is given by 
μ= γ·I, where γ is the gyromagnetic ratio of the nuclei (γ=2.675 ×10-8 rad·T
-1
s
-1
 for 
1
H). 
For nuclei with I=1/2, in the presence of an external magnetic field B0, there are two 
possible orientations of the spins, corresponding to different energy levels. The number of 
possible spin orientations is given by the magnetic quantum number mI and determined 
according to mI=2I+1. These orientations may be either parallel (lower energy, α) or anti-
parallel (higher energy, β) (Figure 1.7b) and the energy difference (E) between states α 
and β is given by  ΔE=γ·ħ·B0 where ħ is the Planck’s constant, h, divided by 2π. The 
external magnetic field B0 induces a torque (a momentum that causes rotation about an 
axis) on the nuclei, causing the spins to precess around B0 (Figure 1.7a). This motion is 
known as Larmor precession and it occurs at defined frequency, named the Larmor 
frequency ν0, given by ν0= -γ·B0/2π (Hz) or at a rate ω0 given by ω0=-γ·B0 (rad·s
-1
). 
 
Chapter 1  
54 
 
Figure 1.7: a) Precession of an individual magnetic moment μ around the external magnetic field 
B0; b) precession of magnetic moments in the α (mI=1/2) and β (mI=-1/2) spin states and c) 
resultant magnetic moment M0 reflecting the excess of population in spin state α. Adapted from 
(Lindon et al., 2000).  
 
The distribution of the spin states by the two energy levels (e.g. in the case of 
protons) is given by the Boltzmann distribution (Eq. 1.1), where N is the number of spins 
in each spin state, E  is the energy difference between states, k is the Boltzmann constant 
and T the absolute temperature. According to this distribution, in the presence of B0 and at 
thermal equilibrium, there will be an excess of spins in state α thus creating a bulk 
magnetization, M0, parallel to B0 (Figure 1.7b). 
kT
E
e
N
N




 [Eq. 1.1] 
 
Detection of the NMR signal   
For an NMR signal to be detected, a radiofrequency (RF) pulse is applied for a 
given period, usually of the order of μs. This RF has an associated magnetic field, B1, 
oscillating at the same Larmor frequency as the spin. The RF is transmitted via a coil 
surrounding the sample, which induces a magnetic field B1 in the transverse plane, thus 
perpendicular to B0 (Claridge, 1999). To help visualize the concomitant rotating fields and 
precessing vectors, a reference rotating frame (x’, y’) rotating at the Larmor frequency 
around z is used. The applied RF pulse (or 90º pulse) causes the net magnetization M0 to 
flip from the z axis to the x’-y’ plane. After the RF pulse, the magnetization vector is re-
established, so that the transverse magnetization gradually disappears towards z returning 
to the initial value of M0, this process is known by relaxation (described below). To detect 
a) b) c)
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the NMR signal, the receiver coil, which is aligned with the x’-y’ plane, as show in Figure 
1.8a, is crossed by the magnetization vector M0 generating a current which is amplified 
and recorded, known as free induction decay (FID).  
 
 
Figure 1.8: a) Scheme of the magnetization vector M0 precessing on the x’-y’ plane around the z 
axis, cutting the receiver coil aligned with the x’-y’; b) time domain signal of the FID and c) 
frequency domain signal of the FID after applying FT. Adapted from (Keller, 1988, Keeler, 2002).  
 
The resulting FID is a time domain signal, f(t), which is then transformed into the 
frequency domain, f(w), i.e. the NMR spectrum, by applying a Fourier transformation (FT, 
Eq. 1.2). . 



 dtetfwf iwt)()(  [Eq. 1.2] 
 
Relaxation 
The relaxation processes can occur according to two main mechanisms, one named 
as longitudinal (or spin-lattice) and a second process known as transverse (or spin-spin) 
relaxation, respectively characterized by relaxation times T1 and T2. T1 and T2 describe, 
respectively, the exponential decay of the net magnetization in the z axis and in the x’-y’ 
plane. The longitudinal or spin-lattice relaxation relates to the exchange of magnetization 
with the surroundings, the z component of the magnetization (Mz) being expressed in terms 
of T1, the time required for recovery, and given by Eq. 1.3. 
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   [Eq. 1.3] 
The transverse or spin-spin relaxation relates to differences in magnetic fields that 
are experienced by the spins, due to inhomogenities or intra- and inter-molecular 
interactions in the sample. These differences cause the spanning out of the magnetization 
component in the x’-y’ plane ultimately leading to no net magnetization in this plane and it 
is expressed in terms of T2 given by Eq. 1.4 and Eq. 1.5 (Jacobsen, 2007).  
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Moreover, T2 relates to the NMR resonances width, as the half-height line width is 
proportional to 1/π·T2 (Claridge, 1999). Thus, large and slowly tumbling molecules will be 
characterized by large T2 values and therefore give rise to broad NMR resonances. 
 
Chemical shift and scalar coupling 
Each nucleus is surrounded by electrons that create a local magnetic field, opposite 
to the external magnetic field (B0) forming a shielding effect that causes each nucleus to 
experience a different effective magnetic field (Beff). The effective magnetic field is given 
by Beff= B0 (1-σ), where σ is the shielding constant, which reflects the extent to which the 
electron cloud shields the nucleus (Lindon et al., 2000, Jacobsen, 2007). 
Depending on the chemical environment, e.g. neighboring atoms, chemical bonds, 
each nuclei within a molecule resonates at different frequencies (ν) resulting in different 
positions in the NMR spectrum. The resonance frequency of a given nucleus is then 
divided by the spectrometer frequency (νref) and multiplied by 10
6
, resulting in a 
dimensionless value named the chemical shift (δ) and expressed in parts per million (ppm) 
(Eq. 1.6). In this way, the resulting chemical shift is constant and irrespective of the 
frequency of the operating NMR spectrometer. The ppm scale is further calibrated with 
frequencies of the methyl groups bound to the silicon atom of chemically inert compounds 
tetramethylsilane (TMS), dimethylsilapentanesulfonic acid (DSS) or trimethylsilyl 
propionate (TSP), used for 
1
H and 
13
C calibration (Lindon et al., 2000, Jacobsen, 2007).  
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More shielded nuclei, such as those without electronegative atoms (e.g. O, N, Cl) or 
unsaturated groups (e.g. C=C, C=O, aromatic) in the nearby environment, resonate at 
lower frequencies, thus situated in the lower ppm scale, whereas resonance of less shielded 
nuclei, such as those proximal to electronegative or unsaturated groups , are located in the 
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higher ppm scale (Jacobsen, 2007). An example of some typical 
1
H and 
13
C chemical shift 
ranges of common groups is shown in Table 1.8.  
 
Table 1.8: 
1
H and 
13
C  typical chemical shifts values ranges of common chemical groups. Adapted 
from (Fan, 1996). 
1
H chemical shifts 
13
C chemical shifts 
Chemical group δ/ppm Chemical group δ/ppm 
C−CH3 0.7-1.1 −CH3 (methyl) 8-30 
=C−CH3 1.5-1.8 −CH2 (methylene) 14-55 
COCH3 (acetyl) 2.0-2.5 −CH− (methine) 22-60 
N−CH3 2.5-3.3 −C− (quaternary) 30-40 
O−CH3 3.3-4.3 CH2=C−R 100-150 
CO−CH2−C 1.3-2.5 C=C−C=C−R 110-150 
O−CH2−C 4.0-5.0 Heteroaromatic ring 100-165 
C−CH−OH 3.3-4.0 C−OH (alcohol) 44-85 
C−CH−O−ester 4.2-5.3 C−O−C (ester) 55-85 
=CH−C (olefinic) 5.5-8.5 R−COOH (saturated) 165-188 
Aromatic ring 6.0-9.0 R−C=C−COOH 158-174 
−CHO (aldehyde) 9.0-10.2 R−COOR’ (saturated) 158-174 
−COOH 10.5-13.5 R−C=C−COOR’ 152-172 
C−OH (alcohol) 1.5-6.0 R−CHO (saturated) 196-220 
C−OH (phenol) 6.5-18.5 R−C=C−CHO 176-195 
Primary amines 1.1-1.8 Saturated ketones 195-220 
Secondary amines 1.2-2.1 C−N−R2 20-70 
CO−NH 5.0-6.5 R−CO−NH2 150-178 
 
Apart from interacting with the external and the radiofrequency magnetic fields, the 
nuclei also interact with their neighboring nucleus through a process known as spin-spin 
coupling, scalar coupling or J-coupling which occurs via the electrons in the chemical 
bonds. This interaction between neighboring spins (e.g. for a given nuclei A and X) causes 
a shift of their energy levels, depending on their magnetic quantum number mA and mX and 
a parameter that quantifies the strength of the interaction, named coupling constant JAX. The 
spin-spin coupling causes the NMR signal to split into more than one signals, the 
multiplicity of which (i.e. number of peaks in the split signal) given by 12 nI , where n is 
the number of neighbor equivalent nuclei (Lindon et al., 2000, Jacobsen, 2007).  
 
Another relevant feature of 
1
H NMR spectra is that the area under the peaks are 
directly proportional to the number of the corresponding nuclei. This means that for a 
given peak, its integral value is proportional to the number of protons giving rise to that 
signal. Thus, NMR is an inherently quantitative method as long as the spectra are acquired 
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in quantitative conditions, that meaning that an inter-scan delay of 5 times the longest T1 is 
used, so that complete relaxation of all spins is achieved (Jacobsen, 2007). If the previous 
quantification condition was taken into account, the concentration of a given compound 
may be determined following Equation 1.7. This means that the concentration of a given 
compound, e.g. compound B (CB), may be calculated when knowing the concentration of a 
reference compound A (CA), the integrals of the reference (AA) and that of the signal of the 
compound to be quantified (AB) and the number of protons giving rise to the reference (nA) 
and to the signal to be quantified (nB).  
 
AB
BA
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nA
C
C


   [Eq. 1.7] 
 
In metabolomics studies of complex mixtures, e.g. biofluids, it is difficult to 
perform absolute quantification due to 1) the broadly overlapped resonances which 
compromise integration measurements and 2) the limitation of using standard references 
due to their interactions with sample components (e.g. interactions between TSP and 
proteins). One alternative is the use of an Electronic Reference To acess In vivo 
Concentrations (ERETIC).  
 
One- and Two-dimensional  NMR experiments 
One dimensional (1D) NMR experiments usually require a preparation and an 
acquisition step. The preparation step allows the spins to reach equilibrium (determined by 
the relaxation delay which corresponds to d1 parameter and depends on the pulse 
program), the application of an RF pulse immediately followed by signal acquisition. 
There are three common 1D 
1
H NMR experiments for the study of biofluids or complex 
mixtures, depending on the composition of such mixtures. Firstly, the “standard” NMR 
experiment, consisting in a preparation step, with water presaturation, followed by a 90º 
pulse, is used to detect signals from all molecules whilst other two experiments, based on 
diffusion coefficients (diffusion-edited) and on T2 (Carr-Purcell-Meiboom-Gill or CPMG), 
are used to selectively detect signals arising from macromolecules or from small 
molecules, respectively (Meiboom and Gill, 1958, Lindon and Nicholson, 2008). The 
diffusion-edited experiment is performed to detect signals from macromolecules, which are 
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large and slowly tumbling molecules with high T2. In this experiment, an initial 90º pulse 
is applied followed by the application of gradients, which diphase magnetization. A 
following gradient delay is introduced to allow molecules to diffuse and, as diffusion 
depends on the size of the molecule, large molecules will remain in a fairly constant 
position contrarily to small ones. A subsequent gradient, opposite to the initial is applied, 
which refocuses magnetization of macromolecules and attenuates signals from smaller 
molecules. The CPMG experiment, also used to measure T2, is performed to selectively 
detect sharp signals from small molecules, through the use of a spin echo sequence 
followed by a delay. During this delay period, the magnetization decreases exponentially 
with the ratio between /T2. This means that the magnetization from molecules with low T2 
(macromolecules) decreases more rapidly than small molecules with high T2. Thus by 
introducing a  period before acquisition, broad signals are attenuated. 
The 1D spectra (standard and edited) of complex mixtures, such as biofluids, is 
composed of numerous of peaks, which overlap extensively, hindering peak assignment 
and spectral interpretation, therefore, two dimensional (2D) experiments are an absolute 
necessity. 2D NMR experiments are, in general, composed of four steps: preparation, 
evolution (t1), mixing and acquisition (t2). The preparation step is usually a relaxation time 
to allow spins to reach equilibrium followed by a 90º pulse to bring the magnetization to 
the x’-y’ plane. The second dimension is then established through the evolution step, 
during which a series of pulses are applied to transfer the magnetization between nuclei. 
After the evolution time and depending on the experiment, additional pulses may be 
applied which are then followed by acquisition (Lindon et al., 2000, Jacobsen, 2007). 
2D experiments rely on inter-nuclei interactions, which may be homonuclear or 
heteronuclear, to generate frequency information along two axes and, for metabolomic 
studies, usually three experiments are performed: Total Correlation Spectroscopy 
(TOCSY), Heteronuclear Single Quantum Coherence (HSQC), and 
1
H NMR J-resolved (J-
res), although two other complementary experiments may be also helpful, namely 
Correlation Spectroscopy (COSY, useful to map homonuclear coupling over two or three 
bonds) and Heteronuclear Multiple Bond Correlation (HMBC, useful to map 
hetereonuclear coupling across multiple bonds).   
While 2D COSY provides coupling information over two or three bonds, the 
TOCSY spectrum provides further information of coupled protons belonging to the same 
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spin-system, separated by up to five bonds. Thus, the latter experiment provides a mean of 
identifying all resonances within a spin system, playing an essential role for metabolite 
assignment. In the TOCSY experiment, the evolution step is followed by a spin-lock 
sequence during the mixing time, the MLEV-17 (Malcolm Levitt- 17 sequence) that allows 
the coherence transfer between all coupled nuclei in a spin-system. The MLEV-17 
sequence, consists in 16 composite pulses followed by an uncompensated 180º pulse (Bax 
and Davis, 1985), the general scheme of the TOCSY sequence being shown in Figure 1.9. 
 
 
Figure 1.9: TOCSY pulse sequence. 
 
Complementary to TOCSY, the HSQC experiments provide information about the 
chemical shift of 
13
C correlated with the 
1
H chemical shift of the directly bound proton. 
The HSQC experiment starts with a 90º pulse for proton magnetization followed by an 
insensitive nuclei enhanced by polarization transfer (INEPT) sequence that transfers the 
magnetization from proton to the bounded carbon and also recovers magnetization from 
carbon to the proton (see Figure 1.10). This sequence is much more sensitive than those 
involving direct detection of carbon such as the heteronuclear correlation (HETCOR) pulse 
sequence (Jacobsen, 2007). 
 
 
Figure 1.10: HSQC pulse sequence. Figure adapted from (Keeler, 2002). 
 
The J-resolved (or J-res) experiment allows information about chemical shift to be 
separated from scalar coupling. In this experiment, the 1
st
 dimension (F1) contains 
INEPT Evolution
90º 180º 90º 180º 90º
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information about multiplicity, whilst scalar couplings are presented in the 2
nd
 dimension 
(F2), thus enabling the clearer identification of 
1
H multiplets without overlapping and 
allowing the measurement of coupling constants (J). The experiment starts with a 90º pulse 
to create magnetization and, by the midpoint of the evolution time a 180º pulse is applied 
(Figure 1.11a) to refocus proton shifts but not scalar couplings, which appear in the 1
st
 
dimension (F1). The 2
nd
 dimension (F2) contains information about chemical shift and 
coupling constants, which complicates the interpretation of the spectra. To retain only 
chemical shifts in F2 the “tilting” of the multiplets through an angle of 45º is performed, as 
exemplified in Figure 1.11b (Claridge, 1999). Furthermore, the J-res experiment has been 
used for quantification studies for complex mixtures. 
 
 
Figure 1.11: J-res pulse sequence. Figure adapted from (Claridge, 1999). 
 
1.4.2 Mass Spectrometry 
Mass spectrometry is based on the formation of ionic species through the action of 
an ionizing energy, these ions being further separated based on their mass to charge ratio 
(m/z) with intensity proportional to their relative abundance (Hoffmann and Stroobant, 
2007).  One of the great advantages of MS is its sensitivity and selectivity, as it is able to 
detect compounds in lower concentration than NMR (up to picomolar to femtomolar). MS 
also provides specific chemical information such as accurate mass, isotope distribution 
pattern and characteristic fragment-ions for structural identification and assignment (Lei et 
90º 90º
←   t1/2   → ←   t1/2   →
1H
a)
b)
18
Chapter 1  
62 
al., 2011). Some limitations of MS, however, are its destructive nature and limited use for 
metabolite quantification as it is prone to variable ionization of different metabolites and 
ion suppression artifacts (Lindon et al., 2006). Also, metabolite identification using MS 
can be difficult often requiring the use of tandem MS for ions fragments studies. On the 
other hand, MS experiments often require a pre-separation step, depending on the type of 
metabolites on interest, making the technique more advantageous for targeted studies (e.g. 
detailed study of lipids, etc.). For the analysis of complex mixtures, as is the case biofluids, 
MS is usually coupled with gas chromatography (GC) to separate volatile compounds, 
capillary electrophoresis (CE) to separate highly polar and ionic metabolites and liquid 
chromatography (LC) for the study of polar, less-polar and neutral metabolites (Villas-
Bôas et al., 2005, Lei et al., 2011). A recent improvement of the latter separation method is 
ultraperformance LC (UPLC) which uses higher pressures to achieve higher flow rates, 
allowing a greater efficiency in metabolites separation to be achieved (Lindon et al., 2004).  
 
Liquid Chromatography-MS (LC-MS) 
LC-MS experiments require a high pressure liquid chromatography (HPLC) 
equipment coupled to an electrospray ionization (ESI) method and MS spectrometer. ESI 
is produced by applying a potential difference (positive or negative), to a liquid passing 
through a capillary tube and charged molecules are then sprayed into the gas phase. 
Because some molecules ionize better in positive and negative modes, both ESI
+
 and ESI
-
 
are performed (Hoffmann and Stroobant, 2007). In time-of-flight (TOF) MS equipments, 
ions in the gas phase are further separated based on their velocity, i.e. after an initial 
acceleration by an electric field ions enter a field-free region and m/z are determined by 
measuring the time that ions take to move between the source and the detector (Hoffmann 
and Stroobant, 2007). In metabolomic studies, usually quadropole time-of-flight (Q-TOF) 
spectrometers are used due to their stability, sensitivity, rapid acquisition and high mass 
accuracy (Want et al., 2006, Theodoridis et al., 2012). In the quadrupole detector, ions 
travel along a path parallel to four voltage carrying rods and, by applying a given RF and 
voltage current, specific m/z can be selected (Hoffmann and Stroobant, 2007). This 
equipment is further used for fragmentation experiments, named MS/MS experiments, 
where ions are selected by a first MS run, further subjected to collision with an inert gas 
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(Ar or N2) causing fragmentation, and fragments analyzed by a second MS run, these 
experiments being essential for structure determination (Hoffmann and Stroobant, 2007). 
The separation of the components within a complex biological matrix, as the case 
of metabolomics, with the traditional HPLC methods is somehow hampered by its lower 
chromatographic efficiency, sensitivity, resolution and higher analysis time (Want et al., 
2010). Thus, a new ultraperformance liquid chromatography (UPLC) is being increasingly 
used as it utilizes higher pressures and smaller columns with smaller particle size packing 
material, allowing for improved separation and higher resolution. Moreover, the use of 
higher pressures results in faster runs, narrower chromatographic peaks, improved signal-
to-noise ratio (S/N) and increased sensitivity compared to HPLC, as shown in Figure 1.12 
(Want et al., 2006). 
 
 
Figure 1.12:  Total ion chromatogram  and extracted ion chromatogram (EIC) with HPLC and 
UPLC, showing improved separation of metabolites, improved data interpretability, S/N, accuracy 
and sensitivity in UPLC (adapted from (Want et al., 2006)). 
 
1.5 Statistical tools in metabolomics  
The types of datasets used in metabolomics are inherently large and complex, 
containing high amounts of potential biological information. The retrieving of relevant and 
valuable biological information, i.e. subset of variables, and removing data unrelated with 
the biological condition being studied can be quite a challenge (Saccenti et al., 2013). 
Typically, metabolomic studies use multivariate and univariate statistical methods, both 
approaches yielding complementary information. However, prior to the application of the 
actual statistical tools (multi- and univariate analysis) important preprocessing steps, like 
alignment, normalization, scaling, transformation, are required to maximize information 
Extracted Ion ChromatogramsTotal Ion Chomatograms
UPLC
HPLC
Improved 
separation
Improved 
signal/noise
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recovery and results reliability. Traditionally, both unsupervised and supervised methods 
are used sometimes with the tandem application of variable selection. The latter methods 
aim at aiding biological interpretation by removing irrelevant, unreliable or unstructured 
variations. Moreover, the importance of validating the results has been increasingly 
recognized and is presently an absolute necessity in metabolomics. Each of these steps will 
be described in detail throughout this section. 
 
1.5.1 Preprocessing: bucketing, alignment, normalization, scaling and 
transformation 
Bucketing and Alignment 
One of the major challenges when dealing with NMR data is the positional 
variations of peaks in the spectrum, due to changes in pH, temperature, salt concentration 
or instrumental factors. This becomes even a greater challenge in complex biofluids where 
different peaks are affected to different extents (Smolinska et al., 2012). For instance, in 
urine samples there are significant differences in pH and ionic species (Na
+
, K
+
, Ca
2+
 and 
Mg
2+
) which causes chemical shifts variations of metabolites with ionizable groups (-
COOH, NH3, NH2, NH). Citrate is an example of a urinary metabolite with high chemical 
shift variations due to pH. Citrate has three carboxyl groups (R-COOH) attached to two 
CH2 groups, the latter yielding two doublets at 2.54 and 2.69 ppm (chemical structure 
shown in Figure 1.13). Changes in pH induce differences in R-COO
-
 concentration which 
 
 
Figure 1.13: Chemical structure of citrate (left) and histidine (right). Circles indicate protons the 
chemical shift of which is most affected by pH. 
 
Citrate Histidine
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alters field-shielding effects on the molecule protons causing shift in the effective field 
experienced. Resonances of histidine are also highly pH dependent, particularly the two 
singlets arising from ring protons resonating at 7.13 and 7.98 ppm, due to ionization of the 
NH group (see chemical structure in Figure 1.13). Chemical shift variation, within the pH 
range of 7.1-7.7, for the proton resonances of histidine can be up to 0.02 and 0.008 ppm for 
citrate, while other urinary compounds, namely hippurate, creatinine, dimethylamine, 
trimethylamine, glycine and acetate, have an associated deviation inferior to 0.002 ppm 
(Xiao et al., 2009). 
To overcome this difficulty, spectral bucketing, or binning, is commonly 
performed, consisting of integrating the spectrum in fixed or variable widths, with width 
varying from 0.005 to 0.04 ppm. Spectral bucketing is helpful to eliminate differences in 
peak position and reducing matrix complexity although at the cost of spectral resolution 
(Lindon et al., 2007, Smolinska et al., 2012). Alternatively, spectral alignment can be used 
to solve the problem of peak shifts, while maintaining spectral resolution. Several 
alignment   algorithms are available such as interval correlated shifting (icoshift) (Savorani 
et al., 2010), recursive segment-wise peak alignment (RSPA) (Veselkov et al., 2009), fast 
iterative warping algorithm, i.e. fuzzy warping (Alm et al., 2009) and hierarchical cluster-
based peak alignment (CluPA) (Vu et al., 2011). An example of spectral alignment is 
shown in Figure 1.14, highlighting the high chemical shift deviation for citrate resonance 
(2.5-3.2 ppm), in 
1
H NMR spectra of urine, and how it can be corrected using the RSPA 
algorithm.  
After either bucketing or alignment, the spectral dataset are converted into a two 
dimension data table (or matrix), consisting of n rows corresponding to each observation or 
sample, and m columns corresponding to each variable, e.g. chemical shift. 
 
Normalization 
Normalization is a crucial step in preprocessing datasets for metabolomics as it 
aims to overcome differences in concentration, dilution or total amount of sample, making 
all samples within a dataset comparable. This step is particularly important in urine studies 
where fluctuations in sample concentration can reach several orders of magnitude 
(Smolinska et al., 2012). Normalization is applied to each row in the matrix (that is each  
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Figure 1.14: Example of peak position variations in the region of 2.5-3.2 ppm of a) original 
1
H 
NMR spectra of urine  and b) after RSPA alignment. The lower plots represent the intensity of peak 
positions in all samples (adapted from (Veselkov et al., 2009)). 
 
spectrum) typically by dividing each row by a constant, there being several ways to 
compute that constant or normalization factor. A common normalization practice is to  
divide each variable by the total integrated intensity across the whole profile, known as 
total sum, total area, total intensity or integral normalization (Veselkov et al., 2011, 
Smolinska et al., 2012). In urine studies, creatinine normalization is also used as it is based 
on the assumption that creatinine urinary excretion, i.e. creatinine clearance, is constant 
(Jankevics et al., 2008, Smolinska et al., 2012). Due to the uncontrolled composition of 
urine, normalization by total intensity and creatinine normalization poses significant 
pitfalls as both total sum or creatinine integral can vary irrespectively of sample dilution, 
for instance if samples contain extreme concentration of endogenous or drug metabolites 
(Dieterle et al., 2006) or due to creatinine variation caused by changes in diet (Solanky et 
al., 2005, Wang et al., 2005, Stella et al., 2006), lifestyle (Slupsky et al., 2007), and 
muscle mass (Craig et al., 2006). To overcome this, other recent normalization methods 
have been proposed and shown valuable in urine studies, namely probabilistic quotient 
normalization (PQN) (Dieterle et al., 2006), histogram normalization (HN) (Torgrip et al., 
2008), quantile normalization (Veselkov et al., 2011, Kohl et al., 2012), group aggregating 
Citrate
b)  RSPA aligned dataa)  Original data
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normalization (GAN) (Dong et al., 2011) and locally weighted scatter plot smoothing 
(LOESS) (Veselkov et al., 2011).  
In this work, PQN was the normalization method chosen as it is based on the 
calculation of the most probable dilution factor, relatively to controls, whilst reducing the 
contribution of abnormaly concentrated metabolites. Briefly, the method comprises the 
calculation of the quotient between each variable of each spectra and a reference, in this 
case the median value of the control group. Then, the most probable quotient, i.e. the 
median value of all quotients, is selected and used as normalization factor for each sample 
(Dieterle et al., 2006). 
 
Data scaling and transformation 
In projection/compression based methods (described in the next section) 
metabolites present in higher concentrations are given higher importance and can dominate 
the projections hindering potentially valuable variations in metabolites present in lower 
concentration (Smolinska et al., 2012, Xia et al., 2013). Thus, scaling is performed to each 
variable, by dividing the given variable by a scaling factor (Xia et al., 2013). There are 
several scaling such as Unit Variance scaling (UV, also named auto scaling or 
standardization), which consists in mean centering (subtracting mean value of the sample) 
and dividing each variable by its standard deviation, Pareto scaling, consisting in mean 
centering and dividing each variable by the square root of the standard variation of that 
variable, and variable stability scaling, or VAST, which is an auto scaling divided by the 
coefficient of variation of that variable (van den Berg et al., 2006, Smolinska et al., 2012, 
Xia et al., 2013). Apart from scaling, data transformation, such as log or power 
transformation, may also be applied to reduce data variability and to make skewed 
distributions (i.e. asymmetric distributions) more symmetric (van den Berg et al., 2006). 
 
1.5.2 Multivariate analysis methods 
In order to achieve efficient and robust modeling methods, to enable analysis of 
complex biological and biochemical data, and to produce interpretable and reliable models, 
both unsupervised methods and supervised methods are used (Lindon et al., 2007, Trygg et 
al., 2007). Unsupervised methods do not require a priori knowledge about sample classes, 
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for instance control vs. disease, maximizing the main sources of variations and allowing 
the identification of outliers, trends and inherent grouping. Principal Component Analysis 
(PCA) is undoubtedly the most used unsupervised method in metabolomic studies and will 
be explained in detail throughout this section. Nonetheless, other unsupervised methods 
such as hierarchical cluster analysis (HCA), non-linear mapping (NLM), self-organizing 
maps (SOM) and k-means clustering have been used (Lindon et al., 2007, Smolinska et al., 
2012).   
Supervised methods, i.e. methods that require a priori information about samples 
membership, maximize systematic differences between the classes and are absolutely 
essential in metabolomic studies as they enable sample classification and prediction. One 
of the most widely used supervised method is Partial Least Squares-Discriminant Analysis 
(PLS-DA), and its orthogonal variations (OPLS-DA) these being explained in detail 
throughout this section, although other methods, such as Soft Independent Modeling of 
Class Analogy (SIMCA) and Artificial Neural Networks (ANN) have also been used 
(Lindon et al., 2007, Smolinska et al., 2012).  
 
Principal Component Analysis (PCA) 
PCA is a projection-based method that reduces the multidimensional space into a 
low-dimensional space, where each projection contains the variation within the X matrix 
along each Principal Component (PC). The first PC (PC1) contain the largest variation, the 
second PC (PC2) explains the second largest variation and so on. All PCs are a linear 
combination of the original input variables, they are mutually orthogonal and derive from 
the decomposition of the original matrix X according to Eq. 1.8, where T is the matrix of 
projections of X, that is the scores, P is the loadings matrix and E is the residual matrix. 
X=TP
T
 + E     [Eq. 1.8] 
The visualization of sample similarities explained by the PC is carried out with 
basis on the scores and loadings plots. The scores plot represents the observations, the 
samples, with the position of each observation being given by the relative similarity 
between samples, hence similar observations are positioned closer in the scores space. In 
this way, a scatter plot of the first 2 PC’s provides a summary of all observations in the 
dataset, allowing the identification of grouping, trends or outliers. The loadings plot shows 
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the relation between variables, providing a mean to visualize the individual contribution of 
each variable, e.g. chemical shifts or m/z, in the model (Lindon et al., 2007, Trygg et al., 
2007, Smolinska et al., 2012). A general scheme of the construction of a PCA model from 
a multidimensional dataset is shown in Figure 1.15. Here, the multidimensional dataset (X 
matrix) is projected into a two-dimensional plane, with the two first components 
containing the main variation within the X matrix. Relevant information is then recovered 
by means of the scores plot, which shows those observations that are similar/different, and 
of the loadings plot, showing which variables contribute the most for the 
similarity/differences between the observations.  
 
 
Figure 1.15: Scheme of the construction of a projection-based PCA model (adapted from (Trygg et 
al., 2007)). 
 
Partial Least Squares Discriminant Analysis (PLS-DA) and Orthogonal PLS-DA 
(OPLS-DA) 
The PLS method measures the quantitative relationship between two matrices, 
namely between the X matrix, which contains analytical data, and the Y matrix containing 
quantitative values, e.g. measurements of an endogenous metabolite. The method can also 
be used to discriminate between sample classes, named PLS-DA, and in that case the Y 
matrix contains information about sample membership, i.e. controls vs. disease (Lindon et 
al., 2007). PLS-DA, similarly to PCA, is a projection-based method that assumes that data 
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can be approximated in a low-dimensional space by decomposing variation into latent 
variables (LV), which are linear combinations of the original variables. The first LV in a 
PLS-DA model contains the highest source of variation between classes, which is not 
necessarily the highest source of variation within the dataset. (Lindon et al., 2007, Trygg et 
al., 2007, Smolinska et al., 2012). The model can be expressed in terms of X and Y as 
given by Eq. 1.8 and Eq. 1.9, where T represent the scores common to the X and Y matrix 
respectively, P and C represent the loadings of X and Y matrix respectively and E and F 
the respective residual information in X and Y (Smolinska et al., 2012). 
Y=TC
T
 + F [Eq. 1.9] 
Furthermore, the T scores matrix is a linear combination of the X matrix and the 
coefficients weights W, and can be given by Eq. 1.10.  
T=XW(P
T
W)
-1
 [Eq. 1.10] 
Thus, if combining Eq. 1.9 and Eq. 1.10 the Y matrix can be expressed in terms of 
X (Eq. 1.11) named regression equation, where b represents the regression coefficients of 
each variable (Wold et al., 2001). 
Y=XB+F [Eq. 1.11] 
Orthogonal-PLS-DA or OPLS-DA is a modification of the PLS-DA method which 
has also been used in metabolomics. In this case, the systematic variation between the X 
matrix is split into two parts, one is linearly related to Y, and thus to sample classes, and 
one that is unrelated to Y (named orthogonal) which is removed. OPLS-DA is a useful tool 
for model interpretation (Smolinska et al., 2012) although for prediction purposes PLS-DA 
should be used (Tapp and Kemsley, 2009). 
 
Data correlation tools: Statistical Total Correlation Spectroscopy (STOCSY) and 
Statistical HeterospectroscopY (SHY) 
Statistical Total Correlation Spectroscopy, or STOCSY, is a useful tool for peak 
assignment and measurement of metabolite correlations. STOCSY is based on the 
multicolinearity of peaks intensities in a set of spectra, to generate a pseudo-two-
dimensional map that shows the correlation among spectrum intensities, allowing the 
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identification of positive correlations between peaks that arise from the same molecule. 
STOCSY may also provide a mean to identify molecules that interact in the same 
metabolic pathways, because of their biological covariance, by showing a positive or 
negative inter-molecular correlation. The method is computed based on the properties of 
the correlation matrix C, given by Eq. 1.12, where X1 and X2 denote the autoscaled data 
matrices (Cloarec et al., 2005). 
C=
1
1
n
X1
T 
X2 [Eq 1.12] 
STOCSY of NMR data was firstly introduced to measure correlations between 1D 
1
H NMR spectra, the methodology proving its value for metabolite structure assignment 
and interpretation of metabolic variations (Cloarec et al., 2005). An example of the 
application of STOCSY for metabolite assignment is shown in Figure 1.16a) where an 
NMR spectrum of urine is colored accordingly to the correlation coefficient of the 
resonance at 2.512 ppm with the whole spectral region. This means that highly correlated 
resonances, approximately at 2.90, 7.20 and 7.40 ppm (colored in red), arise from the same 
metabolite. 
The concept of STOCSY has further evolved and extended to the study of 
correlation between different nuclei, namely 
1
H and 
13
P named heteronuclear or HET-
STOCSY (Coen et al., 2007, Wang et al., 2008) and correlation between NMR 
experiments, e.g. diffusion-edited vs. CPMG (Wang et al., 2008). An example of HET-
STOCSY is shown in Figure 1.16b, where a 2D map of the correlation between 
31
P and 
1
H 
of CPMG magic angle spinning NMR spectra of intact intestinal tissue is depicted. In this 
plot, 
1
H and 
31
P resonances with high correlation belong from the same molecules. 
Statistical correlation may also be applied for the measurement of metabolic 
relationships between data obtained by different analytical platforms. The method is named 
Statistical Heterospectroscopy or SHY and it has enabled the correlation of NMR vs. MS 
(Crockford et al., 2006, Graça et al., 2012) and NMR vs. mid-infrared spectroscopy (MIR) 
data of the same biofluid (Graça et al., 2013), to correlate NMR data of  different biofluids 
(plasma vs. cerebrospinal fluid-CSF) and biofluids NMR spectra with magnetic resonance 
spectroscopy (MRS) measurements in vivo of brain tissue (Maher et al., 2011). An 
example of inter-techniques correlation is shown in Figure 1.16c) where the correlation 
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between urine 
1
H NMR spectra and the corresponding MS data, that is the same samples 
analyzed by different techniques, is shown. In this case, high correlation between a given 
m/z and NMR peaks suggest that they belong to the same compound. Another example of 
SHY is shown in Figure 1.16d), this figure showing the correlation between two biofluids 
(plasma and CSF). This plot enabled the identification of resonances from the same peaks 
detected in different matrices, as exemplified for propylene glycol, valine and lipoproteins. 
 
 
Figure 1.16: a) 1D STOCSY of the variable at δ2.512 ppm correlated with the whole spectrum of 
urine colored by the correlation coefficient; b) 2D heteronuclear STOCSY (HET-STOCSY) of 
1
H 
vs. 
13
P CPMG magic angle spinning NMR of intact intestinal tissue; c) SHY map of 
1
H NMR vs. 
MS data (m/z 100-350) of urine; d) SHY map of CPMG 
1
H NMR spectra of plasma vs. 
cerebrospinal fluid (CSF). PG: propylene glycol, val: valine. Adapted from (Cloarec et al., 2005, 
Crockford et al., 2006, Wang et al., 2008, Maher et al., 2011). 
 
1.5.3 Univariate statistical methods 
Univariate statistical methods are mostly insufficient for metabolomic studies as 
these only provide comparison for individual variables without taking into account the 
a)
c)
δ 1H (ppm)
δ 1H (ppm)δ 1H (ppm)
δ 1H (ppm)
plasma
m
/z
δ
1
H
 (
p
p
m
) 
C
S
F
δ
3
1
P
 (
p
p
m
)
In
te
n
si
ty
 (
a.
u)
b)
d)
Introduction 
73 
relationship between them. Still, they are commonly applied and often used to support 
multivariate (MVA) results. It is important to apply both uni- and multivariate statistical 
methods, as they may provide complementary information, but not to confirm each other. 
This is because MVA provides information about metabolic relationships which are 
mirrored through metabolites correlation and covariation. On the other hand, univariate 
analysis only compares individual variations without taking into account the rest of the 
profile. Thus, when variable intensities are compared individually the relationship between 
metabolites is not considered and the result can differ from that obtained through MVA. 
This means that a given metabolite can be found relevant through MVA and not be 
individually statistically significant when the rest of the profile is not considered. The 
opposite holds also true, that is individual metabolites can be found to be significantly 
different between groups while no relevant changes are unveiled through MVA. A possible 
explanation resides on the complexity of the dataset which can contain too many 
uninformative variables that mask relevant information (Saccenti et al., 2013).  
Univariate methods are based on hypothesis testing, meaning that they comprise a) 
the definition of the null hypothesis i.e. no difference between the populations’ means or 
medians and b) the probability threshold of the null hypothesis (p-value) rejection (Vinaixa 
et al., 2012). These methods can be parametric or non-parametric if the data follows a 
normal distribution or not, respectively. Thus, the choice of the method is strongly 
dependent on the type of groups and distribution of the data. A compilation of the most 
appropriate test for different data distributions and group definition is shown in Table 1.9. 
Normally distributed data is usually compared through Student t-test (or just t-test) to 
compared two groups, or ANOVA (acronym for analysis of variance), to compare more 
 
Table 1.9: Summary of univariate statistical tests for datasets following normal and non-normal 
distributions. 
a 
Paired groups mean that samples were collected from the same subjects for different 
conditions. Adapated from (Petrie and Sabin, 2009, Vinaixa et al., 2012). 
 Normally distributed data 
(parametric test) 
Non-normally distributed data 
(non-parametric test) 
2 paired
 a
 groups Paired t-test Wilcoxon signed rank test 
2 independent groups Unpaired t-test Wilcoxon rank sum test 
Mann-Whitney 
> 2 paired
 a
 groups Repeated-measures ANOVA  Friedman 
> 2 independent groups One-way ANOVA Kruskal-Wallis 
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than two groups. Conversely, non-parametric tests are used to compare data that do not 
follow a normal distribution. The comparison of non-normally distributed data is usually 
done by applying Wilcoxon signed rank test, Wilcoxon rank sum test, Mann-Whitney test, 
Kruskal-Wallis, Friedman test can be used (Petrie and Sabin, 2009, Vinaixa et al., 2012). 
All aforementioned tests provide a p-value, which reflects the probability of 
wrongly rejecting the null hypothesis. Usually p-value<0.05, or significance level of 95%, 
is used, meaning there is sufficient evidence to reject the null hypothesis in 95% of cases 
(whilst the opposite, p>0.05 means that there is no sufficient evidence to reject the 
hypothesis) (Petrie and Sabin, 2009). 
 
1.5.4 Variable selection methods 
One of the exquisite advantages of NMR- and MS- based metabolomics is the 
simultaneous detection of hundreds of metabolites in one single run. However, when 
dealing with complex samples, such as biofluids, the NMR and MS matrices obtained are 
particularly challenging to work with due to the vast amount of information they contain. 
In such cases, careful simplification of the original dataset by removing irrelevant, 
unreliable or noisy variables through variable selection methods may lead to improved 
model performance, reduced model complexity and biochemical interpretation (Andersen 
and Bro, 2010).  
There are several methods to perform variable selection, the simplest way, but still 
uncommonly used, being the selection of variables based on an univariate test (Smolinska 
et al., 2012). The limited applicability of these methods is due to univariate nature of the 
tests which imply the lost of relationships between variables, thus possibly compromising 
the multivariate profile insight. In most studies, the selection is based on multivariate 
model parameters, namely loadings, b-coefficient and VIP values, but also interval PLS 
(iPLS) (Andersen and Bro, 2010, Smolinska et al., 2012). Selection based on loadings, b-
coefficient and VIP values usually encompasses the definition of a threshold value that 
defines if a given variable is selected or removed. iPLS involves the division of the spectra 
in intervals of equal length and the computation of PLS models for each of those intervals 
in order to select the region or set of regions that give the best result. Out of the 
abovementioned PLS-DA model parameters, selection based on a VIP criteria is the mostly 
used. The mathematical definition of the VIP value (given by Eq.1.13) provides a 
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combination of how well a given variable describes the X (i.e. metabolites) and Y matrix 
(sample class). In that equation 2jfw  is the weight value of variable j in component f, SSYf  is 
the sum of squares of explained variance in component f, J is the total number of variables, 
SSYtotal is the total sum of squares explained by the dependent variable Y and F is the total 
number of components. A VIP value smaller than 1 means that the variable is not 
important for the projection so that it can be removed and vice-versa (Andersen and Bro, 
2010, Quintás et al., 2012, Sun et al., 2012). 
FSSY
JSSYw
VIP
total
F
f
fjf
j




1
2
  [Eq. 1.13] 
In metabolomic studies, variable selection methods have been applied to reduce 
datasets obtained for different biological matrices (e.g. urine, blood plasma and serum, 
liver tissue) in disease research (Cavill et al., 2009, Lin et al., 2011, Quintás et al., 2012, 
Sun et al., 2012, Kaur et al., 2013) but also for food quality control (Di Anibal et al., 
2011). A variant of this strategy is based on the fact that different selection methods yield 
different sets of selected variables and, if the commonly selected variables are considered 
i.e. the intersection of variables selected by different methods, the consistently relevant 
information may be retrieved and analyzed as a potential profile of the condition under 
study. This principle has been applied to the study of non-alcoholic fatty liver disease, 
where variables selected using both regression coefficients and VIP were considered as 
potential biomarkers of the disease (Quintás et al., 2012). A slightly different concept is 
the use of combination of selected features instead of intersection. This approach has been 
applied to the study of liver diseases, where variables were selected using Support Vector 
Machines-recursive feature elimination (SVM-RFE), genetic algorithm and random forest 
(RF) (Lin et al., 2011) and to study type 2 diabetes mellitus (T2DM) by selecting variables 
based on their loading correlation (p[corr]) and RF (Kaur et al., 2013). 
 
1.5.5 Validation methods 
In spite of apparent geometrical sample groups separation obtained through PLS-
DA and OPLS-DA models’ scores plots, these can be meaningless to evaluate differences 
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between groups (Westerhuis et al., 2008). Thus, determining model robustness and 
predictive ability, through validation, is an indispensable step in metabolomic studies. A 
typical study involves two classes, for instance control and disease and, ideally, samples 
should be split into a training set, used to develop and test the model, and an independent 
set, used to verify if the model accurately classifies a new sample in the correct group, e.g. 
control or disease. This type of validation, named external validation, is the ultimate and 
best manner to validate a multivariate model (Westerhuis et al., 2008, Smolinska et al., 
2012).  
When dealing with human health, sample numbers are commonly low and the 
whole sample groups needs to be used as the training set. To overcome this limitation there 
are other ways to validate models without the use of an independent group. For instance, 
internal Cross Validation (CV) indicates how well a model works in predicting new 
samples thus the model’s prediction power. CV is a reliable way to test model predictive 
ability and consists in splitting the data into a number of groups (G), i.e. five to nine, and 
developing parallel training models with all except one group (G-1) leaving that group to 
be used as the prediction test (Wold et al., 2001, Westerhuis et al., 2008). Another way to 
validate the model is to perform permutation tests, which indicates if a given model is 
significantly different from a null hypothesis model, obtained by random guessing, for a 
given population, thus the robustness of the model (Xia et al., 2013). Permutation tests 
imply that samples class labels, i.e. control and disease, are randomly permuted and 
models are recomputed. If the original model is robust, the newly calculated model, after 
samples class permutation, should not be able to correctly predict classes (Westerhuis et 
al., 2008). 
There are other quality assessment parameters to evaluate models performance and 
predictive ability.  The default parameter to evaluate PLS-DA discrimination ability is the 
predictive power Q
2
, which is computed according to Eq. 1.14, where 
iy

 refers to the 
predicted class membership for sample I and 
i
y to the mean y value for all samples. Ideally, 
the value of Q
2 
should equal 1, meaning that predicted classes always matched original 
classes. However due to the inherent variation within- and between classes it is difficult to 
achieve the ideal Q
2
 value. Hence, a good manner to evaluate the predictive power of the 
model is by evaluating the Q
2
 distribution of permuted models and comparing the result 
with the original Q
2
. Minimal overlapping of Q
2
 values of true and permuted models 
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indicates a model with predictive power (Westerhuis et al., 2008) as exemplified in Figure 
1.17a. 
 [Eq 1.14] 
Other helpful parameters to evaluate model robustness comprise the classification 
rate, sensitivity and specificity, given in percentage values, and computed by means of 
confusion matrices. A confusion matrix consists in the number of false positives (FP), false 
negative (FN), true positives (TP) and true negatives (TN) as shown in Figure 1.17b. The 
classification rate refers to the percentage of samples correctly classified in the model, as 
given by Eq. 1.15. The sensitivity, or true positive rate (TPR), refers to the number of the 
true positives as a percentage of all positives, calculated by Eq. 1.16. 1-specificity or false 
positive rate (FPR), refers to the number of false positives as a percentage of all negatives, 
calculated according to Eq 1.17.  
FNFPTNTP
TNTP
CR


  [Eq. 1.15] 
Sensitivity [Eq. 1.16] 
1-specificity  [Eq. 1.17] 
The plotting of sensitivity (TPR) vs. 1-specificity (FPR) leads to the receiver 
operating characteristic (ROC) plot. The traditional ROC plot (shown in Figure 1.17c) 
provides a mean of a) determining if a given test provides useful information on class 
membership (given by sensitivity and specificity) and b) selecting the optimal cut-off value 
for a that given test. To obtain a ROC curve, each pair of sensitivity and 1-specificity are 
obtained for all cut-off values of the given test and connected forming a curve (an example 
being shown in Figure 1.17c). The obtained curve may be used to determine the accuracy 
of that test by considering the area under the curve (AUC). The greater the AUC expresses 
the higher test accuracy for discriminating between classes. This means that an AUC of 1 
(ideal value), reflects perfect discrimination between classes whilst an AUC 0.5 reflects a 
non-discriminating test (Fawcett, 2006, Petrie and Sabin, 2009).  In this work, however, a 
slightly different ROC was used (shown in Figure 1.17c), as they were computed 
considering the sensitivity and specificity of each PLS-DA model, i.e. considering the 
whole profile and calculated through Monte Carlo Cross Validation (MCCV). MCCV 
FNTN
FP
FPR

)(
FPTP
TP
TPR

)(






i
ii
i
ii
yy
yy
Q
2
2
2
)(
)(
1
Chapter 1  
78 
consists in splitting the data into a training and a prediction set, the latter set being used for 
class membership prediction. One advantage of using the MCCV method is that it usually 
performs 500 to 1000 iterations and calculates for each iteration the Q
2
 value and 
confusion matrix (sensitivity and especifity). The MCCV can be further repeated for 
permuted classes, i.e. the Y matrix is randomly permuted, and if the model is robust a 
complete separation of true and permuted classes is seen in the ROC plot (Xu and Liang, 
2001, Xia et al., 2013).   
An example of a ROC plot of an ideal model, obtained by MCCV, is shown in 
Figure 1.17d where it is visible that models obtained with true classes have sensitivity and 
specificity equal to 1 (100%) and are clearly separated from the permuted classes, which 
have both sensitivity and specificity 50% (Westerhuis et al., 2008).  
 
 
Figure 1.17: Examples of a) Q
2
 distribution of true and permuted models, b) confusion matrix 
obtained for two classes. TP: true positive, FN, false negative, FP: false positive, TN: true negative 
and c) traditional and d) MCCV-obtained representations of ROC space plot, TPR: true positive 
rate, FPR: false positive rate. 
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1.6 State of the art of metabolomics in prenatal research 
The merit of metabolomics applied to prenatal health research has been recognized, 
as reflected through the number of publications in this field. Figure 1.18 illustrates the 
number of papers published in relation to metabolomics (based on NMR, MS, HPLC and 
MIR) of pregnancy disorders, these comprising maternal, fetal and newborns conditions, 
plotted as a function of a) publication year, b) biological matrix and c) disorder studied. An 
increasing number of publications is clearly visible from 2011 until the present year, whilst 
until 2010 (coinciding with the beginning of this thesis) a scarce number of papers had 
been reported in literature (Figure 1.18a), supporting the pertinence of this work. 
Regarding the biological matrices used in these studies, maternal blood (plasma and 
serum) has been the most explored biofluid, followed by amniotic fluid, newborn umbilical 
cord blood, maternal urine (four of which resulted from the work presented in this thesis), 
placenta and newborn dried blood spots (Figure 1.18b) in decreasing order. The mostly 
studied disease was found to be PE, followed by FM, PTD, GDM and maternal 
hyperglycemia, CD and perturbations of intrauterine growth (including SGA, IUGR, Low 
birthwieght-LBW and very low birthweight-VLBW) as shown in Figure 1.18c. A brief 
review of the main results reported for each disorder, is presented below whilst a 
comprehensive list of papers (including number of samples, gestational age at sampling, 
analytical technique used, statistical approach and main biochemical findings) is presented 
in Annex I, Table A-I.1 (page 293), grouped by disorder and in decreasing order of number 
of reports per disorder.  
 
Preeclampsia 
Previous studies have reported the effect of PE, mostly at post-diagnosis state, on the 
metabolic profile of AF (Bock, 1994), placenta extracts (Jain et al., 2004, Dunn et al., 
2009, Dunn et al., 2012) and maternal blood serum and plasma (Kenny et al., 2005, Turner 
et al., 2007, Kenny et al., 2008, Turner et al., 2008, Turner et al., 2009). Main findings 
include hypoxia-related changes, oxidative stress and lipids perturbations (Jain et al., 2004, 
Turner et al., 2007, Kenny et al., 2008, Turner et al., 2008, Dunn et al., 2009, Dunn et al., 
2012). Apart from the characterization of the biochemical phenomena accompanying PE, 
an increasing effort towards unveiling early and potential metabolic markers of PE has 
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Figure 1.18: Number of NMR, MS, MIR and HPLC metabolomic studies in relation to pregnancy 
disorders, including maternal, fetal and newborn disorders, shown by a) year published, b) 
biological matrix used and c) disease studied. BALF: bronchoalveolar lavage fluid, CVF: cervico-
vaginal fluid, PE: preeclampsia, FM: fetal malformations, PTD: preterm delivery, PROM: 
premature rupture of the membranes, CD: chromosomal disorders, GDM: gestational diabetes 
mellitus, SGA: small for gestational age, IUGR: intrauterine growth restriction, LBW: low birth 
weight, VLBW: very low birth weight, RDS: respiratory distress syndrome, MAS: meconium 
aspiration syndrome, IEM: inborn error of metabolism.  
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been found in several recent publications, using maternal blood serum and/or plasma 
(Kenny et al., 2010, Odibo et al., 2011, Bahado-Singh et al., 2012, Bahado-Singh et al., 
2012) and maternal urine, in a publication resultant of this work (Diaz et al., 2013), 
collected several weeks prior to diagnosis. It has been suggested that a 14-metabolite 
signature in 2
nd
 trimester maternal plasma discriminates women further developing PE 
with an AUC of 0.92. This signature comprises amino acids, carbohydrates, 
carnitines,dicarboxylic acids, fatty acids, ketones, keto- and hydroxyl- fatty acids, lipids, 
phospholipids and steroids (Kenny et al., 2010). A subsequent report found that 
hydroxyhexanoylcarnitine, alanine, phenylalanine and glutamate were significantly higher 
in 1
st
 trimester maternal plasma of women later developing PE (Odibo et al., 2011). 
Furthermore, the combination of the latter 4 metabolites yielded an AUC of 0.82 for 
prediction of PE and 0.85 for early-onset PE (Odibo et al., 2011). More recently, a couple 
of studies reported significant changes in 1
st
 trimester maternal blood serum in relation to 
early- and late- onset PE (Bahado-Singh et al., 2012, Bahado-Singh et al., 2012). The 
authors reported that early-onset could be predicted based on citrate, glycerol, 
hydroxyisovalerate and methionine (Bahado-Singh et al., 2012) whilst late-onset PE was 
related with changes in valine, pyruvate, 3-hydroxybutyrate, 1-methyl-histidine, glycerol 
and trimethylamine (Bahado-Singh et al., 2012). Moreover, it was found that early- and 
late-onset PE were distinguishable based on glycerol, acetate, trimethylamine and 
succinate at the 1
st
 trimester (Bahado-Singh et al., 2012). 
 
Fetal malformations 
A significant impact on amniotic fluid (AF) composition has been reported in FM 
cases, considering heterogeneous groups (Graça et al., 2009, Graça et al., 2010, Graça et 
al., 2012, Graça et al., 2012, Graça et al., 2013) and specifically for spina bifida (Bock, 
1994, Groenen et al., 2004). AF studies of FM has unveiled derangements in the energy 
metabolism under hypoxia, with higher gluconeogenesis and ketogenesis, deficient use of 
the respiratory chain, changes in polyol and lipids metabolism, the latter with a further 
involvement in membrane phospholipids acting as lung surfactants. Furthermore, a 
significant perturbation in amino acids metabolism have also been found, specifically the 
methionine metabolism in connection with the folic acid pool, and glutamine/glutamate 
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ratio with connection to fetal kidney underdevelopment (Groenen et al., 2004, Graça et al., 
2009, Graça et al., 2010, Graça et al., 2012, Graça et al., 2012, Graça et al., 2013). 
A more systemic metabolic effect of FM has also been evaluated through the 
analysis of maternal blood serum and plasma of women carrying fetuses with 
malformations (Diaz and Pinto et al., 2011) and specifically for cases of neural tube 
defects (NTD) (Zheng et al., 2011, Liang et al., 2012). Changes in energy production and 
lipids conversion along with a derangement in methionine metabolism (in connection with 
the folic acid pool as suggested in the previous AF studies mentioned above), impaired 
mitochondrial respiration and changes in the neurotransmitter γ-aminobutyrate (or GABA), 
neurogenesis and oxidative stress has also been found (Diaz and Pinto et al., 2011, Zheng 
et al., 2011, Liang et al., 2012). Regarding the use of maternal urine for the study of FM, 
three studies of samples collected at 2
nd
 trimester (Diaz and Pinto et al., 2011, Graça et al., 
2012, Diaz et al., 2013) have been reported, two resulting from the work here presented. 
Changes were consistent with previously advanced hypothesis of enhanced 
gluconeogenesis under hypoxia and TCA cycle demand along derangements in methionine 
metabolism, whilst a further perturbation in nucleotide metabolism was newly put forward 
(Diaz and Pinto et al., 2011, Graça et al., 2012, Diaz et al., 2013).  
 
Preterm delivery (PTD) 
The possibility of predicting the onset of PTD has also been subject to several 
researches. In this context, the quest for potentially predictive markers of the condition has 
been pursued through the analysis of AF collected at the 2
nd
 trimester (Graça et al., 2010, 
Romero et al., 2010, Graça et al., 2012, Graça et al., 2013), as well as in a preliminary 
study of cervico-vaginal secretions (CVS) (Auray-Blais et al., 2011) and maternal urine 
(Diaz and Pinto et al., 2011, Diaz et al., 2013), the latter resulting from the work presented 
in this thesis. AF studies has unveiled changes in amino acids, glucose, ketone bodies, 
allantoin, choline, proteins and glycoproteins, suggestive of perturbations in amino acid 
fluxes in the feto-placental unit, increased oxidative stress, hyperglycemia, methionine 
metabolism and changes in glycoprotein content (Graça et al., 2010, Romero et al., 2010, 
Graça et al., 2012, Graça et al., 2013). Studies on umbilical cord and maternal blood 
composition in cases of PTD of VLBW newborns revealed low levels of acetate, and 
increased lipids, pyruvate, glutamine, valine and threonine in maternal plasma, whilst 
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decreased lipoproteins, pyruvate and albumin-lysyl and increased glutamine were found in 
umbilical cord blood reflecting an altered maternal/fetal/placental symbiosis (Tea et al., 
2012). Still, the previous findings reflect the concomitant effect of gestational age and birth 
weight as cases were preterm VLBW. Regarding the newborn, being born preterm has 
been explored through the analysis of neonatal urine collected in the first days of life 
(Foxall et al., 1995, Trump et al., 2006, Atzori et al., 2011). Several changes have been 
found, suggestive of altered renal function, changes in tryptophan-NAD
+ 
pathway and 
tyrosine, arginine and proline metabolism, urea cycle and tyrosine, tryptophan and 
phenylalanine biosynthesis (Foxall et al., 1995, Trump et al., 2006, Atzori et al., 2011). In 
spite of these advanced hypotheses, the knowledge on the biochemical impact of being 
born preterm is still very limited. 
 
Gestational diabetes mellitus (GDM) and hyperglycemia 
The metabolic effect of GDM (at diagnosis) and hyperglycemia (without the 
occurrence of GDM) have been studied through maternal urine analyzed by NMR (Sachse 
et al., 2012) and maternal blood serum analyzed by MS (Scholtens et al., 2013), 
respectively. Increased urinary citrate excretion, was found in urine of a large cohort of 
GDM-affected women at diagnosis and pre-diagnosis (Sachse et al., 2012). The authors 
suggested that citrate increased was related with maternal hyperglycemia but concluded 
that the multivariate model could not reliably identify GDM cases (Sachse et al., 2012). 
Recently, maternal hyperglycemia (without GDM) was associated with higher maternal 
plasma triglycerides, ketone bodies and amino acids, and low 1,5-anhydroglucitol, a 
naturally occurring dietary polyol (Dungan et al., 2006), and a known marker of short-term 
glycemic control and predictor of fetal macrosomia in the 3
rd
 trimester (Scholtens et al., 
2013).The quest for potentially predictive metabolite signature of GDM in 2
nd
 trimester AF 
(Graça et al., 2010, Graça et al., 2012, Graça, 2013) and maternal urine (Diaz and Pinto et 
al., 2011, Graça et al., 2012, Diaz et al., 2013) (two of these publications resulting from 
this work) has also been reported. The overall findings suggest early signs of maternal 
hyperglycemia, changes in amino acids metabolism, altered biotin status, nucleotide 
metabolism and gut microflora preceding the clinical manifestation of the disease (Diaz 
and Pinto et al., 2011, Graça et al., 2012, Diaz et al., 2013). Regarding AF a subtler 
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metabolic effect was registered, the main difference being glucose increase, possibly 
caused by maternal hyperglycemia (Graça et al., 2010, Graça et al., 2012, Graça, 2013).  
The impact of GDM in the newborns has also been studied through umbilical cord 
serum of newborns born to GDM mothers (Dani et al., 2013). The authors found evidence 
of fetal hyperinsulinemia and increased oxidative stress  (a known consequence of GDM), 
enhanced fetal glycolysis and perturbation in amino acids metabolism (consistently with 
findings in maternal biofluids) (Dani et al., 2013). 
 
Chromosomal disorders (CD) 
A few studies have addressed the general effect of CD, by considering 
heterogeneous groups but also specific changes of trisomy 21 (T21), or Down’s Syndrome 
(DS), and for trisomy 18 (T18). Reports on AF of an heterogeneous group of CD have 
unveiled significant changes in sugar metabolism (through the involvement of glucose and 
myo-inositol) and lipids and membranes synthesis (suggested by changes in myo-inositol). 
Maternal urine (Diaz and Pinto et al., 2011, Diaz et al., 2013) (publications comprising the 
results presented in this thesis) and blood serum have also been explored as a possible tool 
for the identification of T21 and T18 as well as to differentiate between these two CD 
types (Bahado-Singh et al., 2013, Bahado-Singh et al., 2013). T21 has been related to 
significant differences in 3-hydroxyisovalerate (3-HIVA), 3-hydroxybutyrate (3-HBA), 
suggestive of perturbations in brain growth and myelination and oxidative stress. The 
authors reported that the model considering these metabolites yielded a AUC of 0.757 
whilst a combination of the same metabolites and maternal age had an AUC of 0.862 
(Bahado-Singh et al., 2013). Shortly after the same research group published a subsequent 
report for the detection of T18 (n=18 cases), stating significant changes in 2-
hydroxybutyrate and glycerol, and that the combination of these metabolites and maternal 
age had and AUC of 0.92. Furthermore, it was found that T21 and T18 samples were 
distinguishable based on trimethylamine (TMA) contents (Bahado-Singh et al., 2013). 
 
Disorders of fetal growth (IUGR, SGA, LBW and VLBW) 
The metabolic effect of fetal growth perturbations has also been addressed through 
metabolomic studies of maternal, fetal and newborn biofluids (Horgan et al., 2010, Horgan 
et al., 2011, Favretto et al., 2012, Ivorra et al., 2012, Alexandre-Gouabau et al., 2013, Diaz 
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et al., 2013), one of which resulted from the work here presented.  Altered amino acid 
transfer into fetal circulation and fetoplacental perfusion along changes in placental lipids 
metabolism has been reported in SGA cases (Horgan et al., 2010, Horgan et al., 2011). 
This altered placental function affects the metabolic symbiosis of mother and fetus which 
has been found in recent reports through the comparison of cord plasma of LBW  (Ivorra et 
al., 2012), VLBW cases (Alexandre-Gouabau et al., 2013) and umbilical vein serum in 
cases of IUGR (Favretto et al., 2012). Impaired fetal growth appears to be related with 
alterations in lipids, fatty acid oxidation, proteins metabolism, DNA methylation, 
polyamine flux and puridine metabolism in the fetus. Moreover, newbors’ urine of IUGR 
babies confirmed perturbations in lipids and proteins metabolism along with evidence of 
altered insulin secretion (Dessì et al., 2011).  
 
Asphyxia, respiratory distress syndrome (RDS) and meconium aspiration 
syndrome (MAS) 
The effect of neonatal respiratory complications, in newborn urine composition has 
been explored, with changes in urinary lactate, energy metabolism and organic acids 
apparently characterizing these conditions (Ma et al., 1995, Chu et al., 2006). In addition, 
umbilical cord blood of hypoxic ischemic encephalopathy (HIE, a complication of neonatal 
asphyxia) and asphyxia without HIE cases have been recently reported. The disorder was 
related with a derangement in energy metabolism arising from neonatal asphyxiation and 
neurological insult, up-regulation of triglyceride, phospholipids catabolism and ketone 
bodies production (Walsh et al., 2012, Reinke et al., 2013). Moreover, the authors reported 
that HIE could be detected based on 5 MS detected metabolites (decenoyl-L-carnitine, 3,5-
tetradecadiencarnitine, phosphocholine C38:0, phenylalanine and proline) with AUC of 
0.92  (Walsh et al., 2012). By using an NMR model, 4 metabolites (3-hydroxybutyrate 
glycerol, O-phosphocholine and succinate) were found to discriminate HIE with an AUC 
of 0.80 and different grades of HIE severity with AUC of 0.88 to 0.95 (Reinke et al., 
2013). 
 
Premature rupture of the membranes (PROM) 
The unveiling of potentially predictive markers of PROM has also been attempted 
by analyzing AF (Graça et al., 2010, Graça et al., 2013), maternal blood plasma and urine 
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(Diaz and Pinto et al., 2011, Diaz et al., 2013) (the latter publications comprising results 
presented in this thesis) collected at the 2
nd
 trimester (i.e. in the pre-diagnosis state). Only 
faint changes were identified in AF, these comprising proteins, amino acids, sugars and 
lactate, and in maternal blood, namely acetate, glutamine, citrate and albumin, whilst no 
change was found in maternal urine (Graça et al., 2010, Diaz and Pinto et al., 2011, Diaz et 
al., 2013, Graça et al., 2013). The low impact of PROM in all maternal biofluids studied 
can be a) a direct reflection of the low gravity of PROM (after the 37
th
 g.w.), as it is 
usually resolved by inducing labor without posing any risk for the mother and fetus, and/or 
b) the high interval from sample collection to diagnosis.  
 
Other relevant studies (poor pregnancy outcome and effect of delivery mode), 
Inborn Errors of Metabolism (IEM) and infections 
 Recently, the possibility to predict poor pregnancy outcomes was attempted by 
comparing maternal blood serum samples collected during the 3
rd
 trimester (Heazell et al., 
2012). However, in this study the poor pregnancy outcome group consisted in cases of 
SGA, pre-PTD and/or neonatal admission samples concomitantly, thus providing a general 
effect rather than disease-specific. 
The metabolic effect of delivery mode, i.e. cesarean section (CS) vs. vaginal 
delivery (VD) has also been studied through the comparison of umbilical cord blood and 
placental extracts (Dunn et al., 2012, Hashimoto et al., 2013). The authors reported 
changes consistent with labor-imposed oxidative stress, which is up-regulated by hormonal 
action and enhanced in VD (Dunn et al., 2012, Hashimoto et al., 2013) .   
In relation to inborn errors of metabolism (IEM), newborn’ dried blood spots, blood 
and urine have been studied. The first study searched for markers of phenylketonuria 
(PKU, a condition known to cause increased levels of phenylalanine in urine and blood) in 
newborns blood spots and urine. PKU was related to higher levels of phenylalanine in both 
biofluids (as expected), but no further interpretation on the disease was advanced 
(Constantinou et al., 2004, Constantinou et al., 2005). A recent study compared the levels 
of 400 compounds in newborns’ dried blood spots of 21 cases of PKU, 21 cases of medium 
chain acyl-coenzyme A dehydrogenase deficiency (MCADD), and 24 other IEM. The 
study was carried out using a novel nanospray high resolution MS (nS-HR-MS) method, 
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the authors concluding that the proposed methodology is suitable for neonatal screening of 
IEM (Dénes et al., 2012).  
Metabolomics of newborn urine has been applied for the study of newborns’ 
infection, namely for bacterial and CMV infections. Whilst no changes were found in 
bacterial infection, newborns infected with CMV were associated with altered energy 
metabolism along with other changes that the authors attributed to be virus related (Trump 
et al., 2006, Fanos et al., 2013).  
 
Healthy pregnancy studies 
Metabolic profiling studies of healthy pregnancies have been published in relation 
to gestational age and maternal nutritional states (Ottolenghi et al., 2010, Athanasiadis et 
al., 2011, Diaz et al., 2012, Dunn et al., 2012, Su et al., 2012), one comprising results 
presented in this thesis. The first publications in relation to gestational age found that 
succinic acid and amino acids contents in AF varied as a function of gestational age 
(Ottolenghi et al., 2010, Athanasiadis et al., 2011). Another study compared placental 
extracts collected at early and late 1
st
 trimester, and found significant changes in lipids 
composition, suggesting changes in fatty acids ß-oxidation for mitochondrial ATP 
production within the 1
st
 trimester (Dunn et al., 2012).  
Maternal serum metabolomic of healthy pregnant women living in a region with 
high prevalence of congenital anomalies has also been studied (Su et al., 2012). The 
authors found a different nutritional and metabolic status in women living in the high 
prevalence area, highlighting a possible role of a panel of nutrients in the 
prevention/development of certain pregnancy complication (Su et al., 2012). ). A similar 
approach was used as a mean to identify the effect of pesticide exposure in pregnant 
women measured through maternal urine (Bonvallot et al., 2013). This recent study 
compared urine from healthy pregnant women living in an agricultural region to evaluate 
the health risk associated with pesticides exposure. The authors concluded that higher 
oxidative stress and disturbed energy metabolism, occurs in higher exposures, a condition 
that could possibly result in disruptions to placental exchanges (Bonvallot et al., 2013). 
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1.7 Aims and scope of this thesis 
This work has entailed five general goals: 
  The first was to establish the dynamic metabolic profile of maternal urine 
characteristic of healthy pregnancies, to unveil the control urinary trajectory describing 
each pregnancy trimester. This information would set the basis for the understanding of 
metabolic deviations in maternal urine composition caused by pregnancy disorders.  
  The second goal was to evaluate the value of urine metabolomics to unveil 
potential biomarkers (either individual metabolites or metabolite profiles) for the 
recognition of FM and CD disorders. This study aims at improving the diagnostic methods 
presently available.  
  The third goal was to search for potentially predictive signatures in 2nd trimester 
maternal urine for disorders developed later in pregnancy, particularly for PTD, GDM, PE, 
IUGR and PROM disorders (for which there are no predictive methods).  
  The fourth goal was to deepen the understanding of the maternal metabolism 
disturbances caused by GDM and to understand the metabolic effect of treatment. Also, 
this work aimed at unveiling a potential pre-treatment metabolic phenotype predictive of 
future treatment requirements, towards the development of individualized healthcare 
strategies.  
  The fifth and final goal was to unveil the metabolic impact of prenatal and 
newborn disorders in the babies’ urine profiles in the first days of life. 
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2. Experimental section 
This research was carried out with the collaboration of the Maternity Bissaya 
Barreto (MBB), Centro Hospitalar de Coimbra, where all samples were collected, from 
2006 to 2012, and the Faculty of Medicine of the University of Coimbra (FMUC) where 
samples were stored immediately after collection. Between January 2008 and June 2011, 
this work was supported by the Portuguese Foundation of Science and Technology (FCT) 
funding through the PTDC/QUI/66523/2006 project. Samples were collected under ethical 
committee approval (Ref. 18/04 and 29/096) and informed consents were obtained, from 
all subjects participating in the study (see Annex II for informed consents and individual 
questionnaires).  
 
2.1 Sampling 
2.1.1 Sample and metadata collection 
A summary scheme of the experimental design is shown in Figure 2.1, with 
indication of the entities involved in this research project. For pregnant women, samples 
were collected during medical appointments, during the morning period, under non-fasting 
conditions due to dietary restrictions in controlling/limiting pregnant women’s diet. 
Approximately 50 mL of pregnant women urine were collected and stored at -20º for up to 
2 hours at MBB. Newborn urine was collected during their stay at the MBB (day 1 to day 6 
of life), after parental consent (Annex II). Samples were collected non-invasively using the 
cotton-ball method. This method consists in placing a sterile cotton-ball inside the 
newborns diaper, for up to 3 hours, to retain urine (approximately 1.5 mL) which is further 
transfer to an sterile vial and frozen at -20ºC for up to 24 hours. All samples were then 
transferred from MBB to FMUC, where they were given a random code (to ensure patients 
confidentiality), frozen and stored at -80ºC. Samples were then transported, in dry ice, to 
CICECO-Chemistry Department, at the University of Aveiro (UA) where they were stored 
and analyzed.  
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Figure 2.1: Experimental layout of the research project showing the involved research entities and 
list of urine sample collection, logistic and storage conditions for pregnant, non-pregnant and 
newborns. CICECO: Centro de Investigação em Materiais Cerâmicos e Compósitos. CHC: Centro 
Hospitalar de Coimbra, FMUC: Faculty of Medicine, University of Coimbra, UA: University of 
Aveiro. 
 
Clinical and obstetrical metadata regarding prenatal and pre-pregnancy health 
history was obtained through individual questionnaires filled at the time of collection and 
at the end of gestation for all pregnancies. Other relevant parameters were obtained, such 
as height, pre-gravid weight and pre-gravid body mass index (BMI), preexisting disorders, 
medications, lifestyle and nutritional habits, smoking habits, blood pressure history, blood 
chemistry and urine analysis, obstetric background, fetal karyotype and ultrasound 
monitoring results. Information about labor (or pregnancy termination for cases of FM or 
CD with poor prognostic) and neonatal outcome was also obtained for each sample. Based 
on the collected metadata, samples were classified into controls, if they were obtained from 
healthy pregnant women with a normal pregnancy course and no preexisting maternal 
pathologies. Criteria for the definitions of other groups are described throughout this 
section.   
 
 
Maternidade Bissaya 
Barreto (MBB)
Cytogenetic Laboratory
FMUC
CICECO- Chemistry 
Department, UA
Sample collection 
conditions
Logistics and storage
Pregnants Non-fasting, aprox. 50 mL
Stored -20º C up 
to 2 h (MBB)
Samples are 
transferred to 
FMUC, 
identified and 
stored at -80ºC
Samples are 
transferred to UA 
and stored at
-80ºC until NMR 
analysis. 
Non-Pregnants
Fasting and non-fasting, 
aprox. 50 mL
Newborns
Cotton-ball method, aprox.
1.5 mL
Stored -20º C up 
to 24 h (MBB)
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2.1.2 Definition of sample groups 
This thesis is divided into four main studies described in chapters 3, 4, 5 and 6. 
Study 1 (Chapter 3) aimed the definition of the dynamic urinary profile of healthy 
pregnancies and the unveiling of the control urinary metabolic trajectory descriptive of 
each pregnancy trimester. In Study 2 (Chapter 4), the possibility of using 2
nd
 trimester 
maternal urine for the diagnosis of fetal disorders and prediction of poor pregnancy 
outcomes was explored. Study 3 (Chapter 5) aimed at the understanding of the metabolic 
alterations in GDM by characterizing the urinary profile at three disease stages (compared 
to controls) as well as improving the knowledge of the metabolic effect of GDM treatments 
and an attempt to predict future treatment requirements. Study 4 aimed at the unraveling of 
the potential of newborn urine metabolomics for the understanding of the metabolic impact 
of prenatal disorders in newborns’ health. A schematic representation of the a) disorders 
investigated in each study and b) gestational times at sampling is shown in Figure 2.2. 
 
 
Figure 2.2: Schematic representation of the disorders investigated in Studies 1 to 4 and 
corresponding gestational times at sampling. 
1st T 2nd T 3rd T
g.w.
Fasting and 
Non-Fasting
Non-Pregnant Newborns
During their stay 
at the maternity 
(day 1-day 6)
Pregnant
Study 1 1st T Control 2nd T Control 3rd T Control Non-Pregnant
Study 2
FM, CD
pre-PTD, 
pre-IUGR, 
pre-PE
Study 3
pre-diag. GDM
Treated GDM
Study 4
Prematures,  
Respiratory depresion, 
LGA, Malformations, 
GDM, maternal  
psychiatric disorder
Diagnosed GDM
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
non-fasting 
conditions
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Sample groups in Study 1: Defining the global urinary profile of pregnancy and 
the metabolic adaptations throughout gestation - a multipoint collection study 
For the study of the urinary profile of healthy pregnancies and the metabolic 
trajectory throughout gestation only control cases were used. Urine samples were collected 
for independent groups of subjects at their 1
st
, 2
nd
 and 3
rd
 trimesters, the number of samples 
for each independent subject group, along with corresponding metadata information being 
listed in Table 2.1. 
 For this study, independent groups were chosen, rather than multiple-collection for 
each subject, in order to consider pregnancy-related changes larger than inter-subject 
variability, reflecting the general population more closely. For a group of non-pregnant 
(NP) women, urine was collected fasting and non-fasting (2 hours after random breakfast), 
in order to evaluate the effect of the typical non-fasting conditions in which sample 
collection took place for pregnant women.  
 
Table 2.1: List of urine samples collected for Study 1, along with corresponding ranges of maternal 
age (in years), pre-pregnancy body mass index (BMI, in kg.m
-2
), gestational age at sampling and at 
delivery (in gestational weeks, g.w.), gravidity (no. pregnancies), parity (no. born children), 
newborn’s birth weight (kilograms, kg), no. pregnant women who were smokers and who were 
taking folic acid supplementation at the time of sampling. NP: non-pregnant. Median values are 
shown in brackets. NA: Not available. 
 Groups studied 
Metadata NP 1
st
 T 2
nd
 T 3
rd
 T 
n 16 16 20 19 
Maternal age range 21-47 (26) 19-40 (31) 21-39 (34) 20-38 (32) 
pre-gravid BMI range 18-35 (22) 19-25 (24) 20-33 (24) 17-35 (23) 
Gestational age at 
sampling/g.w. 
- 11-13 (12) 15-26 (17) 29-39 (35) 
Gestational age at delivery/g.w. - 37-40 (40) 37-40 (38) 37-40 (38) 
Gravidity/Parity - 1-2(1)/0-1(0) 1-6(2)/0-2(1) 1-5(2)/0-3(0) 
Newborn’s birth weight /kg - 
2.59-4.11 
(3.40) 
2.61-3.74 
(3.24) 
2.33-3.95 
(3.27) 
No.  smokers NA 0 1 2 
No. subjects taking folic acid at 
sampling 
NA 12 13 17 
 
Experimental Section 
93 
Sample groups used in Study 2: Second trimester maternal urine for the 
diagnosis of fetal disorders and prediction of poor pregnancy outcomes   
Maternal urine was collected for women carrying fetuses diagnosed with fetal 
malformations (FM) and chromosomal disoders (CD) and for other women with no 
apparent disorder. Subjects were followed until the end of gestation and pathological 
groups were defined as: women that further developed preterm delivery (pre-PTD), 
preeclampsia (pre-PE), intrauterine growth restriction (pre-IUGR) and premature rupture 
of the membranes (pre-PROM), as no sufficient number of samples were gathered for 
other relevant disorders. Sample numbers, maternal age, gestational ages at sampling and 
pre-pregnancy BMI are listed in Table 2.2. 
 
Table 2.2: Maternal urine samples collected for Study 2, along with corresponding age/years and 
gestational age/gestational weeks, g.w. at the time of collection, pre-pregnancy body mass index, 
BMI/kg.m
-2
 and, for pre-diagnosed disorders, the no. of g.w. between sampling and time of 
diagnosis. Values in brackets correspond to median values. 
Subjects group 
 
n 
Maternal 
age /years  
Gestational 
age /g.w. 
Pre-pregnancy 
BMI / kg.m
-2 
g.w. to 
diagnosis 
Controls 84 21-42 (36) 15-26 (17) 17-35 (22) ─ 
FM
 
35  18-45 (31) 14-24 (21) 18-35 (25) ─ 
CD
 
33 25-47 (36) 15-25 (17) 20-35 (24) ─ 
pre-PTD 26 26-41 (36) 16-21 (17) 19-40 (25) 11-20 (17) 
pre-PE 9 24-41 (35) 16-17 (17) 19-33 (24) 14-21 (18) 
pre-IUGR
 
10 29-42 (39) 16-24 (17) 19-33 (24) 2-22 (19) 
pre-PROM 68 22-44 (36) 15-21 (17) 19-36 (23) 18-24 (22) 
 
FM cases were diagnosed by morphological ultrasound after 12 g.w., the group 
comprising cases of central nervous system (CNS), abdominal, urogenital, cardiac, limbs 
and poli-malformations and CD diagnosed ca. 2 weeks after amniocentesis (thus after 
sample collection), comprising trisomies 18 and 21 (T18 and T21), Kleinfelter syndrome, 
mosaicisms, chromosome inversions and translocations. The numbers and specific types of 
FM and CD types are summarized in Table 2.3, showing the heterogeneity nature of these 
groups.  
For undiagnosed later-developing disorders group cases were defined as follows: 
pre-PTD, women that later delivered before the 37
th
 g.w.; pre-PE, women later diagnosed 
with PE according to the criteria of blood pressure ≥ 140/90 mmHg after the 20th weeks of 
Chapter 2 
94 
gestation and  proteinuria ≥ 0.3g/L in 24-hour urine,  pre-IUGR, corresponding to women 
later diagnosed with carrying a IUGR fetus according to the diagnostic criteria of fetal 
growth below the 5% percentile, and pre-PROM, women that had premature rupture of 
membranes prior to labour and after the 37
th
 g.w. 
 
Table 2.3: List of specific types of FM and CD along with corresponding number of samples. 
Fetal Malformations (FM)  
Type   n Type  n 
CNS  Limbs  
Corpus callosum agenesis 3 Club feet 3 
Ventriculomegaly 4 Jaw malformation + club foot 1 
Ventriculomegaly + polydactyly 1 Limb agenesis 1 
Spina bifida 1 Polydactyly 1 
Hydrocephaly 1 Cardiac  
Arnold-Chiari 1 Complex cardiopathy 5 
Holoprosencephaly 1 Hypoplastic left heart syndrome 1 
Urogenital  Polimaformation  
Bladder agenesis 1 Cystic hygroma + bladder 
agenesis 
1 
Hydronephrosis 2 
Cystic hygroma + sexual 
ambiguity 
1 
Multicystic dysplastic kidney 1 Dextrocardia + lung agenesis + 
lung hypoplasia 
1 
 Polycystic kidney 1 
Abdominal  Hypertelorism+ club feet + lung  1 
Enlarged stomach 2 
ectasia + cardiac septum edema 
+ liver fibrosis 
 
Chromosomal Disorders (CD)  
Type n Type n 
Trisomy 21 13 Mosaicism 2 
Trisomy 18 2 Marker chromosome 1 
Klinefelter syndrome 2 Translocations 5 
XYY syndrome 2 Inversions 2 
XXX syndrome 1 Deletions 2 
Triploidy 1   
 
 
Sample groups in Study 3: Gestational Diabetes Mellitus - a deeper insight into 
maternal metabolism disturbances 
For the study of the metabolic perturbances in GDM–affected pregnancies, urine 
samples were collected from independent groups of pregnant women at 2
nd
 and 3
rd
 
trimesters, during routine medical appointments and diabetes appointments. GDM was 
diagnosed after a 75g or 100g oral glucose tolerance test (OGTT) by measuring plasma 
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glucose (PG) at fasting (FPG) and after 1, 2 and 3 (for the latter) hours. GDM was 
diagnosed according to the diagnosis criteria described in Table 1.7.   
 
Disorder groups correspond to samples collected at three different disease stages: 
 Diagnosed GDM:  samples collected at the first medical appointment after GDM 
diagnosis (2
nd
 and 3
rd
 trimester) and before the initiation of any treatment. 
 Pre-diagnosis GDM: samples collected in the 2nd trimester, before any clinical 
manifestation of the disease. 
 Treated GDM: samples collected at follow up medical appointment (2nd and 3rd 
trimester), upon treatment course (1600-2000 kcal diet further complemented with 
insulin therapy). Insulin was prescribed to pregnant women with FPG≥5 mmol/L 
and/or post-prandial, one hour after main meals, PG≥6.65 mmol/L after initiation of 
dietary intervention. 
 Control groups 1, 2 and 3: Due to the significant impact of gestational age on the 
composition of urine, during pregnancy (as will be discussed after in chapter 3), 
three control groups were defined, based on gestational age range, in order to match 
controls to the corresponding disorder group (diagnosed GDM, pre-diagnosis GDM 
and treated GDM, respectively), as far as possible. 
Detailed information about samples number, maternal age range, gestational age range 
(at sampling), interval of time from sampling to diagnosis and pre-pregnancy BMI range 
can be found in Table 2.4. 
 
Table 2.4: List of urine samples collected for Study 3, comprising each independent group of 
GDM-affected subjects (in three different disease stages) and controls (control groups 1, 2 and 3, to 
match each disorder group, as described in the previous paragraph), corresponding maternal 
age/years and  GA/g.w.at sampling, interval between sampling and diagnosis/g.w. and pre-
pregnancy BMI (kg.m
-2
). Median values are shown between brackets. GA: gestational age. 
Group n 
Maternal age 
range/years 
GA 
range/g.w. 
g.w. to 
diagnosis 
Pre-pregnancy 
BMI range/kg.m
-2 
Diagnosed GDM 13 26-41 (34) 16-33 (27) 0-7 (2) 18-36 (25) 
Control group 1 14 24-39 (32) 16-33 (31) ─ 17-34 (23) 
pre-diagnosis GDM 52 30-44 (37) 15-22 (17) 2-21 (13) 18-40 (25) 
Control group 2 113 21-42 (36) 15-26 (17) ─ 16-39 (22) 
Treated GDM 38 18-41 (32) 17-40 (35) 2-22 (4) 18-45 (25) 
Control  group 3 40 20-41 (34) 16-39 (31) ─ 17-34 (23) 
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Sample groups in Study 4: Newborns health status seen through urine 
metabolomics 
Newborns groups were defined based on maternal and newborns’ medical records. 
The control group was defined as healthy newborns, born to healthy mothers and 
pregnancies. For the control group, the effect of different variables which may play as 
confound in the later studies devoted to disorders, namely gender, delivery mode (vaginal 
vs. abdominal), newborns age in days (day 1 to day 4), and GA at birth (37 to 38, 38 to 39, 
39 to 40 and over 40 g.w.). Sample numbers for these possibly confounding effects are 
listed in Table 2.5 (bottom).  
 
Table 2.5: List of newborn urine samples collected Study 4, along with corresponding day of life at 
sampling/days, gestational age range/g.w., birth weight range/kg, and maternal age range/years 
(top); and list of possible confounding effects and corresponding sample numbers (considered only 
for the for the control group (bottom)). Median values are shown between brackets. LGA: large for 
gestational age, Mat: Maternal, F: female, M: male, VD: vaginal delivery, CS: cesarean section. 
Group  
n Day of 
life at 
collection 
GA/g.w. 
Birthweight 
/kg 
Mat. age 
/years 
Gravidity/ 
Parity Total M/F VD/CS 
Control 45 23/23 29/17 1-4 (2) 
37-40 
(39) 
2.46-3.69 
(3.11) 
16-43 
(31) 
1-6 (2)/ 
0-3 (1) 
PROM 36 22/14 21/15 1-3 (2) 
35-40 
(39) 
2.23-4.16 
(3.23) 
19-41 
(33) 
1-4 (1)/ 
0-3 (1) 
LGA 18 14/4 7/11 1-2 (2) 
38-40 
(39) 
3.70-4.76 
(3.92) 
20-38 
(34) 
1-4 (2)/ 
0-3 (1) 
Prematurity 17 11/6 8/9 1-6 (2) 
33-36 
(35) 
1.26-3.28 
(2.36) 
23-41 
(30) 
1-3 (1)/ 
0-2 (0) 
pre-jaundice 12 8/4 8/4 1-3 (2) 
35-40 
(38) 
2.16-3.47 
(2.99) 
24-41 
(33) 
1-3 (1)/ 
0-1 (0) 
Respiratory 
depression 
10 4/6 6/4 1-2 (2) 
36-40 
(39) 
2.49-3.49 
(3.13) 
20-36 
(33) 
1-4 (2)/ 
0-1 (1) 
Malformations 9 6/3 2/7 2-3 (2) 
37-40 
(39) 
2.61-3.59 
(3.02) 
19-40 
(33) 
1-4 (2)/ 
0-3 (1) 
Newborns to 
GDM mothers 
14 8/6 6/8 1-6 (2) 
33-40 
(39) 
1.27-4.77 
(3.28) 
25-40 
(32) 
1-6 (4)/ 
0-3 (1) 
Mat.psychiatric 
disorders 
7 2/5 3/4 1-2 (2) 
38-40 
(39) 
2.44-4.06 
(3.26) 
20-39 
(35) 
1-5 (2)/ 
0-2 (1) 
Mat. respiratory 
disease 
10 5/5 7/3 1-3 (2) 
35-40 
(38) 
2.64-4.16 
(2.88) 
23-36 
(32) 
1-4 (2)/ 
0-3 (0) 
Mat. thyroid 
disease 
9 6/3 6/3 1-2 (1) 
34-40 
(39) 
1.98-3.22 
(2.88) 
20-37 
(32) 
1-4 (2)/ 
0-3 (1) 
Mat. chronic 
hypertension 
8 3/5 5/3 1-6 (2) 
33-39 
(37) 
1.27-4.10 
(2.61) 
25-44 
(32) 
1-4 (2)/ 
0-3 (1) 
 Confounding effects investigated  
Gender F=23 M=23    
Day of life Day 1= 7 Day 2=31 Day 3=2 Day 4=2 NA=4 
GA/g.w. 37≤ GA <38=5 38≤ GA <39=10 39≤ GA <40=18 40≤ GA <41=13 
Delivery mode VD= 29 CS=17  
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Pathological cases were defined for a) newborns disorders, these including cases 
large for gestational age (LGA, birth weight above the 90
th
 percentil), prematurity (babies 
born before the 37
th
 g.w.), pre-jaundice (babies later developing jaundice), respiratory 
depression (babies requiring reanimation with external O2) and malformations 
(heterogeneous group, 1 major malformation and 8 minor malformations) and b) newborns 
from pathological pregnancies, including newborns born to GDM mothers, maternal 
psychiatric disorders (including depression, epilepsy and depressive neurosis), maternal 
respiratory disease (including asthma, bronquitis and sinusitis), maternal thyroid disease 
(including hypo-thyroidism and other thyroid diseases), maternal hypertension and babies 
born from pregnancies affected by PROM. Sample numbers, maternal age, day of life at 
sampling, gestational age at birth (g.w.), birth weight, maternal age, gravidity and parity 
are listed in Table 2.5 (top). 
 
2.2 NMR spectroscopy 
2.2.1 Sample preparation for NMR analysis 
Samples were thawed at room temperature and 800 μL (for pregnant women) and 
600 μL (for newborn urine) were centrifuged (4500g, 5 min). Then, 60 μL of 1.5M 
KH2PO4/D2O phosphate buffer pH 7.00, 0.1%Na
+
/3-trimethylsilylpropionic acid (TSP) 
were added to 540 μL of supernatant, followed by buffering and pH adjustment to 
7.00±0.02 with KOD (4M) or DCl (4M). The mixture was again centrifuged (4500g, 5 
min) and 550 μL were transferred to a 5 mm NMR tube. The initial, that after buffering 
and final pHs are listed in Table Table 2.6. 
2.2.2 Acquisition and processing of NMR data 
All 1D, TOCSY and HSQC spectra were recorded on a Bruker Avance DRX 500 
spectrometer, operating at a proton frequency of 500MHz, and J-res were recorded in a 
600MHz spectrometer Bruker BioSpin, Germany. All spectra were acquired at 300 K. 
Standard 1D spectra were acquired, using a noesypr1d 1D pulse sequence (RD-90º-t1-
90ºtm-90º-acquire) experiment from Bruker library. This experiment performs water 
presaturation, using a presaturation pulse of 60 dB, during the relaxation delay (RD) and 
mixing time (tm) allowing an efficient water suppression. Each FID was multiplied by 0.3 
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Hz exponential line-broadening followed by FT. Spectra were then manually phased and 
baseline corrected, and chemical shifts calibrated internally by TSP at δ=0.0 ppm. A list of 
all acquisition and processing parameters is show in Table 2.7. 
 
Table 2.6: Initial pH, pH after buffering and final pH (after addition of KOD or DCl) ranges, 
median values in brackets, of groups studied in this work. 
 Sample group Intial pH pH after buffering Final pH 
 NP 5.06-7.90 (5.35) 6.51-6.96 (6.66) 6.98-7.02 (7.01) 
P
re
g
n
an
t 
w
o
m
en
 
1
st
 T controls 5.34-7.91 (6.35) 6.54-6.95 (6.84) 6.98-7.02 (7.00) 
2
nd
 T controls 5.03-8.45 (6.67) 6.42-7.09 (6.87) 6.98-7.02 (7.01) 
3
rd
 T controls 5.22-7.76 (6.31) 6.46-6.99 (6.81) 6.99-7.02 (7.01) 
FM 5.14-8.56 (7.04) 6.56-7.06 (6.87) 6.98-7.02 (7.00) 
CD 5.51-8.01 (6.82) 6.60-7.05 (6.89) 6.98-7.02 (7.01) 
pre-PTD 5.24-8.37 (6.55) 6.59-7.02 (6.85) 6.99-7.02 (7.01) 
pre-PE 5.25-7.84 (6.35) 6.72-6.97 (6.89) 6.99-7.02 (7.00) 
pre-IUGR 5.36-7.20 (6.35) 6.70-6.99 (6.88) 6.98-7.02 (7.00) 
pre-diagnosis GDM 5.08-8.11 (6.61) 6.50-7.00 (6.82) 6.98-7.02 (7.01) 
Diagnosed GDM 5.63-7.55 (6.66) 6.53-6.92 (6.79) 6.98-7.02 (7.00) 
Treated GDM 5.36-7.85 (6.52) 6.35-7.02 (6.87) 6.99-7.02 (7.01) 
N
ew
b
o
rn
 
Controls 5.70-6.61 (5.99) 6.67-6.97 (6.85) 6.98-7.02 (7.00) 
Prematures 5.75-7.15 (6.14) 6.80-6.98 (6.90) 6.98-7.02 (7.01) 
Respiratory depression 5.64-7.43 (5.96) 6.77-6.99 (6.86) 6.99-7.02 (7.00) 
LGA 5.55-6.47 (5.87) 6.60-6.91 (6.74) 6.99-7.02 (7.01) 
Malformations 5.50-7.32 (5.90) 6.66-6.96 (6.85) 6.99-7.01 (7.00) 
Maternal GDM 5.32-6.86 (5.97) 6.62-6.92 (6.85) 6.99-7.02 (7.00) 
Maternal psychiatric disorders 5.55-6.81 (5.74) 6.60-6.98 (6.78) 6.98-7.02 (7.00) 
 
The TOCSY experiment was recorded in phase-sensitive mode using States-TPPI 
(time proportional phase incrementation) detection in t1 using a MLEV-17  pulse sequence 
(Bax and Davis, 1985), clmlevprtp. The HSQC spectra were recorded with inverse 
detection and 
13
C decoupling during acquisition using the invietgpsi pulse program. J-
resolved experiments were acquired using the jresgpprqf pulse sequence with presaturation 
during relaxation delay. All NMR data processing was carried out in TOPSPIN 2.0 and 3.2 
versions (Bruker BioSpin, Reinstetten, Germany).  
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Table 2.7: List of acquisition and processing parameters used for 1D and 2D NMR experiments of 
urine. NS: number of scans, RD: relaxation delay, tm: mixing time, t1: fixed delay, SW: spectral 
window, TD: size of FID, RG: receiver gain, SI: size of real spectrum, WDW: type of window 
function, F1: 1
st
 dimension, F2: 2
nd
 dimension, lb: line broadening, efp: exponential multiplication, 
Fourier transform and phase correction. 
Standard 1 D experiment (noesypr1d) 
Acquisition parameters Processing parameters 
NS  128 EFP and lb=0.3 Hz 
RD  4 s Manual phase correction 
tm  100 ms Manual baseline correction 
t1  3μs 
Chemical shift calibration by TSP 
(0.0 ppm) 
SW  10080.65 Hz/ 20.16 ppm 
TD 64 k 
RG 32  
TOCSY experiment (clmlevprtp) 
Acquisition parameters Processing parameters 
NS 24 RD 2 s SI [F1] 1 k 
tm 80 ms pl10 15 dB SI [F2] 4 k 
TD [F1] 2 k TD [F2] 300 WDW qsine 
SW [F1] 8012.82 Hz SW [F2] 8012.82 Hz  
HSQC experiment (invietgpsi) 
Acquisition parameters Processing parameters 
NS 36 RD 2 s SI [F1] 1 k 
TD [F1] 4 k TD [F2] 300 SI [F2] 4 k 
SW [F1] 25153.81 Hz SW [F2] 8012.82 Hz  WDW qsine 
J-resolved  experiment (jresgpprqf) 
Acquisition parameters Processing parameters 
NS 1 RD 1 s SI [F1] 128 
TD [F1] 8192 Hz TD [F2] 40 SI [F2] 8 k 
SW [F1] 78.16 Hz  SW [F2] 10000 Hz WDW qsine 
 
2.2.3 Preprocessing and multivariate analysis of NMR data  
Alignment and normalization 
NMR spectra were converted to a matrix of n rows (corresponding to n samples), 
and m columns (corresponding to variables). The NMR spectra, after removal of water 
(4.60-5.05 ppm) and urea (5.50-6.45 ppm) regions, were aligned using a recursive 
segment-wise peak alignment (Veselkov et al., 2009) to minimize chemical shift variations 
and normalized by PQN (Dieterle et al., 2006) using MATLAB software, version 7.12.0, 
The MathWorks Inc. The script was developed at Imperial College of London and kindly 
spared by Dr. Kirill A. Veselkov. 
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Variable selection for NMR data 
Four variable selection methods were tested, based on the selection of variables 
(spectral data points) with VIP>1 (Quintás et al., 2012, Sun et al., 2012), variables with 
lower standard errors in relation to VIP (VIPcvSE) and to b-coefficients (bcvSE) (Andersen 
and Bro, 2010), given respectively by VIP/VIPcvSE>1 and b/bcvSE>1 and, finally, variables 
selected through the intersection of all three previous methods, i.e. simultaneously with 
high VIP, low VIPcvSE and low bcvSE (Diaz et al., 2013), this method being published in a 
paper originated from the present thesis.  The standard error obtained by cross validation 
(cvSE) is based on the concept of signal to noise ratio using a jack-knife approach. Jack-
knife during cross-validation is a mean to estimate statistical error by re-computing models 
using a random subset of samples (Andersen and Bro, 2010). Thus, the cvSE provides a 
measurement of the uncertainty of a parameter estimate and is helpful for the selection 
variables relevant to the model. This concept was applied to the b-coefficient and VIP 
parameters, chosen due to their complementarities. The b-coefficient reflects the 
discriminant and predictive capability of each variable i.e. their contribution for samples 
classification, whilst VIP values, which reflect the importance of each variable to the 
projection in the low dimensional space, hence, the relevance of each variable for samples 
geometric separation.  
 
Multivariate analysis 
MVA was carried out using SIMCA-P software, version 11.5, by applying PCA 
and PLS-DA to the UV scaled matrix. Model robustness was initially evaluated in terms of 
Q
2
, the goodness of prediction or prediction power, of the original model, that is of the 
model calculated in SIMCA using a 7-fold cross validation. The corresponding loading 
plots were back-transformed by multiplying the loading weight [w] by the variable 
standard deviation. Loading plots were colored according to the VIP value and relevant 
peaks were integrated in the original spectra using Amix 3.9.5, Bruker BioSpin, 
Rheinstetten, Germany. 
 
Model Validation 
Model validation was further assessed by MCCV (7 blocks) using 500 runs, with 
recovery of Q
2 
values and confusion matrices of true and permuted classes. Classification 
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rates (CR), specificity and sensitivity were calculated from confusion matrices, and model 
predictive power was assessed using a ROC curve mapping, a function of the true positive 
rate (TPR or sensitivity) and false positive rate (FPR or 1-specificity). PLS-DA models 
were considered validated when having high predictive power and robustness, given by 
minimal overlapping of the distribution of true and permuted Q
2
, no overlapping of true ad 
permuted models in the ROC plot and high CR, specificity and sensitivity (Wiklund et al., 
2007, Westerhuis et al., 2008). MCCV calculations were carried out using the spark 
algorithm, developed and kindly spared by Dr. António S. Barros. 
 
Univariate analysis 
Integrals were normalized by PQN, i.e. divided by the each samples’ normalization 
quotient in Study 2 to 4 and by total intensity in Study 1. All integrals were compared by 
determining individual statistical significance, calculated by Wilcoxon rank sum test 
(considering a significance level of 95%, p<0.05). For each set of metabolites, the 
biological relevance was determined by the effect size (considered in order to take into 
account sample dispersion and sample number) (Nakagawa and Cuthill, 2007). Effect size 
was calculated according to Eq. 2.1 and Eq. 2.2, where 
1x  and 2x  are the average 
metabolite integrals for sample groups 1 and 2 respectively, s is the pooled variance 
between the two groups, n1 and n2 are the sample numbers respectively for groups 1 and 2, 
2
1s  and 
2
2s  are the and the variances respectively for groups 1 and 2.  
s
xx
sizeeffect 21

  [Eq. 2.1] 
 [Eq. 2.2] 
 
Metabolites variations were shown, for Study 1, using a heatmap representation, 
with integrals values normalized to unity and shown in a qualitative color scale. Statistical 
tests, heatmaps and VIP-coloured loadings plots were carried out using R-statistical 
software. In Study 4, each integrals’ individual biological (effect size) and statistical (p-
value) significance was further represented by means of a Volcano plot whic is a graphical 
summary of the effect size and the p-value (Cui and Churchill, 2003).  
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2.3 Ultraperformance liquid chromatography- mass spectrometry (UPLC-
MS)  
UPLC-MS experiments were performed at the Section of Computational and 
Systems Medicine, Department of Surgery and Cancer of the Faculty of Medicine, 
Imperial College of London, within an ongoing collaboration between that institution and 
the University of Aveiro. 
 
2.3.1 Sample preparation for UPLC-MS analysis 
Samples were thawed at room temperature and centrifuged at 9500g for 10 min. 
Samples were then diluted (in a 1:1 ratio) by mixing 200 μL of supernatant and 200 μL of 
HPLC grade water and transferred to a 96-well plate (kept at 4ºC until analysis). Quality 
control samples (QC) were prepared, by mixing equal volume of all diluted samples, to 
ensure the reproducibility throughout the run.  
 
2.3.2 Acquisition and processing of UPLC-MS data 
Urine samples were analyzed in an Acquity UPLC system (Waters Ltd. Elstree, 
UK) connected to an LCT Premier mass spectrometer (Waters MS Technologies, Ltd., 
Manchester, UK). A high strength silica (HSS, Acquity HSS T3 1.7 μm, 2.1 x 100 mm, 
Waters Corporation, Milford, USA) column and a hydrophilic interaction chromatography 
(HILIC, Acquity BEH HILIC, 1.7 μm, 2.1x100 mm, Waters Corporation, Milford, USA) 
column were used. Both columns were used due to their complementarity as HSS columns 
shows improved retention of more polar metabolites (than alternative traditional reverse 
phase columns (RP)) whilst HILIC columns provide improved means of profiling certain 
polar metabolites not easily retained by RP columns (Want et al., 2010, Spagou et al., 
2011). Solvent gradients were used for both HSS and HILIC with a flow rate of 
0.5mL·min
-1
 and 0.4mL·min
-1
 respectively. The corresponding gradients are shown in 
Table 2.8. 
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Table 2.8: Gradients used for HSS and HILIC columns. HSS solvent A- water with 0.1% formic 
acid, Solvent B- acetonitrile with 0.1% formic acid. HILIC solvent A-95% ammonium acetate 10 
mM /5% acetonitrile with 0.1% formic acid, Solvent B- 50% ammonium acetate 10mM/50% 
acetonitrile with 0.1% formic acid. 
Gradients used for HSS Gradients used for HILIC 
 AHSS (%) BHSS (%)  AHILIC (%) BHILIC (%) 
t=0 100 0 t=0 99 1 
t=1 100 0 t=1 99 1 
t=3 85 15 (linearly decreasing  0 100 
t=6 50 50 until 12 min)   
t=9 5 95 t=12 99 1 
t=10 5 95 t=15 99 1 
t=10.1 100 0    
t=12 100 0    
 
Mass spectrometry (MS) analysis was performed in both positive and negative 
electrospray ionization modes (respectively ESI+ and ESI-), the instrument’s parameters 
being summarized in Table 2.9. The MS was operated in V optics mode with scan time 
0.1s and interscan delay of 0.01s, and data was collected in the range of 50-1000 m/z in 
centroid mode. Leucine enkephalin (a peptide with monoisotopic mass 555.2645 Da, 
commonly used in MS as a reference compound) was used as lock mass (solution of 200 
pg μL-1) by spraying the solution into the instrument at a rate of 3μL·min-1, with lock mass 
scans collected every 15s and averaged over 3 scans to perform mass correction. 10 
conditioning QC were run at the beginning of each experiment, and repeated every 10 
samples to check for reproducibility within runs. Cases and control samples were run in a 
randomized order. 
 
Table 2.9: MS spectrometer acquisition parameters for ESI+ and ESI- modes. 
Instrument parameters 
 ESI+ ESI- 
Capillary voltage 3000 V 2500 V 
Sample cone 30 V 25 V 
Dessolvation temperature 400 ºC 350 ºC 
Source temperature 120 ºC 120 ºC 
Dessolvation gas flow 600 L h
-1
 800 L h
-1
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2.3.3 Preprocessing and multivariate analysis of UPLC-MS data 
Raw data was converted to netCDF format using Waters MassLynx
TM
 software 
version 4.1 Databridge. Chromatograms were converted into a data table using R-statistical 
software, version 2.15.0, along with the XCMS package (Smith et al., 2006). Processing 
scripts were developed in Imperial College of London and kindly spared, courtesy of Dr. 
Mathew Lewis and Dr. Paul Benton. In this work, two preprocessing methods were 
employed as described below. 
 
UPLC-MS data processing method 1:  
Peak detection was applied using the peak picking CentWave algorithm with a peak 
window of 2-15 s for HSS and 3-60 s for HILIC columns. Retention times (RT) were 
corrected by applying a first peak grouping using an m/z bandwith of 0.05 Da and RT error 
of 5 s, followed by a second grouping, this time using a RT error value determined from 
the RT deviation plot. Features were normalized using the median fold change 
normalization to account for differences in samples dilution (Veselkov et al., 2011). An 
initial PLS-DA was computed and variables (in this case, features, i.e. a pair RT_m/z) were 
selected using the variable selection method used for NMR data (i.e. simultaneously 
VIP>1, VIP/VIPcvSE>1 and |bcoeff/bcoeffcvSE|>1), previously described in section 2.3. 
 
UPLC-MS data processing method 2:  
UPLC-MS data were subjected to an initial prefilter, to remove features that are not 
detected in at least 5 scans with intensity higher than 1000, followed by peak picking  as 
described in processing method 1. The prefilter prior to peak peaking is extremely useful in 
removing noise and background from the dataset and consequently reducing their influence 
of the definition of features. Features were then grouped, also as described in processing 
method 1. A following MinFrac Filter was applied, this to remove features not present in at 
least 50% of at least one of the groups. Features were normalized as in processing method 
1 . Finally, a coefficient of variation (Eq. 2.3) based filter is also applied, with features 
with coefficient of varation higher than 30% (calculated for the QCs) were removed. 
  
  [Eq. 2.3]  
 
Coefficient of variation =
standard error
mean
100
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Multivariate analysis, model validation and univariate analysis of UPLC-MS 
data 
The resulting data tables were analyzed by applying PCA and PLS-DA, using 
SIMCA-P version 11.5, combined with UV and Pareto scaling and logarithmic 
transformation. Reproducibility was confirmed for every dataset trough PCA of cases and 
QC samples. Model validation was performed by MCCV, as for the NMR results. For 
validated models, features were analyzed by the S-plot, which combines covariance and 
correlation of each feature with the scores. Features with covariance or |p|>0.02 and 
correlation or |pcorr|>0.6 were selected for univariate analysis. As for NMR data, individual 
significance of feature intensities was calculated by Wilcoxon test and, for each set of 
significant features (p<0.05), the effect size (Nakagawa and Cuthill, 2007) was determined, 
according to Eq. 2.1 and Eq. 2.2.. 
 
2.4 Statistical correlation analysis 
Statistical total correlation spectroscopy (STOCSY) was performed for each 
unassigned NMR resonance in order to identify peaks arising from the same molecule 
and/or metabolically related compounds. Correlation and covariance was calculated 
between each unidentified peak and the complete spectrum matrix. The correlation 
coefficient (r) was then plotted in the covariance map, 1D STOCSY, (Cloarec et al., 2005) 
without any threshold to facilitate the identification of correlated peaks. 
 
For unidentified MS features, statistical heterospectroscopy (SHY) was applied by 
calculating the correlation between each MS feature and the full NMR matrix. The 
correlation coefficient was computed using Pearson correlation and plotted in a 1D 
STOCSY, i.e. using the covariance map (Cloarec et al., 2005). A correlation and 
significance threshold of |r|>0.8 and significance p<0.01 were applied. All correlations 
were checked by scatter plotting every pair of metabolite integrals/features intensities to 
confirm validity and rule out  any spurious correlation.  
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3. Defining the global urinary profile of pregnancy and the metabolic 
adaptations throughout gestation - a multipoint collection study 
This chapter begins by presenting the results obtained for the characterization of 
maternal urine composition through 1D and 2D NMR experiments and the resulting 
complete list of metabolites identified. Secondly, the results obtained for the impact of 
non-fasting conditions as a possible confounding effect in urine metabolomic studies are 
presented. Finally, the overall changes found in maternal urine composition with and 
throughout healthy pregnancies are presented, with results of the metabolic profiling of 
urine for each pregnancy trimester and suggestions of possible metabolic interpretations. 
 
3.1 Typical 1H NMR spectrum of maternal urine and spectral assignments  
Generally, a typical 
1
H NMR spectrum of urine contains hundreds of peaks arising 
from numerous metabolites. As urine is mainly composed of small molecules originating 
sharp peaks, only 1D standard (noesypr1d) NMR spectra were acquired, as CPMG or 
diffusion-edited experiments were not justified. However, the peaks observed in the 
standard spectra overlap extensively, yielding complex spectra and hindering metabolite 
assignment. Typical 
1
H NMR urine spectra of healthy pregnant women, in their 1
st
, 2
nd
 and 
3
rd
 T, and that of NP women are shown in Figure 3.1. In this figure, the large complexity 
and extensive peak overlap are clearly visible, justifying the absolute need for 2D NMR. 
Thus, 2D NMR spectra TOCSY, HSQC and J-res were used and expansions of a TOCSY 
and HSQC spectra of urine (0.5-4.6 ppm) are shown in Figure 3.2 with indication of some 
assignments. TOCSY is extremely helpful for the assignment of complete spin systems, 
especially when peaks are present in low intensities and often obscured in the 1D spectrum 
due to overlap with other resonances. On the other hand, the HSQC is particularly helpful 
for the assignment of singlet resonances, which would have no scalar correlation and are 
therefore not observed in TOCSY spectra.  
Other relevant assignment tools comprise statistical TOCSY (STOCSY) and the 
traditional spiking experiments, an example of each procedure being shown in Figure 
3.3a,b respectively. In the STOCSY example, the phenylacetylglutamine (PAG) multiplet 
at 7.43 ppm was correlated with the whole spectra and peaks arising from the same 
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Figure 3.1: 500 MHz 
1
H NMR urine spectra of a) NP and pregnant women at b) 1
st
 T , c) 2
nd
 T and 
d) 3
rd
 T. Assignments (amino acids in 3-letter code): 1: Ile 2: Leu, 3: Val, 4: 3-hydroxybutyrate, 5: 
3-aminoisobutyrate, 6: 3-hydroxyisovalerate, 7: lactate, 8: Thr, 9: 2-hydroxyisobutyrate, 10: Ala, 
11: Lys, 12: acetate, 13: phenylacetylglutamine (PAG), 14: p-cresol sulphate (p-CS), 15: succinate, 
16: citrate, 17: dimethylamine, 18: creatine, 19: creatinine, 20: malonate, 21: cis-aconitate, 22: 
choline, 23: carnitine, 24: betaine, 25: trimethylamine-N-oxide (TMAO), 26: taurine, 27: Gly, 28: 
guanidoacetate (GAA), 29: trigonelline, 30: glucose, 31: urea, 32: furoylglycine, 33: N-methyl-2-
pyridone-5-carboxamide (2-Py), 34: Tyr, 35: His, 36: hippurate, 37: hypoxanthine, 38: formate. 
The rectangles guide the eye for some visible spectral changes. Remaining assignments are shown 
in Table 3.1. 
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Figure 3.2: Expansions of the 2D NMR TOCSY and HSQC spectra of urine (respectively a and b), 
in the region from 0.5-4.6 ppm. Legend (amino acids in 3-letter codes): 1: 4-deoxyerythronic acid 
(4-DEA), 2: 3-aminoisobutyrate, 3: 4-deoxythreonic acid (4-DTA), 4: thr, 5: lys, 6: 2-ketoglutarate 
(2-KG), 7: phenylacetylglutamine (PAG), 8: gln, 9: his, 10: succinate, 11: citrate, 12: 
trimethylamine (TMA), 13: creatine, 14: creatinine, 15: choline, 16: gly, 17: guanidoacetate 
(GAA), 18: hippurate. 
 
molecule (multiplet at 1.93 and 2.11, triplet at 2.27, doublet at 3.67, multiplet at 4.18, 7.36, 
and 7.43 ppm) showed high covariance and correlation (r>|0.90|), thus enabling the 
assignment of the complete spin system. The advantages of STOCSY over TOCSY is that 
it resolves the problem of overlapped resonances (occurring in 2D also) as well as allows 
the identification of the metabolically related compounds, due to their biological 
covariance. In this example, PAG was found to have high correlation and covariance with 
p-cresol sulphate (p-CS, indicated with * in figure), a known metabolically related 
compound, as both metabolites are produced from protein degradation by the gut 
microflora and resultant of the breakdown of tyrosine conjugated with glutamine and 
breakdown of phenylalanine and conjugated with sulphate, respectively for PAG and p-CS 
(Heinzmann et al., 2012).  
An example of a spiking experiment to assign betaine and TMAO singlets is shown 
in Figure 3.3b. In this figure, a urine spectrum is shown in black and, for the same sample, 
after the addition of betaine and TMAO standards, respectively in pink and green. The 
resulting spectra enable the assignment of these two adjacent singlets at 3.27 ppm and 3.28 
ppm, respectively betaine and TMAO, as well as the second betaine singlet at 3.91 ppm. In 
spite of this being an ancient idea, spiking experiments are extremely helpful to identify 
singlets (which have no correlation through TOCSY or STOCSY) but also other low 
intensity peaks, which can be difficult to identify through TOCSY or HSQC. 
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Figure 3.3: a) STOCSY for the assignment of phenylacetylglutamine (PAG) spin system and the 
metabolically related compound p-cresol sulphate (p-CS, peaks indicated with *) and b) example of 
spiking experiment for the assignment of betaine (pink) and trimethylamine-N-oxide (TMAO, 
green).  
 
Overall, 64 metabolites were identified in maternal urine, including amino acids 
and derivatives, organic acids and sugars, all having been previously identified in urine 
(Rezzi et al., 2007, Appiah-Amponsah et al., 2009, Wishart et al., 2009, Ellis et al., 2012, 
Rivière et al., 2012, Sachse et al., 2012, Bouatra et al., 2013). Peak identification was 
confirmed by comparison with databases, namely the human metabolome database 
(HMDB) (Wishart et al., 2009, Bouatra et al., 2013) and Bruker Biorefcode 2.0.0 (courtesy 
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of Bruker BioSpin, Rheinsteten, Germany), as well as comparison with previous reports 
(Rezzi et al., 2007, Appiah-Amponsah et al., 2009, Ellis et al., 2012, Rivière et al., 2012, 
Sachse et al., 2012). The complete list of assignments obtained is shown in Table 3.1 along 
with the corresponding chemical shifts, multiplicity, assignment and, in some cases, carbon 
chemical shift (measured in HSQC spectra). Metabolites confirmed by spiking are noted 
with 
a
 and those confirmed with STOCSY are noted with 
b 
in the same table. 
 
Table 3.1: List of metabolite assignments in maternal urine 
1
H NMR spectra, recorded in a 500 
MHz spectrometer, pH 7.00±0.02. Legend: s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of 
doublets, m: multiplet. 
a 
Metabolites assigned through spiking and 
b
 through STOCSY. 
Assignment δH ppm (multiplicity, assignment/ δC ppm) 
1,6-anhydroglucose 5.46 (br, C1H), 3.69 (m, C3H, C4H), 3.54 (m, C2H), 4.10 
(dd, CH), 4.62 (dd, CH2), 3.76 (dd, CH2) 
1-methyl-histidine 
a
 
 
3.07 (dd, βCH2); 3.16 dd, β’CH2); 3.72 (s, CH3); 3.96 (dd, 
αCH2); 7.05 (s, ring); 7.78 (s, ring) 
2-hydroxyisobutyrate (2-HIBA) 1.36 (s, CH3) 
2-ketoglutarate (2-KG) 3.45 (t, βCH2), 3.01 (t, γCH2) 
3-aminoisobutyricacid 1.19 (d, CH3/17.87); 2.61 (m, αCH); 3.06 (dd, βCH2)  
3-hydroxybutyrate (3-HBA) 1.2 (d, CH3); 2.31(m, CH2); 2.41 (m, CH2); 4.15 (m, CH) 
3-hydroxyisovalericacid (3-HIVA) 1.27 (s, βCH3/31.02); 2.37 (s, αCH2) 
3-methyl-histidine
 a
 3.28 (dd, βCH2/28.05); 3.75 (s, NCH3/35.18); 3.97(dd, 
αCH/56.52); 7.15 (s, C6H/126.33); 8.12 (s, C2H/140.81) 
4-deoxyerythronic acid (4-DEA) 1.11 (d, γCH3/18.26); 4.08 (d, αCH/78.67); 4.10 (m, 
βCH/71.54) 
4-deoxythreonic acid (4-DTA) 1.23 (d, γCH3/21.37); 3.84 (d, αCH/79.04); 4.12 (m, 
βCH/71.59) 
4-hydroxyhippurate 3.95 (s, CH2); 6.98 (d, C3H, C5H ring); 7.76 (d, C4,2H, 
C6H ring) 
4-hydroxyphenylacetate (4-HPA) 
 
3.46 (s, CH2/46.3); 6.86 (d, C3H, C5H ring/118.4); 7.17 (d, 
C2H, C6H ring/133.3) 
Acetate 1.93 (βCH3) 
Acetoacetate 3.46 (s, CH3); 2.29 (s, CH2) 
Acetone 2.24 (s, CH3) 
Acetyl-carnitine 2.15 (s, CH3), 2.5 (dd, αCH2), 2.61 (dd, αCH2,), 3.19 (s, 
N(CH3)3), 3.61 (d, βCH2) , 3.85 (dd, βCH2) 
Alanine 1.49 (d,βCH3/18.99); 3.78 (q, αCH)  
Allantoin 5.39 (s, CH/66.19) 
Ascorbate
 a
 3.76 (m, CH2(OH)); 4.01 (m, CH (OH)); 4.52 (d,C1H)  
Betaine
 a
 3.27 (s, CH3/56.13); 3.91 (s, CH2/69.11) 
Carnitine 
 
2.44 (dd, αCH2/45.74; 3.23 (s, N(CH3)3/72.80; 3.43 (m, 
γCH2/72.80; 4.57 (m, βCH2/66.88) 
Choline 3.20 (s, N(CH3)3/56.52); 3.52 (m, NH/70.60); 4.07 (m, 
CH2(OH)) 
cis-aconitate 3.12 (d, CH/46.13); 5.79 (t, CH2/127.13) 
Citrate 2.54 (d, CH2/48.17); 2.69 (d, ´´CH2/48.17) 
Creatine 3.04 (s, NCH3/39.66); 3.94 (s, NCH2/56.55 
Creatinine 3.05 (s, NCH3/32.86); 4.06 (s, NCH2/59.05) 
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Assignment (continues) δH ppm (multiplicity, assignment/ δC ppm) 
Dimethylamine (DMA) 2.73 (s, CH3/37.41) 
Dimethylglycine (DMG) 2.93 (s, (CH3)2/46.21); 3.72 (s, CH) 
Formate 8.46 (s, CH/173.97) 
Fumarate 6.53 (s, CH) 
Furoylglycine
 b
 
 
3.93 (s, CH2); 6.65 (dd, C4H ring/114.98); 7.19(d, C3H 
ring); 7.70 (d, C5H ring) 
Galactose 3.49 (dd, C4H), 3.64 (dd, C3H), 3.75 (m, C1H, C2H, CH2), 
3.83 (m, C3H), 3.93 (d. C2H), 3.98 (d, C2H), 4.10 (t, C1H), 
4.60 (d, CH2), 5.28 (d, C5H) 
α-Glucose  3.23 (dd, C2H); 3.44 (m, C4H); 3.50 (t, C3H); 3.72 (dd, 
C6H’) ; 3.90 (m, C6H); 4.65 (d, C1H)   
β-Glucose 3.42 (t, C4H); 3.54 (dd, CH); 3.71 (t, C3H); 3.77 (dd, C6H); 
3.84 (m, C5H) ; 5.25 (d, C1H/94.97)    
Glutamine
 a
 2.15 (m, βCH2/29.24); 2.47 (m, γCH2/33.67); 3.79(t, 
αCH/57.41) 
Glycine 3.57 (s, αCH2/44.45) 
Guanidoacetate (GAA) 3.80 (s, CH2/47.44) 
Hippurate 
 
3.97 (d, CH2/46.65); 7.56 (t, C4H, C6H ring/131.60); 7.64 
(t, C3H, C5H ring/134.99); 7.83(d, C4H/129.97); 8.52 (br, 
NH) 
Histidine 
 
3.18 (dd, βCH2/30.40); 3.28 (dd, β’CH2/30.40);4.01(dd, 
αCH2/57.64); 7.13 (s, C4H ring/120.05); 7.98 (s, C2H 
ring/138.74) 
Hypoxanthine 8.20 (s, C2H ring); 8.22 (s, C8H) 
Indoxyl sulphate (IS) 7.21 (dd, C8H/122.53), 7.28 (dd, C7H/125.01), 7.36 (s, 
C2H/119.08), 7.51 (d, C6H/115.04), 7.70 (d, C9H/120.57) 
Isoleucine 
 
0.94 (t, δCH3); 1.01 (d, βCH2); 1.26 (m, γCH2); 1.47(m, 
β’CH2); 1.98 (m, γ’CH2); 3.62 (d, αCH) 
Lactate 1.34 (d, CH3/22.43); 4.11 (q, CH/71.53) 
Lactose
 
 
 
3.28 (dd, C2H); 3.55 (m, C’2H); 3.59 (dd, C2H); 3.66 (m, 
C’3H, C3H,C5H); 3.73 (m, C’6H, C’5H); 3.79 (m, C6H); 
3.86 (m, C6H, C3H); 3.94 (m, C6H, C’4H, C4H); 4.46 (d, 
C’1H/ 105.8); 5.25 (d, C1H)  
Leucine 0.96 (t, γCH3); 1.7 (m, CH2); 3.73 (t, αCH) 
Lysine 
 
1.48 (m, γCH2/24.28); 1.73 (m, δCH2/29.06); 1.92 (m, 
βCH2/32.60); 3.03 (t, εCH2)/42.02); 3.77 (t, αCH/57.28) 
Malonate 3.11 (s, CH2/48.7) 
N-methyl-2-pyridone-5-carboxamide 
(2PY)
 b
 
3.62 (s, CH3); 6.66 (d, C3H ring/120.85); 7.97 (dd, C4H 
ring); 8.33 (d, C6H ring/145.46) 
N-methylnicotinamide (NMND) 4.48 (s, NCH3/51.30); 8.18 (m, C5H ring); 8.90 (d, C4H 
ring); 8.97 (d, C6H ring); 9.29 (s, C2H ring) 
p-cresol sulphate (p-CS)
 b
 2.35 (s, CH3); 7.21 (d, C2H, C6H ring/124.12); 7.29 (C3H, 
C5H ring/125.04)  
Phenylacetylglutamine (PAG)
 b
 1.93 (m, βCH2) ; 2.11 (m, β’CH2); 2.27 (t, γCH2/34.44); 3.67 
(d, CH2); 4.18 (m, αCH); 7.36 (m, C2H, C4H, C6H 
ring/132.01); 7.43 (m, C3H, C5H ring/131.84) 
Pyruvate
 a
 2.39 (s, CH3) 
Scyllo-inositol
 a
 3.37 (s, CH) 
Succinate 2.41 (s, CH2/36.85) 
Sucrose 3.48 (t, C4H), 3.56 (dd, C2H), 3.63 (s, C1’H2), 3.77 (t, 
C3H), 3.83 (dd, CH2, C’6H2), 3.85 (m, C5H), 3.89 (m, 
C’5H, ), 4.06 (t, C’4H), 4.22 (d, C’3H), 5.41 (d, C1H) 
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Assignment (continues) δH ppm (multiplicity, assignment/ δC ppm) 
Tartrate
 a
 4.35 (s, CH(OH)) 
Taurine
 a
 3.26 (t, CH2SO3); 3.43 (t, NCH2)  
Threonine 1.33 (d, CH3/22.44); 3.61 (d, βCH/63.36); 4.26 (dd, 
αCH/68.90) 
Trigonelline  4.44 (s, CH3/50.98); 8.09 (t, C3H ring); 8.84 (br, C2H, C4H 
ring); 9.12 (s, C6H ring/148.73) 
Trimethylamine (TMA) 3.89 (s, CH3/47.40)  
Trimethylamine-N-oxide 
a
 (TMAO) 3.28 (s, CH3/62.31) 
Tyrosine 3.06 (dd); 3.21 (dd); 3.95 (dd); 6.91 (d, C3H, C5H 
ring/118.83); 7.20 (d, C2H, C6H ring/124.15)  
Urea 5.79 (br s, NH2) 
Valine 0.99 (d, γCH3); 1.04 (d, γ’CH3); 2.27 (m, βCH); 3.61 (d, 
αCH)  
Xylose
 a
 3.23 (dd, C3H), 3.33 (dd, C6H), 3.42 (t, C4H), 3.53 (dd, 
C3H), 3.63 (m, C6H, C5H, C4H), 3.93 (dd, C6H), 4.59 (d, 
C2H), 5.21 (d, C2H) 
 
3.2 Impact of non-fasting conditions on urine metabolomic studies 
In this work, due to limitations in controlling/restricting pregnant women diet in the 
daily hospital setting, all samples were collected in non-fasting conditions, during the 
morning period and after non-uniformised breakfast. This apparent constraint can become, 
in fact, one strong point of the study since developing multivariate models which are 
independent of confounding effects (arising from dietary and lifestyle habits), enables 
clinical applications to be envisaged, in situations where the ideal fasting condition (or 
standardized meals) are not possible or easy e.g. biofluid analysis at check-in at the clinic 
for immediate patient evaluation. 
Many previous metabolomics studies have evaluated the effect of diet in urine 
composition, usually by subjecting participants to controlled diets and collecting samples 
after predefined times, these interventions often being lengthy (e.g. weeks). In this context, 
the effect of several diets has been investigated, showing relevant changes in urine 
metabolomic profiles after consumption of specific foods, namely meat or animal protein 
(Stella et al., 2006, Bertram et al., 2007, Heinzmann et al., 2012), vegetarian diets (Stella 
et al., 2006), soy-rich diets (Solanky et al., 2005), tea (Wang et al., 2005, van Velzen et al., 
2009), chocolate (Rezzi et al., 2007, Martin et al., 2009), fruits (Heinzmann et al., 2012), 
wine and grapes (Heinzmann et al., 2012),  lingoberries (Lehtonen et al., 2013). Also, the 
effect of long-term dietary habits have been explored (Zuppi et al., 1998, Lenz et al., 2004, 
Holmes et al., 2008), a thorough  review of the metabolic effects of nutritional 
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interventions having been recently published (Llorach et al., 2012). Moreover, studies 
comparing urine samples collected fasting and non-fasting, after standardized breakfast, 
have also been pursued using a mass spectrometry approach (Favé et al., 2011, Lloyd et 
al., 2011). These studies showed that urinary changes between samples collected at fasting 
and postprandial were robust and reproducible within individuals suggesting a 2-4 h 
postprandial window for urine collection after a standardized breakfast (Favé et al., 2011). 
Furthermore, the effect of time of day for urine collection, morning vs. afternoon, has also 
been addressed (Saude et al., 2007, Slupsky et al., 2007) showing the susceptibility of 
urine composition during the day due to diet or circadian rhythms. 
 
3.2.1 Effect of non-fasting on urine composition 
In the present work, in order to evaluate the impact of non-fasting in the urinary 
metabolome in a female population, samples were collected for a group of NP in overnight 
fasting conditions and then approximately 2 hours after random breakfast, conditions in 
which collection occurred for all pregnant women enrolled in this study. The score plots of 
both PCA and PLS-DA showed higher dispersion of samples collected non-fasting, 
compared to those collected fasting (Figure 3.4). However, in spite of the apparent 
separation seen in the PLS-DA score plot, the model was found to be weak, as given by the 
Q
2
 value of 0.295, and model robustness assessed by MCCV yielded a classification rate of 
66%, sensitivity 65% and specificity 80% and approximately 40% of true models having 
Q
2≤-1. Nonetheless, the analysis of the loading plot unveiled differences in some 
metabolites, these being further evaluated by spectral integration and univariate 
comparison.  
 
Relevant and significant variations included decreased creatinine and hypoxanthine 
(effect size higher than -1) and increased furoylglycine (effect size 1.93), four unassigned 
spin systems/spectral regions (singlet at 2.48 ppm, singlet at 4.40 ppm, doublet at 8.45 ppm 
and region 6.47-6.57 ppm) in non-fasting, these being listed  in Table 3.2 along with the 
corresponding effect sizes and p-values. Whithin these metabolites, only creatinine and 
furoylglycine had been previously linked to dietary interventions  (Kumps et al., 2002, 
Solanky et al., 2005, Wang et al., 2005, Stella et al., 2006) but not hypoxanthine.  
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Figure 3.4: a) PCA and b) PLS-DA scores scatter plots of 
1
H NMR spectra of urine from NP 
women collected under fasting (●) and non-fasting (○) conditions and c) corresponding PLS-DA 
loading weights w[1] colored by VIP [1]. Ui: unassigned resonance i in order of appearance in 
Table 3.2, R
2
x: variation explained by the X matrix R
2
y: variation explained by the Y matrix, LV: 
latent variable.  
 
3.2.2 Proposed metabolic interpretation of the urinary changes under non-
fasting 
Urinary creatinine has been previously found to vary with diet, namely increased 
after chamomile tea (Wang et al., 2005) and meat (Stella et al., 2006) and decreased after 
soy-rich diets consumption (Solanky et al., 2005). Furoylglycine is formed by the 
conjugation of glycine with 2-furoic acid, the excretion of this compound having been 
related with diet, namely consumption of chocolate and heated juices (Kumps et al., 2002). 
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Increased urinary hypoxanthine have been associated with impaired ATP metabolism and 
in ischemia (Turgan et al., 1999) and after physical exercise (Enea et al., 2010), but not in 
relation to diet. Regarding unassigned resonances, a relevant variation was found for U1 
(effect size 2.28), along with U2 and U3 (effect size higher than 1.60), and the unassigned 
region 6.47-6.57 (effect size 1.91). 
 
Table 3.2: List of urinary changes noted, for the group of NP women, under non-fasting conditions 
compared to overnight fasting conditions. 
a 
Chemical shifts correspond to signals used for 
integration; values in square brackets correspond to peaks correlated through STOCSY; s: singlet, 
d: doublet, dd: doublet of oublets; 
b
 Ui: unassigned resonances number in order of appearance. 
c 
Significance level 95% (p-value <0.05). 
d
 Variation shown as effect size. 
Chemical shift 
(multiplicity)
a
 
Assignment
b
 
Variation (effect 
size, p-value)
c,d
 
2.48 (s) U1 ↑ (2.28, 9.5×10-6) 
4.06 (s) Creatinine ↓ (-1.10, 3.9×10-3) 
4.40 (s) [8.05, 8.54, 8.78] U2 ↑ (1.60, 8.3×10-3) 
6.65 (dd) Furoylglycine ↑ (1.93, 3.0×10-5) 
8.20 (s), 8.22 (s) Hypoxanthine ↓ (-1.35, 1.5×10-3) 
8.45 (d) U3 ↑ (1.64, 7.4×10-3) 
6.47-6.57  ↑ (1.91, 5.5×10-5) 
 
Therefore, it may be concluded that these studies could benefit from sample 
collection under fasting conditions, specifically towards controlling the contribution of diet 
as a confounding effect and in reducing sample dispersion. Nevertheless, the overall 
impact of non-fasting in multivariate models was found to be weak (supported by MCCV 
results). On the other hand, univariate analysis of individual resonances’ intensities 
confirmed the statistical (p-values 10
-3
-10
-6
) and biological significance (effect size higher 
than |1|) of 7 spin systems/spectral regions, meaning that a possible contribution of the 
non-fasting condition must be considered when interpreting variations of these metabolites.  
 
3.3 Following healthy pregnancy metabolism by NMR metabolic profiling of 
maternal urine 
3.3.1 Effect of healthy pregnancy on urine metabolite profile 
In this study, comparison of urine from healthy NP and pregnant women in their 1
st
, 
2
nd
 and 3
rd
 trimesters was carried out in order to characterize the time course metabolic 
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changes of healthy pregnancies, as viewed through the metabolite composition of maternal 
urine. This multipoint collection study unveils metabolite changes describing the expected 
healthy pregnancy progression so that, in future studies, a deviating trajectory in 
pathological pregnancies may be detected as a means of diagnostic.  
Typical 
1
H NMR spectra of urine collected for non-pregnant (NP) women and 
pregnant women in their 1
st
, 2
nd
 and 3
rd
 trimesters (T) of pregnancy are shown in Figure 3.1 
along with some relevant assignments. Indeed, some relevant changes can be visually 
inferred such is the case of isoleucine ( 3rd T), leucine ( 3rd T), 4-deoxyerythronic acid 
(4-DEA,  1st and 3rd T), 3-hydroxybutyrate (3-HBA,  3rd T), alanine ( 1st, 2nd and 3rd T), 
guanidoacetate (GAA,  1st T), histidine ( 1st T) and tyrosine ( 1st T), indicated by 
rectangles in the same figure. 
 
Urinary metabolic changes characteristic of each pregnancy trimester 
In order to confirm the visually observed changes, mentioned in the above 
paragraph, and identify other relevant changes in the 
1
H NMR spectra, as a function of 
gestation time, MVA was carried out considering each pair of sample groups, i.e. NP vs. 1
st
 
T, 1
st
 T vs. 2
nd
 T and 2
nd
 T vs. 3
rd
 T. Model robustness and predictive power was assessed 
by MCCV (quality parameters shown in Annex III, Table A-III.1 and Figure A-III.1) and 
the PLS-DA model scores and loadings plots obtained are shown in Figure 3.5.  
 
The PLS-DA scores plot corresponding to NP vs. 1
st 
T samples (Figure 3.5a), 
shows a clear group separation, with high Q
2
 (0.727) expressing its reliability. MCCV 
revealed 90% sensitivity and specificity, 88% classification rate and high median Q
2
 value 
(0.724), reflecting the good predictive power of this model. These results highlight that the 
major metabolic adaptions occurring in the 1
st
 T of pregnancy, compared to the NP state, 
have a significant impact on urine composition. This high impact in 1
st
 T urine was 
somehow expected based on previous reports, which had shown significant variations of 
selected amino acids in urine of pregnant and non-pregnant women (Miller et al., 1954, 
Hytten, 1973, Cho and Cha, 2005, Creasy et al., 2009).   
 
Chapter 3 
118 
 
Figure 3.5: PLS-DA scores and loading plots, colored by the VIP value, for a,b) NP vs. 1
st
 T, c,d) 
1
st
 vs. 2
nd
 T and e,f) 2
nd
 vs. 3
rd
 T. Ui: unassigned spin systems defined in Table 3.3, three-letter code 
for amino acids, GAA: guanidoacetate, 4-DTA: 4-deoxythreonic acid, 4-DEA: 4-deoxyerythronic 
acid. R
2
x: variation explained by the X matrix R
2
y: variation explained by the Y matrix, LV: latent 
variable. Arrows indicates outlier samples. 
 
The PLS-DA score plots of 1
st
 vs. 2
nd 
T and 2
nd
 vs. 3
rd 
T show a clear separation 
between pregnancy trimesters (Figure 3.5) supported by Q
2
 values of 0.483 and 0.580, 
respectively, although to with a smaller magnitude than the NP vs. 1
st
 T. MCCV, however, 
of the 1
st
 vs. 2
nd 
T model showed lower classification rate, 70%, lower sensitivity, 75%, 
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and especially lower specificity, 64% (higher rate of false positives), along with a low 
median Q
2
 value (0.324). The lower predictive power of this model, in the particular 
conditions of this study, is explained by the closeness of gestational ages (medians of 12 
and 17 g.w., respectively for 1
st
 and 2
nd
 trimesters (Table 2.2, Experimental Section) and 
also reflects that metabolic changes between 1
st
 and 2
nd
 trimesters are not as marked as in 
the previous pregnancy stage. Regarding the 2
nd
 vs. 3
rd 
T model, MCCV showed improved 
classification rate (80%), specificity and sensitivity (82% and 86%, respectively), with 
median Q
2
 of 0.416. Regarding to the two samples noted in Figure 3.5 (NP vs. 1
st
 T, 1
st
 vs. 
2
nd
 T and 2
nd
 vs. 3
rd
 T), which represent two samples collected at 1
st
 and 3
rd
 T clearly 
distant from the bulk of the 1
st
 and 3
rd
 T groups. The visual inspection of the corresponding 
spectra of these outlier samples revealed high concentrations of hippurate and TMAO, both 
metabolites possibly relating to diet (Llorach et al., 2012). 
 
The analysis of the corresponding loading weights plots for each model enabled the 
identification of the main compounds varying between the four groups. Relevant 
metabolites were integrated and tested for statistical (p-value<0.05) and biological (effect 
size) significance. Overall, 21 metabolites were found to vary significantly at some stage 
during pregnancy, their variations (described by direction, effect size and p-value) being 
listed in Table 3.3. Out of this 21-metabolite signature, 9 were in agreement with literature 
(namely leucine, isoleucine, alanine, carnitine, taurine, glycine, threonine, tyrosine and 
histidine) while 8 metabolites were registered to vary in connection to pregnancy for the 
first time (namely 4-DEA, 4-deoxythreonic acid (4-DTA), 3-HBA, choline, GAA, 
creatinine, lactate and furoylglycine) these being noted with 
 
in Table 3.3, the remaining 4 
metabolites being still unassigned. 
The results obtained showed that the urinary profile of the 1
st
 T was characterized 
by the increased excretion of alanine, glycine, histidine, tyrosine, 4-DEA, GAA and four 
unassigned metabolites (singlet at 0.55, 0.63 and 2.15 ppm and a doublet at 1.18 ppm) 
along with decreased creatinine and furoylglycine. Out of these, only U2 (singlet at 0.63 
ppm) and alanine increased significantly throughout pregnancy (the variation of alanine 
being expected based on literature (Hytten, 1973, Creasy et al., 2009)). Regarding the 2
nd 
T, urine exhibits increased alanine, U2, 4-DTA and glycine along with decreased taurine
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Table 3.3: List of metabolites/resonances changes in urine from the NP state to 1
st
,  2
nd
 and 3
rd
 
trimesters. 
a 
Chemical shifts shown correspond to signals used for integration; value in square 
brackets for correspond to correlated peak seen through TOCSY or STOCSY; s: singlet, d: doublet, 
t: triplet, q: quartet, dd: doublet of doublets, m: multiplet. 
b 
Significance level: 95% (p-
value<0.05). 
c 
Magnitude of variations shown as effect size. Ui: unassigned resonance for 
compound i. 
d
Peak overlapped with other resonances. 
e
Putatively assigned as acetyl-carnitine. 
Metabolites observed to vary in maternal urine, for the first time throughout pregnancy. 4-DEA: 
4-deoxyerythronic acid, 3-HBA: 3-hydroxybutyrate, 4-DTA: 4-deoxythreonic acid, GAA: 
guanidoacetate. 
  Variation (effect size
c
, p-value
b
) 
δH/ppm and 
multiplicity 
Assignment NP vs. 1
st
 T 1
st
 T vs. 2
nd
 T 2
nd
 T vs. 3
rd
 T 
0.55 s [0.78 m] U1 ↑(2.7, 3.1×10-6) ─ ↑(2.47, 1.4×10-7) 
0.63 s U2 ↑(3.3, 1.8×10-6) ↑(0.9, 1.1×10-2) ↑(2.55, 3.9×10-7) 
0.96 t Leucine ─ ─ ↑(0.92, 3.1×10-3) 
1.01 d Isoleucine ─ ─ ↑ (2.07, 1.9×10-6) 
1.11 d 4-DEA ↑(0.78, 4.2×10-2) ─ ↑(1.61, 1.3×10-4) 
1.18 d [1.45, 3.82] U3 ↑(0.82, 2.7×10-2) ↓(-0.9, 1.4×10-2) ─ 
1.20 d 3-HBA ─ ─ ↑ (1.57, 6.1×10-5) 
1.23 d 4-DTA ─ ↑(0.92, 1.7×10-2) ↑(0.86, 2.6×10-2) 
1.49 d Alanine ↑(1.02, 1.3×10-2) ↑(0.88, 3.4×10-2) ↑(0.63, 4.8×10-2) 
2.15 s U4
 d,e
 ↑(0.84, 2.5×10-2) ─ ─ 
3.20 s Choline ↑(0.88, 3.9×10-2) ─ ─ 
3.23 s Carnitine ─ ─ ↓(-1.76, 1.7×10-5) 
3.43 t Taurine ─ ↓(-1.35, 1.3×10-3) ─ 
3.57 s Glycine ↑(1.45, 1.6×10-4) ↑(0.68, 3.9×10-2) ─ 
3.80 s GAA ↑(1.19, 1.1×10-3) ─ ─ 
4.06 s Creatinine ↓(-1.43, 3.3×10-4) ─ ↓(-0.76, 3.5×10-2) 
4.11 q Lactate ─ ─ ↑(0.37, 2.5×10-2) 
4.26 m Threonine ─ ─ ↑(1.22, 9.1×10-4) 
6.65 dd Furoylglycine ↓(-1.92, 5.9×10-5) ─ ↑(0.96, 1.9×10-3) 
6.91 d Tyrosine ↑(1.11, 4.4×10-3) ─ ─ 
7.13 s Histidine ↑( 1.12, 1.1×10-2) ─ ─ 
 
and U3 (doublet at 1.18 ppm). Within these changes that of alanine, glycine and taurine are 
consistent with previous literature reports (Hytten, 1973, Cho and Cha, 2005, Creasy et al., 
2009) whilst that of 4-DTA was here found for the first time to our knowledge. Finally, 
third trimester urine was characterized by an increase in alanine, leucine, isoleucine, 
threonine, 4-DEA, 4-DTA, 3-HBA, U1 (singlet at 0.55 ppm), U2 and lactate with 
decreased creatinine and carnitine. Out of these changes, the increase of alanine, leucine, 
isoleucine and threonine were consistent with previous findings (Miller et al., 1954, 
Hytten, 1973, Creasy et al., 2009), whilst creatinine, 4-DEA, 4-DTA and 3-HBA were here 
found to vary for the first time to our knowledge. Regarding the unassigned resonances 
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here found to vary across pregnancy, U1 and U2 (singlets at 0.55 and 0.63 ppm) possibly 
arise from bile acids as these type of compounds typically resonate in the 0.5-1.0 region  
(Trump et al., 2006, Duarte et al., 2009), U3 (doublet at 1.18 ppm) and U4 (singlet at 2.15 
ppm) possibly belonging to acetyl-carnitine although definitive assignment was not 
possible due to the low intensity of the peak in this set of spectra and overlapping with 
other resonances.  
Previous reports
 
have indicated that a) the excretion of alanine, glycine, histidine, 
serine and threonine increases during pregnancy; b) the excretion of cysteine, leucine, 
lysine, phenylalanine, taurine, tyrosine and valine increases early on and decreases later in 
gestation and that c) the excretion of arginine, asparagine, glutamate, isoleucine, 
methionine and ornithine is not expected to change significantly (Hytten, 1973, Creasy et 
al., 2009). In this work, alanine, glycine, histidine and threonine were confirmed to 
increase in urine; changes in excreted taurine and tyrosine were confirmed, while leucine 
varied differently than expected (increased in 3
rd
 T). Out of the amino acids not expected to 
change significantly, isoleucine presented a marked increase in the 3
rd
 trimester, 
consistently however with a much earlier report (Miller et al., 1954). In relation to the 
remaining amino acids, arginine, asparagine, cysteine, glutamate, methionine, 
phenylalanine and ornithine were not detected (probably due to their too low 
concentrations for NMR observation) whereas no significant changes could be measured 
for lysine, serine and valine. Moreover, carnitine has been reported to increase in the 1
st
 T 
and decrease in the 3
rd
 T (Cho and Cha, 2005), only the later trend having been found 
significant in this study. 
 
To facilitate visual inspection of the variations, metabolites’ integrals were plotted 
in a qualitative color-coded heatmap (Figure 3.6). In this plot, each line represents one 
subject and each column corresponds to a metabolite set of integrals, normalized to unity 
in order to enable the comparison of variations. This means that the maximum integral 
value is colored in dark red, the minimum value is shown in dark blue and the intermediate 
integrals are shown accordingly to the gradient of color. Inspection of this figure firstly 
reveals the significant extent of inter-subject variability. Still, and in spite of some  
dispersion noted in metabolite intensities, some of the above mentioned variations are 
clearly visible, namely the increases of U1 (0.55 ppm, singlet) and U2 (0.63 ppm, singlet), 
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amino acids alanine, glycine, histidine and tyrosine, choline, 4-DEA, 3-HBA and decreases 
for creatinine, carnitine and furoylglycine. 
 
 
Figure 3.6: Heatmap of normalized integrals of the 21 metabolites varying across pregnancy. Lines 
and columns represent, respectively, subjects and integrals. Integrals are shown in a color scale, 
with dark blue representing the minimum integrals value and dark red the maximum integral value. 
Metabolites are ordered, from left to right, from those exhibiting marked increases to those 
exhibiting marked decreases across pregnancy (* denotes metabolites found to vary across 
pregnancy for the first time). 
 
In order to verify that indeed the metabolic trajectory throughout pregnancy can be 
suitable described by this 21-metabolite profile, MVA was repeated using this selection of 
integrals alone. The resulting two-class models had a significant improvement in terms of 
CR, sensitivity and specificity determined by MCCV (NP vs. 1
st
 T: CR 98%, sensitivity 
98%, specificity 96%; 1
st
 T vs. 2
nd
 T: CR78%, sensitivity: 89%, specificity 68%; 2
nd
 T vs. 
3
rd
 T: CR 99%, sensitivity 96%, specificity 100%, also show in Annex III, Table A-III.1 
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and Figure A-III.2) with the exception of the 1
st
 vs. 2
nd
 T model. Moreover, PCA and PLS-
DA of the four classes using this set of 21 metabolites unveiled an overall metabolic 
trajectory of healthy pregnancies significantly improved compared to the whole 
1
H NMR 
spectra (Figure 3.7b,c compared to a,b). The curved directional path in Figure 3.7d) 
indicates the trajectory followed throughout pregnancy and the sample indicated with a 
short arrow corresponds to one collected relatively late in pregnancy (39 g.w.), thus 
seemingly continuing the samples trend towards pregnancy term. This sample was shown 
to have high contents of choline and U1 (possibly a bile acid), these components revealing 
to be highly determinant at the end of pregnancy.  
 
 
Figure 3.7: a,b) PCA and PLS-DA score plots obtained using the whole 
1
H NMR spectra of urine 
and c,d) PCA and PLS-DA score plots obtained using the selection of 21 relevant integrals of NP, 
1
st
 T, 2
nd
 T and 3
rd
 T pregnant women. The arrow in d) indicates the trajectory across pregnancy. 
R
2
x: variation explained by the X matrix R
2
y: variation explained by the Y matrix, LV: latent 
variable. 
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Based on the PLS-DA obtained using the set of 21 metabolites (shown in Figure 
3.7d), each subject group could then be described by a discrimination function of the type
, with n=21, where each coefficient bi gives the contribution of 
variable i for what can be considered a profile signature for each trimester of a healthy 
pregnancy. These functions describe the weight-distribution of the 21-metabolite integrals 
characteristic of NP and each pregnancy stage. The relative contribution of each variable, 
in this case each integral and corresponding equation for each trimester are shown in 
Figure 3.8. The usefulness of these equations is that they provide class membership for a 
given new sample. This means that by calculating each of the variables, in this case the 
area of each peak (integral), and multiplying that area by the corresponding b coefficient, 
the resulting linear combination yields a y value which converges towards 0, if the sample 
does not belong to that class, in this case that trimester, or 1 if the sample belongs to that 
trimester. It is envisaged that these function can be useful in future profile-matching of the 
urine of new subjects (in a given trimester) to confirm the healthy course of pregnancy or 
detect deviant trajectories. 
 
Elucidation of metabolic relationships using STOCSY  
Further metabolic characterization of each subject group was attempted through 
STOCSY, in order to identify eventual metabolically related compounds. Correlations 
between all 21 metabolites were calculated for each pregnancy trimester along with the 
corresponding p-value. A threshold of r>0.6 and p-value<0.05 was applied and 
correlations were confirmed by scatter plotting each pairs of correlated integrals (not 
shown) to detect spurious correlations.  
Meaningful correlations were found for the 1
st
 T group, namely between U1/U2 (r 
0.70), isoleucine/leucine (r 0.68), isoleucine/U4 (r 0.73) and isoleucine/carnitine (r 0.72), 
3-HBA/U4 (r 0.93) and 3-HBA/carnitine (r 0.74), alanine/GAA (r 0.61), 4-DTA/carnitine 
(r 0.74). For the 2
nd
 trimester groups, relevant correlations were found for U1/U2 (r 0.88), 
isoleucine/leucine (r 0.63). The 3
rd
 trimester group was characterized with correlations 
between U1/U2 (r 0.76), U2/3-HBA (r 0.74), 4-DEA/3-HBA (r 0.73), 4-DTA/3-HBA (r 
0.64) and isoleucine/leucine (r 0.85). The above correlations enables the proposal of 
putative metabolic relationships between branched chain amino acids (BCAA) metabolism,  
 
nnxbxbcy  ...11
Defining the global urinary profile of pregnancy and the metabolic adaptations throughout 
gestation- a multipoint collection study 
125 
 
Figure 3.8: Sets of PLS-DA b-coefficients for each class: a) NP, b) 1
st
 T, c) 2
nd
 T and d) 3
rd
 T and 
corresponding 21-variable discriminant equations (below). Aa: area of peak representative of 
metabolite a; variables ordered by descending values of b-coefficients. ypr[class]: predicted value 
reflecting sample class; ypr=1 or ypr=0 respectively if sample predicted to belong to the class 
indicated or not. GAA: guanidoacetate; FuroylGly: furoylglycine; Crn: creatinine, 4-DTA: 4-
deoxythreonic acid, 4-DEA: 4-deoxyerythronic acid, Lac: lactate, Ui: unassigned i, 3-letter codes 
used for amino acids. 
Ypr[1stT]=0.225-0.001AU1–0.005AU2+0.034ALeu-0.012AIle+0.022A4-DEA+0.13AU3+0.021A3-HBA-0.070A4-DTA-0.052AAla+0.044AU4-.009ACho+0.086ACar+
0.091ATau-0.003AGly+0.023AGAA-0.050ACrn-0.016ALac-0.066AThr-0.077AFuroylGly+0.010ATyr-0.011AHis
Ypr[NP]=0.225-0.022AU1–0.029AU2–0.028ALeu+0.016AIle-0.029A4-DEA-0.048AU4-0.027A3-HBA+0.020A4-DTA-0.015AAla–0.048AU4-0.032ACho-0.030ACar-
0.017ATau-0.049AGly-0.055AGAA+0.069ACrn-0.001ALac+0.009AThr+0.089AFuroylGly-0.042ATyr-0.045AHis
Ypr[2ndT]=0.282-0.037AU1–0.026AU2-0.029ALeu-0.063AIle-0.038A4-DEA-0.054AU3-0.032A3-HBA+0.002A4-DTA+0.031AAla+0.021AU4+0.017ACho-0.006ACar-
0.045ATau+0.036AGly+0.027AGAA-0.009ACrn-0.002ALac+0.005AThr-0.033AFuroylGly+0.048ATyr+0.060AHis
Ypr[3rdT]=0.268+0.060AU1+0.060AU2+0.023ALeu+0.059AIle+0.045A4-DEA-0.030AU3+0.038A3-HBA+0.047A4-DTA+0.036AAla-0.017AU4+0.024ACho-0.049ACar-
0.030ATau+0.017AGly+0.006AGAA-0.010ACrn+0.019ALac+0.052AThr+0.021AFuroylGly-0.015ATyr-0.003AHis
NP 1st T
2nd T 3rd T
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lipids oxidation and ketone bodies production and U4 (putatively acetyl-carnitine) in the 1
st
 
T, a relationship between U1 and U2 (possibly bile acids) and BCAA leucine and 
isoleucine in 2
nd
 T, and finally a metabolic relationship between U1, U2, 4-DEA and 4-
DTA with ketone bodies production in the 3
rd
 T.  
 
3.3.2 Proposed metabolic interpretation of the urinary changes found across 
pregnancy 
The significant changes observed in maternal urine composition throughout 
pregnancy relate mainly to amino acids and some derivatives, choline, carnitine and 3-
HBA, creatinine and four important unassigned resonances. A schematic representation of 
the metabolic pathways adaptations with and throughout pregnancy is shown in Figure 3.9. 
Most observations fit broadly with the existing knowledge of the biochemical phenomena 
accompanying pregnancy (King, 2000, Herrera, 2002, Hod et al., 2008, Creasy et al., 
2009). In addition, changes newly found for choline, creatinine, 4-DEA and 4-DTA, 
furoylglycine, GAA, 3-HBA and lactate, were registered here, to our knowledge for the 
first time in connection to pregnancy. 
 
Amino acid and their derivatives and lipids metabolism 
Pregnancy is usually accompanied by selective aminoaciduria, the exact 
mechanism of which is not fully known (Hytten, 1973, Creasy et al., 2009). Moreover, 
pregnancy is known to be accompanied by increased placental transfer of amino acids, 
favoring nitrogen conservation for fetal growth (King, 2000, Hod et al., 2008), and thus 
leading to diminished circulating levels of many amino acids in plasma, a condition known 
as hypoaminoacidemia. This is also related to an underuse of many amino acids for 
maternal gluconeogenesis, particularly later in gestation, making way for alternative 
substrates such as glycerol (Hod et al., 2008). 
Lower plasma levels of alanine and other urea cycle amino acids (citrulline, 
ornithine and arginine) have been reported throughout pregnancy associated to a slowing 
down of urea synthesis (King, 2000). In spite of the expected redirection of alanine and 
other amino acids to the fetus, their urinary excretion is typically increased, consistently 
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with the findings of this work, an aspect which has been proposed to reflect impaired renal 
reabsorption rather than a saturation phenomenon (Hytten, 1973, Creasy et al., 2009).  
Regarding glycine, its involvement in methionine metabolism might suggest an 
enhanced production from dimethylglycine, DMG (formed through remethylation of 
homocysteine to methionine) (Dasarathy et al., 2010). However, this is an unlikely source 
of glycine in early pregnancy, since the alternative pathway of homocysteine conversion to 
cysteine through transsulfuration (and then to taurine and/or the reduced form of 
glutathione, GSH, Figure 3.9) has been proposed as more effective in early pregnancy, in 
relation to the non-pregnant state (Dasarathy et al., 2010). This is indeed consistent with 
the observed early increase in excreted choline, possibly due to its underuse in the 
remethylation pathway to produce DMG, as well as with the trend for higher taurine levels 
in the 1
st
 T (although with p-value>0.05 the increasing trend is visible in Figure 3.6). It has 
also been suggested that the preferential activation of homocysteine remethylation occurs 
in later gestation, which is connected with the choline/DMG pathway or demethylation of 
tetrahydrofolate (THF) (Dasarathy et al., 2010). The increasing trend seen for choline 
across the whole pregnancy period (shown in Figure 3.6), although not statistically 
significant, suggests that the THF pathway may be favored, possibly in connection to folic 
acid diet supplementation (confirmed for 76% of the pregnant women, information not 
available for the remaining). Furthermore, the concomitant lower taurine levels, in 2
nd
 and 
3
rd
 T, are in agreement with the above mentioned redirection of the methionine pathway.  
Regarding branched amino acids (BCAA) leucine and isoleucine, their variations 
differ from those reported previously (Hytten, 1973, Creasy et al., 2009), both increasing 
significantly in the 3
rd
 T. BCCA oxidation is known to decrease in late pregnancy thus 
increasing BCAA availability for the fetus (King, 2000, Hod et al., 2008) and, similarly to 
other amino acids, this seems to lead to their enhanced excretion. Through integrals 
correlations, or STOCSY, it was found that leucine and isoleucine integrals were 
consistently inter-correlated in all groups (r 0.68, 0.68, 0.63 and 0.85 in NP, 1
st
, 2
nd
 and 3
rd
 
T, respectively), reflecting their common pathway involvement. In addition to this, in the 
1
st
 T, isoleucine showed correlations to carnitine (r 0.72) and U4 (r 0.73), the latter two 
resonances also found to correlate to 3-HBA (r 0.74 and 0.93, respectively for carnitine 
and U4). This hinders a particular importance of isoleucine in lipid oxidation and ketone 
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body synthesis, early on in pregnancy even though increased maternal fat deposition and 
lipogenesis are known to take place preferentially, at that stage (Herrera, 2002).  
Carnitine plays and essential role in lipid metabolism as it enables the entrance of 
long-chain fatty acids into the mitochondria were they undergo β-oxidation producing 
ketone bodies. Enhanced lipid oxidation is known to occur later in gestation (Herrera, 
2002). This enhancement is consistent with the marked decrease of excreted carnitine here 
found in the 3
rd
 T, suggesting its increased use and consistently with previous reports (Cho 
and Cha, 2005), and with the accumulation of urinary 3-HBA. In the same trimester, the 
latter compound was found to correlate with 4-DEA and 4-DTA (r 0.73 and r 0.64, 
respectively), suggesting a possible relationship of these threonine catabolic products 
(Appiah-Amponsah et al., 2009, Ellis et al., 2012) to ketone body production, consistently 
with the ketogenic nature of the amino acid.  
Regarding amino acid derivatives, changes were noted for the first time to our 
knowledge, in the excretion of glycine derivatives guanidoacetate, or GAA, and 
furoylglycine. Higher excretion of GAA have been previously associated to the 
accumulation of arginine in the urea cycle (Brosnan and Brosnan, 2010), thus possibly 
relating to the expected slowing down of that pathway in pregnancy (Figure 3.9). This 
possible involvement in the urea cycle is consistent with a correlation found for GAA with 
alanine (r 0.61) in the 1
st
 T. In relation to furoylglycine, a conjugation product of glycine 
with 2-furoic acid, it is well known that this compound relates strongly to diet, having been 
related to the consumption of chocolate and heated juices (Kumps et al., 2002). Its relation 
to diet was confirmed in this work, by its significant increase in the non-fasting test group 
(shown in section 3.2, Table 3.2) so that it is possible, therefore, that the increase (0.96 
effect size) in furoylglycine in the 3
rd
 T may arise from a spurious diet effect. However, the 
significant decrease in the 1
st
 T (ca. 2-fold, p  10-5, Table 3.3) allows for the suggestion 
that a specific relationship of furoylglycine to pregnancy may exist, possibly in relation to 
lipid metabolism as is the case of other acyl-glycines (Ombrone et al., 2011, Dunn et al., 
2012). Finally, still in relation to energy metabolism, it is interesting to note that the 
documented tendency for increased excretion of glucose in pregnancy (Hytten, 1973, 
Creasy et al., 2009) was not detected as significant in the specific conditions of this study, 
probably indicating its reduced magnitude compared to the impact of other effects such as 
inter-subject variability and non-fasting. Furthermore, other changes found previously in 
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lactose (Hytten, 1973) were not observed in this study, whereas lower abundance sugars 
(ribose, fucose, fructose) and vitamins (nicotinic acid, folic acid), also expected to change, 
could not be detected.  
 
Creatinine metabolism  
Creatinine excretion was found to decrease significantly with pregnancy, for the 1
st
 
time to our knowledge, in spite of earlier evidence that 24 hour urinary creatinine excretion 
was not altered during pregnancy (Gallery et al., 1996). Creatinine is formed from creatine, 
which is obtained either from diet or from the conversion of GAA (Figure 3.9), its levels in 
serum known to decrease throughout pregnancy due to increased glomerular filtration rate 
(Creasy et al., 2009). The observed decrease in creatinine excretion may reflect the latter 
effect, however, other variables may contribute to it, namely a possible alteration of 
creatine synthesis in relation to urea cycle defects (Brosnan and Brosnan, 2010), or the 
effect of diet (Solanky et al., 2005, Stella et al., 2006). In relation to the latter, a relative 
decrease in excreted creatinine was indeed observed in samples collected non-fasting 
(Table 3.2). However, since all samples in this main study were collected in non-fasting 
conditions, the consistent decrease across pregnancy may also reflect gestation itself. 
 
Important unassigned spin systems 
Within the four unassigned resonances seen to change throughout pregnancy, U1 
(0.55, s and 0.78 ppm, m) and U2 (0.63 ppm, s) stand out as highly significant. The 
possibility of these peaks arising from bile acids was investigated through comparison with 
the spectra of standard compounds (namely, cholic acid, glycocholic acid, 
chenodeoxycholic acid, deoxycholic acid and glycochenodeoxycholic acid), however, no 
conclusive assignments could be achieved. Both resonances are positively correlated to 
each other, in all subject groups but, since their relative intensities are variable, it may be 
concluded that they originate from metabolically related entities rather than from one 
single compound. In the 3
rd
 T, U2 further correlates to 3-HBA (r 0.74), which suggests a 
possible relation of the unassigned singlet to ketone body formation. Regarding U3 (1.18 
ppm, 1.45 and 3.82 ppm), correlations were observed in 3
rd
 T with leucine (r 0.64) and 
isoleucine (r 0.85), suggesting that the compound may be involved in the expected 
alterations of BCAA oxidation later in gestation. In relation to U4 (putatively acetyl-
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carnitine), the noted positive correlations with 3-HBA and isoleucine (r 0.93 and r 0.73, 
respectively) also suggest a possible involvement in ketone body synthesis. 
 
 
Figure 3.9: Schematic representation of the metabolic pathways adaptations with and throughout 
healthy pregnancy. Metabolites in bold were identified in 
1
H NMR spectra of maternal urine. 
Amino acids in 3-letter code; 4-DEA: 4-deoxyerythronic acid, 4-DTA: 4-deoxythreonic acid, 3-
HBA: 3-hydroxybutyrate, DMA: dimethylamine, DMG: dimethylglycine, GAA: guanidoacetate, 
Hcy: homocysteine, GSH: gluthathione, THF: tetrahydrofolate. 
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3.3.3 Summary of changes across pregnancy 
To sum up, the general increase in amino acid excretion confirmed the expected 
aminoaciduria accompanying pregnancy, with leucine and isoleucine being more 
significantly excreted than expected based on the literature, possibly in connection to a 
marked slowing down of BCAA oxidation in the 3
rd
 T. STOCY analysis suggested that 
isoleucine was also somehow involved in lipid oxidation (through correlation with 
carnitine) and ketone body synthesis (through correlation with 3-HBA), in the 1
st
 T. 
Threonine and its degradation products, 4-DEA and 4-DTA were found to correlate with 3-
HBA, possibly in the connection to ketogenesis. The newly noted change in choline was 
suggested to relate, together with taurine, to methionine metabolism and preferential 
homocysteine methylation through THF, later in pregnancy. Furthermore, the over 
excretion of glycine derivative GAA was suggested to relate to the urea cycle deregulation 
known to accompany pregnancy, whereas another glycine derivative often associated with 
diet, furoylglycine, was proposed to have a possible particular relationship to pregnancy, 
due to its marked change in pregnant women, compared to the NP state. A similar proposal 
was advanced in relation to creatinine, in spite of its concomitant clear dependence on diet 
(creatinine was found to decrease in samples collected non-fasting). Finally, it is important 
to note the marked dependence of unassigned resonances U1 (singlet at 0.55 ppm) and U2 
(singlet at 0.63 ppm), throughout pregnancy for which a significant gestational age 
dependence was found, albeit the presently hampered knowledge as to their exact origin. 
Second trimester maternal urine for the diagnosis of fetal disorders and prediction of poor 
pregnancy outcomes 
133 
4. Second trimester maternal urine for the diagnosis of fetal disorders 
and prediction of poor pregnancy outcomes   
In this chapter, the metabolic impact of FM, CD and later developing PTD, PE, 
IUGR and PROM on the composition of maternal urine was investigated. A novel variable 
selection method was employed to more efficiently extract information from urine NMR 
spectra. In addition, a preliminary external validation for selected cases was performed 
and, in the case of the pre-PTD, comparison of NMR and UPLC-MS data was carried out. 
 
4.1 Impact of diagnosed fetal disorders on maternal urine composition 
4.1.1 Fetal malformation (FM) cases 
For the study of FM, maternal urine collected for women carrying malformed 
fetuses, diagnosed by ultrasound and undergoing amniocentesis, was compared with that of 
controls (healthy women with healthy pregnancies). Sample numbers and metadata are 
presented in Section 2.1.2 b), Tables 2.2 and 2.3 in Experimental Section.  
Following a preliminary study, using a smaller cohort and different data treatment 
(bucketing and no variable selction) published in an initially stage of this work (Diaz and 
Pinto et al., 2011), some changes were expected in maternal urine of women carrying 
malformed fetuses. The work described below implies the use of a larger cohort and 
improved analytical strategies.  
The visual comparison of the average 
1
H NMR spectra of urine of healthy 
(controls) and FM cases revealed some subtle changes mainly in the aliphatic region, 
namely in 3-hydroxybutyrate (3-HBA), alanine, acetone, acetoacetate, succinate, and 
aromatic region, namely in 4-hydroxyphenylacetate (4-HPA) and tyrosine (Figure 4.1). 
PLS-DA was applied to the NMR datasets to aid more detailed comparison of control and 
FM cases, although the obtained model was found to have no predictive power, as given by 
the low Q
2
 value (0.251) and MCCV results showing high overlap of Q
2
 distributions for 
true and permuted models and poor ROC, low classification rate (69%), specificity (75%) 
and sensitivity (49%) rates (Figure 4.2, Table A-III.2, Annex III). The lack of model 
robustness probably arises from the complex nature of urine, which typically contains 
information reflecting several different factors, such as diet,drugs, environment (Bouatra et 
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al., 2013), these factors having comparable (or possibly even higher) impact in urine 
composition to the changes found for FM. Thus, it was necessary to devise a way to 
retrieve the spectral data associated with sample class, in this case control vs. FM. This was 
carried out by applying a variable selection methodology to remove irrelevant, unreliable 
and noisy variables. The development and validation of a variable selection method is 
described in detail throughout the next section. 
 
 
Figure 4.1: Average 500 MHz 
1
H NMR spectra of 2
nd 
T maternal urine of a) controls (n=84) and b) 
women carrying malformed fetuses (n=35). Curved lines indicate regions where changes are noted 
and arrows point at specific changing metabolites. 
 
4.1.1.1 Development and validation of a variable selection methodology 
To develop the variable selection method for NMR data, two PLS-DA parameters 
were considered due to their complementarity, namely the VIP and b-coefficient values. b-
coefficients values derive from the discrimination function and reflect the discriminant and 
predictive capability of each variable i.e. their contribution for samples classification. In 
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addition, VIP values reflect the importance of each variable to the projection in the low 
dimensional space i.e. the relevance of each variable for samples geometric separation. 
Both parameters are based on the multivariate method PLS-DA, thus both taking into 
account the concomitant changes and interactions between variables/metabolites. Because 
these interactions are determinant for the definition of the overall profile, univariate 
methods were not used for the development of this variable selection methodology, as 
these would only take into account individual metabolites changes.  
In this work, four variable methodologies were tested. The first method explored 
(method i) was based on the selection of variables with VIP>1, these variables being by 
definition relevant for class separation. The method had been previously reported for the 
study of cancer through blood plasma metabolomics (in an animal model) (Sun et al., 
2012) and foodstuff adulteration (specifically the contamination of commercial spices with 
Sudan dyes colorants) (Di Anibal et al., 2011). The second and third methods explored 
(respectively named as methods ii) and iii)) were based on signal uncertainty using a jack-
knife approach obtained by cross-validation (Andersen and Bro, 2010). For these methods, 
the VIP- and b-coefficient standard errors were obtained, as determined by cross-
validation, respectively VIPcvSE and bcvSE. Method ii) consisted in selecting variables with 
VIP/VIPcvSE>1 whilst the method iii) was based on selecting variables with |b/bcvSE|>1. 
Lastly, the interception of all previous variable selection methods was attempted and 
named as method iv), corresponding to the selection of variables with simultaneously high 
VIP and low VIP- and b-coefficient standard errors. The principle of data interception has 
been used before in only one instance (study of nonalcoholic fatty liver disease (Quintás et 
al., 2012)) although based on different criteria.  
Upon application of each variable selection method, PLS-DA were recalculated 
using the resulting data subsets and resubmitted to MCCV, with the resulting model quality 
parameters, validation results and number of selected variables shown in Table A-III.2, 
Annex III. The best models were obtained with method iv), the interception method, which 
yielded good model parameters (Q
2
, Q
2
median, classification rate, sensitivity and specificity). 
Figure 4.2 illustrates the performance of this variable selection method when applied to the 
study of FM. The significant reduction in samples dispersion can be seen in the PLS-DA 
score plots after variable selection (Figure 4.2a,d) as well as the noteworthy improvement 
in Q
2
 distribution, with significantly reduced overlap of true and permuted models (Figure 
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4.2b,e) and improvement in specificity and sensitivity, visible through ROC plots (Figure 
4.2c,f). Moreover, a significant improvement in classification rate (CR), sensitivity and 
specificity (respectively 84%, 74% and 87%) was achieved, compared to those obtained 
using the original dataset (respectively 69%, 49% and 75%).  
 
 
Figure 4.2: PLS-DA scores plots (a, d), Q
2
 distributions (b, e), and ROC plots (c, f) of true and 
permuted models obtained for the original 
1
H NMR spectra of urine of controls (⧫, n=84) and FM 
(◊, n=35) and for the same spectra after variable selection using intersection method iv). TPR, true 
positive rate; FPR, false positive rate. 
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This selection method enabled the most drastic variable reduction of the original 
dataset without compromising the model’s predictive power, as the best result was 
consistently obtained using this variable selection method. The significant data reduction 
poses two major advantages, the first being that only spectral regions that accurately define 
the condition (thus, the potential metabolic profile) are retrieved. The second advantage 
consists of the lowering of the variables/samples ratio, thus reducing the risk of model 
overfitting. All NMR results presented from this point onwards were obtained using this 
variable selection methodology. 
 
To retrieve the urinary profile on the basis of the PLS-DA separation, the average 
NMR spectrum of the control and FM groups were compared along with indication of the 
subset of spectral variables selected. An example of this spectra comparison is shown in 
Figure 4.3, for the 0.5-4.6 ppm spectral region. In this figure, the gray dots under the 
bottom spectra indicate variables selected, and the insets note that relevant variables may  
 
 
Figure 4.3: Average 
1
H NMR spectra of a) control and b) FM groups (0.5-4.6 ppm) with indication 
of spectral variables, i.e. data points/gray dots under bottom spectra, selected by variable selection 
method  iv. 
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fall in regions with low signal intensity but confirmed to always bear visible resonances at 
the appropriate level of vertical expansion. This demonstrates the importance of low 
intensity, and often unassignable, NMR signals in incorporating the potential fingerprint of 
a given disorder. 
 
4.1.1.2 Unveiling urinary metabolic signatures of general FM and central 
nervous system (CNS) malformations 
The group of selected variables supporting the separation seen in the PLS-DA score 
plot in Figure 4.2d enabled a NMR signature to be identified for FM cases. This signature 
comprises changes in 17 assigned compounds, 7 unassigned spin systems (Ui) (singlet at 
0.63 ppm, doublet at 1.08 ppm, doublet at 1.15 ppm, singlets at 1.99 ppm, 2.05 ppm, 2.06 
ppm and 2.39 ppm) and several unassigned spectral regions (defined as spectral regions 
comprising overlapped unidentifiable resonances). Each metabolite, unassigned compound 
or spectral region were tested for statistical (p-value) and biological significance (effect 
size) (Table 4.1, left). In this table, metabolites that may originate from diet (either directly 
e.g. xylose, 3-methylhistidine, or through their interaction with the gut microflora e.g. 4-
hydroxyphenylacetate (4-HPA), scyllo-inositol) are marked with 
b
. 
 
Overall, 18 signals were found to vary with statistical relevance (p<0.05). PLS-DA 
was repeated considering only this set of significant integrals (p<0.05), the resulting scores 
plot and MCCV results being shown in Figure 4.4. Through this figure, it becomes clear 
that no reliable group separation was achieved (with high overlap of samples in the scores 
plot and of Q
2 
values distribution of true and permuted models) when only significant 
integrals were taken into account. This finding supports the idea that using full spectral 
resolution of NMR spectra (including unassigned signals and signals with no individual 
significance, p>0.05) is of paramount importance for an effective disease signature to be 
achieved.  
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Table 4.1: Metabolite/resonance changes in maternal urine of FM vs. controls and CNS vs. other FMs. 
a
Chemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in square brackets; s: 
singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, m: multiplet, br: broad. 
b
Metabolites related 
to diet and/or gut microflora; U10 correlates to trigonelline, suggesting a dietary dependence, as previously 
found in non-fasting (Chapter 3). 
c
Changes specific of CNS malformations. 
d
Consistent with previous 
findings published as result of this work (Diaz and Pinto et al., 2011). 
e
Peaks with minimal variations. Ui: 
unassigned compound i by appearance order. 4-DTA: 4-deoxythreonic acid, DMG: dimethylglycine, 3-HBA: 
3-hydroxybutyrate, 2-HIBA: 2-hydroxyisobutyrate, 4-HPA: 4-hydroxyphenylacetate, IS: indoxyl sulphate, 2-
KG: 2-ketoglutarate, NMND: N-methylnicotinamide, TMA: trimethylamine. Only p-values<0.05 are shown.   
FM n=35 vs. controls n=84 CNS n=12 vs. other FMs n=23 
Compound 
δH/ppm and 
multiplicity
a
 
Variation (effect 
size, p-value) 
Compound 
δH/ppm and 
multiplicity
a
 
Variation (effect 
size, p-value) 
3-HBA 1.2 d, 4.15 m ↑(0.80, 3.16×10-2) 2-HIBAc, e 1.36 s ↑(0.05) 
3-Me-histidine
 b
 3.75 s, 7.15 s ↑(0.50, 6.24×10-3) 2-KG c 2.45 t, 3.01 t ↑(0.38) 
4-HPA
 b
 6.86 d ↓(-0.47, 3.2×10-2) 3-Me-histidineb 3.75 s, 7.15 s ↑(0.21) 
Acetoacetate 2.28 s, 3.45 s  ↑(1.00) 4-DTA c 1.23 d, 4.12 m ↓(-0.26) 
Acetone 2.23 s ↑(0.30) 4-OH-hippurateb 6.98 d, 7.76 d ↑(0.47) 
Acetyl-carnitine 2.15 s, 3.19 s ↑(0.42) Acetyl-carnitine 2.15 s, 3.19 s ↑(0.59, 2.1×10-3) 
Alanine 1.48 d ↓(0.11) Alanine c 1.48 d ↑(0.44) 
cis-aconitate 
d
 3.12 d ↑(0.20) Allantoin c 5.39 s ↑(0.52) 
Isoleucine 
d
 1.01 d ↑(0.76, 9.94×10-4) Acetate c 1.93 s ↓(-0.91, 3.7×10-3) 
Lactose 4.46 dd ↑(0.33) Carnitine c 3.23 s, 2.44 dd ↑(0.92, 2.3×10-2) 
Lysine 1.73 m, 1.91 
m 
↓(-0.35, 1.4×10-2) Choline b, e 3.20 s ↓(-0.02) 
NMND 
d
 4.48 s, 8.90 d,  ↑(0.67, 7.1×10-4) Citrate c  2.54 d, 2.67 d ↑(0.73) 
 8.97 d, 9.28 s  DMG
 c
 2.93 s ↑(0.72) 
Scyllo-inositol
 b
 3.36 s ↓(-0.40, 3.92×10-2) Furoylglycine b 6.65 q, 7.70 d ↓(-0.65) 
Succinate 2.41 s ↓(-0.30) Glutamine c  2.15 m, 2.47 m ↓(-0.64, 3.4×10-2) 
Threonine 
d
 4.26 dd ↑(0.56, 1.72×10-2) Isoleucine 1.01 d ↑(0.73) 
Tyrosine 6.91 d ↓(-0.38, 4.04×10-2) IS b 7.70 d ↑(0.45) 
Xylose 
b
 4.58 d, 5.21 d ↑(0.35) Lactose 4.46 dd, 5.25 d ↑(0.95) 
U1 
d
 0.63 s ↑(0.51, 3.87×10-4) Leucine c 0.97 t ↑(0.82) 
U2 1.08 d [2.50,  ↓0.76) Scyllo-inositol b 3.36 s ↑(0.40) 
 3.55, 3.72]  Succinate 
c
 2.41 s ↑(0.48) 
U3 1.15 d [3.45, 
3.55] 
↓(-0.40, 1.83×10-2) Trigonelline b 4.44s, 8.84br, 
9.12 s 
↓(-0.54) 
U4 1.99 s ↓(-0.40) TMA b 2.89 s ↑(0.29) 
U5 2.05 s ↑(0.74, 2.49×10-3) Valine c 0.99 d, 1.04 d ↑(0.39) 
U6 
d
 2.06 s ↑(0.78, 1.47×10-3) U2 1.08 d [2.50,  ↑(0.88) 
U7 2.39 s ↑(0.82, 4.84×10-2)  3.55, 3.72]  
Unassigned spectral regions U3 1.15 d [3.45,  ↓(-0.39) 
0.65-0.73  ↑(0.84)   3.55]  
0.77-0.83 ↑(0.62) U8 d 2.87 s ↑(0.74) 
1.40-1.43 ↑(0.14) U9 c 2.91 s ↑(1.04, 3.5×10-3) 
3.41-3.42  ↓(-0.17) U10 b 4.40 s, 8.78 d ↓(-0.58) 
3.85-3.87 ↑(0.61,3.03×10-2) U11 c 6.84 br, 6.86 br,  ↑(0.97) 
5.30-5.32 ↑(0.13)  6.92 br, 7.31 s  
5.35-5.38 ↑(0.33,4.09×10-2) U12 c 0.55 s ↑(0.41) 
6.56-6.57 ↓(-0.37) U13 c 0.83 s ↑(0.66) 
8.16-8.22 ↑(0.57, 3.32×10-3) U14 c 0.93 s ↑(0.19) 
8.34-8.36 ↑(0.52, 5.26×10-3) U15 c 1.10 d ↓(-0.21)  
   U16 
c, e
 1.25 d ↓(-0.06) 
   U17 
c
 6.81 s ↑(0.14) 
   U18 
c
 9.36 s ↓(-0.64) 
   Unassigned spectral regions 
   3.88-3.90 ↓(-0.60, 4.9×10-2) 
   + 15 selected regions, p>0.05, mostly at 0-4.6 ppm 
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Figure 4.4: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV of the set of integrals of the statistically relevant (p<0.05) 
metabolites/regions for FM (, n=35) vs. Controls (, n=84) (see Table 4.1, left). TPR: true 
positive rate, FPR: false positive rate. 
 
The possibility of specifying FM type through maternal urine was also considered 
and, indeed, it was found that CNS malformations were distinguishable from the remaining 
FM types, as shown in the PLS-DA score plot obtained after variable selection (Figure 
4.5a). MCCV of this model revealed high predictive power (Q
2
 0.705, and low 
overlappingof Q
2
 distribution of true and permuted models) and robustness (with 87% CR, 
83% sensitivity, 90% specificity) as shown in Figure 4.5b,c) and Table A-III.2, Annex III). 
This result expresses the potential of urine metabolomics to aid and complement clinical 
determination of FM type.  
 
The metabolic profile of CNS was retrieved, and is recorded in Table 4.1 (right). 
Changes were also analysed in terms of specificity and some apparently CNS specific 
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changes were identified. Changes considered specific included reversed variations such as 
that noted for alanine, this being decreasing in FM vs. controls whilst increasing in CNS vs. 
other FMs. Specific CNS changes were noted for 13 metabolites and 9 unassigned 
resonances these being indicated with a 
c
 in Table 4.1, right. 
 
 
Figure 4.5: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes given by MCCV, obtained for 2
nd
 trimester maternal urine of women carrying fetuses with 
CNS malformations (, n=12) vs. other types of FM (, n=23). TPR: true positive rate; FPR: false 
positive rate. 
 
To unveil the urinary metabolic signatures of the general FM group and of CNS 
malformations, a novel circular representation of the selected profile with corresponding 
importance of each selected variables was devised. In this plot, shown in Figure 4.6, named 
here as VIP-wheel representation, the inner circle represents an average 
1
H NMR spectrum 
of the control group and each point represents a variable selected with the magnitude of 
VIP in the radial dimension. Inspection of this plot enables the urinary metabolic signature 
of FM (shown in red) and that of CNS (shown in orange) to be unveiled, thus illustrating 
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visually the specific features of the latter disorder. For instance, N-methylnicotinamide 
(NMND) was clearly selected as important for the FM profile with high VIP values in the 
radial scale but not for CNS. Specific changes for CNS are also visible, namely for citrate, 
acetate and TMA, which were selected with high VIP values, but not in FM.  
 
 
Figure 4.6: VIP-wheel representations of the NMR metabolite signatures obtained for FM (red) 
overlaid with CNS malformations (orange). The average 
1
H NMR spectrum of controls is 
represented in the inner circle, with the corresponding ppm scale shown in the outer black circle. 
Each dot represents a variable (spectral data point) selected by the intersection method, positioned 
in a radial VIP scale according to its VIP value. Some distinguishing features are indicated. 
 
4.1.1.3 Preliminary external validation 
The possibility of classifying new samples using the previously developed models 
is of paramount importance, especially when a clinical application is envisaged. The 
recommended approach would be to divide samples into training and prediction sets, i.e. 
samples used to develop and to test the model, respectively. In this work the training phase 
of the study, consisting of the development of the initial PLS-DA model used for further 
external validation, was carried out with the initially available samples (84 controls and 35 
FM). Subsequently, new samples were collected and 29 new controls and 6 new FM cases 
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(these including 2 CNS and 4 other types of malformations) became available to test the 
model. In order to do this, the 
1
H NMR spectra of all samples (FM and controls, training 
and prediction sets) were re-aligned and normalized, as described in the Experimental 
Section, and MVA was repeated considering only those variables selected in the previous 
model (this corresponds to the variable subset selected using the intersection method and 
shown in Figure 4.2 and Figure 4.3) using the same initial FM and control groups (training 
sets). The scores of the new set of samples (i.e. the prediction set) were predicted and 
classification was attempted based on the discrimination function and shown in the form of 
a confusion matrix. The resulting PLS-DA score plots of the training and prediction sets 
are shown in Figure 4.7 left, along with the corresponding confusion matrix for the new 
FM and control cases. The same approach was carried out to attempt malformation type 
classification, using the variable subset determined for CNS vs. other FM types model, 
shown previously in Figure 4.5. The resulting predicted scores and confusion matrix are 
shown in Figure 4.7 right.  
 
Figure 4.7: Original and predicted score plots and confusion matrices for a,c) FM and controls and 
b,d) CNS and other FM types. CR: classification rate, Sens: sensitivity, Spec: specificity. 
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The prediction results obtained the FM vs. controls model, show the overlap of the 
training and prediction sets samples (Figure 4.7a), although the scores corresponding to the 
predicted FM and control samples (prediction set), respectively red and blue diamonds, are 
not as separated as samples used in the training set, shown in black opened and dashed 
diamonds. Moreover, classification results, i.e. classification rate 77%, sensitivity 33% 
(expressing a very low TPR, i.e. classification of FM cases, or true positives, as only 2 out 
of 6 were correctly classified) and specificity 86%, computed through the confusion matrix 
shown in Figure 4.7c. In relation to the CNS vs. other FM model, samples from the training 
and prediction sets are overlapped in the score plot (Figure 4.7c), but no separation trend is 
visible between CNS and other FM predicted scores, shown in red and blue dots 
respectively. Moreover, a significant decrease in Q
2
 (0.119) was obtained, indicating the 
low predictive power of the model. Regarding sample classification, poor results were 
obtained, the classification rate being 67%, sensitivity 50% (as only 1 out of the 2 CNS 
samples was correctly classified) and specificity 75%. 
The results obtained with external validation, show that the model here presented is 
not yet robust and capable of classifying new samples. We believe that this limitation may 
be related to two factors. One consists on the unbalanced sample numbers of the groups 
used to build the models (84 controls, 35 FM; 12 CNS and 23 other FM). This means that 
the classification of a new sample in the larger groups (in this case controls or other FM) is 
more probable. A potential solution to this limitations would be to increase the number of 
samples in the FM and CNS groups, thus using more balanced groups. A second limitation 
may arise from the initial step of spectral alignment, as it is very dependent on the set of 
samples being aligned. This means that when performing alignment to different sets of 
samples it is impossible to assure that each spectral point (variable, 0.0003 ppm width) 
corresponds always to the same information, i.e. peak intensity, due to peak positional 
differences caused by spectral alignment. One possible manner to overcome this pitfall 
would be to use spectral bucketing instead of full resolution data followed by spectral 
alignment, thus assuring that each bucket window corresponds always to the same spectral 
information in all samples. Both bucketing and alignment have advantages/disadvantages 
and these must be weighted for each specific application envisaged. The use of full spectral 
resolution, after peak alignment provides significant gain in resolution and its use is 
invaluable to unveil spectral changes often occurring in narrower ranges compared to 
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bucket widths. On the other hand, the use of spectral bucketing  may be advantageous if a 
clinical application is envisaged since it allows more reproducible and independent (of the 
sample set) models to be obtained. 
 
4.1.1.4 Proposed metabolic interpretation of urinary changes in general FM 
and CNS malformations 
Regarding the general FM signature, listed in Table 4.1 left, changes were consistent 
with previously advanced hypotheses regarding the biochemical perturbation occurring in 
cases of FM. A general scheme of the metabolic pathways affected in FM and CNS is 
depicted in Figure 4.10, along with those affected in CD and T21 as will be presented and 
discussed in the following section. 
It had been proposed that FM cases show decreased glucose levels in AF (Graça et 
al., 2010)
 
which reflects the activation of gluconeogenesis and energy production through 
lipid oxidation and ketone body synthesis (Graça et al., 2010, Diaz and Pinto et al., 2011, 
Graça et al., 2012). In this work, higher maternal urinary excretion of all three ketone 
bodies (acetone, acetoacetate and 3-hydroxybutyrate, 3-HBA) was observed. These 
findings are in agreement with enhanced lipid oxidation, leading to over production and 
excretion of ketone bodies and production of acetyl-CoA. The resulting acetyl-CoA feeds 
the TCA cycle in extrahepatic tissues, enhancing its activity, which had been found in FM 
cases (Graça et al., 2012). This perturbation is further supported by the higher cis-aconitate 
excretion found in this cohort and consistent with a previous exploratory report published 
as result of this work (Diaz and Pinto et al., 2011). The increase in excreted acetyl-
carnitine suggests that an excess of acetyl-CoA is formed, locking carnitine in its 
acetylated form, also supporting the perturbation in lipid oxidation. Decreased succinate, 
substrate of the enzyme complex II of the respiratory chain, was found in maternal urine of 
FM cases. Increased succinate had been previously found in AF (Graça et al., 2010) 
suggestive of an inadequate use of the respiratory chain for energy production. Thus, the 
lower excretion of succinate found in this cohort may suggest its possible diversion to the 
fetus. Relevant changes were also found regarding amino acid excretion, possibly 
reflecting their selective use as gluconeogenesis substrates, possibly preferentially for 
alanine, lysine, and tyrosine, which are being less excreted, compared to isoleucine and 
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threonine, which are being increasingly excreted. Out of these amino acids, alanine, lysine, 
tyrosine and isoleucine had been found decreased in AF of FM cases due to increased 
amino acid catabolism to replenish glucose (Graça et al., 2010, Graça et al., 2012). 
Furthermore, increased isoleucine and threonine had been found in maternal urine of FM in 
a previous exploratory report resultant of this work, this variation being associated with 
enhanced gluconeogenesis and TCA cycle demand (Diaz and Pinto et al., 2011). Other 
significant change found in this work is the higher excretion of NMND, a metabolite 
involved in nucleotide metabolism and particularly the tryptophan-NAD
+
 pathway (Salek 
et al., 2007). Increased NMND had been found in smaller cohort (initial work within this 
thesis, published in (Diaz and Pinto et al., 2011)) being further confirmed in this larger 
cohort. Furthermore, higher lactose excretion was found in the FM group, this having been 
seen in healthy pregnant women (Hytten, 1973, Sachse et al., 2012) but not in relation to 
prenatal disorders. 
 
CNS malformations seem to be characterized by an abnormal change in the acetyl-
carnitine/carnitine balance, reflecting somewhat higher circulating acetyl-CoA levels and 
an underuse of carnitine, possibly reflecting a relatively lower level of lipid oxidation 
compared to other FM types. This finding is consistent with previous reports which had 
shown changes in maternal plasma lipids in CNS cases (Diaz and Pinto et al., 2011). The 
decrease in acetate suggests its use as substrate for acetyl-CoA synthesis, contributing to 
enhanced TCA cycle activity. This suggestion is also supported by the increased excretion 
of intermediates 2-ketoglutarate (2-KG), citrate and succinate. Succinate is further 
involved in the respiratory chain, which has been found to be impaired in women carrying 
fetuses with neural tube defects (NTD) (Zheng et al., 2011) and increased levels of 
succinate have been reported in AF in cases of spina bifida (Groenen et al., 2004). CNS 
cases also show specific disturbances in branched chain amino acids (BCCA) metabolism 
(higher excretion of leucine, isoleucine and valine) and of other amino acids (alanine and 
glutamine) and amino acids derivatives 4-deoxythreonic acid (4-DTA) and 
dimethylglycine (DMG). Among these changes, the increase of DMG here found may 
relate to methionine metabolism, known to be altered in NTD cases (Dasarathy et al., 
2010) and found to be down regulated in women carrying fetuses with this type of 
malformations (Zheng et al., 2011). Furthermore, decreased valine and increased 
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glutamine (the latter variation being in the opposite direction to that found in this work) 
had been previously found in the maternal serum (Zheng et al., 2011) of women carrying 
fetuses affected by NTD. Increased excreted allantoin and indoxyl sulphate (IS) suggest 
oxidative stress in CNS cases, with allantoin being an oxidation product of uric acid and a 
marker of oxidative stress, and  IS having been suggested to mediate the oxidative stress 
process  (Žitňanová et al., 2004, Dou et al., 2007). Moreover, an apparent contribution 
from gut microflora metabolites was also found in CNS signature, given by changes in 4-
hydroxyhippurate, choline (residual change), trigonelline and trimethylamine (TMA) 
excretion.  
 
4.1.2 Chromosomal disorder (CD) cases 
4.1.2.1 Unveiling urinary metabolic signatures of general CD and trisomy 21 
(T21) 
The metabolic effect of carrying a fetus with a CD was evaluated by comparing 
1
H 
NMR spectra of maternal urine from cases and controls, collected at the time of 
amniocentesis during the 2
nd
 trimester of pregnancy. Diagnosis was done by determination 
of the amniocytes karyotype in the cytogenetics laboratory of the FMUC and results were 
available approximately two weeks after amniocentesis. Sample numbers and metadata are 
shown in Tables 2.2 and 2.3 (Experimental Section).  
An initial PLS-DA of maternal urine of CD and controls, using the original NMR 
dataset, revealed a separation trend (not shown) between groups, although MCCV resulted 
in low CR, sensitivity and specificity (respectively 68%, 34% and 73%) along with high 
overlapping Q
2
 values of true and permuted models. As also was the case for FM, this 
unsatisfactory result may be explained by the low impact of the disease in urine 
composition, compared with the amount contained in urine. Thus, the variable selection 
method presented and discussed in Section 4.1.1.1 was applied to CD and PLS-DA was 
recalculated. This resulted in a clearer distinction of CD and controls cases (Figure 4.8a), 
although some dispersion was still visible between CD samples possibly due to the 
heterogeneous nature of the group. Regarding the two outlier samples visible in the score 
plot, visual inspection of the corresponding spectra revealed high resonances of glucose, 
whilst one the samples had also high lactate, pyruvate and 2-KG.  
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Figure 4.8: a) PLS-DA scores plot, c) Q
2
 distributions plot and e) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for CD ( , n=33) vs. Controls (, n=84) and b) PLS-DA scores 
plot, d) Q
2
 distributions plot and f) ROC plot of
 
true and permuted classes, given by MCCV 
obtained for T21 (○, n=13) vs. Other CD (●, n=20). TPR: true positive rate, FPR: false positive 
rate. 
The PLS-DA model was found to have high predictive power (low overlapping of 
Q
2
 distribution of true and permuted models) and MCCV parameters (CR 85%, sensitivity 
87% and specificity 84%), these being summarized in Table A-III.2, Annex III and shown 
in Figure 4.8c,e. The analysis of the urinary profile explaining the difference between cases 
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and controls revealed 25 compounds, 4 unassigned (doublet 1.15 ppm, singlet 2.39 ppm, 
doublet 1.25 ppm and singlet at 4.54 ppm) and several spectral regions, these being listed 
in Table 4.2 left. The overall changes include higher excretion of amino acids (glutamine, 
histidine, isoleucine and threonine) with the exception of tyrosine that decreases, higher 
ketone bodies, glucose an pyruvate, as well as higher 2-KG, citrate, choline, creatine, 
creatinine, guanidoacetate (GAA), NMND and other metabolites related from the gut 
microflora. 
 
The possibility to differentiate CD types was also attempted, this being only 
possible for T21 as a low number of samples were available for the remaining types (see 
Table 2.3 of Experimental Section). The PLS-DA model obtained after variable selection 
revealed a clear separation of T21 from other CD types, as shown in Figure 4.8b), with 
high model performance (CR 94%, sensitivity 92%, specificity 95%, summarized in Table 
A-III.2, Annex III) and predictive power (almost no overlapping of Q
2
 obtained for true 
and permuted models), shown in Figure 4.8d,f). T21 cases were found to hold a distinctive 
NMR signature from other CDs, this being listed in Table 4.2 right, with specific variations 
noted for 9 metabolites (N-methyl-2-pyridone-5-carboxamide (2-Py), allantoin, glucose, 
glycine, histidine, lysine, malonate, NMND and taurine) and 10 unassigned resonances 
with variations specific of T21 noted with 
c 
in the same table. Out of these changes, only 2-
Py, U10 (possibly related to diet/gut microflora, as was found to change due to non-fasting 
condition, Section 3.2) and 7 unassigned regions were found statistically different 
(p<0.05).  
 
The specific urinary metabolic signature of CD and the distinctive features of T21 
were represented through the VIP-wheel. The resulting fingerprints of the disorders are 
shown in Figure 4.9, where the selected profile of both CD and T21 are shown in dark and 
light blue, respectively. This representation shows specific changes with high importance 
in CD, namely for pyruvate, citrate, 4-OH-hippurate, histidine and 1-methyl-histidine. For 
T21 cases, specific signatures were seen for unassigned regions 0.70-0.82, 1.40-1.85 and 
2.21-2.23 ppm (this regions typically containing resonances from C-CH3 and =C-CH3). 
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Table 4.2: Metabolite/resonance changes in maternal urine of CD vs. controls and T21 vs. other 
CDs. 
a 
Chemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in 
square brackets; s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, m: multiplet, br: 
broad. 
b
 Metabolites related to diet and/or gut microflora. c Changes specific of T21 disorders. d 
Consistent with previous findings published as result of this work (Diaz and Pinto et al., 2011). Ui: 
unassigned compound i following numbering in Table 4.1. DMA: dimethylamine, GAA: 
guanidoacetate, 2-Py: N-methyl-2-pyridone-5-carboxamide, other abbreviations defined in Table 
4.1. Only p-values<0.05 are shown. 
CD n=33 vs. controls n=84 T21 n=13 vs. other CDs n=20 
Compound 
δH/ppm and 
multiplicity
a
 
Variation(effect 
size, p-value) 
Compound 
δH/ppm and 
multiplicity
a
 
Variation(effect 
size, p-value) 
1-Me-histidine
 b
 3.72 s, 7.05 s,  ↑(0.50, 3.2×10-2) 2-Py c 6.67 d, 8.33 d ↓(-0.73, 4.8×10-2) 
 7.78 s  4-OH- hippurate
b
 6.98 d, 7.76 d ↓(-0.41) 
2-KG 2.45 t, 3.01 t ↑(0.54, 3.0×10-2) Allantoin c 5.39 s ↑(0.43) 
3-HBA 1.20, d ↑(0.46, 3.8×10-2) Choline b 3.20 s ↓(-0.60) 
4-DTA 1.23 d ↓(-0.16) Glucose c 5.25 d, 3.23 dd ↓(-0.68) 
4-HPA
 b
 6.86 d, 7.17 d ↓(-0.35) Glycine c 3.57 s ↑(0.39) 
4-OH- hippurate
b
 3.95 s, 6.98 d ↓(-0.34, 2.3×10-2) Histidine c 4.01 q, 7.13 s,  ↓(0.52) 
Acetone  2.23 s ↑(0.43)  7.98 s  
Acetoacetate 2.28 s, 3.45 s ↑(0.34) IS b 7.51 d, 7.70 d ↓(-0.47) 
Choline 
b,d
 3.20 s ↑(0.35) Lysine c 1.73 m, 1.91 m ↓(-0.65) 
Citrate 2.54 d, 2.69 d ↑(0.45) Malonate c 3.11 s ↓(-0.49) 
Creatine 3.93 s ↑(0.40) NMND c 4.48 s, 8.90 d,  ↓(-0.60) 
Creatinine 4.06 s ↑(0.37, 8.5×10-3)  8.97 d  
DMA
 b
 2.73 s ↓(-0.17) Taurine c 3.43, t ↓(-0.40) 
GAA 3.80 s ↑(0.56) U1 c 0.63 s ↑(1.10) 
Glucose 5.25 d, 3.23 dd,  ↑(0.46) U10 b  4.40 s, 8.78 d ↑(0.59, 1.1×10-2) 
 3.50 t, 3.44 m  U16
 c
 1.25 d ↓(-0.26) 
Glutamine 2.47 m ↑(0.24) U20 c 2.01 s ↑(0.58) 
Histidine 4.01 q, 7.98 s ↑(0.37) U21 c 2.03 s ↑(0.25) 
Isoleucine 1.01 d ↑(0.41) U22 c 2.78 s ↑(0.70) 
Lactose 4.46 d ↓(-0.21) U23 c 2.84 s ↑(0.36) 
NMND 8.90 d, 8.97 d,  ↑(0.30) U24 c 3.30, s ↓(-0.52) 
 9.12s  U25 
c
 6.81 d ↑(0.57) 
Pyruvate 2.38 s ↑(0.28) U26 c 7.01 s ↓(-0.75) 
Scyllo-inositol 
b
 3.36 s ↓(-0.40) U27 c 7.68 s ↓(-0.46) 
Sucrose 
b
 5.41 d ↑(0.54) Unassigned spectral regions  
Threonine 4.26 dd ↑(0.27) 0.74-0.76  ↑(0.81, 3.3×10-2) 
Trigonelline
 b
 4.44s, 8.84br,  ↓(-0.29) 0.80-0.82  ↑(1.30, 3.3×10-3) 
 9.12s  0.92-0.93  ↑(0.92, 3.0×10-2) 
Tyr 6.91 d ↓(-0.29) 1.40-1.43 ↑(0.94, 2.0×10-2) 
U3 1.15 d [3.45, ↓(-0.44) 1.65-1.68 ↑(0.88, 1.6×10-2) 
 3.55]  1.78-1.81 ↑(0.84, 2.4×10-2) 
U7 2.39 s ↑(0.63, 1.2×10-2) 1.84-1.85 ↑(0.91, 2.4×10-2) 
U16 1.25 d ↓(-0.21)   
U19 4.54, s ↓(-0.21)    
Unassigned spectral regions     
3.05-3.08 ↑ (0.38, 1.2×10-2)   
+ 6 selected regions, p>0.05, at 0-4.6 and 6-10 ppm  
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Figure 4.9: VIP-wheel representations of the NMR metabolite signatures obtained for CD (dark 
blue) overlaid with T21 (light blue). The average 
1
H NMR spectrum of controls is represented in 
the inner circle, with the corresponding ppm scale shown in the outer black circle. Each dot 
represents a variable (spectral data point) selected by the intersection method, positioned in a radial 
VIP scale according to its VIP value. Some distinguishing features are indicated. 
 
4.1.2.2 Proposed metabolic interpretation of the urinary signature of general 
CD and T21 
A representation of the metabolic pathways affected in CD and T21 is shown in 
Figure 4.10, along with changes found for FM and CNS. In terms of the biochemical 
characteristics, CD cases were characterized by common effects to FM, namely regarding 
the higher excretion of ketone bodies and changes in nucleotide metabolism, along with 
evidence of enhanced TCA cycle activation (Table 4.2, Figure 4.10). Further common 
variations were found for unassigned singlet at 2.39 (increased) and the doublet at 1.15 
ppm (decreased) in both CD and FM groups, reflecting some kind of common metabolic 
perturbation (unidentified at this stage). This finding hints at underlying general metabolic 
responses in cases of fetal pathologies, as CD are often associated with the occurrence of a 
malformed phenotype although with varying severity (see Table 1.5 in Introduction). 
Increased excretion of NMND suggests a perturbation in nucleotide metabolism, 
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particularly the tryptophan-NAD
+ 
pathway (Salek et al., 2007), as found for the FM group. 
Another perturbation found for CD is the higher excretion of citrate and 2-KG both 
intermediates of the TCA cycle and consistent with an enhancement of this cycle. 
Increased excretion the two latter metabolites were also found specifically in the CNS 
group but not in the heterogeneous FM group, thus suggesting a common perturbation 
between CD and CNS malformations. Increased ketone bodies (3-HBA, acetone and 
acetoacetate, the first being the only ketone body varying with individual significance) 
reflect perturbations in energy production, as was advanced for the FM group. 
Furthermore, higher 3-HBA has been reported in 1
st
 trimester maternal blood serum of 
women carrying fetuses with T21 possibly associated with changes in brain growth and 
myelination as 3-HBA is an important substrate for the synthesis of phospholipids and 
sphingolipids (Bahado-Singh et al., 2013).  
A specific feature of CD relatively to FM, concerns the increased excretion of 
glucose and sucrose along with decreased lactose in CD (Figure 4.10), which is consistent 
with a derangement in sugar metabolism previously suggested by changes in AF (Graça, 
2013). Moreover, increased glucose suggest its catabolic underuse, along with increased 
pyruvate, either due to metabolic changes and/or renal adaptations expected in healthy 
pregnancy progression (Creasy et al., 2009), but not in relation to CD. Evidence of altered 
amino acids metabolism was also found in CD cases, namely by decreased tyrosine and 
increased glutamine, histidine, isoleucine and threonine along with decreased 4-DTA, a 
product of threonine catabolism (Appiah-Amponsah et al., 2009) in CD cases. Changes in 
amino acids metabolism are supported by previous findings in AF (Amorini et al., 2012, 
Graça, 2013). Higher GAA and creatine were also found in CD, possibly reflecting a 
perturbation creatine biosynthesis or a slowing down of urea cycle (Brosnan and Brosnan, 
2010) although no relation has been previously reported regarding these pathway and CD. 
Finally, some relevant changes were also found for metabolites deriving from the gut 
microflora, namely for 4-HPA, 4-OH-hippurate, choline, DMA, scyllo-inositol and 
trigonelline. This finding unveils and important relationship between gut microflora and 
CD, although its exact nature cannot, at this point, be further explored.  
In relation to the T21 group within the overall CD group, a distinctive profile was 
found relatively to other CDs (shown in light blue in Figure 4.9). The tandem decrease of 
2-Py and NMND, both involved in nucleotide metabolism with 2-Py being formed from 
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NMND, suggest a pronounced perturbation in nucleotide metabolism. Several specific 
changes of T21 were found regarding amino acids excretion, namely increased glycine and 
decreased histidine, lysine and taurine in maternal urine. Changes in amino acid 
concentrations have been reported in AF of T21 cases namely decreased isoleucine, 
leucine, glycine, lysine, taurine, valine, ornithine and glutamate and increases in glutamine 
(Amorini et al., 2012) with changes of glycine and glutamate possibly reflecting a negative 
effect of fetal neuronal functions. Furthermore, the variation found in this study for taurine 
gains additional value in relation to methionine metabolism. The gene encoding the 
enzyme cystathione beta synthase (CBS, enzyme catalyzing the conversion of 
homocysteine to cystathione) is located on chromosome 21, thus subjects with T21 have an 
enhanced activity of CBS leading to alterations in methionine metabolism (Obeid et al., 
2012). Another interesting finding is the increased excretion of allantoin, as found for the 
CNS group.  This is consistent with the known role of oxidative stress in T21 (Bahado-
Singh et al., 2013). Indeed, higher allantoin levels have been previously reported in plasma 
of T21 subjects reflective of increased oxidative stress (Žitňanová et al., 2004). An 
additional specific change of T21 was found for malonate. Malonate is a competitive 
inhibitor of succinate in the respiratory chain (Amaral et al., 2012) and possibly reflects a 
perturbation at this level, although no further evidence supporting this possibility was 
found in literature. 
With regard to the unassigned resonances, one last mention on the relevance of 
these peaks/compounds, as these play an important role in the definition of the T21 
signature. This signature comprises 11 unassigned resonances, 10 of these being specific to 
the disease along with 7 spectral regions with individual significance, some of these being 
indicated in Figure 4.9. STOCSY was performed in order to attempt improving the 
knowledge on possible metabolic relationships of the unassigned compounds. A relevant 
positive correlation was obtained for the singlet at 7.68 ppm (increased in other CDs), 
which correlated with creatinine (r 0.91). Still, no variation was found for creatinine or 
creatinine metabolism in this group, thus hampering the proposal of a relevant biochemical 
interpretation. Hence, a significant part of the metabolic signature of T21 is still unknown 
and important assignment work is still crucial so that a more complete metabolic picture 
can be drawn. 
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Figure 4.10: Schematic representation of the metabolic pathways possibly affected in FM, CNS, 
CD and T21 cases. Metabolites in bold were identified in 
1
H NMR spectra of maternal urine. 
Colored arrows indicate direction of variation in each group. Dashed arrows indicate 
transformations occurring through several reactions. Amino acids in 3-letter code; NaMN: nicotinic 
acid mono nucleotide, NaAD: nicotinic acid adenine dinucleotide, NAD
+
: nicotinamide adenine 
dinucleotide, NADP: nicotinamide dinucleotide phosphate, ADP: adenosine diphosphate, NMND: 
N-methyl-nicotinamide, 2-Py: N-methyl-2-pyridone-5-carboxamide, 4-Py: N-methyl-4-pyridone-3-
carboxamide, 4-DEA: 4-deoxyerythronic acid, 4-DTA: 4-deoxythreonic acid, 3-HBA: 3-
hydroxybutyrate, DMA: dimethylamine, TMA: trimethylamine, DMG: dimethylglycine, GAA: 
guanidoacetate, Hcy: homocysteine, GSH: gluthathione, THF: tetrahydrofolate. 
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4.2 Prediction of poor pregnancy outcomes through second trimester 
maternal urine metabolomics 
4.2.1 Women later developing preterm delivery (PTD) 
The possibility of predicting the development of PTD was attempted in this study 
by comparing control urine to maternal urine samples collected during the 2
nd
 trimester, 
11-20 weeks before delivery (sample group here named pre-PTD). A more detailed 
description on sample groups metadata is shown in Section 2.1.2 b), Table 2.2 of 
Experimental Section. For this sample group, the quest for novel biomarkers capable of 
predicting the disorder was carried out by comparing samples analyzed by 
1
H NMR and 
UPLC-MS. Furthermore, external validation, using the initial NMR model used as a 
training set, was also attempted for 6 pre-PTD samples and 29 controls. 
 
Table 4.3: Sample numbers, maternal age (in years), gestational age at sampling (in gestational 
weeks, g.w.) and interval from collection to diagnosis for controls and pre-PTD samples used in the 
1
H NMR  and UPLC-MS (right). Due to differences in sampling and acquisition two additional 
pre-PTD samples were available when UPLC-MS experiments were performed, the number of 
samples used in each model is not exactly the same. 
 
1
H NMR work  UPLC-MS work 
Metadata Control pre-PTD  Control pre-PTD 
n 84 26  25 28 
Maternal age (years) 21-42 (36) 26-41 (36)  26-39 (35) 21-41 (36) 
Gestational age (g.w.) 15-26 (17) 16-21 (17)  15-26 (17) 16-21 (17) 
g.w. to diagnosis ─ 11-20 (17)  ─ 11-20 (17) 
 
4.2.1.1 Unveiling a pre-diagnosis urinary metabolic signature of pre-PTD by 
NMR 
The initial PLS-DA score plot (not shown) revealed a separation trend between pre-
PTD and control samples, although insufficient results were obtained by MCCV (see Table 
A-III.2, Annex III). Thus, the spectra dataset was reduced by applying variable selection 
and the profile preceding the development of PTD was unveiled. The resulting PLS-DA 
scores plot showed a clear separation in the score plot, with satisfactory predictive power 
(Q
2 
0.458), CR, sensitivity and specificity (84%, 79% and 84%, respectively). The 
obtained PLS-DA score plot along with Q
2
 distribution and ROC plot, of true and 
permuted models, are shown in Figure 4.11.  
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Figure 4.11: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for Controls (■, n=84) vs. pre-PTD (, n=26). TPR: true 
positive rate, FPR: false positive rate. 
 
The metabolic signature here presented as potentially predictive of PTD, and 
explaining the separation trend seen in Figure 4.11a) is listed in Table 4.4. Variations were 
also evaluated relatively to other pre-diagnosis conditions evaluated in this work and 
changes considered specific are indicated with a 
c
 in Table 4.4 whilst changes common to 
all pre-diagnosis disorders (increased 4-DEA and decreased creatinine, possibly reflecting 
a general stress effect) are indicated with a 
d
 in the same table. 
 
The profile of pre-PTD was analysed through a VIP-wheel representation of the 
selected variables and corresponding VIP value, as shown in Figure 4.12. Some distinctive 
findings of pre-PTD are indicated, namely for ascorbate, 4-OH-hippurate, unassigned 
singlet at 1.99 ppm (U4), 1.45-1.70 ppm and 6.73-6.76 ppm. The overall pre-PTD 
signature comprises changes in 21 metabolites, 4 unassigned compounds and 6 spectral 
regions (with p<0.05). Out of these changes only 3-methylhistidine and 4-HPA both 
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related with diet and/or gut microflora, decrease with individual significance in pre-PTD. 
Moreover increased 3-HBA, acetoacetate, GAA , isoleucine, threonine and unassigned 
singlet at 0.55 ppm, along with decreased ascorbate, betaine, histidine, and unassigned 
singlet at 4.54 ppm were found to be specific of pre-PTD. 
 
Table 4.4: Metabolite/resonance changes in maternal urine for the pre-PTD group compared to 
controls. 
a
 Chemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in 
square brackets; s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, m: multiplet, br: 
broad. 
b
 Metabolites related to diet and/or gut microflora. 
c
 Changes specific of the disorder, 
relatively to other pre-diagnosis disorders here evaluated. 
d
 Changes common to all pre-diagnosis 
disorders. 
e
 Consistent with an initial exploratory report published as result of this work (Diaz and 
Pinto et al., 2011). Ui: unassigned compound i following numbering in Table 4.1 and Table 4.2. 
PAG: phenylacetylglutamine, 3-HIVA: 3-hydroxyisovalerate, 4-DEA: 4-deoxyerythronic acid, 
other abbreviations defined in Table 4.1 and Table 4.2. Only p-values<0.05 are shown. 
pre-PTD n=26 vs. Controls n=84 
Compound δH/ppm and multiplicity 
a
 Variation (effect size, p-value) 
2-HIBA 
e
 1.36 s ↑(0.19) 
2-Py 6.67 d, 8.33 d ↑(0.22) 
3-HBA
c
 1.20 d ↑(0.44) 
3-HIVA 1.27 s ↓(-0.13) 
3-Me-histidine
 b
 3.75 s, 7.15 s ↓(-0.42, 4.4×10-3) 
4-DEA 
d, e
 1.11 d ↑(0.46) 
4-HPA
 b
 6.86 d, 7.17 d ↓(-0.45, 1.0×10-2) 
4-OH-hipurate 
b
 6.98 d, 7.76 d ↑(0.41) 
Ascorbate 
c
 4.52 d ↓(-0.28) 
Acetone 2.23 s ↑(0.68) 
Acetoacetate 
c
 2.28 s, 3.45 s ↑(0.51) 
Betaine 
c
 3.26 s ↓(-0.10) 
Carnitine 3.23 s ↓(-0.23) 
Citrate 2.54 d, 2.69 d ↑(0.38) 
Creatinine
 d
 3.05 s, 4.06 s ↓(-0.15) 
GAA 
c
 3.80 s ↑(0.26) 
Histidine
 c
 7.99 s ↓(-0.21) 
Isoleucine
 c
 1.01 d ↑(0.34) 
Lactose 4.46 d ↓(-0.21) 
PAG
 b 
 2.27 t, 4.18 m, 7.43 t ↓(-0.32) 
Threonine
  c
 4.26 dd ↑(0.45) 
U4 1.99 s ↓(-0.43) 
U28 2.96 q [2.88, 4.02] ↑(0.25) 
U19 
c
 4.54 s ↓(-0.25) 
U12 
c
 0.55 s ↑(0.35) 
Unassigned spectral regions 
0.66-0.73 ↑(0.51, 1.5×10-2) 
1.37-1.44 ↑(0.67, 1.4×10-4) 
1.45-1.47 ↑(0.66, 6.4×10-3) 
1.60-1.65 ↑(0.63, 3.2×10-3) 
5.33-5.34 ↓(-0.44, 2.3×10-2) 
6.73-6.76 ↓(-0.66, 3.9×10-3) 
+ 13 selected regions, p>0.05 
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Figure 4.12: VIP-wheel representations of the NMR metabolite signatures obtained for pre-PTD. 
The average 
1
H NMR spectrum of controls is represented in the inner circle, with the 
corresponding ppm scale shown in the outer black circle. Each dot represents a variable (spectral 
data point) selected by the intersection method, positioned in a radial VIP scale according to its 
VIP value. Some distinguishing features are indicated 
 
4.2.1.2 Preliminary external validation of NMR models 
External validation was attempted for pre-PTD by predicting new samples (29 
controls and 6 pre-PTD samples) in the previously developed model. However, the same 
pitfall (discussed for the FM group) affected this prediction attempt as sample spectra had 
to be re-aligned, and PLS-DA repeated using only the set of variables previously selected. 
The resulting PLS-DA model has significantly decreased prediction power (Q
2
 0.181) 
reflecting the absence of groups separation seen in the scores plot (Figure 4.13). 
Furthermore, unacceptable results were obtained for class prediction, shown in the 
confusion matrix, since no pre-PTD sample could be correctly classified, yielding a 
sensitivity of 0%.  
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Figure 4.13: a) Original and predicted score plots and b) confusion matrices obtained for pre-PTD 
and controls CR: classification rate, Sens: sensitivity, Spec: specificity 
 
These poor prediction results are probably due to a) the unbalanced number of 
samples used and b) data preprocessing steps, namely the realignment of the new NMR 
spectra. Thus, the use of groups balanced in number and more reproducible preprocessing 
steps such as bucketing is desirable, as discussed in section  4.1.1.3 
 
4.2.1.3 Unveiling a pre-diagnosis urinary metabolic signature of PTD by 
UPLC-MS 
To gain broader knowledge on the urinary NMR metabolic signature preceding 
PTD, maternal urine of pre-PTD and control groups were analyzed by UPLC-MS, as the 
method has higher sensitivity compared to NMR (pM of UPLC-MS vs. mM of NMR). 
Samples were run using both HSS and HILIC columns in both positive and negative 
ionization modes, as described in Section 2.3 of Experimental Section.  
Figure 4.14 shows an example of a total ion chromatogram (TIC) of control 
maternal urine sample, obtained using the HSS column in the positive ionization mode 
(ESI+). As done for the NMR data, these complex datasets were converted into tables and 
further subjected to MVA in order to extract class-related changes. However, prior to 
MVA, important processing steps must be performed in order for relevant and reliable 
information to be obtained. Two processing methods were tested and results are described 
as follows: 
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Figure 4.14: Total ion chromatogram (TIC) of a control urine sample using HSS column in ESI+ 
mode. 
 
Results obtained with processing method 1 
As, in the context of this thesis, a variable selection method based on multivariate 
parameters was developed and found extremely powerful for the unveiling of subtle 
disease profiles analyzed by 
1
H NMR, the first approach was to apply the same 
methodology to the UPLC-MS data. Briefly, UPLC-MS data was processed (features were 
grouped, aligned and normalized), PLS-DA was computed and variables (in this case, 
features, i.e. a pair RT_m/z) were selected using the intersection method (i.e. 
simultaneously VIP>1, VIP/VIPcvSE>1 and |bcoeff/bcoeffcvSE|>1, a more detailed description 
of the method having been presented in Section 4.1.1.1).  
The first approach was to calculate the PLS-DA of controls vs. pre-PTD of each 
dataset (HSS/ESI+, HSS/ESI-, HILIC/ESI+, HILIC/ESI-) using UV and Pareto scaling and 
Log transformation. The robustness and predictive power of all PLS-DA models was 
evaluated by MCCV and, for all models, insufficient results were obtained (high 
overlapping of Q
2
 values of true and permuted models, low CR, specificity and sensitivity). 
Thus, as was done for NMR data, each dataset (Column/Detection mode/Scaling or 
transformation) was subjected to variable selection and the resulting matrix resubmitted to 
PLS-DA and MCCV. Apparently good and reliable separations, between controls and pre-
PTD samples, were found, further supported by the resulting model Q
2
 and validation 
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parameters (Table A-IV, Annex IV). Features were selected for further analysis based on 
the S-plot (i.e. covariance vs. correlation of each feature and the 1
st
 LV) and features with 
high covariance (|p|>0.02) and correlation (|pcorr|>0.6). Furthermore, these features were 
evaluated in terms of their covariance and covariance standard error ratio (p[1]/pcvSE[1]) 
with those having a ratio higher than 4 (i.e. error below 25%) being selected for univariate 
analysis (p-value and effect size).  
The PLS-DA model obtained using HSS/ESI+/Log transformation yielded a CR of 
97%, sensitivity 96% and specificity 97%. Nevertheless, only one feature (RT= 2.92 min 
and m/z 590.04) was found to fulfill all the established requirements (described in the 
above paragraph). However, inspection of the original dataset revealed that this same 
feature was in fact noise. This drawback was found for all features selected through PLS-
DA models of datasets obtained with this variable selection methodology. Thus, it was 
concluded that the method is not suitable for UPLC-MS data processing and the second 
processing method was done with results presented in the following section.  
 
Results obtained with processing method 2 
The second processing method employed involves features selection based on three 
univariate steps, comprising an initial prefilter step, a MinFrac filter and a coefficient of 
variation filter. The prefilter was applied before grouping and alignment, which removed 
features that are not detected in at least 5 scans with intensity higher than 1000. This 
prefilter step is extremely useful in removing noise and background from the initial dataset, 
subsequently reducing their influence of the definition of features. Secondly, features were 
grouped, aligned and normalized, followed by the application of a MinFrac Filter, meaning 
that features not present in at least 50% of at least one of the groups are removed from the 
dataset. Finally, a coefficient of variation filter is also applied, with features with 
coefficient of variation higher than 30% (calculated for the QCs) were removed.  
The initial appreciation of the resulting datasets obtained with this processing 
method and applied to each pair column/detection model/scaling or transformation 
revealed very good reproducibility of the UPLC runs. PCA score plots of samples (controls 
and pre-PTD) and QC show clustering of the QC samples for each dataset 
(Column/Detection mode/Scaling or transformation), these being shown in Figure A-IV.1, 
Annex IV.  
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Controls and pre-PTD samples, analyzed by HSS/ESI+, HSS/ESI-, HILI/ESI+ and 
HILIC/ESI-, were compared using UV and Pareto scaling and Log transformation, the 
resulting PLS-DA and MCCV parameters being summarized in Table A-IV.2, Annex IV. 
The best result was obtained for HSS/ESI+/Log, showing a separation trend between 
classes in the PLS-DA score plot and marginally satisfactory prediction power, seen 
through the low overlapping of Q
2
 of true and permuted models and robustness, with CR of 
69%, sensitivity 69% and specificity 70%, as shown in Figure 4.15. However, two control 
outliers were identified, these being noted in the PLS-DA score plot shown in Figure 
4.15a, and the removing of these two samples caused the dropping of Q
2
 to -0.169, 
suggestive an unstable model and very dependent of these two samples. 
 
 
Figure 4.15: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for 
 Controls (■, n=25) vs. pre-PTD (, n=28). TPR: true 
positive rate, FPR: false positive rate. 
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In spite of the results obtained through MVA, two features fulfilling the pre-
established requirements (i.e. high covariance (|p|>0.02) and correlation (|pcorr|>0.6, and 
covariance to covariance standard error ratio (p[1]/pcvSE[1]>4) were found and selected for 
further analysis (RT 3.22 min, m/z 673.14 and m/z 689.11), after removing the two control 
outliers. The MS spectrum collected at RT 3.22 (Figure 4.16a), shows that these two 
features (indicated with a red arrow) are well defined, not noise or background as those 
found with the previous method.  
 
Figure 4.16: a) MS spectrum, of a control sample, recorded at RT 3.22 min. Red arrows indicates 
two features selected through MVA and black arrow indicates a possible m/z belonging to the same 
compound. b) Scatter plots of feature intensities, with corresponding r and p-value of the 
correlation. 
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Furthermore, the m/z 348.07 was found eluting at the same RT but with higher 
intensity than m/z 673.14 and 389.11, possibly suggesting that it belongs to the same 
compound. To confirm this, features intensities were correlated in the control group, as 
these were increased in this class (with exception of one control sample with high intensity 
of m/z 348.07 but not the other two features). The resulting scatter plots are shown in 
Figure 4.16b) along with the r and p-value of the correlation between each pair of features, 
where it is shown that the three features probably belong to the same compound, as 
supported by the high r (r<0.96) and low p-value (10
-3
-10
-4
 orders of magnitude). Thus, 
univariate comparison of the intensities of these three features in the control and pre-PTD 
samples (without the three outlier samples) was done, the resulting effect size and p-value 
being shown in Table 4.5.  
 
Table 4.5: Changes in maternal urine for pre-PTD compared to controls analyzed by HSS/ESI
+
. 
Only p-values < 0.05 are shown. 
pre-PTD (n=28) vs. Controls (n=22) 
RT(min) m/z Variation (effect size, p-value) 
3.22 689.11 ↓ (-0.75, 5.65×10-3) 
3.22 673.14 ↓ (-0.67, 1.66×10-2) 
3.22 348.07 ↓ (-0.36) 
 
The results obtained with univariate comparison and correlations suggest that the 
three features belong to the same compound, those with m/z 673.14 and 689.11 probably 
being dimers of the m/z 348.07. At this stage, however, no possible assignment was found, 
hindering any metabolic interpretation. Thus, Statistical HeterospectroscopY (SHY) was 
attempted to possibly unveil these features assignment or a common metabolic 
relationship.  
 
4.2.1.4 Statistical correlation of NMR and MS data 
SHY is a powerful statistical tool to aid metabolite assignment and to unveil 
metabolic relationships, as presented in previous reports (Crockford et al., 2006, Coen et 
al., 2007, Wang et al., 2008, Graça et al., 2012). The concept beyond SHY is similar to 
that of 1D STOCSY (presented in Section 3.1), i.e., NMR peaks and MS features 
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corresponding to the same molecule have high covariance and correlation, enabling the 
assignment of a given compound detected by both analytical techniques. Furthermore, 
metabolically related compounds also show meaningful covariance and correlation 
enabling the identification of a shared metabolic relationship.  
SHY of MS and NMR data was initially tested for some features of known 
assignment, as exemplified in the 1D STOCSY shown in Figure 4.17a). In this example the 
MS feature corresponding the trigonelline ion M+H
+
 (detected with the HSS column in the 
positive ionization mode, eluting at 4.44 min with m/z 139.06) was correlated with the 
NMR spectra. A high correlation and covariance was found between the NMR spin system 
of trigonelline (singlet 4.44 ppm, multiplet 8.78 ppm and singlet 9.12 ppm) and the MS 
feature, with r 0.98 and p-value 3.18×10
-22
. This correlation was confirmed by scatter 
plotting the intensities of both NMR and MS dimensions. 
MS features found relevant for the separation of pre-PTD and control samples were 
also correlated with the NMR data and, for the feature with m/z 673.14, the obtained 1D 
STOCY is shown in Figure 4.17b). In spite of an apparently good correlation between the 
trimethylamine-N-oxide (TMAO) resonance, with r 0.73 and p-value 1.17×10
-4
, and 
feature with m/z 673.14, the scatter plot of the intensities in the MS and NMR dimensions 
showed that this was a spurious correlation supported by only one sample (noted with an 
arrow in Figure 4.17b). SHY was repeated for the remaining two MS features, the 
correlation result being similar to that shown in the previous example. 
 
Results obtained for the pre-PTD group analyzed by UPLC-MS showed significant 
changes for only two features, although no assignment was obtained hindering any further 
metabolic interpretation. Nevertheless, relevant conclusion can be drawn regarding UPLC-
MS processing, namely the inadequacy of the VIP- and b-coefficient-based variable 
selection methodology application to the complete UPLC-MS dataset, as noise and 
background variables were being selected and wrongly yielding apparently reliable 
models. Furthermore, the importance of applying noise and background filters in this type 
of datasets is reinforced, in order to avoid erroneous conclusions and the suggestion of 
supposedly disease markers. Future works entails the analysis of other disorders groups, 
namely pre-IUGR, pre-PE and GDM, for which data has been acquired although results 
were not available in time for inclusion in this thesis. 
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Figure 4.17: MS/NMR SHY analysis of a) trigonelline MS feature (139.06 m/z, 4.44 min) and b) 
relevant MS feature (673.14 m/z, 3.22 min) and the NMR spectra of urine. Arrow notes one sample 
compromising the correlation result. 
 
4.2.1.5 Proposed metabolic interpretation of pre-diagnosis urinary changes in 
PTD 
In spite of the premise that broader and complementary knowledge could be gained 
by analyzing pre-PTD samples through both NMR and UPLC-MS no significant findings 
could be obtained with the later technique, which shows the crucial importance of factors 
such as analysis conditions choice (e.g. LC column, MS detection method), analytical 
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reproducibility, increased dataset complexity due to the enhanced sensitivity and higher 
difficulty in compounds assignment. Hence, a possible metabolic interpretation could only 
be advanced based on the NMR data, albeit being less sensitive. A general scheme of the 
metabolic pathways found, in this study, to be affected in pre-PTD is depicted in Figure 
4.22, along with perturbations found for other pre-diagnosed conditions which will be 
discussed in the following sections. 
The overall changes noted in 
1
H NMR spectra of urine from women who further 
developed PTD fit previously advanced hypothesis whilst also unveiling new information. 
Increased excretion of ketone bodies acetone, acetoacetate and 3-HBA, the latter two being 
specific of pre-PTD were found in this work, consistently with reported changes in AF 
(Graça, 2013). The increased ketone bodies observed here with the tandem decrease of 
carnitine suggest enhanced lipid oxidation several weeks before delivery. In fact, decreased 
lipids in umbilical cord blood plasma of preterm babies and increased lipids in their 
mothers blood plasma have been found, at the time of delivery, reflecting increased 
oxidation in the fetal compartment or altered placental transfer (Tea et al., 2012). 
Decreased ascorbate was also found specific of pre-PTD, possibly in connection with 
oxidative stress. Ascorbate directly strengthens and stimulates collagen synthesis, and 
protects fetal membranes from ROS damage (a possible cause of membranes rupture) 
(Woods Jr et al., 2001). Moreover, the hypothesis of increased oxidative stress during 2
nd
 
trimester of women later developing PTD has been advanced and supported by increased 
allantoin contents in AF. Still, in this work no changes were found for this metabolite in 
maternal urine. The pre-PTD group was also characterized by increased threonine and 
isoleucine, along with decreased histidine excretion. Increased threonine and decreased 
isoleucine and histidine has been found in AF  possibly due early perturbation of the fetal-
placental unit altering amino acid transfer or changes in protein synthesis (Graça et al., 
2012, Graça, 2013). Other specific changes registered in pre-PTD include decreased 
betaine and increased GAA, these metabolites involved in methionine metabolism and urea 
cycle, respectively. Betaine donates a methyl group to homocysteine to form methionine, 
also generating dimethylgycine (DMG). Previous reports have indicated 
hyperhomocysteinemia (increased homocysteine in blood) at 24-37 g.w. of women at risk 
of PTD and perturbations in the methionine pathway have been implicated in several 
adverse pregnancy outcomes (Dasarathy et al., 2010, Micle et al., 2012). Although no 
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concomitant changes were found in this work for other metabolites involved in methionine 
metabolism (i.e. choline or DMG), decreased betaine could indicate an early perturbation 
of the methionine cycle operation. The increased GAA urinary excretion may suggest a 
slowing down of the urea cycle (Brosnan and Brosnan, 2010) although no reference 
supporting this hypothesis was found in other reports. Relevant variations were also found 
in metabolites related to the gut microflora, namely for increased 4-OH-hippurate and 
decreased PAG, 3-Me-histidine and 4-HPA, the former two being the only metabolites 
with individual significance (p<0.05) in this profile. These results suggest an important and 
novel role of gut microflora in the PTD pathological process, although the nature of the 
relationship remains, at this stage, unknown.   
 
4.2.2 Women later developing preeclampsia (PE) 
The possibility of predicting PE through urine metabolomics was also attempted by 
comparing samples collected 14-21 weeks before PE diagnosis and controls. A more 
complete description of samples metadata and diagnosis criteria is shown in Section 2.1.2 
of the Experimental Chapter.  
 
4.2.2.1 Unveiling a pre-diagnosis urinary signature of PE 
In this work, a limited number of samples of women further developing PE (pre-
PE, n=9) was obtained and compared to the control group (n=84). An initial PLS-DA 
revealed no significant changes in the 
1
H NMR profile when considering the original 
dataset, as supported by the MCCV results in Table A-III.2, Annex III. However, when 
reducing the dataset with the variable selection method previously presented, a significant 
improvement was observed in the PLS-DA model and validation, with satisfactory 
predictive power given by Q
2 
of true and permuted models, CR 94%, sensitivity 75% and 
specificity 94% as shown in Figure 4.18 and Table A-III.2, Annex III. 
 
The analysis of the variables selected, thus explaining the separation visible in the 
PLS-DA score plots in Figure 4.18 revealed a metabolic signature potentially predictive of 
PE, this being listed in Table 4.6. Pre-PE samples were characterized by changes 
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21metabolites, 4 unassigned spin systems (singlet at 0.93 ppm, 1.99 ppm, 4.40 ppm and 
doublet at 8.78 ppm,  and singlet at 4.51 ppm) and 2 regions with p<0.05. These changes 
were analyzed in terms of individual significance and effect size, along with specificity, 
relatively to other pre-diagnosis disorders, these being indicated with a 
c
 whilst changes 
common to all pre-diagnosis disorders (possibly reflecting a general stress effect) are 
indicated with a 
d
 in Table 4.6. The pre-PE metabolic signature was plotted by means of a 
VIP-wheel, this representation enabling the visualization of the selected variables with 
higher VIP value. The obtained plot is shown in Figure 4.19 with indication of some 
distinguishing features. 
 
 
Figure 4.18: ) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for pre-PE (, n=9) vs. Controls (, n=84). 
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Table 4.6: Metabolite/resonance changes in maternal urine for pre-PE compared to controls.
 
a
Chemical shifts selected by variables selection; s: singlet, d: doublet, t: triplet, q: quartet, dd: 
doublet of doublets, m: multiplet, br: broad. 
b
 Metabolites related to diet and/or gut microflora. 
c
Changes specific of the disorder, relatively to other pre-diagnosis disorders here evaluated. 
d
Changes common to all pre-diagnosis disorders. Ui: unassigned compound i following numbering 
in Table 4.1, Table 4.2 and Table 4.4 p-CS: p-cresol sulphate, other abbreviations defined in Table 
4.1, Table 4.2 and Table 4.4. Only p-values < 0.05 are shown. 
pre-PE n=9 vs. Controls n=84 
Compound δH/ppm and multiplicity 
a
 Variation (effect size, p-value) 
2-KG 2.45 t, 3.01 t ↓(-0.49) 
2-Py 8.33 d ↑(0.62) 
3-Me-histidine
 b
 7.15 s ↑(0.33) 
4-DEA
d
 1.11 d, 4.12 m ↑(1.25) 
4-OH- hippurate 
b
 7.76 d ↓(-0.03) 
Acetate
c
 1.92 s ↓(-0.26, 2.9×10-2) 
Carnitine 3.23 s ↓(-0.45) 
Cis-aconitate 3.12 d ↑(0.10) 
Citrate 2.54 d, 2.69 d ↑(0.31) 
Creatinine
 d
 3.05 s, 4.06s ↓(-0.18) 
Formate
c
 8.46 s ↓(-0.21) 
Fumarate
c
 6.53 s ↓(-0.20) 
Galactose 5.28 d ↓(-0.47,2.0×10-2) 
Glutamine
 c
 2.15 m, 2.47 m ↑(0.05) 
Hippurate 
b
 3.97 d ↑(0.34) 
Isoleucine
 c
 1.01 d ↓(-0.26) 
IS 
b ,e
 7.51 d, 7.70 d ↑(0.52) 
Lactose 4.46 d ↓(-0.43) 
NMND
 
 4.48 s, 8.90 d, 8.97, d, 
9.28 s 
↑ (0.22) 
PAG
 b
 2 7 t, 3.67 d ↓(-0.19) 
p-CS
 b 
 2.34 s, 7.21 d, 7.28 d ↓(-0.34) 
Scyllo-inositol 
b
 3.36 s ↓(-0.68, 1.3×10-2) 
Succinate 2.41 s ↓(-0.38, 1.5×10-2) 
Sucrose 5.41 d ↑(0.71) 
Trigonelline
b
 4.44 s, 8.84 br,  ↓(-0.10) 
 9.12 s  
Tyrosine 6.91 d ↓(-0.33) 
U14 0.93 s ↓(-0.10) 
U4
 
 1.99 s ↓(-0.04) 
U10 
b, 
 4.40 s, 8.78 d ↓(-0.06) 
U35
 c
 4.51 s ↑(0.33) 
Unassigned spectral regions 
1.28-1.30 ↓(-0.30,4.5×10-2) 
1.54-1.58
 e
  ↑(0.05, 4.8×10-2) 
+ 28 selected regions, p>0.05, at 0-4.6 and 6-10 ppm 
 
In spite of the exploratory nature of this model (due to the limited number of 
samples for the pre-PE group), the results obtained revealed some apparently specific 
changes of the disease, these although requiring future confirmation in a larger cohort. 
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Moreover, the MCCV confirmation of the PLS-DA model reliability supported the 
possibility of a possible metabolic interpretation to be advance.  
 
 
Figure 4.19: VIP-wheel representations of the NMR metabolite signatures obtained for pre-PE. The 
average 
1
H NMR spectrum of controls is represented in the inner circle, with the corresponding 
ppm scale shown in the outer black circle. Each dot represents a variable (spectral data point) 
selected by the intersection method, positioned in a radial VIP scale according to its VIP value. 
Some distinguishing features are indicated. 
 
4.2.2.2 Proposed metabolic interpretation of pre-diagnosis urinary changes in 
PE 
In this cohort, apparently specific pre-PE variations were found for acetate, 
formate, fumarate, isoleucine and glutamine (although with a residual change), IS and an 
unassigned singlet at 4.51 ppm. An interesting finding is the concomitant change in TCA 
cycle precursor (decreased acetate) and intermediates (decreased fumarate and succinate 
along with increased cis-aconitate and citrate), suggestive of a profound perturbation in 
this pathway (Figure 4.22). Increased citrate and decreased succinate had been found in AF 
of women diagnosed with PE (Bock, 1994). Moreover, decreased succinate and acetate 
have been reported in 1
st
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latter possibly due to changes in lipids metabolism (Bahado-Singh et al., 2012). Another 
finding consistent with changes in lipids metabolism is the carnitine decrease found in this 
cohort, which is suggestive of increased lipids oxidation (Cho and Cha, 2005). Carnitine 
had been previously found to increase in 1
st
 T maternal serum of later developing PE 
women, as a reflection of enhanced metabolism of lipids (Bahado-Singh et al., 2012). 
Another specific change of pre-PE, within the pre-diagnostic disorders here studied, is the 
increased urinary excretion of IS. Increased urinary IS can reflect increased oxidative 
stress, as suggested for the FM study, as this metabolite has been found to mediate this 
process (Dou et al., 2007). Moreover, increased oxidative stress has been suggested by 
changes in placental extracts of PE pregnancies (Dunn et al., 2012). Nucleotide 
metabolism appears to be also altered, as suggested by the tandem increase in NMND and 
2-Py found in this cohort. Increased urinary excretion of NMND and 2-Py suggest 
alterations in nucleotide metabolism and has been reported in connection to type 2 diabetes 
(Salek et al., 2007), but not to PE. Regarding amino acids, the pre-PE group was 
associated with decreased isoleucine and tyrosine, the first having been previously found to 
increase in maternal urine (Glew et al., 2004) and the second found to increase in maternal 
plasma (Turner et al., 2008), both at the post-diagnosis state. 
 
4.2.3  Women carrying fetuses later diagnosed with intrauterine growth 
restriction (IUGR) 
For this study maternal urine of women who were diagnosed with intrauterine 
growth restriction (pre-IUGR) of the fetus later in pregnancy was compared to controls. A 
detailed description of samples metadata and diagnosis criteria is shown in Section 2.1.2 of 
the Experimental Section.  
 
4.2.3.1 Unveiling a pre-diagnosis urinary metabolic signature of IUGR 
As for pre-PE, only a limited number of samples were available for the study of 
pre-IUGR (n=10), hindering a more definite interpretation of the findings. These samples 
were compared to healthy controls (n=84) and, in spite of a separation trend being visible 
in the PLS-DA score plot (not shown), the MCCV revealed insufficient results, as shown 
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in Table A-III.2, Annex III. Thus, the original dataset was compressed, by applying the 
variable selection methodology here developed. The resulting PLS-DA model confirmed 
the separation between classes and MCCV validated the models’ robustness (CR 94%, 
sensitivity 99% and specificity 94%) and predictive power of the model, as shown in 
Figure 4.20 and Table A-III.2, Annex III. 
 
 
Figure 4.20: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for pre-IUGR (○, n=10) vs. Controls (, n=84). 
 
The variables supporting the separation seen in Figure 4.20, revealed a potentially 
predictive urinary signature of IUGR. These variables/metabolites are listed in Table 4.7 
along with corresponding effect size and p-value. The pre-IUGR profile comprised 
variations in 25 metabolites, 11 unassigned spin systems (singlet at 0.93 ppm, doublet at 
1.08 ppm, singlet at 1.82 ppm, 1.99 ppm, 2.03 ppm, 2.05 ppm, 2.37 ppm, 2.91 ppm, quartet 
at 2.96 ppm, singlet at 4.40 ppm, doublet at 8.78 ppm, broad resonance at 6.92 ppm) and 5 
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Table 4.7: Metabolite/resonance changes in maternal urine for pre-IUGR compared to controls.
 
a
Chemical shifts selected by variables selection; s: singlet, d: doublet, t: triplet, q: quartet, dd: 
doublet of doublets, m: multiplet, br: broad. 
b
 Metabolites related to diet and/or gut microflora. 
c
Changes specific of the disorder, relatively to other pre-diagnosis disorders here evaluated. 
d
Changes common to all pre-diagnosis disorders. Ui: unassigned compound i following numbering 
in Table 4.1, Table 4.2, Table 4.4 and Table 4.6. Abbreviations defined in Table 4.1, Table 4.2, Table 
4.4 and Table 4.6. Only p-values < 0.05 are shown. 
pre-IUGR n=10 vs. Controls n=84 
Compound δH/ppm and multiplicity 
a
 Variation (effect size, p-value) 
1-Me-histidine
 b
 7.05 s, 7.78 s ↑(0.43) 
2-HIBA 1.36 s ↑(0.77)  
2-KG 2.45 t, 3.01 t ↓(-0.25) 
3-HIVA 1.27 s ↓(-0.50) 
3-Me-histidine
 b
 7.15 s ↓(-0.29) 
4-DEA
d
 1.11 d ↑(0.40) 
4-HPA
 b
 6.86 d, 7.17 d ↓(-0.35) 
4-OH- hippurate
 b
 6.98 d, 7.76 d ↓(-0.42) 
Acetone
 c
 2.23 s ↓(-0.05) 
Alanine
 c
 1.48 d ↓(-0.38) 
Choline
 b
 3.20 s ↓(-0.20) 
Creatinine 
d
 3.05 s, 4.06 s ↓(-0.37) 
DMA
 b
 2.72 s ↓(-0.43) 
Furoylglycine
b
 6.65 q ↓(0.22) 
Galactose 5.28 d ↓(-0.43) 
Glutamine
 c
 2.15 m, 2.47 m ↓(-0.63) 
Glycine 3.57 s ↓(-0.57) 
Leucine
 c
 0.97 t ↓(-0.47) 
Lysine
 c
 1.73 m, 1.91 m ↓(-0.49) 
Succinate 2.41 s ↓(-0.38) 
Tartrate
 b
 4.34 s ↑(0.93, 4.1×10-2) 
Threonine
 c
 1.34 d, 4.26 dd ↓(-0.26) 
TMA
 b
 2.88 s ↓(-0.36) 
Trigonelline
 b
 4.44 s, 8.84 br, 9.12 s ↑(0.75) 
Tyrosine 6.91 d ↓(-0.48) 
U14 0.93 s ↓(-0.30) 
U2 1.08 d [2.50, 3.55, 3.72] ↓(-0.13) 
U29
 c
 1.82 s ↑(0.41) 
U4 1.99 s ↓(-0.56) 
U21
 c
 2.03 s ↓(-0.42) 
U5
 c
 2.05 s ↓(-0.23) 
U34
 c
 2.37 s ↓(-0.35) 
U9
 c
 2.91 s ↓(-0.52) 
U28
 c
 2.96 q [2.88,4.02] ↓(-0.44) 
U10
 b
 4.40 s, 8.78 d ↓(-0.02) 
U11
 c
 6.92 br ↓(-0.51) 
Unassigned spectral regions 
3.17-3.19 ↓(-0.64, 1.9×10-2) 
3.28-3.29 ↓(-0.65, 1.6×10-2) 
4.32-4.37 ↑(1.01, 4.6×10-2) 
7.00-7.01 ↑(1.52, 1.2×10-2) 
7.47-7.49 ↑(1.02, 9.2×10-3) 
+ 22 selected regions, p>0.05, at 0-4.6, 6-10 ppm 
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unassigned regions with p<0.05 As for previous disorders, these variations were analyzed 
in terms of specificity, relatively to other pre-diagnosed conditions and metabolites found 
to be specific of pre-IUGR are indicated with 
c  
while those common to all pre-diagnosed
 
disorders are indicated with a 
d  
in Table 4.7. The VIP-wheel representation of the selected 
variables enabled the identification of some distinctive features of the pre-IUGR profile, as 
shown in Figure 4.21. 
 
 
Figure 4.21: VIP-wheel representations of the NMR metabolite signatures obtained for pre-IUGR. 
The average 
1
H NMR spectrum of controls is represented in the inner circle, with the 
corresponding ppm scale shown in the outer black circle. Each dot represents a variable (spectral 
data point) selected by the intersection method, positioned in a radial VIP scale according to its 
VIP value. Some distinguishing features are indicated 
 
4.2.3.2 Proposed metabolic interpretation of pre-diagnosis urinary changes in 
IUGR 
In this cohort, 7 amino acids were found to be decreased in maternal urine, namely 
alanine, glutamine, leucine, lysine, threonine, glycine and tyrosine, the first 5 being 
specific of pre-IUGR (Figure 4.22). IUGR is associated with decreased circulating amino 
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Figure 4.22: Schematic representation of the metabolic pathways possibly affected in pre-PTD, 
pre-PE and pre-IUGR cases. Metabolites in bold were identified in 
1
H NMR spectra of maternal 
urine. Colored arrows indicate direction of variation in each group. Dashed arrows indicate 
transformations occurring through several reactions. Amino acids in 3-letter code; PAG: 
phenylacetylglutamine, p-CS: p-cresol sulphate, other abbreviations defined in Figure 4.10. 
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 acids and decreased transfer to the fetus through the placenta (Regnault et al., 2005, 
Horgan et al., 2010, Horgan et al., 2011).  The results found in this preliminary study 
highlight the possibility of detecting a suboptimal amino acid maternal status several 
weeks before the clinical manifestation of the disease. An interesting question would be to 
determine if it is the maternal amino acid deficiency that causes the development of the 
disease, although at this stage, no conclusions can be advanced. Decreased TCA cycle 
intermediates 2-KG and succinate were also found in pre-IUGR samples as well as several 
metabolites originating from the gut microflora (indicated with a
 b
 in Table 4.7) although 
no corroborating findings has been reported in literature. On the other hand, previous 
evidence of altered lipids metabolism in IUGR after diagnosis (Dessì et al., 2011, Horgan 
et al., 2011) were not confirmed in this cohort, in the pre-diagnosis stage. One final note 
with regard to the 11 unassigned spin systems, 7 of these being specific of this condition, 
and 5 spectral regions (with p<0.05) found in the metabolic signature of pre-IUGR. It 
would be of great importance to advance the identification of these compounds so that a 
more comprehensive metabolic interpretation can be proposed. 
 
4.2.4 Women later developing premature rupture of membranes (PROM) 
The final pre-diagnosed condition to be studied in this project was premature 
rupture of the membranes after the 37
th
 g.w. (here named pre-PROM). Within the 
conditions here studied PROM (after the 37
th
 g.w.) poses the lesser impact on maternal and 
fetal outcomes as this is managed through labor induction without posing significant risks.  
In this work, maternal urine was collected in the 2
nd
 trimester, 18 to 24 weeks before 
PROM and compared to controls. A more complete description of samples numbers, 
metadata is given in Experimental Section 2.1.2. After the initial PLS-DA and MCCV of 
that model, the 
1
H NMR dataset was reduced by variable selection and model was 
recalculated and resubmitted to validation. The resulting PLS-DA score plot and MCCV 
parameters are summarized in Table A-III.2, Annex III and shown in Figure 4.23. In this 
figure a separation trend is visible between controls and pre-PROM although with some 
overlapping of samples.  
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Figure 4.23: a) PLS-DA scores plot, b) Q
2
 distributions plot and c) ROC plot of
 
true and permuted 
classes, given by MCCV obtained for pre-PROM (, n=68) vs. Controls (, n=84). 
 
Regarding the MCCV results, in spite of the low overlapping of Q
2 
of true and 
permuted models, confusion matrices yielded a CR of 70%, sensitivity of 68% and 
specificity of 72%, these values being significantly lower than those obtained for the 
remaining disorders. Thus, this group was found to be indistinguishable of controls in 
terms of their 2
nd
 trimester urinary metabolome. 
 
4.3 Summary of the impact of fetal and maternal disorders 
A summary of the main biochemical findings of fetal and maternal disorders here 
studied on 2nd trimester maternal urine composition is shown in Figure 4.24, along with 
the corresponding validation parameters in decreasing order of impact. As shown in Figure 
4.24, it was found that T21 compared to other CD types caused the highest impact, with 
CR, sensitivity and specificity ranging from 92-95%, followed by the CNS compared to 
other FM types, which had CR, sensitivity and specificity of 83-90%. These results support 
the premise of a possible non-invasive diagnostic procedure of T21 and CNS 
malformations based on maternal urine metabolomics. The impact of general CD and FM 
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cases studied here through the consideration of heterogeneous groups, were associated with 
slightly lower CR, sensitivity and specificity (85%, 87%, 84% and 88%, 74%, 87%, 
respectively for CD and FM). These lower validation parameters obtained for these 
disorders may be a consequence of the heterogeneous nature of the groups used 
(comprising several CD and FM types). Nevertheless, in spite of the relatively lower CR, 
sensitivity and specificity, the results here obtained are still higher than 2
nd
 trimester non-
invasive diagnostic methods presently available in clinical practice (CR 17-74% for FM by 
ultrasound, depending on the population and operator skill, and 60-75% for T21-no 
reference for heterogeneous CDs were found).  
Figure 4.24: Summary of the main biochemical findings of fetal and maternal disorders and 
corresponding validation parameters in decreasing order of impact. 
Disorder 
studied
Main biochemical findings
Validation 
parameters
T21
Methionine and nucleotide metabolism, increased 
oxidative stress and perturbations in the respiratory 
chain
CR: 94%
Sensitivity: 92%
Specificity: 95%
CNS
Methionine and amino acids metabolism, increased 
oxidative stress, perturbations in the respiratory 
chainand enhanced TCA cycle
CR: 87%
Sensitivity: 83%
Specificity: 90%
CD
Enhanced ketone bodies production, derangements 
in sugars, amino acids and nucleotide metabolism, 
enhanced TCA cycle operation, urea cycle and/or 
creatine biosynthesis 
CR: 85%
Sensitivity: 87%
Specificity: 84%
FM
Enhanced gluconeogenesis and TCA cycle ,  
perturbation in the respiratory chain, increased lipids 
oxidation and ketone bodies production and 
perturbations in nucleotide metabolism
CR: 88%
Sensitivity: 74%
Specificity: 87%
pre-PTD
Perturbations in amino acid metabolism and/or 
placental transfer and increased lipids oxidation and 
oxidative stress 
CR: 84%
Sensitivity: 79%
Specificity: 84%
pre-IUGR
Decreased amino acids levels
CR: 94%
Sensitivity: 99%
Specificity: 94%
pre-PE Perturbations in TCA cycle 
CR: 94%
Sensitivity: 75%
Specificity: 94%
pre-PROM —
CR: 70%
Sensitivity: 68%
Specificity: 72%
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Regarding the prediction of later developed disorders the highest impact was found 
for PTD, followed by IUGR, PE and PROM. The pre-PTD model was associated with CR 
84%, sensitivity 79% and specificity 84%. The low sensitivity of this model expressing a 
low true positive rate (TPR), meaning that some women that later develop PTD are 
misclassified as controls. A possible explanation for this limitation may be the interval 
between sampling and diagnosis (11-20 g.w.). The pre-IUGR and pre-PE models, in spite 
of their exploratory nature due to very low number of samples available (n<10), yielded 
good validation results (all above 94% with exception of the sensitivity of the pre-PE 
model (75%), i.e. low TPR). The low sensitivity or TPR of pre-PE may be a direct 
consequence of the low number of samples used and/or the interval from sampling to 
diagnosis (14-21 g.w.). Lastly, the pre-PROM condition was here associated with CR, 
sensitivity and specificity ranging from 68-72%, thus considered indistinguishable of 
controls. The absence of changes in pre-PROM may be due to the lower impact of this 
pregnancy disorder and/or the interval from sampling to diagnosis (18-24 g.w.). 
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5. Gestational Diabetes Mellitus: a deeper insight into maternal 
metabolism disturbances 
This chapter describes a study of the metabolic effects of gestational diabetes 
mellitus (GDM), at several disease stages, through urine metabolomics. Hence, maternal 
urine NMR profiling was carried out at three different stages: a) Diagnosed GDM (samples 
collected at the time of diagnosis, prior to treatment initiation), b) pre-diagnosis (samples 
collected at 2
nd
 trimester, 2-21 weeks prior to the clinical manifestation of the disease) and 
c) Treated GDM (samples collected during GDM treatment). Firstly, the urinary metabolic 
signature of each GDM stage was unveiled through comparison with healthy gestational 
age (GA) matched controls. Additionally, the study of the metabolic effect of insulin and 
non-insulin treatments was sought, by comparing insulin-treated and non-insulin-treated 
subjects. Secondly, a novel pharmacometabolomic application for GDM treatment was 
attempted, by exploring the possibility to predict future insulin treatment requirement. 
These results demonstrate, for the first time, the enticing possibility of unveiling a 
metabolic phenotype potentially predictive of individual future GDM treatment 
requirements.  
   
5.1 Maternal urine composition at the time of GDM diagnosis 
5.1.1 Unveiling an urinary metabolic signature of GDM 
The first disease stage to be characterized in the GDM study was the diagnosed 
state, i.e. samples collected at the time of diagnosis, at 16-33 g.w., prior to treatment 
initiation, in order to broaden the understanding of the metabolic effect of the disease in its 
more exacerbated state. Detailed description of sample metadata and diagnostic criteria is 
shown in Section 2.1.2 and Table 2.4 of Experimental Section.  
The average 
1
H NMR spectra of maternal urine collected at each disease stage are 
shown in Figure 5.1, along with some relevant assignments. Visually identifiable 
differences in the average composition of urine, are indicated in Figure 5.1c, namely in the 
aliphatic region from 1.0-1.5 ppm and 1.9-2.5 ppm as well as the aromatic region from 7-8 
ppm. 
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Figure 5.1: Average 500 MHz 
1
H NMR spectra of a) pre-diagnosis (median GA 17 g.w.), b) 
Diagnosed (median GA 27 g.w.) and c) Treated GDM (median GA 35 g.w.) groups. Some relevant 
assignments are noted in a,b) and curved lines in c) indicate regions with major visual changes. 
Legend (3-letter code for a.a.): 1: 4-deoxyerythronic acid (4-DEA), 2: thr, 3: lactate, 4: alanine, 5: 
acetate, 6:  phenylacetylglutamine (PAG), 7: p-cresol sulphate (p-CS), 8: citrate, 9: creatinine, 10: 
creatine, 11: gly, 12: guanidoacetate (GAA),  13: xylose, 14: glucose, 15: lactose, 16: galactose, 17: 
allantoin, 18: sucrose, 19: 1,6-anhydroglucose, 20: tyr, 21: his, 22: hippurate, 23: 3-methylhistidine, 
24: hypoxanthine, 25: N-methyl-2-pyridone-5-carboxamide (2-Py), 26: trigonelline, 27: N-
methylnicotinamide (NMND). Vertical arrow indicates disease evolution from pre-diagnosis, 
diagnosed and treated stages.  
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In order to unveil the urinary signature of GDM, samples collected at the time of 
diagnosis were compared with controls. The Diagnosed GDM group comprises samples 
collected during the 2
nd
 (n=8) and 3
rd
 (n=5) trimesters of pregnancy (GA range from 16-33 
g.w.). As gestational age was found to cause a significant impact on the composition of 2
nd
 
and 3
rd
 trimester maternal urine, these differences having been discussed Chapter 3, a 
control group matched, as much as possible, in number (approximately the same number of 
samples) and GA (2
nd
 T, n=6, 3
rd
 T, n=8, GA range of 16-33 g.w.) was selected, here 
named control group 1. For this study, a total of 113 2
nd
 and 25 3
rd
 trimester controls were 
available. However, if all control samples (2
nd
 and 3
rd
 trimester) were used, the resulting 
control group would be significantly unbalanced in terms of GA and the resulting urinary 
profiles would reflect mainly the GA rather than GDM. So, in order to avoid potentially 
erroneous results the control group was selected based solely on number and GA at 
sampling. The resulting score plot of the PLS-DA model, obtained with the full resolution 
spectral data, and corresponding MCCV results is shown in Figure 5.2 (left). In spite of the 
separation trend between GDM and controls in the score plot (Figure 5.2a), there is 
significant dispersion within the two groups. Moreover, MCCV yielded marginally 
satisfactory results with CR 77%, sensitivity 74% and specificity 81%, and some overlap 
of Q
2
 distribution of true and permuted models (Figure 5.2c,e and Annex III, Table A-
III.3). Thus, the 
1
H NMR dataset was reduced (using the variable selection method 
presented in Chapter 4), PLS-DA was recalculated using the resulting subset of variables 
and these were resubmitted to MCCV (Figure 5.2 right). A significant reduction in sample 
dispersion became visible in the new PLS-DA score plot shown Figure 5.2b, this model 
having very good prediction power, supported by the almost absent overlap of Q
2
 
distributions, as well as high robustness, with CR 96%, sensitivity 93% and specificity 
100% (Figure 5.2d,f, Table A-III.3). 
 
In the PLS-DA score plot shown in Figure 5.2b, two circles indicate one control 
and one Diagnosed GDM sample both collected at 16 g.w., i.e. the minimum GA in both 
groups. The location of this control sample in negative LV2 relatively to other controls, 
whilst the GDM sample is clustered with the rest of the disorder group, suggests that the 
GA effect is significant in healthy pregnancies (consistent with findings presented in 
Chapter 3.3), but not so much for the GDM sample. In fact, the position of the latter 
Chapter 5 
184 
(collected at the 16
th
 week of gestation) seems to be determined by a particular profile 
specific of the disease and not of GA. 
 
 
Figure 5.2: PLS-DA score plots (a,d), Q
2
 (b,e) and ROC plots (c,f) of true and permuted models 
obtained for the original 
1
H NMR spectra of urine of Diagnosed GDM (n=13) vs. control group 1 
(n =14) (left)  and for the same spectra after variable selection method presented in section 4.1.1.1 
(right). TPR: true positive rate, FPR: false positive rate. Circle indicates two samples collected at 
16 g.w. (minimum GA of both groups) showing clustering of the GDM group due to disease effect 
and higher distance in the control group due to GA, consistent with findings previously shown in 
Chapter 3.3. 
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The analysis of the subset of variables explaining the separation obtained through 
PLS-DA enabled a metabolic signature of GDM to be identified and characterized in terms 
of effect size and p-value (Table 5.1). The resulting signature profile comprised variations 
in 18 metabolites (including sugars, organic acids and amino acids), 4 unassigned spin 
systems (doublet at 1.25 ppm and singlets at 2.02 ppm, 2.03 ppm and 7.06 ppm) and 10   
 
Table 5.1: Metabolite/resonance changes in maternal urine of women diagnosed with GDM 
compared to controls.
 a 
Chemical shifts selected by variables selection; TOCSY or STOCSY 
correlated peaks in square brackets; s: singlet, d: doublet, t: triplet, q: quartet, dd: doublet of 
doublets, m: multiplet, br: broad. 
b 
Peaks possibly related to diet and/or gut microflora. 
c
 Consistent 
with previous findings in maternal urine (Sachse et al., 2012). Ui: unassigned compound i by 
appearance order. 2-KG: 2-ketoglutarate, 4-HPA: 4-hydroxyphenylacetate, DMA: dimethylamine, 
DMG: dimethylglycine, p-CS: p-cresol sulphate. Only p-values<0.05 are shown. 
Diagnosed GDM (n=13) vs. Control group 1 (n=14) 
Compound δH/ppm and multiplicity 
a
 Variation (effect size, p-value) 
1,6-anhydroglucose
b
 5.46 br ↓(-0.65) 
2-KG 2.45 t ↑(1.22, 7.80×10-3) 
4-HPA
b
 7.17 d ↓(-0.27) 
4-OH-hippurate
b
 6.98 d, 7.76 d ↓(-0.26) 
Betaine 3.26 s ↑(0.84, 2.55×10-2) 
Citrate
c
 2.54 d, 2.69 d ↑(0.47) 
Creatine
b
 3.04 s, 3.94 s  ↑(1.41,3.95×10-3) 
Creatinine
b
 3.05 s, 4.06 s ↓(-0.25) 
DMA
b
 2.72 s  ↓(-0.35) 
DMG 2.93 s ↑(1.00, 1.45×10-2) 
Furoylglycine
b
  6.65 q ↓(-0.42) 
Glycine 3.57 s ↑(0.19) 
Glutamine 2.47 m ↑(1.01) 
Hippurate
b
 3.97 d, 7.56 t, 7.64 t, 7.83 d, 8.52 br ↓(-1.20, 1.68×10-2) 
p-CS
b
 2.35 s, 7.29 d ↓(-0.57) 
Sucrose
b
 5.41 d ↓(-0.77) 
Succinate 2.41 s ↑(0.94, 2.91×10-2) 
Threonine 4.26 dd ↑(0.98, 2.22×10-2) 
U1 1.25 d [3.88] ↓(-0.99, 4.27×10-2) 
U2 2.02 s ↑(0.89, 5.43×10-2) 
U3 2.03 s ↑(0.70, 9.45×10-2) 
U4 7.06 s ↓(-1.17, 5.60×10-3) 
Unassigned spectral regions 
2.91-2.93  ↑(1.24, 6.61×10-4) 
2.95-2.98  ↑(1.10, 1.25×10-2) 
3.18-3.23  ↑(0.95, 2.22×10-2) 
3.81-3.82  ↑(0.85, 4.27×10-2) 
5.11-5.13  ↓(-1.55, 3.72×10-5) 
5.36-5.37  ↓(-1.00, 2.91×10-2) 
5.47-5.49  ↓(-1.27, 6.62×10-3) 
7.47-7.50  ↓(-1.10, 6.62×10-3) 
8.14-8.17  ↓(-2.02, 9.67×10-6) 
8.23-8.32    ↓(-1.69, 5.28×10-4) 
+ 15 unassigned spin systems and 3 spectral regions with p>0.05 
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spectral regions (i.e. regions comprising unassignable/overlapped resonances) with 
individual significance (p<0.05). Moreover, metabolite variations found consistent with 
previous reports are indicated with 
c
 (found only for citrate) while those arising from gut 
microflora and/or diet are noted with 
b
 in Table 5.1. 
 
5.1.2 Proposed metabolic interpretation of urinary changes in GDM 
A schematic representation of the main metabolic pathways affected in the 
Diagnosed GDM group is shown in Figure 5.7 (page 199), along with changes in other 
GDM states discussed throughout this chapter. Amino acids glycine, glutamine and 
threonine were found increased in GDM, the latter with individual significance. Increased 
glycine has been found in plasma of GDM-affected women (Pappa et al., 2007) and 
increased glutamine in urine of T2DM (Salek et al., 2007) both variations being related to 
enhanced gluconeogenesis, this enhancement also explaining the concomitant increase in 
threonine found in this study. TCA cycle intermediates citrate, 2-ketoglutarate (2-KG) and 
succinate were also found to increase, the last two with individual significance. Citrate has 
been found to increase in urine of women diagnosed with GDM (Sachse et al., 2012), but 
also in urine of T2DM (Salek et al., 2007) and T1DM (Deja et al., 2013), whilst succinate 
and 2-KG have been reported to decrease (opposite direction) in urine of T2DM (Salek et 
al., 2007). Moreover, increased urinary excretion of TCA intermediates has been 
associated with altered kidney function or systemic stress produced by hyperglycemia in 
T2DM (Salek et al., 2007). Thus, the variations found in this cohort are consistent with 
enhanced TCA cycle operation, along with a possible contribution of altered renal 
function, as occurs in T1DM and T2DM. Betaine and dimethylglycine (DMG), both 
metabolites involved in methionine metabolism, were found significantly increased in 
GDM women. Betaine is metabolized from choline, and donates a methyl group to 
homocysteine to form methionine, also generating DMG which is then converted to 
glycine (Dasarathy et al., 2010). Changes in methionine metabolism has been associated 
with several pregnancy related disorders, namely with the occurrence of fetal 
malformations, preeclampsia, spontaneous abortion, placental abruption and premature 
delivery (Dasarathy et al., 2010), but not to GDM. Moreover, increased betaine and DMG 
have been linked with choline degradation in the gut microflora or due to altered 
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lipoprotein turnover/byosinthesis in T2DM (Salek et al., 2007). Decreased creatinine and 
increased creatine were also found in this cohort, only the latter being individually 
significant. Creatinine is formed from creatine, which is obtained either by diet or from 
conversion of guanidoacetate (GAA) during the urea cycle (Brosnan and Brosnan, 2010). 
Moreover, creatine and creatinine have been reported to decrease in urine of T2DM due to 
changes in the glomerular filtration rate (Salek et al., 2007). The variations found in this 
cohort suggest a perturbation in creatinine synthesis, supported by the unbalanced 
creatine/creatinine excretion, along with a possible contribution of renal function 
alterations.  
Metabolites deriving from gut microflora and/or diet were also found to vary in this 
study, particularly hippurate, which is significantly decreased in GDM women, along with 
decreased 4-hydroxyphenylacetate (4-HPA), 4-OH-hippurate, p-cresol sulphate (p-CS), 
dimethylamine (DMA), furoylglycine and sugars 1,6-anhydroglucose and sucrose. Out of 
these metabolites, only hippurate has been related with diabetes, although different reports 
differ regarding the direction of variation of this metabolite. Two studies have reported 
decreased urinary hippurate in relation to T2DM (Salek et al., 2007) and T1DM (Deja et 
al., 2013), whilst one other study reported increased hippurate in urine of T1DM (Zuppi et 
al., 2002). Regarding the expected glucosuria in GDM cases, a consequence of 
hyperglycemia as in other types of diabetes, such was not found in this work. Visual 
inspection of the NMR spectra revealed that only 2 out of the 13 GDM samples contained 
high glucose levels, thus not representing the bulk of the group. For this reason, urinary 
glucose was not found to be part of the metabolic signature of the GDM, at this stage, 
although larger cohorts are needed to confirm this finding. Moreover, it is known that 
urinary excretion of glucose in pregnancy occurs due to adaptations in renal function 
(Hytten, 1973, Creasy et al., 2009) not necessarily indicating a pathological situation.  
It is important to note again that all the above changes should be confirmed in a 
larger cohort (n>>13), although the results presented here are a good starting point for the 
recognition of exacerbated GDM effects. 
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5.2 Women later developing GDM 
5.2.1 Unveiling a pre-diagnosis urinary metabolic signature of GDM 
For this study, urine of women diagnosed GDM 2-21 g.w. after sampling, prior to 
any clinical manifestation of the disease (named pre-diagnosis GDM) was compared to a 
GA-matched controls (control group 2). As GA at sampling for all 2
nd
 trimester controls 
(15-26 g.w.) was approximately the same as that of the pre-diagnosis GDM group (15-22 
g.w.), all samples were used for the comparison. A more detailed description on sample 
numbers and metadata is shown in Section 2.1.2 and Table 2.4 of Experimental Section.  
The comparison of the original datasets of pre-diagnosis GDM samples and 
controls through PLS-DA revealed a separation trend in the score plot (not shown) 
although MCCV showed that the model was neither robust nor had predictive power (see 
model and MCCV parameters in Annex III, Table A-III.3,). Thus, the 
1
H NMR dataset was 
compressed through variable selection and PLS-DA recalculated and tested through 
MCCV. The resulting model revealed a separation trend between controls and disease in 
the score plot, as shown in Figure 5.3a, as well as good predictive power, given by the Q
2 
 
distribution of true and permuted models, and robustness, with CR 87%, sensitivity 84% 
and specificity 89%, as shown in Figure 5.3b,c and Table A-III.3.  
 
The analysis of the subset of variables explaining the separation seen though PLS-
DA enabled a potentially predictive metabolic signature to be unveiled (Table 5.2). This 
signature comprises variations in 24 metabolites (including amino and organic acids, 
ketone bodies, sugars and metabolites derived from the gut microflora), 5 unassigned spin 
systems (doublet at 1.08 and 1.15 ppm, singlets at 1.99 and 1.82 ppm, and a triplet at 4.30 
ppm) and 15 spectral regions with p<0.05. Metabolite variations here found consistent with 
previous findings (including two papers published as a result of this work) are indicated 
with 
c
 in Table 5.2, namely higher 3-hydroxyisovalerate (3-HIVA), 4-deoxyerythronic acid 
(4-DEA), acetate, choline, citrate, glucose, N-methylnicotinamide (NMND), 
trimethylamine (TMA), xylose, unassigned doublet at 1.08 ppm and lesser 4-HPA, 
creatinine, DMA, hippurate, p-CS, phenylacetylglutamine (PAG), unassigned doublet at 
1.15 ppm and singlets at 1.99 and 1.82 ppm. In the same table, changes common to other 
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pre-diagnosis disorders, described in Chapter 4.2, are noted with 
d 
(higher 4-DEA and 
lesser creatinine) whilst 
b
 denotes metabolites arising from diet and/or gut microflora.  
 
 
Figure 5.3: a) PLS-DA score plots, b) Q
2
 and c) ROC plots of true and permuted models obtained 
for pre-diagnosis GDM (n=52) vs. control group 2 (n =113). TPR: true positive rate, FPR: false 
positive rate.  
 
The comparison of the urinary profile of Diagnosed and pre-diagnosed GDM 
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R2x=0.203   R
2
y=0.589   Q
2=0.423   LV=2
 pre-diagnosis GDM (n=52)
 Control group 2 (n=113) 
LV [1]
L
V
 [
2
]
0
20
40
60
80
100
120
-1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
a)
Q2 values
 True Classes      Permuted classes
T
P
R
 (
se
n
si
ti
v
it
y
)
FPR (1-specificity)
 True Classes      Permuted classes
c)b)
-100
-50
0
50
-100 -50 0 50 100
Chapter 5 
190 
Table 5.2: Metabolite/resonance changes in maternal urine for pre-diagnosis GDM compared to control 
group 2. 
a
Chemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in square 
brackets; s: singlet, d: doublet, t: triplet, dd: doublet of doublets, br: broad. 
b
Peaks possibly related to diet 
and/or gut microflora. 
c
Consistent with previous findings in maternal urine (Diaz and Pinto et al., 2011, 
Graça et al., 2012, Sachse et al., 2012, Diaz et al., 2013). 
d
Changes common to all pre-diagnosed disorders 
presented in Chapter 4.2. Ui: unassigned compound i ordered following Table 5.1. 3-HBA: 3-
hydroxybutyrate, 3-HIVA: 3-hydroxyisovalerate, 4-DEA: 4-deoxyerythronic acid, 4-DTA: 4-deoxythreonic 
acid, GAA: guanidoacetate, NMND: N-methylnicotinamide, PAG: phenylacetylglutamine, TMA: 
trimethylamine, other abbreviations defined in Table 5.1. Only p-values<0.05 are shown. 
pre-diagnosis GDM (n=52) vs. Control group 2 (n=113) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
3-HBA 1.20 d ↑(0.39, 3.31×10-2) 
3-HIVA
c
 1.27 s, 2.37 s ↑(0.31, 9.75×10-2) 
4-DEA
c, d
 1.11 d ↑(0.56, 2.82×10-3) 
4-DTA 1.23 d ↑(0.20, 3.97×10-2) 
4-HPA
b,c
 6.86 d, 7.17 d ↓(-0.41, 3.13×10-3) 
4-OH-hippurate
b
 3.95 s, 6.98 d ↑(0.31) 
Acetate
c
 1.93 s ↑(0.40) 
Acetoacetate 2.29 s, 3.46 s ↑(0.35) 
Allantoin 5.39 s ↓(-0.14) 
Carnitine
c
 3.23 s ↓(-0.23) 
Choline
b,c
 3.20 s ↑(0.34, 7.28×10-2) 
Citrate
c
 2.54 d, 2.69 d ↑(0.39, 9.47×10-2) 
Creatinine
b,c, d
 4.06 s ↓(-0.18) 
DMA
b,c
 2.72 s ↓(-0.30) 
Glucose
c
 5.25 d ↑(0.74, 1.90×10-2) 
GAA 3.80 s ↑(0.16) 
Hippurate
b,c
 3.97 d, 7.56 t, 7.64 t, 7.83 d, 8.52 br ↓(-0.39, 6.39×10-4) 
Histidine 4.01 dd ↑(0.10) 
NMND
c
 4.48 s, 8.90 d, 8.97  d, 9.29 s ↑(0.57, 3.96×10-3) 
p-CS
b
 7.21 d, 7.29 d ↓(-0.34) 
PAG
b, c
 2.27 t, 7.35 t, 7.43 t ↓(-0.45, 9.99×10-3) 
Threonine 4.26 dd , 3.60 d ↑(0.35, 3.61×10-2) 
TMA
b,c
 2.88 s ↑(0.45) 
Xylose
b,c
 4.59 d, 5.21 d ↑(0.22, 1.62×10-2) 
U5
c
 1.08 d [2.50, 3.55, 3.72] ↑(0.36, 1.21×10-2) 
U6
c
 1.15 d [3.45, 3.55, 3.89] ↓(-0.29, 8.60×10-2) 
U7
c
 1.99 s ↓(-0.31, 6.48×10-2) 
U8
c
 1.82 s ↓(-0.26, 4.77×10-2) 
U9     4.30 t [4.18] ↑(0.46, 3.23×10-3) 
Unassigned spectral regions 
0.81-0.82  ↓(-0.35, 7.22×10-2) 
1.94-1.96  ↓(-0.36, 2.34×10-2) 
3.24-3.26  ↑(0.66, 1.62×10-3) 
3.46-3.52  ↑(0.75, 3.02×10-3) 
3.53-3.56  ↑(0.43, 3.46×10-3) 
3.66-3.69  ↓(-0.41, 1.22×10-2) 
3.71-3.76  ↑(0.48, 1.78×10-2) 
3.77-3.80  ↑(0.27, 8.79×10-2) 
3.83-3.86  ↑(0.63, 9.21×10-3) 
3.89-3.90  ↑(0.39, 7.34×10-2) 
3.92-3.93  ↑(0.46, 6.58×10-2) 
4.14-4.16  ↑(0.40, 3.79×10-3) 
4.17-4.21  ↓(-0.30, 2.15×10-2) 
6.72-6.78  ↓(-0.59, 7.12×10-5) 
7.08-7.09  ↓(-0.36, 1.04×10-2) 
+ 11 unassigned spin systems and 9 spectral regions with p>0.05 
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5.2.2 Proposed metabolic interpretation of the pre-diagnosis changes in GDM 
The main changes found for the pre-diagnosed group compared to controls are 
noted in the schematic representation of the affected metabolic pathways shown in Figure 
5.7 (page 199). Regarding amino acid metabolism, a significant increase was found for 
threonine, along with its catabolic products 4-deoxythreonic acid (4-DTA) and 4-DEA 
(structures shown in Figure 5.4), and for histidine. The increased excretion of 4-DTA and 
4-DEA was related to ketone bodies production in the 3
rd
 trimester of healthy pregnancy, 
determined through STOCSY (as presented and discussed in Chapter 3.3), possibly due to 
the ketogenic nature of threonine. Consistently with the changes in ketone bodies 
production, 3-HBA and acetoacetate levels were found to increase for the first time in this 
work.  Moreover, the tandem increase in ketone bodies and decreased carnitine, also 
suggest increased β-oxidation of fatty acids, a condition known to occur in T1DM and 
T2DM (Messana et al., 1998, Zuppi et al., 2002, Salek et al., 2007, Suhre et al., 2010), and 
found here for the first time to precede GDM diagnosis. 
 
 
Figure 5.4: Chemical structure of 4-deoxyerythronic acid (4-DEA) and 4-deoxythreonic acid (4-
DTA). 
 
Increased citrate in both Diagnosed and pre-diagnosed states, and consistently with 
previous reports, one published in the context of this thesis, (Sachse et al., 2012, Diaz et 
al., 2013), highlights the relevance of this metabolite for GDM urinary signature. Higher 
citrate excretion had been found in previous pre-diagnosis GDM studies, in T2DM and 
T1DM possibly due to changes in renal function (Salek et al., 2007, Deja et al., 2013). 
Decreased creatinine was found in the pre-diagnosis state, as in the Diagnosed GDM group 
and in previous T2DM reports also due to changes in renal function (Salek et al., 2007). 
Nonetheless, decreased creatinine was also found in all pre-diagnosis disorders studied in 
4-deoxyerythronic acid 
(4-DEA)
4-deoxythreonic acid 
(4-DTA)
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this work (pre-PTD, pre-IUGR and pre-PE, presented and discussed in Chapter 4.2) 
possibly reflecting common stress effect, thus compromising its individual value for 
specific disease prediction. 
A notable finding refers to metabolites deriving from the gut microflora, namely for 
choline, TMA, DMA, hippurate, PAG, 4-HPA, 4-OH-hippurate and p-CS. This finding 
emphasizes the involvement of the gut microflora in the development of the disease 
(although the exact nature remaining unknown) and reinforces the importance of these 
metabolites in the definition of a potentially predictive profile for GDM. The involvement 
of the gut microflora in GDM is consistent with previous pre-diagnosis GDM reports, 
published as result of this work (Diaz et al., 2013), pre-T2DM (Chen et al., 2008, Zhao et 
al., 2010), T2DM (Messana et al., 1998, Salek et al., 2007, Zhang et al., 2009, Suhre et al., 
2010) and T1DM (Lanza et al., 2010, Culeddu et al., 2012, Deja et al., 2013) reports. Out 
of the metabolites involved in the gut microflora and found varying in this cohort, 
hippurate and PAG gain additional relevance as both metabolites decrease with individual 
significance (p<0.05), and both having been previously found decreased in pre-diagnosis 
GDM (Diaz et al., 2013), and pre-T2DM (Zhao et al., 2010). Another important variation 
preceding the development of GDM is the choline increase, which had been previously 
found in maternal urine, using smaller cohorts and analyzed by 
1
H NMR and UPLC-MS, 
and is now reinforced (Diaz and Pinto et al., 2011, Graça et al., 2012, Diaz et al., 2013). 
Choline is degraded by the gut microflora to DMA (found decreased in this cohort) and 
TMA (found increased in this cohort) or converted to betaine and DMG in the methionine 
cycle (Salek et al., 2007). Choline is also a precursor of lipids’ synthesis, namely for very 
low density lipoproteins (VLDL) through the formation of phosphorylcholine (Zhang et 
al., 2009). Indeed, decreased choline has been found in serum of T2DM subjects, this 
variation having been related to changes in lipids metabolism and gut microflora (Zhang et 
al., 2009).The pre-diagnosis GDM metabolic signature was also characterized by increased 
NMND and decreased allantoin, the first having been previously found increased in similar 
GDM reports, although considering smaller cohorts (Diaz and Pinto et al., 2011, Diaz et 
al., 2013). Moreover, the same variation (increased NMND, decreased allantoin) had been 
reported in urine of T2DM subjects, these being suggestive of profound perturbation in 
nucleotide metabolism. NMND is involved in the tryptophan-NAD
+
 pathway, which 
supplies nucleotides to the liver, being further metabolized to N-methyl-2-pyridone-5-
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carboximde (2-Py), whilst allantoin is a degradation product of purines metabolism (Salek 
et al., 2007). These findings suggest that a nucleotide metabolism perturbation precedes 
the clinical manifestation of GDM, although no variation regarding this pathway was 
found at the time of diagnosis. Other relevant changes include increase 3-HIVA, a 
metabolite previously found in one exploratory report (Diaz and Pinto et al., 2011) 
possibly reflecting altered biotin status. 
 
5.3 Impact of GDM treatment on urine metabolic composition 
5.3.1 Unveiling urinary metabolic signatures of GDM treatment responses 
For this study, maternal urine was collected from GDM affected women, during the 
course of treatment (either through diet alone, or diet and insulin) here named Treated 
GDM in order to gain a deeper understanding of the general metabolic response to GDM 
treatment. As the Treated GDM group included samples collected in the 2
nd
 (n=10) and 3
rd
 
trimesters (n=28), with GA range of 17-40 g.w., a GA-matched control group was defined, 
here named control group 3 (n=16 and n=24 for 2
nd
 and 3
rd
 trimesters respectively), with 
GA range of 16-39 g.w.. As was presented in section 5.1 for control group 1, a control 
group matched, as much as possible, in number and GA was selected for this comparison 
in order to minimize a possible confounding contribution of GA (detailed description of 
sample numbers and metadata in Section 2.1.2 c and Table 2.4 of Experimental Section).  
 
The PLS-DA of the whole 
1
H NMR spectra of Treated GDM (including both types 
of treatments) and controls showed a separation trend which however was not validated by 
MCCV. Thus, variable selection was applied and the original matrix was reduced. The 
resulting PLS-DA revealed a clear separation between Treated GDM and controls (Figure 
5.5a), the model having high predictive power (see Q
2
 distribution) and robustness (CR 
89%, sensitivity 88% and specificity 89%), as shown in Figure 5.5b,c and summarized in 
Table A-III.3, Annex III. This finding indicates that, in spite of GDM treatment, maternal 
metabolism does not completely return to a normal situation as differences are still 
detectable in relation to the control group (healthy situation). Thus, the urinary metabolic 
signature of Treated GDM (Table 5.3) comprises different contents in 21 
metabolites/regions. Among these, some changes were not observed in either of the 
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previous disease stages, seeming therefore to be specific of the effects of treatment (Figure 
5.7, page 199). These comprised isoleucine, valine, malonate, cis-aconitate, scyllo-inositol, 
trigonelline, ascorbate, formate, lactose, mannose, and 6 new unassigned. 
 
 
Figure 5.5: a,d) PLS-DA score plots, b,e) Q
2
 and c),f ROC plots of true and permuted models 
obtained for Treated GDM (n=38) vs. control group 3 (n=40) (left) and for Insulin-treated  (n=8) 
vs. Non-insulin-treated GDM (n=30) (right). TPR: true positive rate, FPR: false positive rate.  
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Table 5.3: Metabolite/resonance changes in maternal urine of Treated GDM compared to control group 3 
(left) and of Insulin-treated vs. Non-insulin-treated (right). 
a 
Chemical shifts selected by variables selection; 
TOCSY or STOCSY correlated peaks in square brackets; s: singlet, d: doublet, t: triplet, q: quartet, dd: 
doublet of doublets, m: multiplet, br: broad. 
b 
Peaks possibly related to diet and/or gut microflora.
 
Ui: 
unassigned compound i following numbering in Table 5.1 and Table 5.2. 
* 
Insulin-resistant changes. 2-HIBA: 
2–hydroxyisobutyrate, other abbreviations defined in Table 5.1 and Table 5.2. Only p-values<0.05 are 
shown. 
Treated GDM (n=38) vs. Control group 3 (n=40) Insulin-treated (n=8) vs. Non-insulin-treated (n=30) 
Compound 
δH/ppm and 
multiplicity
 a
 
Variation (effect 
size, p-value) 
Compound 
δH/ppm and 
multiplicity
 a
 
Variation (effect 
size, p-value) 
4-DEA 1.11 d ↑(0.74, 8.45×10-4) 2-HIBA b 1.36 s ↑(0.56, 9.53×10-3) 
4-DTA 1.23 d ↑(0.84, 2.75×10-4) 3-aminoisobutyrate c 1.19 d ↓(-0.85) 
4-HPA
b
 6.86 d, 7.17 d ↓(-0.49, 1.95×10-2) 3-Me-histidineb,  3.75 s, 7.78 s ↓(-0.80, 4.96×10-2) 
4-OH-hippurate
b
 6.98 d, 7.76 d ↓(-0.12) 4-OH-hippurateb, * 6.98 d ↓(-0.61, 3.43×10-2) 
Acetate 1.93 s ↑(0.38) Cholineb, 3.20 s ↓(-0.31) 
Ascorbate 4.52 d ↓(-0.27) Cis-aconitate  3.12 ↓(-0.17) 
cis-aconitate 3.12 d ↑(0.33) Citrate* 2.54 d, 2.69 d ↑(0.84, 7.48×10-3) 
Citrate 2.54 d, 2.69 d ↑(0.46) Creatinine b 3.05 s, 4.06 s ↑(0.44) 
DMG 2.93 s ↑(0.48) DMG 2.93 s ↓(-0.65) 
Formate 8.46 s ↑(0.21) Furoylglycineb, * 6.65 q ↓(-0.48) 
Glutamine 2.15 m ↑(0.08) GAA 3.80 s ↑(0.36) 
Isoleucine 1.01 d ↑(0.48, 1.70×10-2) Glutamine* 2.15 m, 2.47 
m 
↑(0.47) 
Lactose 4.46 d ↑(0.36) Glucose 3.23 dd, 3.44 
m, 
↓(-0.42) 
Malonate 3.11 s ↓(-0.49)  3.50 t, 3.72 dd  
Mannose 5.19 d ↑(0.38) Glycine 3.57 s ↓(-0.52) 
Scyllo-inositol
b
 3.37 s  ↓(-0.35) Hypoxanthine  8.19 s, 8.21 s ↑(0.41) 
Sucrose
b
 5.41 d ↓(-0.51, 5.44×10-3) Malonate  3.11 s ↑(0.49) 
Threonine 4.26 dd, 3.61 d ↑(0.52, 1.61×10-2) NMND  8.90 d, 8.97 d,  ↓(-1.08, 1.35×10-2) 
Trigonelline
b
 4.44 s, 8.84 br,  ↑(0.14)  9.28 s  
 9.12 s  PAG
b
 7.36 t, 7.43 t ↑(0.25) 
Valine 0.99 d ↑(0.47, 6.06×10-2) Tyrosine  6.90 d, 7.20 d ↑(0.34) 
Xylose
b
 3.53 dd, 4.59 d,  ↑(0.58, 3.31×10-2) Valine 0.99 d, 1.04 d ↑(0.10) 
 5.21 d    U15
*
 2.12 d ↑(0.71, 3.43×10-2) 
U10 6.48 d [6.95 d] ↓(-0.68, 1.61×10-2)    
U11 2.84 s ↑(0.49, 6.06×10-2) Unassigned spectral regions  
U12 2.05 s ↑(0.59, 7.92×10-3) 1.65-1.68  ↑(0.47, 1.07×10-2) 
U13 2.06 s ↑(0.52, 1.30×10-2) 2.82-2.83 ↑(0.50, 3.77×10-2) 
U14 1.25 d [3.88] ↑(0.45, 7.59×10-2) 5.47-5.50  ↑(0.98, 8.46×10-3) 
U15 2.12 d ↑(1.51, 5.88×10-7) 6.75-6.80  ↑(0.31, 4.14×10-2) 
Unassigned spectral regions + 10 Unassigned spin systems and 13 spectral regions with  
0.95-0.96  ↑(0.48, 6.35×10-2) p>0.05   
1.13-1.17  ↑(0.74, 1.28×10-3)    
1.41-1.43   ↑(0.69, 3.43×10-3)    
1.57-1.58  ↑(0.53, 3.15×10-2)    
1.59-1.63   ↑(0.61, 3.00×10-3)    
1.64-1.66  ↑(0.75, 1.10×10-3)    
1.85-1.89  ↑(0.98, 1.21×10-4)    
2.08-2.10  ↑(0.54, 1.75×10-2)    
3.38-3.39  ↓(-0.27, 4.91×10-2)    
3.58-3.60  ↓(-0.36, 5.15×10-2)    
3.63-3.64  ↑(0.50, 1.52×10-2)    
6.53-6.57  ↓(-0.70, 2.49×10-2)    
6.60-6.64  ↓(-0.60, 2.05×10-3)    
8.48-8.51  ↓(-0.54, 2.76×10-2)    
8.57-8.59  ↓(-0.59, 1.61×10-2)    
9.36-9.37  ↓(-0.60, 5.26×10-3)    
+ 6 unassigned spin systems and 12 spectral regions    
with p>0.05    
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The specific metabolic effect of insulin treatment compared to dietary control was 
sought, in order to unveil specific urinary signatures of each therapeutic approach (insulin 
and diet or diet alone). For this study, urine samples from the Treated GDM group were 
divided into Insulin-treated (n=8) and Non-insulin-treated (n=30, i.e. diet only), and 
compared through PLS-DA (after variable selection). A significant impact on maternal 
urine was found in relation to the two types of GDM treatments, as shown in the PLS-DA 
score plot in Figure 5.5d. MCCV confirmed the high predictive power (seen by Q
2
 
distribution) and robustness (CR 94%, sensitivity 100% and specificity 93%) of this model, 
as shown in Figure 5.5e,f and Table A-III.3.  
 
The Insulin-treated group showed higher contents of 2-hydroxyisobutyrate (2-
HIBA), citrate, creatinine, GAA, glutamine, hypoxanthine, malonate, PAG, tyrosine, 
valine, an unassigned doublet at 2.12 ppm (U15) and 4 unassigned spectral regions with 
p<0.05, and lower contents of 3-aminoisobutyrate, 3-me-histidine, 4-OH-hippurate, 
choline, cis-aconitate, DMG, furoylglycine, glucose, glycine, and NMND compared to the 
Non-insulin-treated group (diet alone) (Table 5.3, right). Variations were also analyzed in 
terms of responsiveness and resistance to insulin treatment, i.e. variations common in 
nature and direction to the Diagnosed GDM state (present prior to- and during treatment) 
were considered insulin-resistant. On the other hand, metabolites found to vary upon 
insulin treatment but not characterizing the Diagnosed GDM group were considered 
insulin-responsive. Within the insulin-treatment signature here identified, 4-OH-hippurate, 
citrate, furoylglycine and glutamine (noted with 
*
 in Table 5.3, right) were found to be 
insulin-resistant while the remaining variations were identified as insulin-responsive.  
 
Finally, the concomitant comparison of Insulin-treated vs. Non-insulin-treated vs. 
control group 3 was carried out, aiming at understanding the efficacy of each treatment in 
returning to normal metabolism (characteristic of controls). This was computed by a 3-
class PLS-DA  (Figure 5.6) which showed a clear separation between controls, subjects 
treated by insulin plus diet and those treated by diet alone, thus confirming different 
metabolic responses to the two therapeutic approaches. 
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Figure 5.6: 3LV PLS-DA score plot of control group 3 vs. Insulin-treated GDM vs. Non-Insulin-
treated GDM. 
 
The class separation seen in Figure 5.6 shows that Insulin-treated subjects are more 
different from controls than Non-insulin-treated women, as expressed by the higher 
distance in the score plot relatively to the control group. This result confirms that maternal 
metabolism does not completely recover to a normal situation in either treatments although 
Non-insulin-treated subjects’ metabolism seems closer to that of controls, compared to 
Insulin-treated cases. A possible explanation for this finding is that insulin therapy is 
prescribed to pregnant women that maintain high plasma glucose levels after initiation of 
the dietary intervention (specific cutoff values shown in Section 2.1.2, Experimental 
Section), i.e. presenting higher GDM severity. Thus, the higher differentiation found for 
subjects undergoing insulin treatment may in fact reflect the severity of the disease rather 
than the treatment efficacy itself. Finally, the results obtained with the 3-class PLS-DA 
model indicate the ability of the method to follow individual treatment responses,with 
potential application in treatment efficacy assessment and identification of treatment 
adjustments requirements.  
 
 Control group 3 (n=40),
 Insulin-treated (n=8),
 Non-insulin treated (n=30)
R2x=0.223   R
2
y=0.693   Q
2=0.290   LV=3
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5.3.2 Proposed metabolic interpretation of the effect of GDM treatments 
General effects of treatment 
A schematic summary of the metabolic disturbance found in this study upon GDM 
treatments is shown in Figure 5.7, with indication of two metabolites (4-HPA and citrate) 
whose levels are not improved (i.e. are not closer to controls) by treatment. Regarding the 
general effect of GDM treatment (Treated GDM group), compared to controls, a marked 
perturbation in amino acids metabolism was evident through the significant increase in 
threonine, and its catabolic products 4-DTA and 4-DEA, along with increased valine and 
isoleucine. Increased excretion of threonine, valine and isoleucine suggests their underuse 
for gluconeogenesis, as has previously been reported in relation to T2DM treatment (van 
Doorn et al., 2007). Regarding branched chain amino acids (BCAA), increased valine and 
isoleucine had been found in umbilical cord plasma and serum and in maternal serum of 
GDM-affected pregnancies, possibly due to altered placental amino acid exchange and/or 
placental-fetal metabolism (Cetin et al., 2005, Dani et al., 2013). Higher acetate, cis-
aconitate and citrate, precursors and intermediates of the TCA cycle, were found increased 
relatively to controls, although these variations were not found to be individually 
significant, suggesting a slightly higher TCA operation in GDM cases.  
Other relevant changes were again found in metabolites deriving from diet and/or 
gut microflora, as was the case for Diagnosed and pre-diagnosed GDM. Accordingly, 
GDM treatment lead to a decrease in scyllo-inositol and an increase in trigonelline (no  
changes in  hippurate were seen, contrary to previous reports showing hippurate variation 
in treated T2DM subjects (van Doorn et al., 2007)). In addition, we found decreased 4-
HPA and 4-OH-hippurate commonly to the Diagnosed GDM group, thus possibly 
reflecting a characteristic perturbation of the disease or treatment resistance, as these 
metabolites were left unchanged upon treatment. Changes in the urinary excretion of 
sugars were found in Treated GDM, namely increased xylose, mannose and lactose and 
decrease sucrose. As all subjects from the Treated GDM group were under strict dietary 
control, changes in sugars and metabolites deriving from diet and/or gut microflora can be 
a direct reflection of these restrictions.  
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Figure 5.7: Schematic representation of the metabolic pathways possibly affected in several GDM 
stages. Metabolites in bold were identified in 
1
H NMR spectra of maternal urine. Colored arrows 
indicate direction of variation in each group. Dashed arrows indicate transformations occurring 
through several reactions. Amino acids in 3-letter code; NaMN: nicotinic acid mono nucleotide, 
NaAD: nicotinic acid adenine dinucleotide, NAD
+
: nicotinamide adenine dinucleotide, NADP: 
nicotinamide dinucleotide phosphate, NMND: N-methyl-nicotinamide, 2-Py- N-methyl-2-pyridone-
5-carboxamide, 4-Py: N-methyl-4-pyridone-3-carboxamide, 4-DEA: 4-deoxyerythronic acid, 4-
DTA: 4-deoxythreonic acid, 3-HBA: 3-hydroxybutyrate, DMA: dimethylamine, TMA: 
trimethylamine, DMG: dimethylglycine, GAA: guanidoacetate, Hcy: homocysteine, GSH: 
gluthathione, THF: tetrahydrofolate.Blue ellipses indicate metabolites which resist to treatment.  
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Effect of insulin and diet treatment compared to diet alone 
A summary scheme of the metabolic pathways affected due to insulin treatment is 
shown in Figure 5.8 along with indication of insulin-resistant in red and insulin-responsive 
variations in blue. Regarding the metabolic effect of Insulin treatment (compared to the 
Non-insulin-treated group, i.e. diet alone), amino acids valine, tyrosine and glutamine were 
found to increase (the latter found to be insulin-resistant, meaning also present prior to 
treatment), possibly due to their underuse for energy metabolism, whilst decreased glycine 
suggests a further involvement in methionine metabolism (Figure 5.8). In fact, the 
concomitant decreases in DMG, and choline in the Insulin-treated group can be interpreted 
as a slowing down of the methionine cycle. This is supported by a previous report of an 
animal T2DM model (Ratnam et al., 2006) showing that insulin inhibits betaine-
homocysteine methyltransferase (BHMT), which transfers a methyl group from betaine to 
homocysteine forming methionine and DMG. Increased GAA and creatinine, also found in 
Insulin-treated subjects, possibly reflect a perturbation of the urea cycle (Brosnan and 
Brosnan, 2010) and/or creatinine biosynthesis. It has been suggested that insulin action 
decreases the expression of carbamoyl phosphate synthetase, a key enzyme in the urea 
cycle (Wilcox, 2005) and we propose that this possibly explains the deregulation of this 
pathway.  
Urine of Insulin-treated subjects were also found to have lower cis-aconitate and  
higher malonate levels, possibly reflecting changes in TCA cycle and respiratory chain 
(Amaral et al., 2012). Moreover, a significant increase in citrate was found in Insulin-
treated women, this metabolite being found to be insulin-resistant (i.e. the high levels 
found prior to treatment are maintained). Citrate has been reported to increase with 
hyperglycemia in GDM subjects (Sachse et al., 2012) and in T1DM subjects with poor 
glycemic control (Deja et al., 2013). As mentioned above, insulin therapy is prescribed for 
pregnant women with more severe GDM, i.e. women that maintain high plasma glucose 
levels after initiation of the dietary intervention. Although information about plasma 
glucose levels or glycemic control was not available for this group of subjects, it seems 
possible that the increase in urinary citrate in the insulin-treated group reflects the higher 
severity of GDM in these women. Another finding is that of urinary glucose excretion, 
which was found to decrease in insulin-treated subjects, possibly reflective of an effective 
treatment action. However, as urinary glucose is not a reliable indicator of metabolic 
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control in GDM due to changes in renal glucose handling in pregnancy (Hod et al., 2008) 
no definitive conclusions can be drawn.  
 
 
Figure 5.8: Schematic representation of the metabolic pathways possibly affected in GDM women 
undergoing insulin and diet treatment compared to those only under dietary treatment. Metabolites 
in bold were identified in 
1
H NMR spectra of maternal urine. Metabolites found insulin-resistant 
are shown in red, those insulin-responsive are shown in blue. Short arrows indicate direction of 
variation in the Insulin-treated group. Dashed arrows indicate transformations occurring through 
several reactions. Amino acids in 3-letter code; Abbreviations defined in Figure 5.7 
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and PAG along with lesser 3-methylhistidine, furoylglycine and 4-OH-hippurate were 
found in women treated with insulin plus diet compared to those treated by diet alone (the 
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latter two metabolites being insulin-resistant). A significant decrease in NMND excretion 
was found in Insulin-treated women, this metabolite being involved in nucleotide 
metabolism, particularly in the tryptophan-NAD
+
 pathway. Increased urinary NMND has 
been found in T2DM (Salek et al., 2007) and, in this work, in the pre
-
diagnosis GDM 
stage. Moreover, 3-aminoisobutyrate, formed through the degradation pathway of 
pyrimidines (van Kuilenburg et al., 2004), and hypoxanthine, formed from purine 
degradation (Enea et al., 2010), were found decreased in Insulin-treated subjects, again 
supporting a perturbation in nucleotide metabolism due to insulin therapy.  
Regarding relevant unassigned spin resonances, emphasis must be given to the 
unassigned doublets at 1.25 ppm (U14) and at 2.12 ppm (U15). U14 was found decreased 
at the time of diagnosis (Diagnosed GDM group) and increased upon GDM treatment, 
irrespectively of the therapeutic approach, thus possibly reflecting a general treatment 
effect. U15 was found to be significantly increased upon treatment (Treated GDM group 
compared to controls), with a further increase in Insulin-treated subjects, possibly 
reflecting either disease severity and/or specific insulin treatment effect. 
 
5.4 Prediction of GDM treatment response: a possible 
pharmacometabolomic application  
This study aimed at exploring the possibility of predicting future GDM treatment 
requirements based on the individual pre-treatment urinary profile, envisaging improved 
personalized therapeutic approaches. This potential application is the basis of the 
pharmacometabolomic concept, which “seeks to predict the response of an individual to a 
stimulus (e.g., drug, toxin, surgery, nutrition) prior to stimulus or other perturbation” 
(Nicholson et al., 2011). Thus, the hypothesis here tested was that each individual has an 
inherent phenotype which correlates to her response to treatment.  
 
5.4.1 Unveiling a pre-treatment metabolic phenotype predictive of GDM 
treatment requirements 
In spite of the low number of samples available, the possibility to identify a 
potentially predictive metabolic phenotype of future insulin treatment requirements was 
attempted by comparing the subgroups (found within the Diagnosed GDM group) of 
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subjects later requiring insulin treatment (n=6) and subjects not requiring insulin treatment 
(n=7), all samples being collected prior to treatment initiation. 
The PLS-DA of the original 
1
H NMR dataset revealed a separation trend in the 
score plot (not shown), although the model was not found to have predictive power or 
robustness (as shown by MCCV parameters in Table A-III.3, Annex III). Thus, upon the 
application of variable selection the reduced dataset was resubmitted to PLS-DA and 
MCCV, the resultant model having CR 94%, sensitivity 95% and specificity 94%. The 
corresponding PLS-DA model score plot, Q
2
 distribution and ROC are shown in Figure 5.9 
and Table A-III.3.  
 
Figure 5.9: a) PLS-DA score plots, b) Q
2
 and c) ROC plots of true and permuted models obtained 
for Insulin-requiring GDM (n=6) vs. Non-insulin-requiring GDM (n=7). TPR: true positive rate, 
FPR: false positive rate. 
 
The subset of variables selected, with basis on PLS-DA separation, unveiled a 
metabolic signature potentially predictive of future insulin treatment requirement (Table 
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5.4). This signature included variations in 23 metabolites, 1 unassigned singlet (at 0.63 
ppm) and 2 spectral regions with p<0.05. This means that subjects later needing insulin 
have an original profile characterized by higher 2-Py, 4-HPA, acetate, betaine, creatine, 
creatinine, hippurate, lysine, NMND and tyrosine and lower 2-KG, 3-aminoisobutyrate, 3- 
HBA, 3-HIVA, 4-OH-hippurate, acetoacetate, acetone, cis-aconitate, citrate, formate, 
lactose, malonate, succinate and unassigned singlet at 0.63 ppm (U16). Moreover, 
 
Table 5.4: Metabolite/resonance changes in maternal urine of Insulin-requiring compared to Non-
insulin-requiring subjects. 
a 
Chemical shifts selected by variables selection;; s: singlet, d: doublet, t: 
triplet, q: quartet, dd: doublet of doublets, m: multiplet, br: broad. 
b 
Peaks possibly related to diet 
and/or gut microflora. *Insulin-dependent changes. Ui: unassigned compound i following 
numbering in Table 5.1, Table 5.2 and Table 5.3.  2-KG: 2-ketoglutarate, 2-Py: N-methyl-2-
pyridone-5-carboxamide, 3-HBA: 3-hydroxybutyrate, 3-HIVA: 3-hydroxyisovalerate, 4-HPA: 4-
hydroxyphenylacetate, NMND: N-methyl-nicotinamide. Only p-values<0.05 are shown. 
Insulin-requiring (n=6) vs. Non-insulin-requiring (n=7) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
2-KG
*
 2.45 t, 3.01 t ↓(-0.59) 
2-Py
*
 6.67 d ↑(0.03) 
3-aminoisobutyrate
*
 1.19 d ↓(-0.76) 
3-HBA
*
 1.20 d ↓(-1.22) 
3-HIVA
*
 1.27 s, 2.37 s ↑(1.01) 
4-HPA
b, *
 7.17 d ↑(1.08) 
4-OH-hippurate
b
 3.95 s, 6.98 d, 7.76 d ↓(-1.77, 1.4×10-2) 
Acetate
*
 1.93 s  ↑(0.23) 
Acetoacetate
*
 2.28 s ↓(-0.85) 
Acetone
*
 2.23 s ↓(-1.00) 
Betaine 3.27 s ↑(0.80) 
cis-aconitate
*
 3.12 d  ↓(-0.18) 
Citrate
*
 2.54 d ↓(-0.14) 
Creatine
b, *
 3.04 s ↑(0.27) 
Creatinine
b
 3.05 s ↑(0.45) 
Formate
*
 8.46 s ↓(-0.97) 
Hippurate
b, *
 8.52 br ↑(1.08) 
Lactose
*
 4.46 d  ↓(-0.46) 
Lysine
*
 1.73 m ↑(0.50) 
Malonate
*
 3.11 s ↓(-0.46) 
NMND
*
 4.48 s ↑(0.19) 
Succinate
*
 2.41 s ↓(-0.80) 
Tyrosine
*
 7.19 d ↑(0.77) 
U16
*
 0.63 s ↓(-1.45, 3.5×10-2) 
Unassigned spectral regions 
1.41-1.44  ↓(-1.65, 1.40×10-2) 
5.44-5.45  ↑(0.62, 2.21×10-2) 
+ 17 unassigned spin systems and 34 spectral regions with p>0.05 
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metabolites were analyzed in terms of insulin dependence, meaning that variations found 
different, in nature and direction, compared to the Diagnosed GDM stage were classified 
as insulin-dependent (i.e. only present in women later requiring insulin treatment). The 
remaining variations (namely betaine, creatine and 4-OH-hippurate, noted with 
*
 in Table 
5.4) were found commonly, in nature and direction, with the Diagnosed GDM group, thus 
considered non-insulin-dependent. 
In order to evaluate if this pre-treatment urinary signature distinguishes future 
treatment requirements, not only from each other but also from controls (no disease), a 
PLS-DA was computed considering simultaneously the three groups: control group 1 vs. 
Insulin-requiring vs. Non-insulin-requiring subjects. The resulting 3LV PLS-DA score plot 
(Figure 5.10) showed a clear separation between the three groups with high predictive 
power (Q
2 
0.439), suggesting that each of the three groups hold a specific urinary 
signature.  
 
Figure 5.10: 3LV PLS-DA score plot of control group 1 vs. Insulin-requiring GDM vs. Non-
insulin-requiring GDM. 
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This result reinforces the value of maternal urine for a pharmacometabolomic 
application, which can be implemented towards the development of early and personalized 
therapeutic approaches.  
 
5.4.2 Proposed metabolic interpretation of pre-treatment urinary profiles 
The individual urinary phenotype predictive of future insulin therapy requirements 
is schematized in Figure 5.11, with indication of insulin-dependent variations in red and 
non-insulin-dependent variations in blue. The results suggest that subjects later requiring 
insulin treatment show a priori perturbations in energy metabolism namely through the 
increase in lysine and tyrosine, both precursors of acetyl-CoA, and fumarate. An increase 
in TCA precursor acetate and decrease in its intermediates (2-KG, cis-aconitate, citrate, 
and succinate) along with lower ketone bodies excretion (3-HBA, acetoacetate and 
acetone) were also found. The overall findings are consistent with a slowing down of TCA 
cycle operation and ketone bodies production leading to a decrease in acetyl-CoA 
production and accumulation of its precursors. Still in connection with the TCA cycle, the 
decrease in malonate, a competitive inhibitor of succinate in the respiratory chain, possibly 
suggests perturbations in the respiratory chain and/or a consequence of succinate’s 
decrease. Regarding metabolites deriving from the gut microflora, decreased 4-OH-
hippurate and increased 4-HPA and hippurate, were found in the Insulin-requiring group. 
An involvement of nucleotide metabolism was also registered in women further requiring 
insulin therapy, as suggested by the tandem  increase of NMND and 2-Py (despite the latter 
having a residual change) and decreased 3-aminoisobutyrate, a product of pyrimidine 
degradation (van Kuilenburg et al., 2004). These findings hint at a perturbation in 
nucleotides metabolism, in particular the tryptophan-NAD
+
 pathway, in women later 
requiring insulin therapy, thus possibly reflecting disease severity. Increased urinary 3-
HIVA was also found in Insulin-requiring women, this metabolite having been found in 
urine in connection to cadmium exposure and related with mitochondrial damage (Ellis et 
al., 2012) whilst in connection to GDM, the opposite variation was found in the pre-
diagnosis GDM stage (Section 5.2). Increased creatinine and creatine were also found for 
Insulin-requiring women, the latter having also been found at diagnosis, possibly reflective 
of the disease and not insulin requirement. 
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Figure 5.11: Schematic representation of the metabolic pathways possibly affected in GDM women 
further requiring insulin treatment compared that never required insulin therapy. Metabolites in 
bold were identified in 
1
H NMR spectra of maternal urine. Metabolites found insulin-dependent are 
shown in red, those non-insulin-dependent are shown in blue. Short arrows indicate direction of 
variation in the Insuli- requiring group (relatively to Non-insulin-requiring). Dashed arrows 
indicate transformations occurring through several reactions. Amino acids in 3-letter code; 
Abbreviations defined in Figure 5.7. 
  
5.5 Summary of the impact of GDM in maternal urine 
The results presented in this chapter demonstrate the impact of three GDM stages 
(diagnosed, pre-diagnosis and treated GDM) in maternal urine compared to GA-matched 
controls, with the main biochemical findings and validation results summarized in Figure 
5.12.  
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Figure 5.12: Summary of the main biochemical findings suggested for each GDM stage and 
corresponding validation parameters.  
 
The first novelty presented in this chapter, with high potential value in the clinical 
environment, was the possibility of identifying women later developing GDM prior to any 
clinical manifestation of the disease (following two previous publications resultant of this 
work). It was here found that 2
nd
 trimester maternal urine carries a metabolic signature 
predictive of GDM development, with CR 87%, sensitivity 84% and specificity 89%. The 
lower model validation parameter obtained was the sensitivity or true positive rate (TPR), 
i.e. meaning that some women are still not being identified as later developing GDM. 
Higher number of samples and external validation are still required to validate a possible 
predictive method for GDM based on urine metabolomics. 
The second novelty presented in this chapter was the study of the general effect of 
GDM treatment and the demonstration that maternal metabolism does not return 
completely to the normal/healthy situation. Whithin the registered changes, only renal 
function and methionine metabolism appear to be normalized. Additionally, it was found 
that subjects treated by insulin plus diet compared to diet alone hold a particular metabolic 
signature (CR 89%, sensitivity 88% and specificity 89%) and that women treated only by 
Group studied Main biochemical characteristics
Validation 
parameters
Diagnosed GDM
TCA cycle, amino acids and methionine 
metabolism, renal function and gut microflora
CR: 96%
Sensitivity: 93%
Specificity: 100%
Pre-diagnosed
GDM
Hyperglycemia and increased citrate, ketone
bodies production and fatty acids ß-oxidation, 
amino acids and nucleotide metabolism, biotin 
status, gut microflora
CR: 87%
Sensitivity: 84%
Specificity: 89%
Treated GDM 
(insulin and/or 
diet)
TCA cycle, amino acids metabolism and gut 
microflora
CR: 89%
Sensitivity: 88%
Specificity: 89%
Insulin-treated 
GDM
TCA cycle, amino acids, methionine
metabolismand nucleotides metabolism, urea 
cycle and gut microflora
CR: 94%
Sensitivity: 100%
Specificity: 93%
Insulin-requiring 
GDM
TCA cycle, amino acids and nucleotides 
metabolism, respiratory chain, renal function, 
and gut microflora
CR: 94%
Sensitivity: 95%
Specificity: 94%
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diet were more similar to controls than those treated by insulin and diet (possibly due to 
different disease severity). Moreover, Insulin-treated subjects were differentiated from 
Non-insulin-treated subjects with CR 94%, sensitivity 100% (meaning that all insulin-
treated women are correctly classified) and specificity 93%. The method here presented 
may provide a valuable tool to assess GDM treatment efficacy and treatment adjustment 
requirements.  
The final part of this work explored the novel possibility of predicting individual 
future treatment requirements, i.e. a possible pharmacometabolomic application of 
maternal urine. The results here presented showed that women later requiring insulin 
treatment were distinguished from those never requiring insulin treatment with CR 95%, 
sensitivity 94% and specificity 95%. In spite of the exploratory nature of this model, given 
the very limited number of samples available for this study (n=6 and n=7), these results 
support the premise of predicting individual treatments requirements towards the 
development of personalized therapeutic approaches. Confirmations of these findings are 
still required through the use of larger cohorts and external validation. 
Newborn health status seen through urine metabolomics 
211 
6. Newborn health status seen through urine metabolomics 
This chapter describes the results obtained for the NMR metabolomic study of 
newborn urine to characterize a) the metabolic phenomena accompanying newborn 
disorders and b) the impact of prenatal disorders on newborns health, in the first days of 
life. These findings are presented in four sections, the first section (6.1) encompassing the 
characterization of newborn urine composition. The following section (6.2) presents the 
results obtained for the impact of potential confounding effects, namely gender, delivery 
mode, day of life (day 1 and day 2) and gestational age at birth (after 37 gestational weeks, 
g.w.). The third section (6.3) shows the study of the effects of newborn disorders on 
newborn urine, namely addressing prematurity (birth before 37 g.w.), respiratory 
depression (newborns requiring oxygen supply after birth), large for gestational age (LGA, 
birth weight above 90
th
 percentile), malformations (comprising cardiac, renal, soft tissues, 
malformations and situs inversus), pre-jaundice (babies later developing 
hyperbilirrubinemia requiring phototherapy) and PROM (membrane rupture prior to labor 
after 37
th
 g.w.). The above are presented and discussed in decreasing order of impact on 
newborn´s urine. The following section 6.4 aims at understanding the impact of the in 
utero period in newborn’s health, specifically the effect of being born to mothers affected 
by GDM, respiratory disease, thyroid disease, chronic hypertension and psychiatric 
disorders. The concomitant study of confounding effects and several newborns and 
maternal disorders enabled their comparison for the unraveling of disease-specific changes, 
this aspect being discussed in the final subchapter 6.5. 
 
6.1 Typical NMR urine spectra of newborn urine and assignments 
Contrary to an initial idea that newborn urine might be simpler than adult urine, it 
was observed that the 
1
H NMR spectrum of newborn urine is as complex as adult urine. 
The average 
1
H NMR spectrum of the control group is shown in Figure 6.1a along with 
some assignments. There are major differences in the composition of newborn urine and 
that of pregnant and non-pregnant women (previously shown in Figure 3.1). For instance, 
the aromatic region of urine spectrum characterized by metabolites deriving from the gut 
microflora, has significantly lower intensity in newborns (compared to adult pregnant and 
non-pregnant women), which is consistent with a lower microbiota colonization  
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Figure 6.1: Average 500 MHz 
1
H NMR spectra of a) healthy newborns (control group), and 
newborns born b) premature, c) affected by a respiratory depression episode after birth and d) 
newborns born to GDM mothers groups. Some assignments are noted on a) and major visual 
changes (see arrows) are indicated in b,c and d) for each disorder group. Legend: 1: 3-
aminoisobutyrate, 2: 3-HBA, 3: lactate, 4: threonine, 5: alanine, 6: acetate, 7: acetone, 8: succinate, 
9: DMA, 10: DMG, 11: creatine, 12: creatinine, 13: betaine, 14: glycine, 15: myo-inositol, 16: 
glucose, 17, lactose. 18: fumarate, 19: 2-Py, 20: histidine, 21: formate, 22: NMND. Abbreviations 
defined in Table 6.1. 
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and activity upon the first days of life. It is known that the newborns’ microbiota is seeded 
at birth and influenced by the delivery mode (vaginal vs. cesarean section), breast feeding 
and weaning and that the microflora is highly developed over the first weeks of life 
(Nicholson et al., 2012), thus justifying the lower intensity of the aromatic region found in 
newborn urine in this study.  
 
In total, 56 metabolites were identified in newborn urine, including amino acids and 
derivatives, organic acids, and sugars. Within the resulting list of assignments only 
phenylacetylglutamine (PAG) and indoxyl sulphate (IS) were here identified in newborn 
urine, for the first time to our knowledge (noted with * in Table 6.1) Assignments were 
carried out with basis on 2D NMR experiments (TOCSY and HSQC), STOCSY and 
comparison with Bruker Biorefcode 2.0.0 (courtesy of Bruker BioSpin, Rheinsteten, 
Germany) and HMDB (Wishart et al., 2009) databases, as previously described in Chapter 
3.1. The complete list of assignment is show in Table 6.1, along with the corresponding 
1
H 
chemical shifts, multiplicity, assignment and, when possible, 
13
C chemical shifts. 
Metabolite abbreviations are defined in the same table and used throughout this section.  
 
Table 6.1: List of assignments in newborn urine 
1
H NMR spectra, at pH 7.00±0.02. Assignments 
carried out with basis on literature, spectral databases Bruker Biorefcode and HMDB (Wishart et 
al., 2009), as well as 2D NMR experiments (TOCSY and HSQC), and spectra of standards. s: 
singlet, d: doublet, t: triplet, q: quartet, dd: doublet of doublets, m: multiplet. *Metabolites 
identified in newborn urine for the first time to our knowledge. 
Assignment δH ppm (multiplicity, assignment/ δC ppm) 
1-methylhistidine 
 
3.07 (dd, βCH2); 3.16 dd, β’CH2); 3.72 (s, CH3); 3.96 (dd, αCH2); 
7.05 (s, ring); 7.78 (s, ring) 
2-hydroxyisobutyrate (2-HIBA) 1.36 (s, CH3) 
2-ketoglutarate (2-KG) 3.45 (t, βCH2), 3.1 (t, γCH2) 
3-aminoisobutyricacid 1.19 (d, CH3/17.87); 2.61 (m, αCH); 3.06 (dd, βCH2)  
3-hydroxybutyrate 
 (3-HBA) 
1.20(d, CH3); 2.31(m, CH2); 2.41 (m, CH2); 4.15 (m, CH) 
3-hydroxyisovalericacid  
(3-HIVA) 
1.27 (s, βCH3/31.02); 2.37 (s, αCH2) 
3-methylhistidine 3.28 (dd, βCH2); 3.75 (s, NCH3); 3.97(dd, αCH); 7.15 (s, C6H); 
8.12 (s, C2H) 
4-deoxyerythronic acid  
(4-DEA) 
1.11 (d, γCH3/18.26); 4.08 (d, αCH/78.67); 4.10 (m, βCH/71.54) 
4-deoxythreonic acid 
 (4-DTA) 
1.23 (d, γCH3/21.37); 3.84 (d, αCH/79.04); 4.12 (m, βCH/71.59) 
4-hydroxyhippurate 3.95 (s, CH2); 6.98 (d, C3H, C5H ring); 7.76 (d, C4,2H, C6H ring) 
4-hydroxyphenylacetate  
(4-HPA) 
3.46 (s, CH2); 6.86 (d, C3H, C5H ring); 7.17 (d, C2H, C6H ring) 
Acetate 1.93 (βCH3) 
Acetoacetate 3.46 (s, CH3); 2.29 (s, CH2) 
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Assignment (continues) δH ppm (multiplicity, assignment/ δC ppm) 
Acetone 2.23 (s, CH3) 
Adipate 1.55 (m, βCH2), 1.91 (m, αCH2) 
Alanine 1.49 (d,βCH3/18.99); 3.78 (q, αCH)  
Allantoin 5.39 (s, CH/66.19) 
Ascorbate 3.76 (m, CH2(OH)); 4.01 (m, CH (OH)); 4.52 (d,C1H)  
Betaine 3.26 (s, CH3/56.13); 3.90 (s, CH2/69.11) 
Choline 3.20 (s, N(CH3)3/56.52); 3.52 (m, NH/70.60); 4.07 (m, CH2(OH)) 
cis-aconitate 3.12 (d, CH/46.13); 5.79 (t, CH2/127.13) 
Citrate 2.54 (d, CH2/48.17); 2.69 (d, ´´CH2/48.17) 
Creatine 3.04 (s, NCH3/39.66); 3.94 (s, NCH2/56.55 
Creatinine 3.05 (s, NCH3/32.86); 4.06 (s, NCH2/59.05) 
Dimethylamine (DMA) 2.73 (s, CH3/37.41) 
Dimethylglycine (DMG) 2.93 (s, (CH3)2/46.21); 3.72 (s, CH) 
Ethanolamine 3.15 (t, CH2NH2/43.84), 3.84 (t, CH2OH/60.01) 
Formate 8.46 (s, CH/173.97) 
Fumarate 6.53 (s, CH) 
Galactose 3.49 (dd, C4H), 3.64 (dd, C3H), 3.75 (m, C1H, C2H, CH2), 3.83 
(m, C3H), 3.93 (d. C2H), 3.98 (d, C2H), 4.10 (t, C1H), 4.60 (d, 
CH2), 5.28 (d, C5H) 
α-Glucose  3.23 (dd, C2H); 3.44 (m, C4H); 3.50 (t, C3H); 3.72 (dd, C6H’) ; 
3.90 (m, C6H); 4.65 (d, C1H)   
β-Glucose 3.42 (t, C4H); 3.54 (dd, CH); 3.71 (t, C3H); 3.77 (dd, C6H); 3.84 
(m, C5H) ; 5.25 (d, C1H/94.97)    
Glutamine 2.15 (m, βCH2/29.24); 2.47 (m, γCH2/33.67); 3.79(t, αCH/57.41) 
Glycine 3.57 (s, αCH2/44.45) 
Hippurate 3.97 (d, CH2); 7.56 (t, C4H, C6H ring); 7.64 (t, C3H, C5H ring); 
7.83(d, C4H); 8.52 (br, NH) 
Histidine 3.18 (dd, βCH2); 3.28 (dd, β’CH2);4.01(dd, αCH2); 7.13 (s, C4H 
ring); 7.98 (s, C2H ring) 
Hypoxanthine 8.20 (s, C2H ring); 8.22 (s, C8H) 
Indoxyl sulphate (IS) 
*
 7.21 (dd, C8H), 7.28 (dd, C7H), 7.36 (s, C2H), 7.51 (d, C6H), 7.70 
(d, C9H) 
Lactate 1.34 (d, CH3/22.43); 4.11 (q, CH/71.53) 
Lactose 3.28 (dd, C2H); 3.55 (m, C’2H); 3.59 (dd, C2H); 3.66 (m, C’3H, 
C3H,C5H); 3.73 (m, C’6H, C’5H); 3.79 (m, C6H); 3.86 (m, C6H, 
C3H); 3.94 (m, C6H, C’4H, C4H); 4.46 (d, C’1H/ 105.8); 5.25 (d, 
C1H)  
Lysine 1.48 (m, γCH2/24.28); 1.73 (m, δCH2/29.06); 1.92 (m, 
βCH2/32.60); 3.03 (t, εCH2)/42.02); 3.77 (t, αCH/57.28) 
Methylguanidine 2.83 (s, CH3/29.68) 
Myo-inositol 3.29 (t, C5H/76.87), 3.55 (dd, C1H, C3H/73.55), 3.63 (t, C4H, 
C6H/74.94), 4.08 (t, C2H/74.85) 
N-methyl-2-pyridone-5-carboxamide 
(2-Py) 
3.62 (s, CH3); 6.66 (d, C3H ring/120.85); 7.97 (dd, C4H ring); 8.33 
(d, C6H ring/145.46) 
N-methylnicotinamide (NMND) 4.48 (s, NCH3/51.30); 8.18 (m, C5H ring); 8.90 (d, C4H ring); 8.97 
(d, C6H ring); 9.29 (s, C2H ring) 
Phenylacetylglutamine (PAG) 
*
 1.93 (m, βCH2) ; 2.11 (m, β’CH2); 2.27 (t, γCH2); 3.67 (d, CH2); 
4.18 (m, αCH); 7.36 (m, C2H, C4H, C6H ring); 7.43 (m, C3H, 
C5H ring) 
Pyruvate 2.39 (s, CH3) 
Scyllo-inositol 3.36 (s, CH) 
Succinate 2.41 (s, CH2/36.85) 
Taurine 3.26 (t, CH2SO3); 3.43 (t, NCH2)  
Threonine 1.33 (d, CH3/22.44); 3.61 (d, βCH/63.36); 4.26 (dd, αCH/68.90) 
Trigonelline  4.44 (s, CH3); 8.09 (t, C3H ring); 8.84 (br, C2H, C4H ring); 9.12 
(s, C6H ring) 
Newborn health status seen through urine metabolomics 
215 
Assignment (continues) δH ppm (multiplicity, assignment/ δC ppm) 
Trimethylamine (TMA) 2.89 (s, CH3/47.40)  
Trimethylamine-N-oxide (TMAO) 3.27 (s, CH3/62.31) 
Tyrosine 3.06 (dd); 3.21 (dd); 3.95 (dd); 6.91 (d, C3H, C5H ring); 7.20 (d, 
C2H, C6H ring)  
Urea 5.79 (br s, NH2) 
Xylose 3.23 (dd, C3H), 3.33 (dd, C6H), 3.42 (t, C4H), 3.53 (dd, C3H), 
3.63 (m, C6H, C5H, C4H), 3.93 (dd, C6H), 4.59 (d, C2H), 5.21 (d, 
C2H) 
 
6.2 Impact of delivery mode and gender in the urine of healthy newborns 
The goal of the work presented in this section was to determine the impact of 
possible confounding effects in newborn urine, i.e. to identify factors that could introduce 
variability in normal/healthy situations thus conditioning the results obtained for the 
subsequent study of disorders. In order to achieve this, control samples were used to 
compare the effect of a) delivery mode: vaginal delivery (VD) vs. cesarean section (CS), b) 
gender: male vs. female, c) day of life at sampling: day 1 vs. day 2 (no comparison was 
possible for subsequent days due to low number of samples available for other days of 
life), and d) gestational age (GA) at birth: 37 vs. 38 gestational weeks (g.w.), 38 vs. 39 g.w. 
and 39 vs. 40 g.w.. Sample numbers for each of the condition investigated are listed in 
Table 2.5 of Experimental Section.  
The impact of each confounding effect was evaluated through PCA and PLS-DA, 
considering the original spectra and after variable selection using the method presented in 
Chapter 4. All PLS-DA models were submitted to validation through MCCV and evaluated 
in terms of robustness, determined through classification rates (CR), specificity and 
sensitivity, and predictive power, given by Q
2
 values distribution of true and permuted 
models. The resulting model quality parameters and MCCV results are summarized in 
Table A-III.4, Annex III, the best models being consistently obtained by using the reduced 
dataset and noted in bold in the same table. Among the confounding effects investigated in 
this work, delivery mode was found to cause the highest impact in newborn urine, followed 
by gender, both models being subjected to further analysis and presented in detail below. 
Regarding day of life at sampling, specifically day 1 vs. day 2, the PLS-DA model was 
found to have relatively low robustness and predictive power given by poor ROC space 
result and Q
2
 values distribution (not shown). Previous urine metabolomic studies of 
healthy term newborns had shown significant decreases in NMND, taurine and bile acids 
Chapter 6 
216 
and increases in betaine from day 1 to day 6 (Trump et al., 2006), but did not discuss 
changes specifically from day 1 to day 2. Nevertheless, the reduced number of samples 
available for day 1 (n=7) compared to day 2 (n=31) can be compromising the result 
obtained in this work and, hence, higher number of samples are necessary, preferably 
including a larger range of days, so that more definitive conclusions can be drawn.    
 
6.2.1 Effects of delivery mode on urine composition: results and proposed 
metabolic interpretation 
In spite of the acknowledgement of the importance of the birth process on future 
health, there is scarce literature focused on the impact of delivery mode in the metabolic 
adaptations to post-natal life. A few reviews have reported that CS seems to be associated 
with higher respiratory morbidity, namely the need for respiratory support due to impaired 
lung adaptation mediated during labor (Boutsikou and Malamitsi-Puchner, 2011), and 
significant changes in gut microflora which can be related to later decrease immune 
responses (Boutsikou and Malamitsi-Puchner, 2011, Hyde et al., 2012), development of 
allergic rhinitis and asthma  (Funkhouser and Bordenstein, 2013), increased risk of 
childhood onset Type 1 Diabetes (Cardwell et al., 2008, Boutsikou and Malamitsi-
Puchner, 2011), celiac disease and inflammatory bowel disease  (Funkhouser and 
Bordenstein, 2013).  
 
Results of delivery mode effects 
In this work, urine from newborns born by VD and CS were clearly separated in the 
PCA and PLS-DA score plots, as shown in Figure 6.2a,b, the latter model having 
satisfactory ROC results (CR of 88%, sensitivity of 79% and specificity 94%) along with 
low overlapping of Q
2
 values of true and permuted models, as shown in Figure 6.2c,d. 
Regarding the CS sample noted in Figure 6.2b (see arrow), inspection of the corresponding 
NMR spectrum revealed high resonance of 4-hydroxyphenylacetate (4-HPA), 
phenylacetylglutamine (PAG) (both metabolites being increased in the VD group) along 
with high mannose and an unassigned broad resonance at 5.52 ppm. The metabolic profile 
associated with delivery mode was given by the subset of variables used in the PLS-DA 
model, this profile being registered in Table 6.2. Delivery mode caused changes in 15 
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metabolites, mainly comprising metabolites derived from the gut microflora and organic 
acids, 3 unassigned singlets (at 0.56, 2.06 and 3.96 ppm) and 9 unassigned spectral regions 
(i.e. regions with unidentifiable and/or broadly overlapped resonances) with p<0.05. At the 
end of this table (and as will be done for other urinary profile tables presented in this 
chapter) the relevant literature review of delivery mode related changes is shown for 
comparison. 
 
Figure 6.2: a) PCA and b) PLS-DA score plots, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for urine of newborns born through cesarean section (CS, n=17) compared to 
vaginal delivery (VD, n=29). TPR: true positive rate, FPR: false negative rate. Arrows notes outlier 
sample. 
 
To facilitate visual evaluation of changes related to delivery mode, the urinary 
profile was plotted in terms of each variable’s VIP by means of a VIP-wheel representation 
(Figure 6.3a).  Moreover, each integral was represented in a Volcano plot, shown in Figure 
6.3b. The Volcano plot can be regarded as a graphical summary of the biological and 
statistical significance given respectively by the effect size and the p-value (Cui and 
Churchill, 2003). One advantage of using this plot is the easiness of  interpretation, as it is 
easy to visually identify the most relevant metabolites/resonances which are located in the  
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Table 6.2: Metabolite/resonance changes in newborn urine of newborns born through vaginal 
delivery (VD) compared to cesarean section (CS). 
a 
Chemical shifts selected by variables selection; 
s: singlet, d: doublet, t: triplet, m: multiplet. 
b 
Peaks possibly related to diet and/or gut microflora. 
Ui: unassigned compound i by order of appearance. 2-KG: 2-ketoglutarate, 4-DEA: 4-
deoxyerythronic acid, 4-HPA: 4-hydroxyphenylacetate, DMA: dimethylamine, IS: indoxyl 
sulphate, PAG: phenylacetylglutamine. Only p-values<0.05 are shown. 
Impact of delivery mode in the newborn urine profile 
CS (n=17) vs. VD (n=29) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
1-Me-histidine
 b
 7.04 s, 7.78 s ↑(0.50) 
2-KG 2.45 t ↑(0.09) 
4-DEA 1.11 d ↓(-0.14) 
4-HPA
 b
 7.17 d ↓(-0.56) 
Acetone 2.23 s ↑(0.68, 1.64×10-2) 
Betaine 3.26 s, 3.91 s ↑(0.51) 
Cis-aconitate 3.12 d ↑(0.44) 
DMA
 b
 2.72 s ↑(0.61, 4.64×10-2) 
Ethanolamine 3.84 t ↑(0.47) 
IS
 b
 7.51 d, 7.70 d ↓(-1.01, 1.28×10-3) 
Lactose
 
 4.46 d, 5.25 d, 3.28 t, 3.55 
m, 3.59 d, 3.66 m, 3.73 t,  
3.79 m, 3.94 m 
↑(0.61) 
  
  
Myo-inositol 3.55 dd ↓(0.29) 
PAG
 b
 7.36 m, 7.43 m ↓(-0.71, 1.35×10-2) 
Trigonelline
 b
 9.12 s, 8.84 m ↓(-1.34, 2.35×10-2) 
Tyrosine 6.91 d ↓(-0.44) 
U1 0.56 s ↓(-0.71, 2.98×10-2) 
U2 2.06 s ↑(2.04, 2.38×10-3) 
U3 3.96 s ↑(0.93, 1.64×10-2) 
Unassigned spectral regions 
0.87-0.89  ↓(-0.61, 3.73×10-2) 
2.90-2.92  ↑(0.80, 9.17×10-3) 
2.94-2.99  ↑(1.05, 1.18×10-3) 
3.19-3.20  ↑(0.97, 3.71×10-3) 
3.22-3.24  ↑(0.5, 4.71×10-2) 
3.97-4.01  ↑(0.75, 2.98×10-2) 
6.71-6.74  ↓(-0.71, 3.73×10-2) 
7.24-7.30  ↓(-0.91,3.38×10-4) 
8.64-8.67  ↓(-0.80, 1.54×10-3) 
+ 4 Unassigned spin and 5 Regions with p>0.05 
Literature review:  
CS without labor compared to VD:  isoleucine, fructose, mannose, glucose, allose, 
glucuronic acid, inositol and cysteine in umbilical cord blood (Hashimoto et al., 
2013); CS compared to VD:  hepatic glycerol,  glycerol phosphate dehydrogenase 
activity (in piglets liver) (Hyde et al., 2010) 
 
 upper lateral side of the plot. This means that metabolites positioned in the upper right or 
(if increased or decreased, respectively) part of the plot have simultaneously higher 
biological importance (i.e. higher effect size), and higher statistical significance (given by 
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the –log10 of the p-value). In the specific Volcano plot shown in Figure 6.3b, 
metabolites/resonances on the right side of the plot are increased in newborns born through 
CS whilst metabolites in the left side of the plot are increased in VD. 
Visual inspection of the VIP-wheel and Volcano plot (Figure 6.3a,b) of the effect 
of delivery mode showed that newborns born through CS had higher contents of acetone 
and DMA along with an unassigned singlet at 2.06 and 3.96 ppm and unassigned spectral 
regions 2.94-2.99, 3.19-3.20, 2.90-2.92, 3.97-4.01, 0.87-0.89 and 3.22-3.24 ppm (aliphatic 
and bile acids regions). On the other hand, resonances of IS, PAG and trigonelline, 
metabolites known to derive from gut microflora, were found to be highly relevant for the 
VD profile along with higher contents of the unassigned singlet at 0.56 ppm and spectral 
regions 7.24-7.30, 8.64-8.67, 6.71-6.74 ppm (aromatic regions). Peaks arising from 
metabolites deriving from the gut microflora are typically located in the aromatic region 
(6-9 ppm) of the urine spectra, this region indeed contributing significantly for the 
separation obtained with the PLS-DA model, as shown in the VIP-wheel and Volcano plot 
in Figure 6.3a,b.  
 
Proposed metabolic interpretation of changes related with delivery mode 
Differences found, in this study, in newborn urine according to delivery mode are 
consistent with previous knowledge on gut microflora colonization in VD vs. CS, increased 
stress associated with labor and possibly altered hepatic metabolism. Delivery mode plays 
an important role in the selecting the first the gut microflora colonizers, with babies born 
through CS having reduced number of bacteria and delayed the appearance of some 
bacterial species (Morelli, 2008). This different gut microflora colonization in babies born 
through VD can in fact explain the increase in gut derived metabolites PAG and 
trigonelline here found. Another interesting finding regards the significant increase in 
urinary excretion of IS in VD newborns. IS is formed in the liver from indole, a product of 
intestinal tryptophan breakdown and sometimes related with microflora metabolism (Suhre 
et al., 2010, Heinzmann et al., 2012). Besides the possible microflora connection, IS has 
also been found to mediate oxidative stress in vitro in endothelial cells (Dou et al., 2007) 
and to induce nephrotoxicity (Suhre et al., 2010). With regard to delivery mode, increased  
oxidative stress has indeed been suggested in neonates born through VD compared to CS 
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Figure 6.3: a) VIP-wheel representation of the NMR urinary signature of newborns born through 
vaginal delivery vs. cesarean section (each point in the ppm scale represents a selected variable 
with corresponding VIP value in the radial scale). The inner and outer circles represent, 
respectively, the average urine spectrum of healthy newborn urine (control group) and 
corresponding ppm scale. Main differences between VD and CS are noted. b)  Volcano plot of 
effect size vs. –Log (p-value) of metabolite/resonances integrals’ listed in Table 6.2. Dashed line 
indicates p-value=0.05. 
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(Vakilian et al., 2009, Hashimoto et al., 2013, Watanabe et al., 2013). Thus, higher urinary 
IS here found in VD can be a reflection of delivery mode related stress, although a 
concomitant contribution of gut microflora metabolism needs to be acknowledged.   
Regarding the CS group, a significant increase was found for acetone, U2 and U3 
(singlets at 2.06 and 3.96 ppm) and unassigned resonances in the aliphatic region (mainly 
at 2.90-3.20 ppm). In relation to acetone, ketone bodies are formed in the liver during fatty 
acids ß-oxidation producing acetyl-CoA that enters the TCA cycle. A previous animal 
study showed that piglets born through CS had profound changes in liver metabolism, and 
showed evidence of decreased gluconeogenesis from glycerol (Hyde et al., 2010). 
Although no concomitant changes were found for other ketone bodies, the acetone increase 
seen here can reflect changes in hepatic fatty acids ß-oxidation  and gluconeogenesis, 
consistently with changes previously found in the animal model.  
 
6.2.2 Effect of gender on urine composition: results and proposed metabolic 
interpretation 
Previous metabolomic studies have unveiled gender related differences in adults’ 
urine these being associated with differences in muscle mass, leading to altered excretion 
of creatine and creatinine (Slupsky et al., 2007, Psihogios et al., 2008), and hormonal 
effects, causing differences in mitochondrial metabolism specifically in TCA cycle 
(Kochhar et al., 2006, Slupsky et al., 2007), methylamines (Kochhar et al., 2006, Psihogios 
et al., 2008) and lipids metabolism, specifically in ß-oxidation of fatty acids (Slupsky et 
al., 2007). The list of metabolites reported in literature to change in relation to gender is 
listed in Table 6.3 below.  
 
Results of gender effects 
Gender-related differences were found to pose the second highest impact in 
newborn urine composition, following delivery mode. A clear separation between urine of 
male and female newborns was obtained through PCA and further confirmed through PLS-
DA as shown respectively in Figure 6.4a,b. The PLS-DA model was found to be robust 
and have predictive power, determined by the low overlap of Q
2
 values, CR 76%, 
sensitivity 75% and specificity 76%, shown in Figure 6.4c, d.  
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Table 6.3: Urinary changes in relation to gender in adult cohorts: a literature review. 
Compound and variation Reference 
3-HBA ↑Male (Psihogios et al., 2008) 
Acetone ↑Male (Slupsky et al., 2007) 
Acetylcarnitine ↑Male (Slupsky et al., 2007) 
Carnitine ↑Male (Slupsky et al., 2007) 
Citrate ↑Female 
(Kochhar et al., 2006, Slupsky et al., 2007, 
Psihogios et al., 2008)  
Creatine ↑Female (Slupsky et al., 2007, Psihogios et al., 2008)   
Creatinine ↑Male (Slupsky et al., 2007, Psihogios et al., 2008)   
DMA 
↑Male 
↑Female 
(Kochhar et al., 2006, Psihogios et al., 2008)  
Fumarate ↑Female (Slupsky et al., 2007) 
Glutamic acid ↑Male (Ramautar et al., 2011) 
Glycine ↑Female (Psihogios et al., 2008) 
Hippurate ↑Female (Psihogios et al., 2008) 
Hypotaurine ↑Male (Ramautar et al., 2011) 
Lactate ↑Female (Psihogios et al., 2008) 
Methionine ↑Male (Ramautar et al., 2011) 
Methylhistidine ↑Male (Ramautar et al., 2011) 
NMND ↑Male (Ramautar et al., 2011) 
Phenylalanine ↑Female (Psihogios et al., 2008) 
Proline betaine ↑Male (Ramautar et al., 2011) 
Pyroglutamic acid ↑Male (Ramautar et al., 2011) 
Succinate ↑Female (Psihogios et al., 2008) 
Taurine ↑Male (Kochhar et al., 2006, Psihogios et al., 2008)  
Threonine ↑Male (Ramautar et al., 2011) 
TMAO ↑Male (Psihogios et al., 2008) 
 
The analysis of the subset of variables used in the PLS-DA model enabled a 
gender-specific metabolic signature to be unveiled, this being registered in Table 6.4. 
Changes were found for 20 identified metabolites, including 3 sugars, 3 amino and 4 
organic acids, 1 ketone body, 3 products of nucleotide metabolism, 4 gut microflora 
derived metabolites, 2 others (creatine and myo-inositol), 6 unassigned spin systems (triplet 
at 5.35 ppm, doublet at 5.41 ppm, multiplet at 5.45 ppm, doublet at 5.59 ppm, doublet at 
6.07 ppm and singlet at 7.93 ppm) and 11 spectral regions with p<0.05. Out of these 
variations, 3 metabolites (namely acetone, DMA and fumarate) were found consistently 
with previous gender-specific changes reported in adults, these being noted with 
c
 in Table 
6.4. On the other hand, 5 metabolites were found to vary in opposite direction to that 
reported in adult cohorts (indicated with 
d
 in the same table), namely decreased creatine, 
hippurate, and increased NMND, taurine and threonine found increased in this study in 
females the opposite direction being reported in female adults. 
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Figure 6.4: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for newborn urine of males (n=23) compared to females (n=23). TPR: true 
positive rate, FPR: false negative rate. 
 
To enable visual identification of the most relevant metabolites/regions varying 
between male and female newborns, the urinary profile was plotted in a VIP-wheel (Figure 
6.5a), which shows that metabolites with higher importance (VIP) are myo-inositol, lysine, 
taurine, allantoin, U9 (putatively xanthine), resonances at the sugar region and unassigned 
region 6.11-6.48 ppm (typically containing resonances of purines and pyrimidines (Wevers 
et al., 1999)). Also, the effect size and p-value for each metabolite/region were plotted in a 
Volcano plot (Figure 6.5b) highlighting resonances with simultaneously high biological 
(effect size) and statistical (p-value) significance. In this figure, metabolites increased in 
females are located in the right hand side of the plot whilst metabolites increased in males 
are positioned in the left hand side of the plot.  
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Table 6.4: Metabolite/resonance changes in newborn urine of males compared to females. 
a 
Chemical shifts 
selected by variables selection; TOCSY or STOCSY correlated peaks in square brackets; s: singlet, d: 
doublet, t: triplet, m: multiplet, br: broad. 
b 
Peaks possibly related to diet and/or gut microflora. 
c
 metabolites 
varying consistently in nature and direction and 
d
 in opposite direction to gender-related changes reported in 
adults (Kochhar et al., 2006, Slupsky et al., 2007, Psihogios et al., 2008, Ramautar et al., 2011).
 
Ui: 
unassigned compound i by appearance order and following Table 6.2. NMND: N-methylnicotinamide, other 
abbreviations defined in Table 6.2. *Putatively assigned as xanthine. Only p-values<0.05 are shown. 
Impact of gender in the newborn urine profile 
Female (n=23) vs. Male (n=23) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
2-KG 2.45 t, 3.01 t ↑(0.29) 
4-OH-hippurate
 b
 6.98d ↓(-0.24) 
Acetone
 c
 2.23 s ↓(-0.58) 
Allantoin 5.39 s ↑(0.81, 1.3×10-3) 
Cis-aconitate 3.12 d ↑(0.26) 
Creatine
 d
 3.04 s ↓(-0.39) 
DMA 
b, c
 2.72 s ↓(-0.36) 
Formate 8.46 s ↓(-0.45) 
Fumarate
 c
 6.53 s ↑(0.34) 
Galactose 4.59 d, 5.28 d ↓(-0.15) 
Glucose 3.24 dd, 3.92 dd, 5.25 d ↑(0.83, 1.2×10-2) 
Hippurate
 b, d
 7.56 t, 7.64 t, 7.84 d ↓(-0.40) 
Lactose 5.25 d ,3.55 m, 3.59 d, 3.66 m, 3.73 t, 
3.79 m, 3.94 m 
↑(0.93, 3.6×10-2) 
Lysine 1 3  ↓(-0.71, 3.6×10-2) 
Methylguanidine 2.83 s ↑(0.49) 
Myo-inositol 3.29 t, 3.55 dd, 3.63 t, 4.08 t ↓(-0.86, 4.9×10-3) 
NMND
 d
 4.48 s, 8.18 m, 8.90 d, 8.98 d, 9.28 s ↑(0.24) 
Scyllo-inositol
 
 3.36 s ↓(-0.61, 1.8×10-2) 
Taurine
 d
 3.43 t ↑(0.69, 4.5×10-2) 
Threonine
 d
 4.26 dd ↑(0.58) 
U4 5.35 t [3.64] ↑(0.67, 2.7×10-2) 
U5 5.41 d [3.56, 3.78] ↑(0.72, 6.3×10-6) 
U6 5.45 m [2.84] ↓(-0.72, 1.1×10-2) 
U7 5.59 d [1.61 m, 2.06, 2.96] ↓(-0.75, 1.8×10-2) 
U8 6.07 d ↓(-0.71, 1.7×10-2) 
U9
*
 7.93 s ↑(1.01, 3.1×10-3) 
Unassigned spectral regions 
1.57-1.66  ↓(-0.57, 4.0×10-2) 
2.17-2.20  ↓(-0.65, 4.5×10-2) 
2.80-2.82  ↑(0.54, 8.6×10-3) 
4.32-4.34  ↑(0.74, 1.6×10-2) 
6.11-6.12  ↓(-0.85, 1.3×10-2) 
6.30-6.34  ↓(-0.75, 2.0×10-2) 
6.36-6.38  ↓(-0.63, 1.8×10-2) 
6.39-6.41  ↓(-0.84, 1.1×10-2) 
6.46-6.49  ↓(-1.09 1.5×10-3) 
6.60-6.62  ↓(-0.83, 1.3×10-2) 
8.03-8.07  ↑(0.81, 1.2×10-2) 
+ 6 Unassigned spin and 6 regions with p>0.05 
Literature review in urine of adults:  
↑Male: 3-HBA (Psihogios et al., 2008), acetone (Slupsky et al., 2007), creatinine (Slupsky et al., 2007, 
Psihogios et al., 2008), DMA (Kochhar et al., 2006, Psihogios et al., 2008), NMND (Ramautar et al., 
2011), taurine (Kochhar et al., 2006, Psihogios et al., 2008), threonine (Ramautar et al., 2011), TMAO 
(Psihogios et al., 2008); ↑Female: citrate (Kochhar et al., 2006, Slupsky et al., 2007, Psihogios et al., 
2008), creatine (Slupsky et al., 2007, Psihogios et al., 2008), fumarate (Slupsky et al., 2007), glycine 
(Psihogios et al., 2008), hippurate (Psihogios et al., 2008), lactate (Psihogios et al., 2008), succinate 
(Psihogios et al., 2008). 
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Inspection of the VIP-wheel and Volcano plot (Figure 6.5) showed that female 
newborns have higher contents of an unassigned doublet at 5.41 ppm, allantoin, glucose, 
lactose, taurine, U9 (putatively xanthine) and other unassigned spin systems and spectral 
regions. On the other hand, male newborns were found to have higher myo- and scyllo-
inositol and lysine along with several unassigned regions and spin systems from 5.45 to 
6.62 ppm. 
 
Proposed metabolic interpretation of changes related with gender 
In this study, variations in DMA, fumarate, and acetone were found commonly (in 
nature and direction) with previously reported variations in adult cohorts whilst creatine, 
hippurate, NMND, taurine and threonine varied in opposite direction (Kochhar et al., 2006, 
Slupsky et al., 2007, Psihogios et al., 2008, Ramautar et al., 2011). Additionally, other 16 
metabolites were reported in literature to be gender dependent, however, only 8 of those 
were here identified in newborn urine but not found to vary in this cohort. These findings 
suggest a different gender-related effect in adults and in newborns. 
In this cohort, metabolites/resonances with higher importance for class separation 
as well as statistical and biological relevance are shown in Figure 6.5a,b. Urine from 
females was characterized by higher allantoin, unassigned doublet at 5.41 ppm (U5) and 
unassigned singlet at 7.93 ppm (U9). Through comparison with standards databases 
(Bruker biorefcode and HMDB (Wishart et al., 2009) the singlet at 7.93 ppm was found to 
possibly belong to xanthine. Still, due to the low intensity of this resonance, definitive 
confirmation with HSQC was not possible at this stage thus remaining as putative 
assignment. Allantoin is an end product of purine metabolism, formed from oxidation of 
xanthine to uric acid (Caussé et al., 2007), as shown in  Figure 6.6. The significant and 
concomitant increases of allantoin and putatively for xanthine suggest altered purine 
degradation in females, although no metabolic explanation corroborating this hypothesis 
was found in literature. 
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Figure 6.5: a) VIP-wheel representation of the NMR urinary signature M vs. F (each dot represents 
a selected variable with corresponding VIP value in the radial scale). The inner and outer circles 
represent, respectively, the average urine spectrum of healthy newborn urine (control group) and 
ppm scale. Main differences between male and female are noted. b)  Volcano plot of effect size vs. 
–Log (p-value) of metabolite/resonances integrals’ listed in Table 6.4. Dashed line indicates p-
value=0.05. 
 
Regarding male newborns, significantly higher myo-inositol and metabolites 
resonating in spectral regions 5.50-5.56 ppm (sugars region) and 6.46-6.48 ppm (purines 
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and pyrimidines region (Wevers et al., 1999)) were registered, the latter variation 
supporting the previous hypothesis of altered purines degradation due to gender. Myo-
inositol can be endogenously synthesized from glucose (Croze and Soulage, 2013) 
(glucose being found to decrease in females) and is converted to scyllo-inositol (also found 
increased in females) in the gut microflora. These findings suggest an apparent alteration in 
sugars metabolism associated with gender in the first days of life. As no literature was 
found supporting differences in gender-related sugar and nucleotide metabolism in adults, 
it can be suggested that these differences are potentially unique to this early age. 
 
 
Figure 6.6: Degradation pathways of purines. Metabolites detected in urine are noted in bold. The 
small arrow indicate gender-related variation found in this study. 
 
6.3 Impact of newborns disorders on newborn urine composition 
6.3.1 Prematurity 
Preterm birth is the major cause of perinatal morbidity and mortality (Hacker et al., 
2004) with 24% of neonatal deaths in developed countries being related to complications 
of prematurity (Kliegman et al., 2011). Common neonatal complications due to 
prematurity include respiratory problems (respiratory distress syndrome (RDS) and apnea), 
cardiovascular (patent ductis arteriosus and bradycardia), gastrointestinal (poor 
gastrointestinal function and hyperbilirrubinemia), metabolic/endocrine (hypocalcemia, 
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hypoglycemia, hyperglycemia and hypothermia), central nervous system complications 
(intraventricular hemorrhage and hypotonia), renal  complications (hyponatremia, 
hypernatremia, hypekalemia) and infection risk (Kliegman et al., 2011). The assessment of 
long-term effect of being born prematurely has inspired a few studies, these having shown 
alterations in brain metabolites  and structure in adolescents  (Gimenez et al., 2008) and 
lipids metabolism in young adults  born premature (Thomas et al., 2011). 
 
6.3.1.1 Unveiling an urinary metabolic signature of premature newborns 
In this study, the urine from premature newborns (born before the 37
th
 g.w.) was 
compared to controls (the detailed description of samples metadata being show in Table 
2.5 of Experimental Section). Visual comparison of the average 
1
H NMR spectra of cases 
and controls (Figure 6.1a,b) enabled the identification of significant differences, namely 
for 3-HBA 3-aminoisobutyrate, acetone, myo-inositol, fumarate, formate and NMND, 
these being noted in the same figure. In order to confirm these changes and unveil a more 
complete metabolic picture of premature newborns, PCA and PLS-DA were applied to the 
original and reduced dataset after variable selection. PCA revealed a separation trend 
between groups (along PC1) this being confirmed through PLS-DA, as shown in the 
corresponding score plots in Figure 6.7a,b. One note regarding the outlier visible in the 
PCA score plot, this dot corresponding to a premature newborn and the sample being 
collected on the 6
th
 day of life, born from a mother affected by Crohn’s disease and 
hypertension during the last week of gestation. Visual inspection of the corresponding 
NMR spectrum revealed a higher concentration of acetate and 2-ketoglutarate (2-KG) in 
this sample, suggesting a perturbation of the TCA cycle and decreased NMND and higher 
resonances in the bile acids region, consistent with previous reports (Trump et al., 2006), 
whilst revealing no changes in taurine and betaine as previously suggested from day 1 to 
day 6 (Trump et al., 2006). A distinction was also noted for a control sample located 
within the premature samples in the PCA score plot (Figure 6.7a), this sample 
corresponding to the same outlier identified in the PLS-DA score plot of VD vs. CS 
(Figure 6.2). MCCV confirmed the PLS-DA model’s predictive power, given by low 
overlapping of Q
2 
of true and permuted models and median Q
2
 0.603, and robustness, 
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supported by ROC plot, CR, sensitivity and specificity of 92%, as shown in Figure 6.7c,d 
and Table A-III.4, Annex III. 
 
Figure 6.7: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for urine of premature newborns (n=17) compared to controls (n=46). TPR: true 
positive rate, FPR: false negative rate. 
 
The metabolic changes underlying the separation seen in the PLS-DA between 
premature newborns and controls, was further retrieved and analyzed in terms of biological 
and statistical significance (given by effect size and p-value, respectively). The overall 
changes unveiled in this study are listed in Table 6.5 with the corresponding variation 
(along with a summary of changes reported in literature in the last row for comparison). 
Relevant changes were found for 24 metabolites (comprising 5 organic acids, 3 products of 
nucleotide metabolism, 2 ketone bodies, 2 amino acids and derivatives, 2 metabolites 
involved in lung surfactant production, 3 markers of renal function, 5 metabolites derived 
from gut microflora and 2 others), 4 unassigned spin systems (singlets at 4.51, 6.59 and 
7.93 ppm, the latter possibly belonging to xanthine, and a doublet at 6.76 ppm) and 5 
unassigned spectral regions (with p<0.05). 
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Table 6.5: Metabolite/resonance changes in newborn urine of premature newborns. 
a 
Chemical shifts selected 
by variables selection; TOCSY or STOCSY correlated peaks in square brackets; s: singlet, d: doublet, t: 
triplet, m: multiplet. 
b 
Peaks possibly related to diet and/or gut microflora. 
c
Consistent with previous reports 
(Foxall et al., 1995, Constantinou et al., 2005, Trump et al., 2006), 
d 
Consistent with findings in 2
nd
 T 
maternal urine of pre-PTD women (Section 4.2.1). Ui: unassigned compound i by order of appearance and 
following Table 6.2 and Table 6.4. 2-Py: N-mehyl-2-pyridone-5-carboxamide, 3-HBA: 3-hydroxybutyrate, 3-
HIVA: 3-hydroxyisovalerate, 4-DTA: 4 deoxythreonic acid, other abbreviations defined in Table 6.2 and 
Table 6.4. Only p-values<0.05 are shown. 
Premature newborns (n=17) vs. Control (n=46) 
Compound δH/ppm and multiplicity 
a
 Variation (effect size, p-value) 
1-Me-histidine
 b
 7.78 s ↓(-0.83, 4.2×10-3) 
2-Py 6.66 d, 8.33 d ↓(-0.96, 1.3×10-3) 
3-aminoisobutyrate 1.19 d, 2.61 m, 3.06 dd ↓(-1.37, 7.5×10-7) 
3-HBA 1.20 d ↓(-0.49, 4.8×10-3) 
3-HIVA 1.27 s ↑(0.54, 4.3×10-2) 
3-Me-histidine
 b, d
 7.15 s, 8.12 s ↓(-0.53) 
4-DTA 1.23 d ↓(-0.61, 4.8×10-2) 
4-OH-hippurate
 b, d
 7.76 d ↑(0.32) 
Acetone 2.23 s ↓(-0.55) 
Cis-aconitate 3.12 d ↓(-1.37, 2.6×10-6) 
Citrate
 d
 2.54 d, 2.69 d ↑ (0.45, 4.6×10-2) 
Creatine 3.04 s, 3.93 s ↓(-0.58, 2.9×10-2) 
Creatinine
 d
 3.05 s, 4.06 s ↓(-0.85, 1.2×10-3) 
DMA
 b
 2.72 s ↓(-0.88, 5.5×10-3) 
Ethanolamine 3.15 t, 3.84 t ↓(-0.97, 6.2×10-4) 
Formate 8.46 s ↑(0.89, 5.2×10-3) 
Fumarate 6.53 s ↑(0.42) 
IS
 b
 7.51 d ↑(1.00, 4.8×10-2) 
Lactate 4.11 q ↓(-0.76, 6.7×10-3) 
Lysine 1.73 m ↑(0.63, 2.4×10-2) 
Methylguanidine 2.83 s ↓(-0.78, 4.7×10-3) 
Myo-inositol
 c
 3.26 t, 3.53 dd, 4.07 t ↑(0.87. 2.0×10-2) 
NMND
 c
 4.48 s, 8.18 m, 8.90 d, 8.97 d, 
9.28 s 
↑(1.20, 4.5×10-4) 
Succinate 2.41 s ↑(0.61, 5.0×10-2) 
U10 4.51 s ↑(0.67, 3.2×10-3) 
U11 6.59 s ↑(1.48, 1.8×10-5) 
U12 6.76 d ↓(-1.17, 6.5×10-5) 
U9 7.93 s ↓(-0.83, 1.8×10-3) 
Unassigned spectral regions 
1.99-2.01  ↑(0.73, 1.6×10-2) 
2.75-2.79  ↓(-1.26, 8.8×10-5) 
2.89-2.92  ↓(-1.06, 2.0×10-4) 
3.35-3.37  ↑(1.05, 8.6×10-3) 
7.18-7.20  ↑(1.12, 5.5×10-3) 
+ 5 unassigned spin systems and 8 spectral regions with  p>0.05 
Literature review:  
↑ taurine (Foxall et al., 1995, Trump et al., 2006), ↑ TMAO (Foxall et al., 1995, Constantinou et al., 
2005), ↑ myo-inositol (Foxall et al., 1995), ↑ betaine (Constantinou et al., 2005), ↑NMND (Trump et 
al., 2006), hippurate, tryptophan, phenylalanine, malate, tyrosine, hydroxybutyrate, N-acetylglutamate 
and proline (direction not specified) (Atzori et al., 2011) 
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Moreover changes consistent with previous reports are noted with 
c
 (namely myo-
inositol and NMND) and changes also found at 2
nd
 T maternal urine of pre-PTD women 
are noted with 
d
 (3-Me-histidine, 4-OH-hippurate, citrate and creatinine) in Table 6.5. 
Whithin this profile, the variations noted for 3-aminoisobutyrate, cis-aconitate, 
ethanolamine, NMND and unassigned regions 2.75-2.79 and 2.89-2.92 ppm, must be 
acknowledge for their marked statistical significance (p-values ranging from 10
-4
 to10
-7
).  
 
The urinary metabolic signature of prematurity is shown in Figure 6.8 through the 
VIP-wheel plot (a, top) and Volcano plot (b, bottom), with metabolites with higher VIP, 
statistical and biological noted. Out of the metabolites found to vary in premature 
newborns, the variation of 3-aminoisobutyrate, cis-aconitate, ethanolamine, myo-inositol, 
2-Py, NMND, formate, U11 and U12 clearly stand out in Figure 6.8a,b, due to their 
corresponding high VIP, effect size and low p-value (ranging from 10
-3
 to 10
-7
 orders of 
magnitude). Lastly, one unassigned region (7.58-7.62 ppm) is noted in the VIP-wheel, 
which was found to be relevant for the PLS-DA separation (given by the high VIP value in 
the radial scale) but had individual significance below the limit here defined (p-
value<0.05) supporting the importance of taking into account the whole profile rather than 
solely integrals with individual significance. 
 
6.3.1.2 Proposed metabolic interpretation of changes related with prematurity 
In this cohort, the metabolites found to have higher importance in relation to 
prematurity were NMND (involved in nucleotide metabolism), 3-aminoisobutyrate (a 
product of pyrimidines metabolism), formate (involved in purine biosynthesis), cis-
aconitate (involved in the TCA cycle), ethanolamine and myo-inositol (precursors of lung 
surfactants phosphatidylethanolamine and phosphatidylinositol, respectively) and creatine, 
creatinine, indoxyl sulphate (IS) and methylguanidine (possibly reflective of altered renal 
functionnad/or oxidative stress). 
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Figure 6.8: a) VIP-wheel representation of the NMR urinary profile of premature newborns. The 
inner and outer circles represent, respectively, the average urine spectrum of healthy newborn urine 
(control group) and ppm scale. Main differences are noted. b)  Volcano plot of effect size vs. –Log  
(p-value) of metabolite/resonances integrals shown in Table 6.4. Dashed line indicates p-
value=0.05. 
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(Figure 6.9). Higher NMND had been previously found in premature newborn urine, this 
variation having been attributed to the high concentration of tryptophan in fetal blood and 
its regulation after birth (Trump et al., 2006). In this thesis, NMND was found to increase 
in premature newborns whilst 2-Py decreases. The variation found in NMND can be, as for 
the previous study (Trump et al., 2006), a reflection of altered tryptophan metabolism after 
birth. Nevertheless, the concomitant decrease of 2-Py suggests a more profound 
perturbation in nucleotide metabolism. This hypothesis is further supported by the 
significant decrease of 3-aminoisobutyrate, the end product of the pyrimidine degradation 
pathway, particularly of thymine (Figure 6.9), suggesting reduced pyridine degradation. 
Moreover, formate, an essential metabolite for de novo purine biosynthesis, through 
activation by tetrahydrofolate (THF) (Lamarre et al., 2013), was found to increase in the 
premature group.  The suggestion of altered purines synthesis is consistent with previous 
studies of umbilical cord blood of premature very low birth weight (VLBW) newborns, 
which reported altered purines biosynthesis namely comprising an increase of methyl-
adenosine and cytosine and a decrease in amino acid precursors (Alexandre-Gouabau et 
al., 2013).  
 
Figure 6.9: a) Metabolic pathway of tryptophan-NAD+ biosynthesis and b) thymine degradation 
pathway. NaMN: nicotinic acid mono nucleotide, NaAD: nicotinic acid adenine dinucleotide, 
NAD+: nicontinamide adenine dinucleotide, NADP: nicotinamide dinucleotide phosphate, ADP: 
adenosine diphosphate, NMND: N-methyl-nicotinamide, 2-Py: N-methyl-2-pyridone-5-
carboxamide, 4-Py: N-methyl-4-pyridone-3-carboxamide. Metabolites detected in the NMR urine 
spectra are noted in bold. Small arrows indicate variation in the premature group (changes with 
|effect size|>0.9). 
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Energy metabolism 
Cis-aconitate, an intermediate of the TCA cycle, was found significantly decreased 
in premature newborns, whilst citrate, fumarate and succinate, also intermediates of the 
cycle were found increased (Figure 6.10). A derangement in energy metabolism is further 
supported by a concomitant change in ketone bodies, ketogenic amino acid lysine, 4-DTA 
(a product of threonine catabolism) and lactate. Previous studies have associated 
prematurity with enhanced use of fatty acids as a source of energy at the time of birth 
(Alexandre-Gouabau et al., 2013).  In this cohort, ketone bodies 3-HBA and acetone were 
found decreased in the premature group suggesting their decreased production from fatty 
acids ß-oxidation or higher ketone bodies consumption for energy production. 4-DTA, a 
product of threonine catabolism was also found to decrease, the excretion of this 
metabolite having been correlated with 3-HBA in connection with formation of ketone 
bodies (described in Section 3.3, Chapter 3). Finally, lactate was found to decrease in the 
premature group, this metabolite being formed from glycolysis under hypoxic conditions. 
Increased urinary excretion (opposite to the variation found here for the premature group) 
 
 
Figure 6.10: Schematic representation of the TCA cycle and ketogenic pathways possibly affected 
in premature newborns. Amino acids in three-letter code, 3-HBA: 3-hydroxybutyrate, 2-KG: 2-
ketoglutarate, 4-DEA: 4-deoxyerythronic acid, 4-DTA: 4-deoxythreonic acid. Metabolites 
identified in urine NMR spectrum are noted in bold. Small arrows indicate direction of variation in 
the premature group, with larger arrows indicating metabolite changes with |effect size|>0.5.  
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of lactate has been reported in asphyxiated newborns due to hypoxia (Ma et al., 1995), but 
not in connection to prematurity. The overall results suggest a perturbation in energy 
metabolism in premature newborns, specifically in the operation of the TCA cycle and 
ketone bodies production. 
 
Lung surfactant production 
Significant variations were also found in this work for ethanolamine and myo-
inositol, respectively precursors of phosphatidylethanolamine and phosphatidylinositol, 
both being membrane phospholipids and acting as lung surfactants (Figure 6.11) as 
reported in (Groenen et al., 2004, Agassandian and Mallampalli, 2013). Apart from these 
compounds, other lung surfactants include phosphocholine (the most abundant), 
phosphatidylglycerol (the 2
nd
 most abundant), shingomielyn and phosphatidylserine (less 
abundants) in the lungs (Agassandian and Mallampalli, 2013). Phosphatidylcholine 
synthesis increases from week 28
th
 until the end of gestation with peak production at 36
th
 
g.w., whilst phosphatidylinositol production increases from the 28
th
 week with maximum 
values between week 32 and 35 and declining until the end of gestation (Grenache and 
Gronowski, 2006, Creasy et al., 2009). The last surfactant to be produced is 
phosphatidylglycerol, appearing after the 36
th
 g.w. until the end of gestation (Grenache and 
Gronowski, 2006). Regarding phosphatidylethanolamine synthesis no reference gestational 
age range was found. 
 
Figure 6.11: Synthesis of phosphatidylethanolamine, phospatidylcholine and phosphatidylinositol. 
CDP: cytidine diphosphate, CMP: cytidine monophosphate monophosphate, AdoMet: S-
adenosylmethionine, AdoHcy: S-adenosylhomocysteine. Metabolites identified in newborn urine 
are noted in bold. Small arrows indicate direction of variation in the premature group (in this case 
metabolite changes with |effect size|>0.8). 
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Increased ethanolamine in urine (ethanolaminuria) of newborns and infants has 
been associated with altered biosynthesis of membrane phospholipids, brain white matter 
degeneration,  and altered quality/quantity of surfactant synthesis (Cole et al., 1988). The 
decreased excretion of ethanolamine seen here in the urine of premature newborns suggests 
its utilization towards phosphatidylethanolamine synthesis, thus indicating an altered 
profile of surfactants formation at the gestational age range these newborns were born (33-
36 g.w.).  
Increased myo-inositol in urine of premature newborns had been previously 
reported, the variation having been related to altered renal function as the compound is 
present in the renal medulla (Foxall et al., 1995). Myo-inositol has also been found 
increased in urine of IUGR newborns possibly due insulin resistance (Dessì et al., 2012). 
In this cohort, premature babies were born approximately at the gestational age 
characterized by higher PI formation (32-35 g.w., which further declines until the end of 
gestation). Thus, increased urinary myo-inositol in premature newborns could be a direct 
reflection of its higher formation (possibly from glucose) to meet the higher demand for PI 
synthesis and/or a consequence of compromised renal function (the latter hypothesis being 
dicussed below). 
 
Renal function and oxidative stress 
Lower creatinine in premature newborn urine has been reported due to immature 
tubular and vascular structures in the kidney, whilst low creatine was related to its 
impaired biosynthesis (Lage et al., 2013). High IS was also found in the premature group, 
this metabolite being known to induce oxidative stress (Dou et al., 2007) and 
nephrotoxicity (Suhre et al., 2010), possibly reflective of increased oxidative stress in 
premature newborns, as has been previously reported (Perrone et al., 2007). Increased IS in 
urine and serum have been related to impaired renal function in adults (Suhre et al., 2010, 
Huang et al., 2012), once more supporting the possibility of compromised renal function in 
premature newborns. In this cohort, methylguanidine was found decreased in urine of 
premature newborns. In addition to IS, methylguanidine is also an uremic toxin formed 
from creatinine, via creatol, its biosynthesis being enhanced by reactive oxygen species 
(Marescau et al., 1997). Thus, the variation here noted for methyguanidine may possibly 
be a direct consequence of decreased creatinine and/or impaired renal function.  
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Other metabolic effects 
Other significant changes were found for 3-HIVA, DMA and 1-methylhistidine, the 
latter two being related with gut microflora. 3-HIVA has been proposed as a marker of 
reduced biotin status, having been found increased in maternal serum of women carrying 
fetuses with trisomy 21 (Bahado-Singh et al., 2013) and in 2
nd
 trimester maternal urine of 
pre-diagnosis GDM (Chapter 5.2). In this cohort, 3-HIVA excretion was found to increase 
in premature newborns, possibly suggesting altered biotin status although no evidence 
supporting of this hypothesis was found in literature.  
 
6.3.2 Respiratory depression episode 
Breathing complications after birth can lead to the development of perinatal 
asphyxia, i.e oxygen deprivation, occurring at the time of birth, with impaired gas 
exchange leading to progressive hypoxemia (low blood oxygen levels) and hypercapnia 
(high carbon dioxide blood levels). A severe case of asphyxia encompasses the further 
development of severe acidosis, depressed apgar score at 5
th
 min, neonatal neurological 
sequelae (i.e. seizures, coma, hypotonia) and multiple organ sequelae (Tax et al., 2013). 
Other respiratory and asphyxia complications include hypoxic ischemic encephalopathy 
(HIE), respiratory distress syndrome (RDS) and meconium aspiration syndrome (MAS). 
HIE occurs due to impaired gas exchange leading to reduced cerebral blood flow, the 
condition being associated with long-term neurological sequelae, including cerebral palsy, 
seizures disorders, cognitive delays and motor disabilities (Creasy et al., 2009, Reinke et 
al., 2013). RDS is defined as respiratory distress within the first hours of life due to a 
deficiency in lung surfactant, thus often associated with preterm birth (Grenache and 
Gronowski, 2006), whilst MAS encompasses delivery through meconium stained amniotic 
fluid, respiratory distress and a characteristic appearance in chest radiographs (Creasy et 
al., 2009). Neonatal respiratory depression is defined as at least one of the following 
situations a) newborns requiring resuscitation, b) acute respiratory depression in the first 
minutes of life after normal cough and breath at birth, c) breathing deterioration after a few 
minutes with decreasing effort to breathe and d) normal appearance at birth followed by 
strenuously breathing with signs of asphyxia (Perlman, 1985). The group of samples used 
in this cohort was defined as newborns affected by a respiratory depression episode 
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requiring external oxygen supply shortly after birth, with immediate recovery (low Apgar 
score at 1
st
 minute with recovery showed by normal score at the 10
th
 minute). 
 
6.3.2.1  Unveiling an urinary metabolic signature of respiratory depression  
In this work, urine from newborns affected by respiratory depression at birth was 
collected 1 to 2 days after the episode/birth and compared to controls, in order to unveil the 
impact of this episode at birth in newborns’ metabolism. Other abovementioned respiratory 
complications were not possible to study as there were no samples available at the time of 
this thesis. In spite of the low number of samples available for the respiratory depression 
group (n=10), this disorder was found to cause the second highest impact in newborn urine, 
following prematurity. Visual comparison of the average 
1
H NMR spectra of control and 
respiratory depression groups revealed significant changes in taurine, myo-inositol, betaine, 
glycine and lactose, some being noted in Figure 6.1c, page 212. To confirm these changes 
and unveil the complete profile of the respiratory depression group, PCA and PLS-DA 
were applied to the original dataset (not shown) and after variable selection (Figure 
6.12a,b).   
No group separation was obtained through PCA, although the corresponding score 
plot unveiled two samples clearly distant from the remaining group and controls, as 
highlighted in Figure 6.12a. The reviewing of the clinical data from these cases showed 
that, interestingly, these samples belong to two newborns born from mothers who smoked 
during pregnancy. It is known that smoking during pregnancy reduces circulating oxygen 
levels and consecutively its transfer to the fetus, causing chronic fetal hypoxia (Moore et 
al., 2008). Visual inspection of the urine NMR spectra of these two cases revealed the 
presence of ethanol in one sample (possibly due to contamination) and high concentrations 
of unassigned multiplets in the aromatic region (7.06 and 7.43 ppm) in the other sample. 
The corresponding PLS-DA, revealed a clear separation between groups (Figure 6.12b), 
with MCCV confirming the robustness and predictive power of the model (CR 91%, 
sensitivity 96% and specificity 91%, low overlap of Q
2
 distributions of true and permuted 
classes and median Q
2
 of 0.500 of the true classes model as shown in Figure 6.12c,d, Table 
A-III.4, Annex III).  
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Figure 6.12: a) PCA and b) PLS-DA score plots, c) Q
2
 values and d) ROC plot of true and 
permuted models obtained for urine of newborns with respiratory depression after birth (n=10) 
compared to controls (n=46). TPR: true positive rate, FPR: false negative rate. 
 
The analysis of the subset of variables on the basis of the separation seen through 
PLS-DA enabled the identification of a metabolic signature characteristic of the respiratory 
depression group (Table 6.6), along with a brief review of relevant literature for 
comparison. The unveiled signature comprises variations in 21 metabolites (4-DEA, 
betaine, creatine, glycine,  myo-inositol and taurine having p-value<0.05), 6 unassigned 
spin systems (singlets at 2.05, 2.06, 2.26, 2.81 and 8.39 ppm) and 5 unassigned spectral 
regions with p-value<0.05. 
Metabolites/resonances of this signature with high VIP are further shown by a VIP-
wheel representation (Figure 6.13a), whilst integrals with high biological and statistical 
relevance are highlighted through the Volcano plot shown in Figure 6.13b (dashed line 
indicates limit of statistical significance, p-value<0.05). The inspection of the VIP-wheel 
and Volcano plot revealed that metabolites with higher contribution for the respiratory 
depression signature were glycine, betaine (the latter two metabolites having the lowest 
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Table 6.6: Metabolite/resonance changes in newborn urine of respiratory depression group. 
a 
Chemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in square 
brackets; s: singlet, d: doublet, t: triplet, m: multiplet.  b Peaks possibly related to diet and/or gut 
microflora. Ui: unassigned compound i by order of appearance and following Table 6.2, Table 6.4 
and Table 6.5. Abbreviations defined in Table 6.2, Table 6.4 and Table 6.5. Only p-values < 0.05 
are shown. 
Respiratory Depression (n=10) vs. Control (n=46) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
1-Me-histidine
 b
 7.78 s ↓(-0.27) 
2-KG 2.45 t, 3.01 t ↓(-0.17) 
3-HBA 2.31 m, 2.41 m, 4.15 m ↓(-0.65) 
3-Me-histidine
 b
 7.15 s ↓(-0.08) 
4-DEA 1.11 d ↓(-0.67, 4.43×10-2) 
4-DTA 1.23 d ↓(-0.49) 
Betaine 3.26 s, 3.90 s ↑(1.10, 6.33×10-3) 
Choline
 b
 3.20 s ↑(0.65) 
Creatine 3.04 s, 3.93 s ↑(0.95, 1.54×10-2) 
DMA 2.72 s ↓(-0.65) 
Formate 8.46 s ↑(0.72) 
Glycine 3.57 s ↑(1.21, 1.65×10-3) 
Hypoxanthine 8.20 s, 8.22 s  ↓(-0.58) 
IS 7.70 d ↑(0.24) 
Lactose
 b
 3.66 m, 3.79 m, 3.94 m, 4.46 d ↑(0.93) 
Lysine 1.73 m, 1.92 m ↓(-0.73) 
Myo-inositol 3.26 t, 3.55 m, 3.64 t, 4.07 t ↑(1.54, 1.18×10-2) 
Taurine 3.43 t, 3.26 t ↑(0.96, 1.10×10-2) 
Threonine 4.26 dd ↓(-0.60) 
Trigonelline
 b
 4.44 s ↓(-0.04) 
Xylose
 b
 5.21 d ↓(-0.15) 
U13 2.05 s ↑(1.00, 1.54×10-2) 
U2 2.06 s ↓(-0.72, 2.1×10-2) 
U14 2.26  s ↓(-0.82, 3.97×10-2) 
U15 2.81 s ↑(0.88, 2.23 ×10-2) 
U16 2.90 s [3.94 s] ↑(0.90, 1.27×10-2) 
U17 8.39 s [6.08 d] ↑(1.10, 4.92×10-2) 
Unassigned spectral regions 
2.08-2.09  ↑(1.00, 1.11×10-2) 
2.10-2.12  ↓(-0.85, 3.76×10-2) 
2.48-2.52  ↓(-0.79, 4.19×10-2) 
6.61-6.62  ↓(-1.03, 3.36×10-2) 
6.63-6.65  ↓(-1.00, 3.36×10-2) 
+8 unassigned spin systems and 16 spectral regions with p>0.05 
Literature review  of studies in newborn urine:  
Perinatal asphyxia: ↑lactate, ↓citrate, succinate, 2-KG, DMA, DMG, glucose (Ma et al., 
1995); ↑ ethylmalonate, 3-hydroxy-methylglutarate, 2-hydroxyglutarate, 2-KG, glutarate, 
methylmalonate, 3-hydroxybutyrate, orotate (Chu et al., 2006) 
 
p-values of this profile, 10
-3
 orders of magnitude), myo-inositol (this metabolite having the 
highest effect size of this profile, 1.54), taurine and 4-DEA. Additionally, unassigned spin 
systems U2, U13, U14, U15 and U17 were also found to have a significant contribution for 
the respiratory depression signature as given by the high VIP value, effect size and 
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statistical significance. Lastly, several unassigned regions from 6.09-6.65, 7.18-7.20 and 
8.13-8.15 were found to be relevant for the urinary profile here unveiled, supported by 
their high VIP value in the VIP-wheel radial scale although, individually, these regions 
were not found to be statistically significant 
 
Figure 6.13: a) VIP-wheel representation of the NMR urinary profile of the respiratory depression 
group. The inner and outer circles represent, respectively, the average urine spectrum of healthy 
newborn urine (control group) and corresponding ppm scale. Main differences are noted. b)  
Volcano plot of effect size vs. –Log (p-value) of metabolite/resonances integrals shown in Table 
6.6. 
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6.3.2.2 Proposed metabolic interpretation of changes related with respiratory 
depression 
This cohort includes urine from newborns affected by a respiratory depression 
episode at birth, with depressed Apgar score at 1
st
 min, but without other clinical signs of 
asphyxia (namely hypoxemia, hypercapnia, acidosis, neonatal neurological and other organ 
sequelae). Still, a parallelism with neonatal asphyxia may be drawn carefully when 
interpreting the results, bearing in mind that neonatal asphyxia implies a more severe case 
of oxygen deprivation and comprises other sequelae.  
In this study, the variation of glycine, betaine, taurine, creatine and 4-DEA were 
found to have the highest individual biological and statistical significance. Increased  
glycine, an excitatory neurotransmitter, has been reported in cerebral spinal fluid (CSF) 
(Gucuyener et al., 1999, Roldan et al., 1999) and brain (Malik et al., 2002) of neonates 
with HIE. It has been suggested that perinatal asphyxia modifies cerebral synthesis of 
neurotransmitters, with enhanced production of glycine (Roldan et al., 1999).  The results 
here presented suggest that this enhanced requirement for glycine could explain the higher 
production and urinary excretion of this amino acid found in the respiratory depression 
group. Glycine is formed from DMG in the methionine metabolism. Glycine is also 
converted to guanidoacetate (GAA), and further methylated to creatine with formation of 
homocysteine, the latter being transsulfurated forming taurine. A schematic representation 
of the metabolic relations between these metabolites is shown in Figure 6.14, with 
indication of metabolites detected in newborn urine in bold and metabolites found to vary 
in this cohort with short arrows. Increased glycine, betaine, choline, creatine and taurine 
here found suggest a profound perturbation in methionine metabolism following the 
respiratory depression episode, probably for the replenishing of the increased glycine 
requirement towards enhanced neurotransmitter formation.  
Another relevant change in this group is the increase in myo-inositol levels. Higher 
myo-inositol levels have been reported in the brain of HIE newborns through in vivo NMR 
measurements (Fan et al., 2003), this finding being related to gliosis (proliferation of 
astrocytes after central nervous system, CNS, injury) and poor myelination, as myo-inositol 
has been labeled as a breakdown product of myelin (Fan et al., 2003). This compound is 
also a precursor of lung surfactant phosphatidylinositol (PI). Hence, higher myo-inositol 
levels can also be related to changes in lung surfactant, possibly leading and explaining the 
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development of the respiratory depression episode. However, the origin of the increase in 
myo-inositol found in this group differs from that noted for premature newborns (section 
6.3.1) as, in the latter group, this variation could be explained by the gestational age at 
birth, which coincided with the peak of PI formation (32-35 g.w. declining until the end of 
gestation). This is not the case of the respiratory depression group (GA range at birth for 
this group is 36-40 g.w.). Thus, it is possible that the increase in myo-inositol excretion 
originates from a perturbation in surfactant production (unexpected based on GA at birth) 
hence causing the episode, and/or altered myelination, the latter being associated with a 
possible brain insult caused by the oxygen deprivation. 
 
 
Figure 6.14: Representation of the metabolic relationship between methionine metabolism, creatine 
biosynthesis, urea cycle and synthesis of lung surfactants (adapted from (Brosnan and Brosnan, 
2010, Dasarathy et al., 2010). Metabolites identified in newborn urine are noted in bold. Small 
arrows direction of variation in the respiratory depression group. 
 
6.3.3 Large for Gestational Age (LGA) 
Newborns are considered large for gestational age, LGA, when their birth weight is 
above the 90% percentile for the corresponding gestational age at birth. Being born LGA 
poses higher risk for birth injuries, including cervical and brachial plexus injuries, phrenic 
nerve damage, with paralysis of the diaphragm, fractured clavicles, cephalohematomas, 
subdural hematomas and ecchymoses of the head and face (Kliegman et al., 2011). 
Additionally, LGA newborns have higher risk of developing hypoglycemia and 
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polycythemia (higher concentration of red blood cells) and also higher incidence of 
congenital anomalies, particularly of the heart (Kliegman et al., 2011). Long-term effects 
such as intellectual and developmental retardation are also more common in these 
newborns (Kliegman et al., 2011).  LGA is often caused by abnormalities in maternal-fetal 
placental circulation and maternal glucose metabolism, this growth perturbation being 
common in newborns of obese women and GDM-affected pregnancies due to fetal 
hyperglycemia and hyperinsulinemia (Hod et al., 2008, Kliegman et al., 2011).  
 
6.3.3.1 Unveiling an urinary metabolic signature of LGA 
In this study, urine from LGA newborns was compared with that of controls i.e. 
healthy newborns with birth weight adequate for gestational age (AGA), more information 
regarding samples metadata being shown in Table 2.5 of Experimental Section. For the 
LGA group only 2 out of the 18 samples were obtained from GDM-affected pregnancies 
(LGA being a common complication of GDM), thus the unveiled urinary profile is likely 
reflective exclusively of LGA and not of GDM. PCA and PLS-DA were applied to the 
original dataset and after variable selection and validated through MCCV. Although no 
group separation was obtained through PCA (Figure 6.15a), the PLS-DA suggested a 
separation trend between LGA and controls, as shown in Figure 6.15b. MCCV suggested a 
relatively robust model, seen through ROC plot analysis and confusion matrices, which 
yielded CR 84%, sensitivity 76%, specificity 86%, and predictive power supported by Q
2 
distribution of true and permuted classes and median Q
2
 of 0.455 for true classes (Figure 
6.15c,d, and Table A-II.4, Annex 2). Regarding the two LGA located on the positive 
direction of LV[2] and noted in Figure 6.15b, visual inspection of the corresponding NMR 
spectra revealed higher levels of the unassigned region 0.70-1.07 ppm in one, and higher 
myo-inositol in the other sample, all metabolites found relevant for the LGA urinary 
signature. 
The subset of variables on the basis of the PLS-DA separation unraveled a urinary 
metabolic signature of LGA (Table 6.7). At the end of this table, a summary of relevant 
changes in newborn urine in cases of other fetal growth perturbations (namely intrauterine 
growth restriction-IUGR) reported in literature is shown. The LGA profile here unveiled 
comprised changes in 13 metabolites, including 4 amino acids and derivatives, 4 organic 
Newborn health status seen through urine metabolomics 
245 
acids, 2 products of nucleotide metabolism, 1 metabolite deriving from the gut microflora 
and 2 others (myo-inositol and creatine) along with 13 unassigned regions with p<0.05, 
mostly at 0.5-1 ppm and 6-7 ppm. Since the LGA group was found to be unbalanced in 
terms of gender,comprising 14 males and 4 females newborns, a possible confounding 
contribution of gender needed to be taken in to account (changes previously listed in Table 
6.4). This means that the increased excretion noted for creatine and hippurate along with 
decreased excretion of 2-KG and fumarate (noted with 
*
 in Table 6.7) may arise from the 
unbalance of gender rather than the LGA condition. 
 
 
Figure 6.15: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for urine of newborns born large for gestational age (LGA, n=18) compared to 
controls (n=46). TPR: true positive rate, FPR: false negative rate. 
 
Furthermore, metabolites/resonances relevant for the profile were highlighted 
through the VIP-wheel representation and Volcano plot shown in Figure 6.16a,b. Through 
the inspection of Figure 6.16 it becomes clear that 2-Py, DMG and myo-inositol, along 
with several unassigned regions mainly at 0.5-1.0 (bile acids region (Trump et al., 2006, 
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Duarte et al., 2009)) and 6-7 (purines and pyrimidines region (Wevers et al., 1999)) ppm 
have the highest individual biological and statistical significance (p-values ranging from 
10
-2
 to 10
-3
) the same metabolites/regions having high VIP. One exception however is that 
of hippurate and unassigned region 1.84-1.90 ppm which were found to be relevant for the 
separation (given their high VIP value) but not individually significant (p-value>0.05). 
 
Table 6.7: Metabolite/resonance changes in newborn urine of LGA group. 
a 
Chemical shifts 
selected by variables selection; s: singlet, d: doublet, dd: doublet of doublets, t: triplet, m: 
multiplet. 
b 
Peaks possibly related to diet and/or gut microflora. *Possible contribution of gender. 
Ui: unassigned compound i by order of appearance and following Table 6.2, Table 6.4, Table 6.5 
and Table 6.6. DMG: dimethylglycine, other abbreviations defined in following Table 6.2, Table 
6.4, Table 6.5 and Table 6.6. Only p-values<0.05 are shown. 
LGA (n=18) vs. Control (n=46) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
2-KG
*
 2.45 t, 3.01 t ↓(-0.18) 
2-Py 6.66 d, 7.97 dd, 8.33 d ↑(1.01, 9.6×10-3) 
Alanine 1.49 d ↑(0.10) 
Citrate 2.54 d, 2.69 d ↓(-0.40) 
Creatine
*
 3.04 s, 3.93 s ↑(0.34) 
DMG 2.93 s ↑(0.77, 6.3×10-3) 
Fumarate
*
 6.53 s ↓(-0.51) 
Glycine 3.57 s ↓(-0.43) 
Hippurate
 b,*
 3.97 d, 7.56 t, 7.64 t, 7.83 d ↑(0.56) 
Myo-inositol 3.29 t, 3.55 t, 3.63 t, 4.08 t ↓(-0.67, 1.7×10-2) 
NMND 8.18 m, 8.90 d, 8.97 d, 9.28 s ↑(0.58) 
Succinate 2.41 s ↑(0.59) 
Taurine 3.43 t ↑(0.14) 
Unassigned spectral regions 
0.5-0.55  ↑(0.76, 1.4×10-3) 
0.57-0.60  ↑(0.56, 3.3×10-3) 
0.64-0.70  ↑(0.70, 1.6×10-3) 
0.77-0.87  ↑(0.79, 2.8×10-2) 
0.89-0.94  ↑(1.04, 2.1×10-3) 
3.35-3.38  ↓(-0.66, 1.4×10-2) 
6.17-6.19  ↓(-0.49, 1.4×10-2) 
6.35-6.36  ↓(-0.48, 3.0×10-2) 
6.39-6.41  ↓(-0.65, 8.0×10-3) 
6.43-6.45  ↓(-0.87, 1.3×10-3) 
6.46-6.47  ↓(-0.80, 4.4×10-3) 
6.68-6.71  ↑(0.55, 3.8×10-2) 
8.01-8.07  ↑(1.30, 2.4×10-2) 
+ 12 unassigned spin systems and 15 spectral regions with p>0.05 
Literature review: IUGR newborn urine:  myo-inositol, creatine, creatinine and 
sarcosine (Dessì et al., 2011) 
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Figure 6.16: a) VIP-wheel representation of the NMR urinary profile of newborns born LGA (inner 
and outer circles represent, respectively, the average urine spectrum of healthy newborn urine 
(control group) and corresponding ppm scale). b)  Volcano plot of effect size vs. –Log (p-value) of 
metabolite/resonances integrals summarized in Table 6.7. Dashed line indicates p-value= 0.05. 
 
6.3.3.2 Proposed metabolic interpretation of changes related with LGA  
To our knowledge, this is the first metabolomic report addressing the effect of 
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Favretto et al., 2012), SGA (Horgan et al., 2011), LBW (Ivorra et al., 2012) and VLBW 
(Alexandre-Gouabau et al., 2013). 
In this cohort, urine metabolites with higher statistical and biological significance 
include myo-inositol, DMG and 2-Py. Myo-inositol was found to decrease in the LGA 
group in this study, the plasma concentration of this metabolite having been found to 
correlate negatively with birth weight in an animal model of LBW vs. normal weight 
(Nissen et al., 2011). Moreover, a previous work reported increased myo-inositol levels in  
urine of IUGR newborns (inverse growth perturbation to LGA) due to reduced insulin 
secretion (Dessì et al., 2011). Myo-inositol is synthesized from glucose and it has been 
reported to have insulin-mimetic properties stimulating cellular glucose uptake and 
glycogen synthesis (Croze and Soulage, 2013). It is also a precursor of lung surfactant 
phosphatidylinositol (PI) (Groenen et al., 2004, Agassandian and Mallampalli, 2013) and a 
breakdown product of myelin after brain insult (Fan et al., 2003). However, alterations in 
lung surfactant production and/or brain insults are unlikely causes of the myo-inositol 
variation encountered in this cohort as all newborns were born at approximately the same 
gestational age (median GA 39 g.w. for controls and LGA), after the peak of PI formation 
(week 32 to 35 (Grenache and Gronowski, 2006, Creasy et al., 2009)) and no clinical 
evidence of brain injury was reported in either LGA or control groups. Thus, the 
significant decrease of urinary myo-inositol in LGA newborns can reflect altered glucose 
handling leading to enhanced fetal growth (glucose being the main fuel for fetal growth).  
Other relevant findings for the LGA group comprise higher urinary DMG and 2-Py 
levels, these being involved in the methionine cycle and nucleotides metabolism, 
respectively. DMG has been found increased in umbilical cord blood plasma and 
correlated with higher birth weight, in a LBW vs. normal weight cohort, due to alterations 
in choline metabolism (Hogeveen et al., 2013).  Moreover, it has been suggested that 
alterations in methionine metabolism could impact on purine and pyrimidine metabolism, 
DNA synthesis and/or cell proliferation, and affect fetal growth (Kalhan and Marczewski, 
2012). Indeed, the results found in this work are consistent with a perturbation in 
methionine metabolism towards enhanced production of DMG. Moreover, the tandem 
increase of 2-Py and NMND was found in LGA newborns, the latter metabolites being end 
products of nucleotides metabolism, specifically the tryptophan-NAD
+
 pathway that 
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supplies pyridines nucleotides to the liver (see Figure 6.9). Hence, higher excretion of 2-Py 
and NMND suggest a further perturbation in nucleotides metabolism.  
Regarding the significant contribution of several unassigned spectral regions that 
characterize the LGA urinary profile, emphasis must be given to the 0.5-1.0 ppm region, 
which typically contains resonances from bile acids (Trump et al., 2006, Duarte et al., 
2009), and is significantly increased in LGA newborns. However, no possible explanation 
was found in literature linking altered urinary bile acids excretion and LGA. Also, the 6-
6.5 ppm range was found significantly decreased in the LGA group, this region typically 
containing resonances of purines and pyrimidines (Wevers et al., 1999), consistently with 
above suggested perturbation in nucleotides metabolism. 
 
6.3.4 Malformations 
6.3.4.1 Unveiling an urinary metabolic signature of malformations 
This study comprised urine from 9 newborns born with a malformation, only 1 
sample being a major malformation (corresponding to a case of situs inverus with 
dextrocardia) and 8 minor malformations (comprising 5 cardiac, 2 soft tissues and 1 
urogenital). This group was compared to controls by applying PCA and PLS-DA to the 
original dataset and after variable selection (the best model being obtained with the 
reduced matrix) and confirmed through MCCV (Table A-III.4, Annex III). No separation 
was obtained by PCA, as shown by the score plot in Figure 6.17a, whilst PLS-DA revealed 
a separation trend between malformations and controls, as shown in Figure 6.17b. The 
PLS-DA model was found to be relatively robust with CR of 89%, sensitivity of 90% and 
specificity of 73% and relatively good predictive power, given by Q
2 
distribution (median 
Q
2
 of 0.391), as shown in Figure 6.17c,d. Regarding the outlier sample noted in both PCA 
and PLS-DA score plots, this sample corresponding to a newborn diagnosed with of a 
cardiac malformation, specifically a interventricular communication (IVC) case, the 
mother being affected by chronic bronchitis. Additionally, visual inspection of the 
corresponding urine spectra showed high levels of galactose. 
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Figure 6.17: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for newborn urine corresponding to the malformations group (n=9) compared to 
controls (n=46). TPR: true positive rate, FPR: false negative rate. Arrows note one outlier sample 
within the malformation group. 
 
The urinary profile of the malformations group was retrieved considering the 
selected subset of variables used (Table 6.8), and the overall signature was found to 
comprise changes in 22 metabolites, including 5 amino acids and derivatives, 4 organic 
acids, 3 products of nucleotide metabolism, 2 ketone bodies and 8 metabolites 
derivingfrom diet and/or gut microflora. Out of the registered profile, 2-Py, citrate, IS and 
succinate were found statistically significant, 1 unassigned singlet at 4.53 ppm (U18) and 1 
unassigned spectral region (8.40-8.42 ppm) with p<0.05. An interesting finding of this 
profile was that increased NMND and decreased succinate were found in newborn urine 
commonly with previous findings in 2
nd
 trimester maternal urine of women carrying babies 
with malformations (Section 4.1.1), these being noted with 
c
 in Table 6.8. Moreover, 7 out 
of the 9 malformation cases were born through CS, so a possible contribution of this 
confounder must to be acknowledged (changes related to delivery mode shown in Table 
6.2). This means that the variation noted for 4-HPA, IS, lactose and PAG (all metabolites 
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possibly deriving from the gut microflora and noted with 
*
 in Table 6.8), may have a 
concomitant contribution from the effect of delivery mode rather than the malformation 
itself. 
 
Table 6.8: Metabolite/resonance changes in newborn urine of the malformation group. 
a 
Chemical 
shifts selected by variables selection; s: singlet, d: doublet, dd: doublet of doublets, t: triplet, m: 
multiplet. 
b
Peaks possibly related to diet and/or gut microflora. 
c 
Metabolites found to vary 
commonly with maternal urine of women carrying babies with malformations (Section 4.1.1.). 
*
Possible contribution of delivery mode. Ui: unassigned compound i by order of appearance and 
following Table 6.2, Table 6.4, Table 6.5, Table 6.6 and Table 6.7. Abbreviations defined in 
following Table 6.2, Table 6.4, Table 6.5, Table 6.6 and Table 6.7. Only p-values<0.05 are shown. 
Malformations  (n=9) vs. Control (n=46) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
2-Py 6.66 d, 7.97 dd 8.33 d ↓(-0.82, 5.4×10-2) 
3-aminoisobutyate 1.19 d, 2.61 m, 3.06 dd ↓(-0.64) 
3-HBA 1.20 m, 2.31m, 2.41 m, 4.16 m ↓(-0.55) 
4-DEA 1.11 d ↑(0.08) 
4-HPA
 b,
 
*
 6.86 d ↓(-0.05) 
Acetone 2.23 s ↓(-0.50) 
Cis-aconitate 3.12 d ↓(-0.46) 
Citrate 2.54 d, 2.67 d ↓(-0.56, 4.3×10-2) 
Choline
 b
 3.20 s ↓(-0.19) 
DMG 2.93 s, 3.72 s ↑(0.74) 
Fumarate 6.53 s ↓(-0.68) 
Glutamine 2.11 m, 2.47 m ↑(0.70) 
Hippurate
 b
 3.97 d, 7.56 t, 7.64 t ↑(0.17) 
IS
 b,*
 7.28 m, 7.50 d, 7.70 d ↓(-0.78, 3.6×10-2) 
Lactose 
b,*
 3.28 t, 4.46 d ↑(0.39) 
Lysine 1.73 m ↓(-0.13) 
NMND
c
 8.90 d, 8.97 d, 9.28 s ↑(0.51) 
PAG
 b,
 
*
 7.36 t, 7.43 t ↓(-0.56) 
Succinate
c
 2.41 s ↓(-0.93, 3.7×10-3) 
Tyrosine 6.90 d ↑(0.41) 
Trigonelline
 b
 8.84 br, 9.12 s ↑(0.16) 
Xylose
 b
 4.59 d, 5.22 d  ↑(0.59) 
U18 4.53 s [1.84 m] ↑(0.77, 4.5×10-2) 
Unassigned spectral regions 
8.40-8.42  ↑(0.99, 2.8×10-2) 
+8 unassigned spin systems and 14 spectral regions with p>0.05 
 
The above mentioned urinary profile of carrying malformations was also plotted by 
means of a VIP-wheel and Volcano plot (respectively in Figure 6.18a,b). An immediate 
observation of the VIP-wheel is the high importance of the aromatic region (shaded in 
orange) for the PLS-DA group separation given by the high VIP values of almost the 
whole region. Out of the metabolites/peaks resonating at this region, only 2-Py, IS and the 
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Figure 6.18: a) VIP-wheel representation of the NMR urinary profile of newborns born LGA (inner 
and outer circles represent, respectively, the average spectrum of the control group and ppm scale) 
Volcano plot of effect size vs. –Log (p-value) of metabolite/resonances integrals listed in Table 6.8. 
Dashed line indicates p-value= 0.05. 
 
unassigned region 8.40-8.42 were found to have individual statistical significance (p-
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6.22-6.23 and 7.10-7.12 ppm, p-value>0.05) and must therefore be acknowledged. 
However, as previously mentioned, 7 out of 9 malformation cases were born through CS, 
this delivery mode being related with changes in the urinary excretion of metabolites 
derived from the gut microflora (these typically resonating in the aromatic region). Hence, 
the increased importance of the aromatic region in this profile  (particularly that of 4-HPA, 
IS and PAG resonances) may be hampered by the concomitant effect of delivery mode 
rather than solely reflecting the effect of carrying a malformation. Regarding other 
metabolites with high contribution for the groups’ separation, the VIP-wheel representation 
and volcano plot showed that succinate, citrate and U18 had high biological and statistical 
relevance for the profile. Moreover, 3-aminoisobutyrate, glutamine, DMG, fumarate, 
acetone, 3.-HBA (all with effect size>|0.5|) and unassigned regions 3.37-3.39 and 4.31-
4.33 were also found to be relevant for the PLS-DA separation (noted in the VIP-wheel 
due to their high VIP values) although without individual statistical significance. 
 
6.3.4.2 Proposed metabolic interpretation of changes related with 
malformations 
In spite of the exploratory nature of this model, given the low number of samples 
available at this stage, a tentative metabolic picture accompanying the occurrence of 
malformations (mostly minor cases) can be drawn. Metabolites with higher biological and 
statistical relevance include succinate, IS, citrate and 2-Py, along with the unassigned 
singlet at 4.53 ppm and the spectral region of 8.40-8.42 ppm. Succinate was found to be 
significantly decreased in the malformation group, possibly reflecting its underuse in the 
respiratory chain. This finding is consistent with previous reports that found succinate to 
increase in AF (Graça et al., 2010) and decrease in maternal urine of women carrying 
malformed fetuses (Chapter 4, Section 4.1.1). Succinate is also an intermediate of the TCA 
cycle along with citrate, cis-aconitate and fumarate, all being decreased in this cohort, 
consistently with a slowing down of this pathway. Decreased IS, previously mentioned to 
induce oxidative stress (Dou et al., 2007) and nephrotoxicity (Suhre et al., 2010), was also 
found in the malformation group. It would be expected that increased oxidative stress in 
the pathological group was reflected by an increase in IS, as suggested for maternal urine 
of CNS malformations cases, described in Section 4.1.1, thus posing an apparent 
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contradiction. Still, IS was found to decrease in urine of newborns delivered through CS, 
as discussed in section 6.2.1, possibly due to labor-related stress. Given that 7 out of the 9 
malformation cases were born through CS, it is possible that the decreased IS levels found 
in the malformation group is a reflection of delivery mode effects rather than the 
malformation itself. Hence, a possible contribution of the confounding effect cannot be 
ruled out at this stage. Nucleotide metabolism, particularly the tryptophan-NAD
+
 pathway, 
also seems to be altered in cases of malformations supported by a decrease in 2-Py, along 
with higher NMND (Figure 6.9). Higher NMND levels were also found in urine of women 
carrying malformed fetuses (section 4.1.1), suggestive of altered nucleotide metabolism. 
The decreased 2-Py and increased NMND levels found in this cohort are consistent with a 
perturbation in nucleotide metabolism is cases of malformations, as previously detected in 
the prenatal period though maternal urine.  
 
6.4 Impact of maternal disorders on newborn urine composition  
The follow-up of pregnancies and their relationship with the newborn health is of 
paramount importance. Indeed, the importance of in utero fetal programming (i.e. the 
understanding of the permanent effect of the prenatal period in the organism’s physiology 
and metabolism) is being increasingly recognized as reviewed in the literature (Freeman, 
2010, Cianfarani et al., 2012). It is known that prenatal disorders affecting maternal-fetal 
placental circulation, maternal glucose metabolism and infection compromise fetal growth, 
predisposing infants to increased medical intervention (Hod et al., 2008, Kliegman et al., 
2011). In this study, information regarding future health of the newborns of this cohort was 
not available at this stage. Still, it was possible to assess the impact of GDM and maternal 
psychiatric disorders in the newborns health status and metabolism during the first days of 
life. 
6.4.1 Maternal Gestational Diabetic Mellitus (GDM) 
GDM poses significant risks for the fetus during the prenatal period, including 
congenital malformations, macrosomia, organomegaly, CNS development delay, chronic 
hypoxemia, stillbirth, preterm birth and birth injury (Hod et al., 2008). Furthermore, major 
short-term implications for the newborn are associated with being born to GDM mothers, 
namely hypoglycemia, hypocalcemia, hypomagnesemia, polycythemia, 
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hyperbilirubinemia, respiratory distress syndrome (RDS) and vascular thrombosis (Hod et 
al., 2008). One important mention concerning the designation of this group is that in 
literature being born to a GDM mother is often called iGDM the prefix i standing for 
infant. As in this study all samples were collected from day 1 to day 6 of life, i.e. within 
the age range considered newborn (from birth to 1
st
 month (Kliegman et al., 2011)) the 
term newborn was adopted to describe this group in this thesis.   
 
6.4.1.1 Unveiling an urinary metabolic signature of GDM 
In this cohort, urine was collected from newborns born to mothers affected by 
GDM (n=14, out of these only 2 were born LGA) and compared to controls. Visual 
comparison of the average NMR spectra of cases and controls revealed differences in 
succinate, creatine and formate contents (noted in Figure 6.1d, page 212).  
PCA and PLS-DA was applied to both original and reduced dataset and model 
validation was achieved by MCCV (model quality parameters compiled in Table A-III.4, 
Annex III). PLS-DA revealed a separation trend between classes in the corresponding 
score plot, this not being found in the PCA (Figure 6.19a,b). The PLS-DA model was 
found to have relatively good CR (82%), sensitivity (73%) and specificity (83%), along 
with median Q
2
 of 0.401 of true models. These parameters, along with the low overlap of 
Q
2 
values obtained for true and permuted models as well as the ROC plot (Figure 6.19c,d) 
showed the models’ relatively satisfactory robustness and predictive power, thus enabling a 
possible metabolic hypothesis to the advanced. 
 
The urinary metabolic profile of being born to a GDM mother was characterized by 
changes in 21 metabolites (comprising 9 metabolites derived from diet and/or gut 
microflora, 3 ketone bodies, 2 amino, 2 organic acids, 2 products of nucleotide metabolism 
and 3 others) 4 of them having p<0.05 (namely 2-KG, ethanolamine, hippurate, IS), 1 
unassigned singlet at 2.81 ppm (U15) and the unassigned region of 8.04-8.06 ppm (Table 
6.9). An interesting finding is the common variation found for 2-KG (increased) and 
hippurate (decreased) which were also found in maternal urine of diagnosed GDM women 
(section 5.1), these being noted with 
*
 in Table 6.9. 
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Figure 6.19: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for newborn urine corresponding to newborns of GDM mothers (n=14) compared 
to controls (n=46). TPR: true positive rate, FPR: false negative rate.  
 
The urinary signature of GDM was also plotted by the VIP-wheel and Volcano 
plots (shown in Figure 6.20a,b) with metabolites/resonances relevant for this profile 
highlighted. The VIP-wheel shown in Figure 6.20a shows that lysine, acetone, succinate, 
2-KG, ethanolamine, 4-HPA, IS, hippurate, U18 and unassigned regions  1.75-1.86 ppm, 
6.32-6.37 ppm and 8.26-8.28 ppm have the highest importance for the group separation 
obtained through PLS-DA. Out of the previous metabolites, only 2-KG, IS, ethanolamine, 
hippurate, U18 along with the unassigned region 8.04-8.06 ppm were found to have high 
individual biological and statistical significance (effect size higher than |0.6| and p-values 
in the order of 10
-2
) as visible in the Volcano plot shown in Figure 6.20b. An interesting 
note is that lysine, acetone, 4-HPA and unassigned region 1.75-1.86 ppm, which were 
found important for the PLS-DA separation were associated with high effect size (>|0.6|) 
but not p<0.05, once more stressing the importance of considering the whole profile rather 
than metabolites with individual statistically significant. 
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Table 6.9: Metabolite/resonance changes in newborn urine of newborns from GDM mothers. 
a 
Chemical shifts selected by variables selection; s: singlet, d: doublet, dd: doublet of doublets, t: 
triplet, m: multiplet. 
b 
Peaks possibly related to diet and/or gut microflora. 
*
Variations found 
commonly with maternal urine of GDM women. Ui: unassigned compound i by order of 
appearance and following Table 6.2, Table 6.4, Table 6.5, Table 6.6, Table 6.7 and Table 6.8. 
Abbreviations defined in Table 6.2, Table 6.4, Table 6.5, Table 6.6, Table 6.7 and Table 6.8. Only 
p-values<0.05 are shown. 
Newborns of GDM mothers (n=14) vs. Control (n=46) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
1-Me-histidine
 b
 3.72 s, 7.78 s ↓(-0.16) 
2-KG
*
 3.01 t ↑(0.90, 1.6×10-2) 
3-HBA 2.31 m, 4.15 m ↓(-0.49) 
4-HPA
 b
 3.46 s, 6.86 d, 7.17 d ↑(0.70) 
Acetoacetate 2.28 s ↓(-0.39) 
Acetone 2.23 s ↓(-0.63) 
Alanine 1.49 d ↑(0.55) 
Allantoin 5.39 s ↓(-0.29) 
Ascorbate 4.01 m, 4.52 d ↑(0.47) 
Creatine 3.04 s, 3.93 s ↑(0.33) 
DMA
 b
 2.72 s ↓(-0.39) 
Ethanolamine 3.15 t, 3.84 t ↓(-0.75, 1.2×10-2) 
Hippurate
 b,
 
*
 3.97 d, 7.56 t, 7.64 t, 7.84 d ↓(-0.78, 1.7×10-2) 
IS
 b
 7.21 dd, 7.28 dd, 7.51 d, 7.70 d ↑(0.91, 4.9×10-2) 
Lactose
 b
 4.46 d, 5.25 d ↓(-0.45) 
Lysine 1.73 m , 1.92 m  ↑(0.62) 
NMND 8.78 m, 8.87 d, 8.90 d, 9.28 s ↑(0.51) 
PAG
 b
 7.36 t ↑(0.37) 
Scyllo-inositol
 b
 3.36 s ↑(0.35) 
Succinate 2.41 s ↓(-0.40) 
Xylose
 b
 4.59 d, 5.21 d ↓(-0.10) 
U15 2.81 s ↑(0.76, 1.4×10-2) 
Unassigned spectral regions 
8.04-8.06  ↑(0.62, 2.0×10-2) 
+14 spin systems and 12 spectral regions with p>0.05 
Literature review:  
Changes in umbilical cord serum in GDM cases:  glucose,  pyruvate, histidine, alanine, 
valine, methionine, arginine, lysine, hypoxanthine, lipoprotein and lipids (Dani et al., 
2013). 
 
6.4.1.2 Proposed metabolic interpretation of changes related with GDM 
The set of metabolites with higher biological and statistical relevance enables a 
potential interpretation of the metabolic status of the newborn born to GDM mothers to be 
put forward. Significantly higher (p-value<0.05) 2-KG and IS levels were found in 
newborns of GDM mothers, reflecting respectively changes in TCA and oxidative stress, 
whilst decreased ethanolamine and hippurate suggest changes in lipids metabolism and gut 
microflora, respectively. Moreover, significantly higher 2-KG was also found in maternal 
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urine collected at the time of GDM diagnosis, whilst decreased hippurate was found at 
diagnosis and at the pre-diagnosis states (discussed in Chapter 5, sections 5.1 and 5.2).  
 
 
Figure 6.20: a) VIP-wheel representation of the NMR urinary profile of newborns born to mother 
with GDM (inner and outer circles represent, respectively, the average urine spectrum of healthy 
newborn urine (control group) and corresponding ppm scale). b)  Volcano plot of effect size vs. –
Log (p-value) of metabolite/resonances integrals listed in Table 6.9. Dashed line indicates p-
value=0.05.  
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Higher oxidative stress in newborn from GDM-affected pregnancies is here 
hypothesized by the significantly higher urinary excretion of IS. This suggestion is in 
agreement with higher oxidative stress, based on higher hypoxanthine levels in umbilical 
cord blood, previously reported in infants of GDM-affected pregnancies (Dani et al., 
2013). Increased excretion of 2-KG in newborn urine suggests an increase in the TCA 
cycle, as previously proposed for maternal metabolism in cases of GDM (Chapter 5, 
section 5.1). Additionally, the common variation (significant increase) of 2-KG in maternal 
and newborn biofluids can be a reflection of a metabolic deviation affecting both mother 
and child in GDM pregnancies. This common deviation was also verified for hippurate 
which decreases significantly in maternal (during pregnancy) and newborn urine in relation 
to GDM.  Lower hippurate in maternal urine was found in GDM cases as aforementioned 
in Chapter 5. Hippurate is a metabolite derived from the gut microflora, the latter known to 
play a relevant role in diabetes. Thus, the significant decrease of urinary hippurate here 
found suggests an involvement of the fetal/newborn gut microflora, possibly reflecting a 
different microbial colonization, as a consequence of altered maternal microflora.  
Decreased ethanolamine was found in this cohort, this metabolite being a precursor 
of phosphatidylethanolamine, a membrane phospholipid also acting as lung surfactant. 
Lower ethanolamine was also found in the premature group possibly reflective of altered 
surfactant synthesis. However, altered lung surfactant production is an unlikely source for 
the ethanolamine decrease found in newborns of GDM mothers, as only 1 case was born 
premature and 1 other case was affected by a respiratory depression episode after birth. 
However, in relation to GDM, it has been previously reported that umbilical cord serum of 
newborns from GDM mothers have higher contents of lipoproteins and lipids as a result of 
altered fatty acid metabolism in the placenta or insulin action (Dani et al., 2013). Thus, it 
seems possible that the ethanolamine decrease found in this cohort could be a reflection of 
altered lipid metabolism, particularly decreased phosphatidylethanolamine synthesis, rather 
than perturbations in lung surfactant production.  
 
6.4.2 Maternal psychiatric disorders 
The number of samples available for the remaining groups of maternal disorders 
were very low (n≤10, Experimental Section). Still, given the importance of the prenatal 
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period in predisposing future health, i.e. fetal programming, an exploratory study of the 
impact of maternal respiratory, thyroid, hypertension and psychiatric disorders in newborns 
health status was attempted. PCA and PLS-DA models were computed and validated using 
the original datasets and after variable selection, the best result being always achieved with 
the compressed matrix (see Table A-III.4, Annex III). Unfortunately, the detailed 
interpretation of variables subsets and the unveiling of the urinary metabolic signatures for 
each of these maternal disorders were not possible in time for this thesis, this subject being 
surely accomplished in a near future. Yet, an initial exploitation of the effect of maternal 
psychiatric disorder in newborns health was attempted. This preliminary analysis was only 
possible for the group of maternal psychiatric disorders, this having been chosen for its 
clinical relevance and to check if valuable information could be retrieved even in cases of 
such limited number of samples.  
 
6.4.2.1  Unveiling an urinary metabolic signature of maternal psychiatric 
disorders 
Urine of newborns born to mothers with psychiatric disorders (comprising 
depression and epilepsy) was compared to controls through PCA and PLS-DA only the 
latter showing a separation trend between classes (score plots being shown Figure 6.21a,b). 
The corresponding MCCV results are shown in Figure 6.21c,d, these showing the models’ 
predictive power (Q
2
 distribution and median Q
2
 0.549) and robustness with CR 91%, 
sensitivity 96% and specificity 90%. Regarding the distribution of true models in the ROC 
plot (noted in Figure 6.21d), the abnormal scattering seen through the left limit (FPR=0 
and TPR approximately from 0.2-0.6) is an artefact caused by the significant unbalance of 
the groups (46 vs. 7 samples).  
 
The suggested urinary metabolic signature is shown Table 6.10. Overall, 15 
metabolites, comprising 2 products of nucleotide metabolism, 3 organic acids, 3 amino 
acids and derivatives, 1 ketone body, 4 metabolites deriving from diet and/or gut 
microflora and 2 others, were found to characterize this group along with 1 unassigned 
singlet at 2.87 ppm and 2 unassigned regions with p<0.05. Metabolites/resonances with 
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higher VIP, biological and statistical relevance are highlighted in the VIP-wheel and 
volcano plot shown in Figure 6.22a,b.  
 
 
Figure 6.21: a) PCA and b) PLS-DA score plot, c) Q
2
 values and d) ROC plot of true and permuted 
models obtained for newborn urine corresponding to the maternal psychiatric disorder group (n=7) 
compared to controls (n=46). TPR: true positive rate, FPR: false negative rate. 
 
The VIP-wheel (Figure 6.22a) revealed that metabolites/resonances with highest 
importance for the PLS-DA group separation were DMG, 2-KG, cis-aconitate, xylose, U19 
and unassigned regions 1.78-1.92, 3.37-3.39, 4.15-4.18, 8.01-8.05 and 8.26-8.30 ppm. 
Within the previous list only DMG, 2-KG, U19, as well as unassigned regions 1.88- 1.92 
and 8.26-8.30 were found to have high biological (effect size>|0.7|) and statistical 
significance (p-value<0.05). Other relevant metabolites include cis-aconitate, hippurate 
and taurine, which were found to have high biological but not statistical significance 
(effect size>|0.5|, p-value>0.05), as visible through the Volcano plot (Figure 6.22b). 
 
 
LV [1]
L
V
 [
2
]
a)
Q2 values
 True Classes      Permuted classes
T
P
R
 (
se
n
si
ti
v
it
y
)
FPR (1-specificity)
 True Classes      Permuted classes
d)c)
PC [1] 26%
P
C
 [
2
] 
9
%
R2x=0.327
b)
PCA PLS-DA
Maternal psychiatric disorders (n=7) vs.  Control (n=46)
R2x=0.319   R
2
y=0.671   Q
2=0.474   LV=2
-80
-40
0
40
80
-100 -50 0 50 100
-80
-40
0
40
80
-120 -60 0 60 120
0
0.2
0.4
0.6
0.8
1
0 0.2 0.4 0.6 0.8 1
0
20
40
60
80
100
-1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
Chapter 6 
262 
Table 6.10: Metabolite/resonance changes in newborn urine of newborns from mother with 
psychiatric disorders.
a 
Chemical shifts selected by variables selection; s: singlet, d: doublet, dd: 
doublet of doublets, t: triplet, m: multiplet, br: broad. 
b 
Peaks possibly related to diet and/or gut 
microflora. Ui: unassigned compound i by order of appearance and following Table 6.2, Table 6.4, 
Table 6.5, Table 6.6, Table 6.7, Table 6.8 and Table 6.9. Abbreviations defined in Table 6.2, Table 
6.4, Table 6.5, Table 6.6, Table 6.7, Table 6.8 and Table 6.9. Only p-values<0.05 are shown. 
Maternal psychiatric disordes (n=7) vs. Controls (n=46) 
Compound δH/ppm and multiplicity
 a
 Variation (effect size, p-value) 
2-KG 2.45 t, 3.01 t ↓(-0.74, 4.6×10
-2
) 
2-Py 8.33 d, 7.97 dd ↑(0.52) 
3-aminoisobutyrate 1.19 d ↑(0.23) 
3-HBA 1.20 d, 2.31 m, 2.41 m, 4.15 m ↓(-0.31) 
4-DEA 1.11 d ↓(-0.23) 
4-HPA
 b
 6.86 d, 7.17 d ↓(-0.42) 
Adipate 1.55 m ↓(-0.16) 
Cis-aconitate 3.12 d ↑(0.63) 
Creatine 3.04 s, 3.93 s ↑(0.53) 
DMG 2.93 s, 3.72 s ↑(1.50, 2.6×10-2) 
Ethanolamine 3.84 t ↓(-0.48) 
Galactose
 b
 5.28 d ↓(-0.48) 
Hippurate
 b
 7.55 t, 7.64 t, 7.84 d, 8.52 br ↓(-0.58) 
Lactose
 b
 4.46 d ↓(-0.48) 
Taurine 3.43 t ↓(-0.56) 
U19 2.87 s ↑(0.80, 2.6e-2) 
Unassigned spectral regions 
1.88-1.92  ↑(0.74, 4.0×10-2) 
8.26-8.30  ↑(0.89, 3.5×10-2) 
+13 unassigned spin systems and 14 spectral regions with p>0.05 
 
6.4.2.2 Proposed metabolic interpretation of the changes related with maternal 
psychiatric disorders 
Within the registered changes, DMG was found to significantly increased (effect 
size 1.50, p-value<0.05) whilst 2-KG was found decreased in the pathological group. The 
increase noted for DMG in tandem with decreased taurine suggest a perturbation of the 
methionine cycle, as DMG is formed through the methylation of homocysteine whilst its 
transsulfuration forms  taurine. Also, the decrease of 2-KG and increased cis-aconitate are 
consistent with changes in TCA cycle activity. Unfortunately, given the exploratory nature 
of the analysis of this group, no further hypothesis can be advance at this stage. However, 
these results suggest that maternal psychiatric disorders affecting the mother during the 
pregnancy pose a metabolic effect on the newborn, which needs to be further explored 
using larger cohorts. 
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Figure 6.22: a) VIP-wheel representation of the NMR urinary profile of newborns from mother 
with psychiatric disorders (inner and outer circles represent, respectively, the average urine 
spectrum of healthy newborn urine (control group) and ppm scale). Main differences are noted. b)  
Volcano plot of effect size vs. –Log (p-value) of metabolite/resonances integrals shown in Table 
6.10 (dashed line indicates p=0.05 defined for statistical significance). Mat: maternal. 
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6.5 Summary of newborns and maternal disorders in newborn urine 
The results presented in section 6.2 showed that the confounding effect with highest 
impact in newborn urine was delivery mode followed by gender, these effects being 
necessarily taken into account when variation in pathological groups (unbalanced in terms 
of delivery mode and gender) were interpreted. Regarding newborns’ and maternal 
disorders (section 6.3 and 6.4), prematurity was found to pose the highest impact in 
newborn urine composition followed by respiratory depression, LGA, newborns from 
GDM mothers, newborns carrying malformations and maternal psychiatric disorder (the 
latter being a preliminary and exploratory study due to limited number of samples 
available). The main biochemical findings for these groups along with the validation 
parameters are summarized and presented in decreasing order of disorder impact in Figure 
6.23. An interesting result was that similar variations were found in both mothers (maternal 
prenatal urine) and newborns (urine collected at birth), in cases of prematurity (increased 
citrate and 4-OH-hippurate, decreased 3-Me-histidine and creatinine), babies 
carryingmalformations (increased NMND, decreased succinate) and newborns born to 
GDM-affected pregnancies (increased 2-KG, decreased hippurate). This indicates that 
these conditions pose specific metabolic perturbations that affect both mother and child, 
which may be detected in the prenatal period (through maternal urine) and confirmed after 
birth in newborn urine.  
The abovementioned figure shows that the highest impact on newborn urine was 
found for prematures and respiratory depression groups, with CR, sensitivity and 
specificity above 90%. Then, LGA and GDM were found to pose the following higher 
impact, with CR and specificity 82-86%, whilst sensitivity ranged from 73-76%. This 
lower sensitivity expresses a low true positive rate (TPR), meaning that true cases (LGA or 
GDM cases) are sometimes misclassified as controls. The effect of carrying a 
malformation was associated with high CR and sensitivity (high TPR) although with lower 
specificity (73%). A low specificity reflects a high false positive rate (FPR), meaning that 
some control samples are misclassified as malformations.   
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Figure 6.23: Schematic summary of the disorders studied, main biochemical findings and 
validation parameters, listed in decreasing order of impact. CR: classification rate. 
 
 
A schematic representation of the main metabolic pathways proposed to be affected 
in relation to delivery mode, gender, and newborns’ and maternal disorders, in newborn 
urine composition, is shown in Figure 6.24. In this figure, colored arrows indicate 
metabolites variations for each condition here studied. The concomitant analysis of all 
disorders here studied revealed specific metabolite changes for selected conditions, namely 
increased glucose in females, decreased acetoacetate in newborns from GDM mothers, 
increased glutamine in babies carrying malformations, decreased hypoxanthine after a 
respiratory depression episode and decreased lactate and creatinine in premature newborns. 
Another notable feature in Figure 6.24 is the decrease of 3-HBA in all disorders (while 
independent of delivery mode and gender), this possibly reflecting a general effect of a 
pathological situation. 
15 
Disorder 
studied
Main biochemical characteristics
Validation 
parameters
Prematurity
Nucleotide and amino acids metabolism, TCA 
cycle, renal function, oxidative stress and 
perturbations in lung surfactant production
CR: 92%
Sensitivity: 92%
Specificity: 92%
Respiratory 
depression
Methionine metabolism, altered lung surfactant 
production and/or altered myelination
CR: 91%
Sensitivity: 96%
Specificity: 91%
LGA Methionine cycle, nucleotide and bile acids 
metabolism
CR: 84%
Sensitivity: 76%
Specificity: 86%
GDM Oxidative stress, TCA cycle, lipids metabolism 
and gut microflora
CR: 82%
Sensitivity: 73%
Specificity: 83%
Malformations
Respiratory chain, TCA cycle and nucleotide 
metabolism
CR: 89%
Sensitivity: 90%
Specificity: 73%
Maternal 
psychiatric 
disorders
TCA cyle and methionine metabolism
CR: 91%
Sensitivity: 96%
Specificity: 90%
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Figure 6.24: Schematic representation of the main metabolic pathways affected in cases of newborn 
and maternal disorders, seen through newborn urine. Amino acids in 3-letter code; NaMN: 
nicotinic acid mono nucleotide, NaAD: nicotinic acid adenine dinucleotide, NAD+: nicontinamide 
adenine dinucleotide, NADP: nicotinamide dinucleotide phosphate, ADP: adenosine diphosphate, 
NMND: N-methyl-nicotinamide, 2-Py: N-methyl-2-pyridone-5-carboxamide, 4-Py: N-methyl-4-
pyridone-3-carboxamide, 4-DEA: 4-deoxyerythronic acid, 4-DTA: 4-deoxythreonic acid, 3-HBA: 
3-hydroxybutyrate, PAG: phenylacetylglutamine, DMA: dimethylamine, PI: phosphatidylinositol, 
PE: phosphatidylethanolamine, PC: phopshatidylcholine, DMG: dimethylglycine, GAA: 
guanidoacetate, Hcy: homocysteine, GSH: gluthathione, THF: tetrahydrofolate. 
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7. Conclusions and future perspectives 
This work employed a metabolomics approach to characterize maternal and 
newborn urine composition of healthy and pathological cases, mainly using NMR 
spectroscopy but also MS in selected instances. The results obtained are presented in 
Chapters 3 to 6, corresponding to a set of four interconnected studies.  
 
The first study aimed at defining and characterizing the urinary metabolic profile 
accompanying healthy pregnancies, to deepen the understanding of the dynamic metabolic 
adaptations taking place during healthy pregnancies. The results were achieved by 
comparing independent groups of healthy subjects (representing the non-pregnant state and 
each of the three pregnancy trimesters) and a 21-metabolite signature characteristic of each 
trimester was unveiled. Within the variations noted, those affecting choline, creatinine, 4-
deoxyerythronic acid (4-DEA), 4-deoxythreonic acid (4-DTA), furoylglycine, 
guanidoacetate (GAA), 3-hydroxybutyrate (3-HBA) and lactate were observed here for the 
first time, to our knowledge, in connection to pregnancy. Other previously known effects 
were confirmed, namely the tendency for aminoaciduria and changes in lipid and 
methionine metabolisms. This work enabled the definition of a dynamic metabolic 
signature describing healthy pregnancies, unveiling novel metabolic aspects and setting the 
basis for a control trajectory against which disease-related deviations may be confronted, 
serving as the basis for improved disease diagnostics and prediction. 
 
All results described below, entailing the analysis of maternal urine in relation to 
pregnancy disorders, are novel in comparison to literature, with the exception of one 
previous report on gestational diabetes. Hence, to our knowledge, this is the first work to 
explore and demonstrate the value of maternal urine as a means to diagnose and/or predict 
prenatal disorders.  
NMR metabolomics of 2
nd
 trimester maternal urine enabled metabolic signatures to 
be unveiled for diagnosed FM (and, specifically of central nervous system (CNS) 
malformations) and CD (and, specifically, of trisomy 21). For FM cases, some of the 
results found were in agreement with previously advanced hypotheses of enhanced 
gluconeogenesis under hypoxia, enhanced TCA cycle operation and underuse of the 
respiratory chain, along with increased lipid oxidation and ketone body production. A 
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novel observation involved changes noted in nucleotide metabolism, specifically the 
tryptophan-NAD
+
 pathway, suggested by the increased excretion of N-methylnicotinamide 
(NMND). CNS malformations were related to known perturbations in methionine 
metabolism (with connection to the folic acid pool) and in the respiratory chain (through 
changes in succinate). As previously suggested, changes in amino acid metabolism was 
here found to translate into a profound deregulation, based on higher excretion of branched 
chain amino acids (BCAA, leucine, isoleucine and valine), alanine and glutamine (only 
glutamine and valine having been previously found to vary in relation to CNS). 
Furthermore, new evidence of enhanced TCA cycle (namely decreased acetate along with 
increased 2-ketoglutarate (2-KG) and citrate) and increased oxidative stress (higher 
excretion of allantoin and indoxyl sulphate-IS) were found in CNS cases. CD cases were 
related to enhanced ketone body production, derangements in sugars and amino acid 
metabolism, consistent with previous knowledge. In addition, new perturbations were 
registered in connection to nucleotide metabolism (supported by higher NMND excretion), 
TCA cycle operation (increased citrate and 2-KG), urea cycle and/or creatine biosynthesis 
(higher excretion of GAA, creatine and creatinine). The urinary profile found for T21 cases 
reflected known perturbations in amino acid metabolism, especially for taurine (related 
with the methionine cycle) and allantoin (reflecting increased oxidative stress). 
Additionally, perturbations in respiratory chain (decreased malonate) and nucleotide 
metabolism (decreased N-methyl-2-pyridone-5-carboxamide (2-Py) and NMND) were 
newly found.  
Bearing added potential clinical interest, predictive signatures were found in 2
nd 
trimester maternal urine for later developing preterm delivery (PTD), intrauterine growth 
restriction (IUGR) and preeclampsia (PE), whilst no early evidence of premature rupture of 
the membranes (PROM) was found. Changes in pre-PTD urine confirmed known 
perturbations in amino acid metabolism in the 2
nd
 trimester and/or placental transfer and 
indications of lipids oxidation and oxidative stress previously noted at delivery. Regarding 
pre-IUGR and pre-PE profiles, some novel aspects of the conditions were advanced, 
namely decreased amino acids in pre-IUGR samples and early perturbations in TCA cycle 
in pre-PE cases.  
All disease studies were carried out by considering subsets of 
1
H NMR resulting 
from a novel variable selection method developed in the context of this thesis, this being 
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one of the major outcomes of this work. Regarding validation procedures, internal 
validation was performed for all models and external validation was attempted in the cases 
of FM and pre-PTD (for which higher sample numbers were available). The latter did not, 
however, yield reliable prediction results within the duration of this thesis, probably due to 
a limitation posed by the necessary pre-processing step of spectral alignment, alternative 
approaches having been discussed. For pre-PTD, an additional study was carried out using 
UPLC-MS, based on the premises that enhanced sensitivity (sub mM to pM) might bring 
new information on the disease. MS data processing for multivariate analysis was found to 
be an important issue, different data processing methodologies having been tested.  The 
best performing method consisted of the application of specific filters to select reliable 
data, however, no significant additional information was obtained, only a possible 
biomarker compound being suggested by statistical correlation (STOCSY) results.  
 
A third study focused on the impact of Gestational Diabetes Mellitus (GDM) on 
maternal urine, comprising the comparison of samples collected at diagnosis (16-33 g.w.), 
prior to diagnosis or pre-diagnosis (15-22 g.w.) and upon treatment (17-40 g.w.), 
compared to gestational age-matched controls. This study provided a better understanding 
of maternal metabolism in GDM pregnancies, showing changes in glucose and energy 
metabolisms, renal function and gut microflora, also found in type 1 and type 2 diabetes. 
The metabolic response to GDM treatment was studied and results showed that maternal 
metabolism does not completely return to the normal situation, with accountable changes 
in TCA cycle, amino acids metabolism and gut microflora. Moreover, 2
nd
 trimester 
maternal urine was found to carry information about metabolic changes preceding the 
clinical manifestation of GDM, supporting a possible application of urine metabolomics in 
the prediction of this disease. These changes confirmed an pre-diagnosis hyperglycemia 
tendency and increased urinary citrate, and unveiled new changes in ketone bodies 
excretion, fatty acids ß-oxidation, amino acids and nucleotide metabolism, altered biotin 
status and perturbation in choline and some gut microflora metabolites. The possibility of 
predicting individual GDM treatment requirements (based on the pharmacometabolomics 
concept), was explored for the first time and, indeed, a pre-treatment metabolic phenotype 
was found in maternal urine. This suggested that women later requiring insulin therapy 
exhibit a pre-treatment signature comprising evidence of TCA slowing down and ketone 
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bodies production, decreased malonate (in connection with respiratory chain), changes in 
nucleotide metabolism (higher 2-Py and NMND), higher creatine and creatinine, and 
metabolites related with gut microflora. This pre-treatment signature can be helpful in 
predicting individual response to future treatment requirements, thus allowing an earlier 
and more effective intervention.  
 
The impact of pregnancy and newborn characteristics on newborn urine 
composition was presented next. In this work, phenylacetylglutyamine (PAG) and indoxyl 
sulphate (IS) were identified  in newborn urine for the first time to our knowledge. A 
significant impact was found in relation to delivery mode and gender, for the first time to 
our knowledge. The changes observed are in agreement with the known higher oxidative 
stress and changes in gut microflora colonization in babies born through vaginal delivery, 
along with decreased hepatic gluconeogenesis in babies born through cesarean section. 
Regarding newborn’s gender, only acetone, dimethylamine (DMA) and fumarate varied 
consistently with changes reported in adult cohorts. In addition, female newborns were 
found to have higher urinary allantoin and myo-inositol was higher in males, indicating 
novel gender-related differences in sugar metabolism and oxidative stress. Regarding the 
effect of the in utero period and subsequent newborn disorders, respiratory depression after 
birth, LGA and babies with malformations were here studied for the first time to our 
knowledge, along with prematurity and GDM (the latter previously studied based on 
umbilical blood only). Prematurity was found to cause the highest impact on urine 
composition, with changes in nucleotides and purine metabolism, lipids ß-oxidation, renal 
function, oxidative stress and new evidence of perturbations in pyrimidine degradation and 
lung surfactant production. Subtler changes were also noted in the urine of newborns  
affected by respiratory depression and LGA. Interestingly, for premature newborns, FM 
babies and those born to GDM-affected mothers, similar changes were noted in the urine 
of newborns and mothers during pregnancy. The last group to be studied (still of a limited 
size, n=7) was that of newborns from mothers with psychiatric disorders, which 
surprisingly suggested changes in 2-KG and DMG, involved in the TCA and methionine 
cycle, respectively. These studies will be pursued in the future, as will those of other 
maternal disorders such as respiratory, thyroid and hypertension (only initially explored in 
this thesis).  
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An important general conclusion of this work was the recognition of the paramount 
importance of considering the full spectral profiles provided by NMR, which correspond to 
disease fingerprints of great complexity, instead of a limited number of discrete signals (or 
metabolites) with individual statistical relevance (p<0.05). Such full spectral profile almost 
invariably includes regions or signals of low intensity and difficult assignment, yet playing 
a determinant role in model robustness and sample classification.  
 
The work presented in this thesis demonstrates the promising use of urine 
metabolomics for detection and prediction of disorders of the mother, fetus and newborn. 
Due to its non-invasiveness and ease of collection, maternal and newborn urine emerges as 
an invaluable matrix to search for novel markers with potential clinical applications. It is 
sincerely hoped that the work described in this thesis can indeed contribute towards the 
improvement of prenatal and newborns healthcare. With this in mind, future work will 
necessarily entail the use of larger cohorts to confirm the changes found in this work for 
2
nd
 trimester urine, specially for T21, and for the prediction of PE, PTD, and fetal growth 
disorders (IUGR, LGA and also small for gestational age). Also, larger sample numbers 
will be required to confirm the enticing possibility of predicting GDM development as well 
as individual GDM treatment requirements suggested in this work. The use of larger 
cohorts will necessarily entail appropriate external validation so that a clinical application 
can be envisaged. Another future endeavor is to search for markers of these disorders in 1
st
 
trimester maternal urine, thus enabling earlier diagnosis and intervention. Finally, 
regarding infant health, the implementation of follow-up strategies for regular collection of 
subject clinical data from day 1 of life onwards (1-2 first years of life or later) would be of 
great value for the prediction of shorter- (1-2 years of life) and longer-term effects of 
pregnancy characteristics. 
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Annex I: Main characteristics of prenatal and newborn health metabolomic studies 
Table A-I.1- Summary of publications reported in literature of metabolomic in prenatal health research (including number of samples, gestational age at 
sampling, analytical technique used, statistical approach and main biochemical findings). Amino acids in three letter-code, 3-HBA: 3-hydroxybutyrate, 
BALF: bronchoalveolar lavage fluid, BSLR: backward stepwise logistic regression, CMM: Correlation matrix map, CS: cesarean section, CV: cross-
validation, CVA: canonical variates analysis, GABA: γ-aminobutyrate, HCA: hierarquical cluster analysis, HIE: hypoxic ischemic encephalopathy, 
HIVA: hidroxyisovalerate, HMLR: hierarchical multiple linear regression, HPLC: high performance liquid chromatography, LC-HRMS: liquid 
chromatography high-resolution mass spectrometry, LDA: linear discriminant analysis, MCADD: medium chain acyl-coenzyme A dehydrogenase 
deficiency, NMND: N-methylnicotinamide, nS-HR-MS: nanospray high resolution MS, NTD: neural tube defect, OSC: orthogonal signal correction, 
GP: genetic programing, PE: preeclampsia, PKU: phenylketonuria, RF: random forest, ROC: receiver operating characteristic, TCA: tricarboxylic acid, 
TMA: trimethylamine, TMAO: trimethylamine-N-oxide, UPCA: unsupervised unfold principal component analysis, VD: vaginal delivery. 
Biofluid 
Subject groups, n 
Gestational age at 
sampling 
Analytical 
technique 
Statistical tools Main biochemical findings Reference 
Preeclampsia 
Amniotic fluid 
PE n=7, Control n=36 
3
rd
 T NMR (600 
MHz) 
Univariate, LDA higher acetate, succinate, choline and 
possibly citrate 
Bock 1994 
Placental extracts 
PE n=3, Control n=5 
At delivery MS,  
TLC-MS 
─ Changes in phospholipid profiles Jain 2004 
Blood plasma 
PE n=87, Control n=87 
At diagnosis  GC-MS Genetic Programming, External 
validation   
No biochemical interpretation Kenny et al.. 2005 
Blood plasma 
PE n=11, Control, n=11 
At diagnosis NMR (500 
MHz) 
Univariate, PCA Lower ketone bodies Turner et al.. 
2007 
Blood plasma 
PE n=11, Control n=11 
At diagnosis NMR (500 
MHz) 
Univariate, PCA Altered aromatic amino acids  Turner et al.. 
2008 
Blood plasma 
PE n=20,  Control n=20 
PE 186-272 (days) 
Control 186-282 (days) 
UPLC-MS Univariate,  External validation, 
ROC 
Ischemic injury and limited oxidative 
capacity 
Kenny et al.. 2008 
Placental villous explants 
Control, n=11 
At delivery GC-MS Univariate, PCA Hypoxia related changes 2-deoxyribose, 
threitolor erythritol and hexadecanoic acid 
Heazell et al.. 
2008 
Blood plasma 
PE n=15, Control n=22 
PE: 36±3
 
g.w. 
Control: 39±1
 
g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA Higher concentrations of ala, gly and 
ergothioneine in plasma erythrocytes 
Turner et al.. 
2009 
Placental villous explants 
PE n=6, Control n=6 
At delivery (g.w. not 
specified) 
UPLC-MS Univariate Hypoxia related changes, namely gln and 
glu, trp metabolism and leukotriene or 
prostaglanding metabolism 
Dunn et al.. 2009 
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Blood plasma 
Test set: pre-PE n=60, Control 
n=60, Validation set: pre-PE 
n=39, Control n=40 
2
nd
 T:  
15±1 g.w. 
UPLC-MS Univariate, PLS-DA, External 
Validation, Permutation test, 
ROC, Genetic algorithm 
14-metabolite signature comprising amino 
acids, carbohydrates, carnitines, 
dicarboxylic acids, fatty acids, ketones, 
keto- and hydroxyl- fatty acids, lipids, 
phospholipids and steroids 
Kenny et al. 2010 
Blood Serum 
pre-PE n=41, Control, n=41 
1
st
 and 2
nd
 T:  
11-14 g.w. 
LC-MS/MS Univariate,  Logistic regression, 
ROC 
Higher hydroxyhexanoylcarnitine, ala, phe 
and glu 
Odibo et al. 2011 
Placental extracts 
PE n=6, Control, n=11 
At delivery:  
PE: 37
+6
-41
+0 
g.w. 
Control: 35
+2
-39
+3 
g.w. 
GC-MS 
UPLC-MS  
Univariate, PCA Altered mitochondrial metabolism, 
specifically vitamin  D, oxidative and 
nitrative stress 
Dunn et al. 2012 
Blood serum 
Late onset pre-PE n=30, Early 
onset pre-PE n=30, Control 
n=59 
1
st
 T:   
11
+6
-13
+6 
g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (permutation 
test, ROC) 
Early-onset: changes in citrate, glycerol, 
HIVA and met, Late-onset: val, pyruvate, 
3-HBA, 1-Me-histidine, glycerol and TMA 
Bahado-Singh et 
al. 2012 
Maternal urine 
Pre-PE n=9: Control n=84 
2
nd
 T:  
15-26 g.w.  
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Variable Selection, Internal 
validation (MCCV), STOCSY 
TCA cycle intermediates and precursors Diaz et al. 2013 
Fetal Malformations 
Amniotic fluid 
Open spina bifida n=9, Control 
n=10 
2
nd
 T (g.w. not specified) NMR (600 
MHz) 
Univariate, LDA Lactate, glu, acetate Bock 1994 
Fetal urine 
Obstructive uropathy n=14 
1
st
 to 3
rd 
T 
13-30 g.w. 
NMR (500 
MHz) 
─ Glycosuria, amino and organic aciduria Foxall et al. 1995 
Amniotic fluid 
Spina bifida n=14, Control n=18 
Spina bifida 28.8±7 g.w., 
Control 24.7±12.2 g.w. 
NMR (500 
MHz) 
Univariate,  Multiple linear 
regression 
Derangement in amino acid metabolism 
(higher succinate and glutamine) 
Groenen et al. 
2004 
Amniotic fluid 
FM n=12, Control n=51 
2
nd
 T  
15-24 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(CV), STOCSY 
Changes in glycolysis and 
gluconeogenesis, kidney 
underdevelopment (glucose, amino and 
organic acids) 
Graça et al. 2009 
Amniotic fluid 
FM n=27, Control n=82 
2
nd
 T  
15-22 g.w. (Control), 14-
25 g.w. (disorders) 
NMR (500 
MHz) 
 
Univariate, PCA, PLS-DA, 
OPLS-DA, iPLS-DA, Internal 
validation (MCCV) 
Enhanced glycolysis under hypoxia and  
reduced use of the respiratory chain, folic 
acid pool 
Graça et al. 2010 
Maternal urine 
FM n=26, Control n=25 
 
2
nd
 T 
FM 14-25 g.w., Control 
16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV),  STOCSY 
enhanced gluconeogenesis under hypoxia, 
TCA cycle demand, derangements in 
methionine and nucleotide metabolism 
Diaz and Pinto et 
al. 2011 
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Maternal blood plasma 
FM n=27, Control n=20 
2
nd
 T 
FM 14-25 g.w. (+ 3 3
rd
 
T), Control 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV),  STOCSY 
Energy metabolism, lipids conversion and 
methionine metabolism (acetone, 3-HBA, 
lipids, betaine) 
Diaz and Pinto et 
al. 2011 
Maternal blood serum 
NTD n=101, Control n=143 
1
st
 T, 2
nd 
T and 3
rd
 T  UPLC-MS 
GC-MS 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(CV)  
Impaired mithodondrial respiration, 
changes in the neurotransmitter GABA 
and changes in methionine metabolism 
Zheng et al. 2011 
Maternal blood serum 
NTD n=80, Control n=95 
2
nd
 and 3
rd
 T 
>28 g.w. NTD n =68, 
Control n =81; ≤28 g.w. 
NTD n =12, Control 
n=14 
UPLC-MS Univariate, PCA, OPLS-DA, 
Internal validation (CV)  
methionine cycle and folic acid pool, 
consistent with previous, perturbation in 
neurogenesis and oxidative stress 
Liang et al. 2012 
Amniotic fluid 
FM n=22, Control n=26 
2
nd
 T
FM 15-25 g.w., Control 
16-22 g.w. 
UPLC-MS Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV), SHY 
Enhanced glycolysis under hypoxia, 
enhanced TCA and fetal kidney 
underdevelopment, lipids b-oxidation 
Graça et al. 2012 
Maternal urine 
FM n=13, Control n=21 
2
nd
 T 
FM 15-25 g.w., Control 
16-22 g.w. 
UPLC-MS Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV), SHY 
Gut microflora, glucuronic 
acid and sulphate conjugation reactions 
Graça et al. 2012 
Maternal urine 
FM n=35, Control n=84 
2
nd
 T  
FM 14-24 g.w., Control 
15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY 
Enhanced gluconeogenesis, lipid oxidation 
and ketone body synthesis, respiratory 
chain and nucleotides metabolism 
Diaz et al. 2013b 
Amniotic fluid 
FM n=34, Control n=40 
2
nd
 T 
FM 14-25 g.w. 
Control 16-22 g.w. 
MIR Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY, SHY 
Decreased glucose (due to fetal hypoxia 
and disturbance of energy metabolism), 
changes in amino  acids: gln, ile, leu, 
increased proteins 
Graça et al. 2013 
Preterm Delivery 
Newborn urine 
Preterm n=5, Control n=6 
Shortly after birth 
Preterm 25-36 g.w., 
Control 38 g.w. 
NMR (500 
MHz) 
─ Altered renal function (taurine, TMAO) Foxall et al. 1995 
Newborn urine 
Preterm n=8, Control n=27 
Day 1 to Day 6 
Preterm 28.9±1.2 g.w., 
Control 39.4±1.0 g.w. 
NMR (600 
MHz) 
Univariate,  K-nearest neighbour 
(kNN) 
Tryptophan/NAD
+
 pathway (taurine, 
NMND) 
Trump et al. 2006 
Amniotic fluid 
Test set: PTD without IAI n=19 
PTD with IAI n=20, Control 
n=16; Validation set: PTD 
without IAI n=33, PTD with IAI 
n=40, Control n=40 
2
nd
 and 3
rd
 T 
Test set 22-33 g.w. 
Validation set: 23-33 
g.w. 
LC-MS Univariate, LDA, External 
validation (RF, confusion 
matrices) 
Changes in amino acids and sugar contents Romero et al. 
2010 
Amniotic fluid 
Pre-PTD n=12, Control n=82 
2
nd
 T  
15-22 g.w. (Control), 14-
25 g.w. (disorders) 
NMR (500 
MHz) 
 
Univariate,  PCA, PLS-DA, 
OPLS-DA, iPLS-DA, Internal 
validation (MCCV) 
Increased oxidative stress, amino acids and 
lung surfactants 
Graça et al. 2010 
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Maternal urine 
pre-PTD n=17, Control n=25 
 
2
nd
 T 
pre-PTD 16-21 g.w., 
Control 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV),  STOCSY 
Choline and amino acids metabolism Diaz and Pinto et 
al. 2011 
Cervicovaginal fluid 
pre-PTD (with short cervix) 
n=5, Control (term with short 
cervix) n=5, Control (term with 
normal cervix) n=5 
3
rd
 T 
pre-PTD with short 
cervix 31-33 g.w., 
Control 30.9-33.3 g.w 
UPLC-MS  PLS-DA No biochemical interpretation Auris-Blais et al. 
2011 
Newbor  urine 
Preterm n=41, Control n=26 
First 12 h of life 
Preterm 32.0±3 g.w., 
Control 39.7±0.8 g.w. 
NMR (400 
MHz) 
Univariate, PCA, PLS-DA, HCA Tyr, arg and proline metabolism, urea 
cycle, tyr, trp and phe biosynthesis 
Atzori et al. 2011 
Amniotic fluid 
pre-PTD n=11, Control n=26 
2
nd
 T 
pre-PTD 16-21 g.w., 
Control 16-22 g.w. 
UPLC-MS Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV), SHY 
Placental dysfunction,  changes in amino 
acids and sugars 
Graça et al. 2012 
Breast milk 
PTD n=20, Control n=3 
 
1-13 weeks after 
delivery. Delivery at 26-
36 g.w. 
Control birth at 42 g.w. 
NMR (500 
MHz) 
GC-MS 
PCA, Internal validation (CV) Changes in carbohydrate over the first 
weeks of lactation 
Marincola et al. 
2012 
Umbilical cord blood plasma 
and maternal blood plasma 
VLBW n=8, FT n=8 
At delivery 
VLBW < 32 g.w., FT > 
37g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (permutation 
tests) 
Altered maternal-fetal-placental symbiosis. 
MB: acetate, lipids, pyruvate, gln, val and 
thr UCB: lipoproteins, pyruvate and 
albumin-lysyl, gln 
Tea et al. 2012 
Umbilical cord blood plasma 
and maternal blood plasma 
VLBW n=7, FT n=8 
At delivery 
VLBW < 32 g.w., FT > 
37g.w. 
LC-HRMS Univariate, PCA, PLS-DA, 
Internal validation (permutation 
tests), HCA, UPCA 
Changes in lipids, fatty acid oxidation, 
proteins metabolism, anti-oxidant defence,  
polyamine and puridine flux  
Alexandre-
Gouabau et al. 
2013 
Maternal urine 
Pre-PTD n=26, Control n=84 
2
nd
 T 
pre-PTD 16-21 g.w., 
Control 15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY 
Enhanced lipid oxidation and oxidative 
stress 
Diaz et al. 2013 
Amniotic fluid 
Pre-PTD n=14, Control n=40 
2
nd
 T 
Pre-PTD 16-21 g.w. 
Control 16-22 g.w. 
MIR Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY, SHY 
Decreased carboxylate-containing 
compounds, higher protein content, 
changes in citrate, ala, his, ile, leu, phe, tyr 
and val 
Graça et al. 2013 
Gestational Diabetes Mellitus and Maternal Hyperglycemia 
Amniotic fluid 
GDM n=5; Control n not 
specified 
3
rd
 T (g.w. not specified) NMR (600 
MHz) 
Univariate, LDA No differences found Bock 1994 
Amniotic fluid 
Pre-diag. GDM n=27; Control 
n=82 
2
nd
 T:  
Disorders: 14-25 g.w. 
Controls: 15-22 g.w. 
NMR (500 
MHz) 
 
Univariate, PCA, PLS-DA, 
OPLS-DA, iPLS-DA, Internal 
validation (MCCV) 
Hyperglycemia, amino acids and lipids 
metabolism, nucleotide biosynthesis and 
renal function 
Graça et al. 2010 
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Maternal urine  
Pre-diag. GDM n=29; Control 
n=25 
2
nd
 T: 
GDM: 16-22 g.w. 
Controls: 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA; Internal validation 
(MCCV), STOCSY 
Nucleotide and amino acids metabolism, 
altered biotin status  
Diaz and Pinto et 
al. 2011 
Blood plasma 
Pre-diag. GDM n=14; Control 
n=20 
2
nd
 T: 
GDM: 16-22 g.w. 
Controls: 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA; Internal validation 
(MCCV), STOCSY 
Methionine metabolism Diaz and Pinto et 
al. 2011 
Amniotic fluid 
Pre-diag. GDM n=23; Control 
n=26 
2
nd
 T: 
GDM: 16-21 g.w. 
Controls: 16-22 g.w. 
UPLC-MS Univariate, PCA, PLS-DA, 
OPLS-DA; Internal validation 
(MCCV), SHY 
Decreased gly and increased sugar 
possibly glucose 
Graça et al. 2012 
Maternal urine  
Pre-diag. GDM n=20; Control 
n=21 
2
nd
 T: 
GDM: 16-21 g.w. 
Controls: 16-22 g.w. 
UPLC-MS Univariate, PCA, PLS-DA, 
OPLS-DA; Internal validation 
(MCCV), SHY 
Increased choline Graça et al. 2012 
Maternal urine  
n=823 participants   
 
1
st
-2
nd
 T 8-20 g.w. 
2
nd
 T 28±2 g.w. 
10-16 w. post partum 
NMR (600 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(permutation tests) 
Increased citrate possibly due to 
hyperglycemia 
Sache et al. 2012 
Maternal blood plasma 
Hyperglycemia n=67, Control 
n=50 
2
nd
 and 3
rd
 T 
24-36 g.w. 
GC-MS Univariate, Linear and logistic 
regression, bootstrapping, false 
discovery rate 
Higher triglycerides, ketone bodies and 
amino acids, and low 1,5-anhydroglucitol 
Scholtens et al. 
2013 
Maternal urine 
Pre-diag. GDM n=42, Control  
n=84 
2
nd
 T:  
GDM:16-22 g.w. 
Controls: 15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Variable Selection; internal 
validation (MCCV), STOCSY 
Hyperglycemia, changes in amino acids 
and nucleotide metabolism, gut microflora 
Diaz et al. 2013 
Umbilical cord blood 
GDM n=30, Controls n=40 
At delivery (> 37 g.w.) NMR (600 
MHz) 
Univariate, PCA, OPLS-DA 
internal validation  (MCCV) 
Fetal hyperinsulinemia, increased 
oxidative stress and fetal glycolysis, 
changes in amino acids metabolism 
Dani et al. 2013 
Chromosomal disorders (CD) 
Amniotic fluid 
T21, n=22 Control n=41 
2
nd
 T  
T21 15.7 g.w., Control 
16.7 g.w. 
GC-MS Univariate  Purines, pyrimidines, creatinine, N-acetyl-
aspartate, methylmalonic acid, malonic 
acid and other amino compounds 
Baggot et al. 2008 
Amniotic fluid 
T21 n=24, Controls n=1257 
2
nd
 T 
15-20g.w. 
HPLC Univariate, cluster analysis Decreased amino acids, fetal kidney 
underdevelopment 
Amorini et al. 
2011 
Maternal urine 
CD n=23, Control n=25 
 
2
nd
 T 
CD 14-25 g.w., Control 
16-21 g.w. 
 Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV), STOCSY 
Changes due to hypoxia or lipids 
metabolism (choline) 
Diaz and Pinto et 
al. 2011 
Maternal blood plasma 
CD n=23, Control n=20 
2
nd
 T 
CD 14-25 g.w., Control 
16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV), STOCSY 
Changes in lipids profiles Diaz and Pinto et 
al. 2011 
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Maternal blood serum 
T21 n=30, Control n=60 
1
st
 T  
11
+0
-13
+6
 g.w. 
NMR (500 
MHz) 
Univariate,  PCA, PLS-DA, 
Logistic regression analysis, 
Internal validation (Permutation 
tests, ROC, GP) 
Increased oxidative stress and  
perturbation in brain growth and  
myelination 
Bahado-Singh 
2013a 
Maternal blood serum 
T18 n=30, T21 n=30, Control 
n=114 
1
st
 T  
11
+0
-13
+6
 g.w. 
NMR (500 
MHz) 
Univariate,  PCA, PLS-DA, 
Logistic regression analysis, 
Internal validation (Permutation 
tests, ROC, GP) 
Increased homocysteine transsulfuration, 
increased oxidative stress in T18. 
Higher TMA in T18 compared to T21 
Bahado-Sing et 
al. 2013b 
Maternal urine 
CD, n=33, T21, n =13, Control, 
n=84 
2
nd
 T  
15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation 
(MCCV),  STOCSY 
Increased ketone bodies and NMND 
excretion, TCA operation, amino acids, 
glucose, pyruvate. Perturbation in 
methionine metabolism in T21  
Diaz et al. 2013 
Perturbations of fetal growth 
Placental extracts 
SGA n=9, Control n=8 
At delivery UPLC-MS Univariate,  PCA, Internal 
validation (CVA, false discovery 
rate) 
altered amino acid transfer into fetal 
circulation and fetoplacental perfusion 
Horgan et al. 
2010 
Maternal blood plasma 
SGA n=8, Control n=6; 2
nd
 T  
pre-SGA n=40, Control n=40 
At delivery 
2
nd
 T 15±1 g.w. 
UPLC-MS Univariate,  PLS-DA, Internal 
validation (ROC, permutation 
test, Genetic algorithm) 
changes in lipids, carnitines and fatty acids 
due to placental dysfunction 
Horgan et al. 
2011 
Newborn urine 
Preterm with IUGR n=26 
Preterm with AGA n=30 
Within 24 h of birth and 
at 96 h of life 
g.w. not specified 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA perturbations in lipids and proteins 
metabolism, altered insulin secretion 
Dessi et al. 2011 
Umbilical cord and maternal 
blood plasma 
LBW n=20, Control n=30 
At delivery 
GA>37 g.w. 
NMR (600 
MHz) 
Univariate,  PCA, PLS-DA, 
Internal validation (CV) 
Changes in carbohydrate storage, impaired 
placental transfer of amino acids, changes 
in DNA methylation.  No differences in 
maternal BP 
Ivorra et al. 2012 
Umbilical vein serum 
IUGR, n=22, Control n=21 
At delivery 
IUGR 32-41.3 g.w., 
Control 36.4-41.2 g.w. 
LC-HRMS Univariate,  PCA, Cluster 
analysis, Internal validation 
(ROC) 
22-met bolite signature suggestive of 
altered amino acid transfer, with emphasis 
to changes in phe, trp and glu 
Favretto et al. 
2012 
Maternal urine 
pre-IUGR n=10, Control n=84 
2
nd
 T  
pre-IUGR 16-24 g.w., 
Control 15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY 
Decreased amino acids Diaz et al. 2013 
Asphyxia, Respiratory Depression Syndrome and Meconium Aspiration Syndrome 
Newborn urine 
Asphyxia n=20, Healthy n=10 
Not specified NMR (400 
MHz) 
─ Increased lactate, changes in TCA cycle  
intermediates 
Ma et al. 1995 
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Newborn urine 
Resuscitation and poor outcome 
n=11, Resuscitation and good 
outcome n=13,  Control n=216 
Resuscitation and poor 
outcome 260±34(days) 
Resuscitation and good 
outcome 276±19 (days) 
Control 277±10 (days) 
Collected 12 and 12-48h 
after birth 
GC-MS Univariate, HCA, Internal 
validation (ROC) 
Increased organic acids Chu et al. 2005 
Newborn BALF 
RDS n=4  
Birth before 34 g.w. NMR (500 
MHz), GC-
MS 
─ Changes in undecane, decanoic acid, 
dodecanoic acid, hexadecanoic acid, 
octadecanoic acid, hexadecanoic acid 
methyl ester, 9-octadecanoic acid, 
tetracosanoic acid, myristic acid, 
phosphate. 
Fabiano et al. 
2011 
Umbilical cord serum 
HIE n=31, Asphyxia without 
HIE n= 40, Control n=71 
HIE 40.3±1.1 g.w., 
Control 1 40.3±0.9 g.w., 
Asphyxia without HIE 
40.1±1.3 g.w., Control 2 
40.1±1.1 g.w. 
Direct flow 
injection and 
LC-MS/MS 
(commercial 
Absolut 
IDQ
TM 
kit) 
Univariate, PLS-DA, CVA, 
BSLR, Internal validation 
(permutation tests, ROC),  
Changes in amino cids, acylcarnitines, 
and  glycerophospholipids 
Walsh et al. 2012 
Umbilical cord serum 
HIE n=25, Asphyxia n=34, 
Controls n=59 
Birth after 36 g.w. NMR (600 
MHz) 
Univariate, CVA, internal 
validation (ROC) 
Altered ketones linked to neurological 
injuries and hypoxia related changes 
Reinke et al. 2013 
Premature rupture of the membranes (PROM) 
Amniotic fluid 
pre-PROM n=34, Control n=82 
2
nd
 T  
15-22 g.w. (Control), 14-
25 g.w. (disorders) 
NMR (500 
MHz) 
 
Univariate,  PCA, PLS-DA, 
OPLS-DA, iPLS-DA, Internal 
validation (MCCV) 
Subtle changes in met, gln and thr Graça et al. 2010 
Maternal urine 
pre-PROM n=38, Control n=25 
 
2
nd
 T 
pre-PROM 15-21 g.w., 
Control 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV),  STOCSY 
No changes found Diaz and Pinto et 
al. 2011 
Maternal blood plasma 
pre-PROM n=18, Control n=25 
 
2
nd
 T 
pre-PROM 15-21 g.w., 
Control 16-21 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
OPLS-DA, Internal validation 
(MCCV),  STOCSY  
Faint changes in acetate, gln, citrate and 
albumin 
Diaz and Pinto et 
al. 2011 
Maternal urine 
pre-PROM n=68, Control n=84 
2
nd
 T 
pre-PROM 15-21 g.w., 
Control 15-26 g.w. 
NMR (500 
MHz) 
Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY 
No changes found Diaz et al. 2013 
Amniotic fluid 
pre-PROM n=37, Control n=40 
2
nd
 T 
Pre-PROM 16-23 g.w. 
Control 16-22 g.w. 
MIR Univariate, PCA, PLS-DA, 
Internal validation (MCCV), 
STOCSY, SHY 
No biochemical  interpretation Graça et al. 2013 
Inborn Errors of Metabolism 
Dried blood spots 
PKU n=5, Control n=49 
PKU 1
st
 weeks 
Control not specified 
NMR (400 
MHz) 
PCA, PLS-DA Increased phe Constantinou et 
al. 2004 
Newborn urine 
PKU n=10, Control n=47 
PKU: day 10 
Control: at birth 
NMR (400 
MHz) 
PCA, PLS-DA Increased phe Constantinou et 
al. 2005 
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Dried blood spots 
PKU n=21, MCADD n=21, 
other IEM n=24, Control n=500 
Not specified nS-HR-MS PCA, LDA No biochemical interpretation Denes et al. 2012 
Infection 
Newborn urine 
Bacterial infections n=17, 
Control n=27 
Collected day1 to day 6 
Bacterial infections 
40.2±0.9 g.w., Control 
39.4±1.0 g.w. 
NMR (600 
MHz) 
Univariate,  K-nearest neighbour 
(kNN) 
No changes found Trump et al. 2006 
Newborn urine 
CMV infected n=12, not-
infected n=11 
First 3 weeks of life NMR (500 
MHz) 
PLS-DA, internal validation (CV, 
permutation test) 
Altered energy metabolism and other virus 
related changes 
Fanos et al. 2013 
Other relevant studies 
Umbilical cord blood 
CS (without labor) n=6, VD 
(with medication) n=16, VD 
(without medication) n=19 
 CS 37.0-40.0 g.w., VD 
(with medication) 39.6-
41.4 g.w., VD (without 
medication) 37.1-40.4 
g.w. 
GC-MS Univariate Labor related stress and hormonal actions 
inducing changes in amino acids, sugars 
and ketone bodies 
Hashimoto et al. 
2012 
Ma ernal blood serum 
Poor pregnancy outcome n=40, 
Control n=40 
3
rd
 T Poor pregnancy 
outcome 28-41 g.w., 
Control 28-42 g.w. 
UPLC-MS Univariate, PCA 
 
changes in lipids metabolism due to 
placental dysfunction 
Heazell et al. 
2012 
Amniotic fluid 
Lung maturity: Immature n=13 
Transitional n=8, Mature n=22, 
2
nd 
trimester n=10 
2
nd
 and 3
rd
 T NMR (600 
MHz) 
Univariate, LDA  Changes in gly, choline, creatinine, 
succinate, glu and ala 
Bock 1994 
Healthy Pregnancy Studies 
Amniotic fluid 
Healthy pregnancy, n=92  
<15 g.w. n=21, 15-18 
g.w. n=24, 19-23 g.w. 
n=21, 24-28 g.w. n=15, 
29-36 g.w. n=11 
GC-MS ─ Changes in succinic acid and gln Ottolenghi et al. 
2010  
Amniotic fluid 
Healthy pregnancy, n=78 
18 g.w. n=18, 19 g.w. 
n=22, 20 g.w. n=17, 21 
g.w. n=10, 22 g.w. n=11 
HPLC Univariate, correlation analysis, 
HMLR 
Changes in ala, gln, val, tau, leu, glu, tyr, 
phe, ile, and met concentration 
Athanasiadis et al. 
2011 
Blood serum 
n=54 (highest FM prevalence) 
n=40 (average FM prevalence) 
2
nd
 T 
High prevalence 9.5-23.6 
g.w., average prevalence 
14.4-18.4 g.w. 
Imunoassays  
GC-MS 
Univariate, PCA, PLS-DA, 
OPLS-DA, internal validation 
(CV, HCA, CMM) 
Lower carbohydrates, lipids, higher amino 
acids and urea-cycle metabolites. Changes 
in trace elements (folate, vitamin D, Se, 
Zn, Cu, Sr, Cd, Pb) 
Su et al. 2011 
Placental extracts 
1
st
 T, ≤8 g.w. n=6; ≥10 g.w. n=6 
At delivery, VD n=6, CS n=5 
1
st
 T: ≤8 g.w.:  ≥10 g.w. 
At delivery: VD: 39
+6
-
40
+3
, CS: 37
+6
-41
+0
 
GC-MS 
UPLC-MS 
Univariate, PCA Lipids composition, suggesting changes in 
fatty acids ß-oxidation for mitochondrial 
ATP. Higher oxidative stress in VD 
Dunn et al. 2012  
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Maternal urine 
Healthy pregnant and NP 
1
st 
T  n=16, 2
nd
 T n=20, 3
rd
T 
n=19, NP, n=16 
1
st 
T: 11-13 g.w., 2
nd
 T: 
15-26 g.w., 3
rd
T: 29-39 
g.w. 
NMR (500 
MHz) 
  
Univariate, PCA, PLS-DA, 
internal validation 
(MCCV),  STOCSY 
21-metabolite signature comprising 
changes in amino acids, lipids oxidation, 
ketone bodies, methionine metabolism and 
urea cycle 
Diaz et al. 2013 
Maternal urine 
Healthy pregnancies, n=83 
1
st
 T 
11 g.w. 
NMR (600 
MHz) 
Univariate, PCA, OSC-PLS-DA Higher oxidative stress and disturbed 
energy metabolism in higher pesticide 
exposure 
Bonvallot et al. 
2013 
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Annex II: Informed consents used in this study 
 
Figure A-II.1: Informed consents given to pregnant women donating urine at the time of amniocentesis. 
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Figure A-II.2: Informed consents given to pregnant women donating samples at each pregnancy trimester.  
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Figure A-II.3: Informed consents given to pregnant women donating urine at the time of delivery and of 
their babies. 
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Annex III: Multivariate model parameters and Monte Carlo Cross Validation 
(MCCV) results 
Table A-III.1: MVA models parameters and MCCV results obtained when considering the whole 
1
H 
NMR spectra  (left) and the 21 relevant integrals (right) found for NP and pregnant women. CR true and 
CR perm: classification rate for true and permuted models, Spec: specificity, Sens: sensitivity, Q
2
m: 
median of true models. 
 PLS-DA of whole 
1
H NMR spectra MVA of 21 selected integrals 
N
P
 v
s.
 1
st
 T
 R
2
X R
2
Y Q
2
 LV R
2
X R
2
Y Q
2
 LV 
0.274 0.907 0.727 2 0.449 0.905 0.848 2 
MCCV MCCV 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
88 47 90 90 0.724 98 48 96 98 0.88 
1
st
 T
 v
s.
 2
n
d
 T
 R
2
X R
2
Y Q
2
 LV R
2
X R
2
Y Q
2
 LV 
0.224 0.894 0.483 2 0.375 0.622 0.281 2 
MCCV MCCV 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
70 49 64 75 0.324 78 49 68 89 0.43 
2
n
d
 T
 v
s.
 3
rd
 T
 R
2
X R
2
Y Q
2
 LV R
2
X R
2
Y Q
2
 LV 
0.240 0.841 0.580 2 0.400 0.857 0.745 2 
MCCV MCCV 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
% CR 
true 
% CR 
perm 
% Spec % Sens Q
2
m 
83 47 82 86 0.416 99 48 100 96 0.77 
N
P
, 
1
st
 T
, 
2
n
d
 
T
, 
3
rd
 T
 R
2
X R
2
Y Q
2
 LV 
R
2
X R
2
Y Q
2
 LV 
0.309 0.544 0.291 3 0.553 0.564 0.465 3 
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Figure A-III.1: True and permuted model Q
2
 distributions (left) and ROC plots (right) given by MCCV of 
the PLS-DA models obtained using all spectral data points for  a,b) NP vs. 1
st
 T, c,d) 1
st
 T vs. 2
nd
 T and 
e,f) 2
nd
 T vs. 3
rd
 T. TPR: true positive rate, FPR: false positive rate. 
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Figure A-III.2:True and permuted model Q2 distributions (left) and ROC plots (right) given by MCCV of 
the PLS-DA models obtained using the selection of 21 relevant integrals for  a,b) NP vs. 1
st
 T, c,d) 1
st
 T 
vs. 2
nd
 T and e,f) 2
nd
 T vs. 3
rd 
T. TPR: true positive rate, FPR: false positive rate. 
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Table A-III.2: PLS-DA Q
2 
(predictive power)
 
and MCCV parameters for a) original dataset and for 
variables datasets selected by b) VIP>1, c) VIP/VIPcvSE > 1, d) b/bcvSE > 1 and e) intersection of methods 
b, c and d. CR: classification rate, Sens: sensitivity, Spec: specificity, Q
2
m: median Q
2
 obtained by 
MCCV.  Best model results in bold. 
Groups Variable selection method No. variables CR (%) Sens (%) Spec (%) Q
2
 Q
2
 median 
F
M
 
 
 None 25591 69 49 75 0.251 0.065 
a) VIP>1 10105 81 71 84 0.456 0.394 
b) VIP/VIPcvSE>1 12490 71 51 77 0.313 0.139 
c) b/bcvSE > 1 11117 84 77 86 0.458 0.410 
d) Intersection of  a, b and c  5743 84 74 87 0.444 0.368 
C
N
S
 v
s 
o
th
er
 
F
M
 
None 25591 62 69 44 0.186 0.647 
a) VIP>1 9906 85 81 86 0.661 0.482 
b) VIP/VIPcvSE>1 20578 70 58 75 0.406 0.040 
c) b/bcvSE > 1 10080 87 83 89 0.636 0.564 
d) Intersection of  a, b and c  7176 87 83 90 0.705 0.647 
C
D
 
None 25591 68 34 73 -0.029 -0.112 
a) VIP>1 10038 80 77 80 0.385 0.450 
b) VIP/VIPcvSE>1 20396 72 52 76 0.138 0.060 
c) b/bcvSE > 1 8797 83 83 84 0.364 0.440 
d) Intersection of  a, b and c  6132 85 87 84 0.428 0.530 
T
2
1
 v
s 
o
th
er
 
C
D
 
None 25591 61 66 51 0.146 -0.152 
a) VIP>1 9765 81 77 83 0.665 0.578 
b) VIP/VIPcvSE>1 20589 68 63 71 0.395 0.017 
c) b/bcvSE > 1 10481 91 90 91 0.645 0.569 
d) Intersection of  a, b and c  7292 94 92 95 0.713 0.696 
P
re
- 
P
T
D
 None 25591 73 32 77 0.014 -0.144 
a) VIP>1 10390 80 67 82 0.348 0.308 
b) VIP/VIPcvSE>1 21215 75 41 87 0.167 -0.047 
c) b/bcvSE > 1 8974 83 76 84 0.415 0.324 
d) Intersection of  a, b and c  6323 84 79 84 0.458 0.422 
P
re
- 
P
E
 
None 25591 91 23 93 0.170 -0.210 
a) VIP>1 9374 93 65 93 0.412 0.287 
b) VIP/VIPcvSE>1 21363 92 33 93 -0.070 -0.070 
c) b/bcvSE > 1 9521 93 55 93 0.466 0.342 
d) Intersection of  a, b and c  5793 94 75 94 0.470 0.400 
P
re
- 
IU
G
R
 None 25591 89 0 90 -0.013 -0.355 
a) VIP>1 8945 90 81 90 0.360 0.343 
b) VIP/VIPcvSE>1 19366 88 1 89 0.180 -0.137 
c) b/bcvSE > 1 8769 92 100 91 0.402 0.486 
d) Intersection of  a, b and c  5627 94 99 94 0.438 0.540 
P
re
- 
P
R
O
M
 
None 25591 48 53 41 -0.145 -0.334 
b) VIP>1 9638 63 60 66 0.232 0.215 
c) VIP/VIPcvSE>1 18989 54 48 57 0.033 -0.139 
d) b/bcvSE > 1 8672 66 69 63 0.275 0.227 
e) Intersection of  a, b and c  5810 70 68 72 0.344 0.341 
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Table A-III.3: PLS-DA Q
2 
(predictive power)
 
and MCCV parameters for a) original dataset and b) after 
variable selection for the GDM study. CR: classification rate, Sens: sensitivity, Spec: specificity, Q
2
m: 
median Q
2
 obtained by MCCV.   
Group Dataset 
No. 
variables 
CR 
(%) 
Sens 
(%) 
Spec 
(%) 
Q
2
 Q
2
median 
Diagnosed GDM 
vs. Control group 1 
Original 25591 77 74 81 0.302 0.308 
Variable Selection 6968 96 93 100 0.750 0.703 
pre-diagnosis  
GDM vs. Control 
group 2 
Original 25591 66 43 72 0.061 0.069 
Variable Selection 6768 87 84 89 0.423 0.442 
Treated GDM  vs. 
Control group 3 
Original 25591 65 64 65 0.141 0.069 
Variable Selection 6728 89 88 89 0.622 0.640 
Insulin-requiring  
vs. Non-insulin-
requiring 
Original 25591 36 34 39 0.463 -0.263 
Variable Selection 7484 94 95 94 0.882 0.700 
Insulin-treated vs. 
Non-insulin-treated 
Original 25591 75 15 79 -0.027 -0.136 
Variable Selection 6243 94 100 93 0.674 0.702 
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Table A-III.4: PLS-DA Q
2 
(predictive power)
 
and MCCV parameters for a) original dataset and b) after 
variable selection. Mat: Maternal, CR: classification rate, Sens: sensitivity, Spec: specificity, Q
2
m: median 
Q
2
 obtained by MCCV.  Best model parameters are noted in bold. 
 
Group Dataset 
% original 
dataset 
CR 
(%) 
Sens 
(%) 
Spec 
(%) 
Q
2
 Q
2
median 
N
ew
b
o
rn
 d
is
o
rd
er
 
Preterm 
Original — 78 68 79 0.241 0.189 
Variable Selection 24.40% 92 92 92 0.556 0.603 
LGA 
Original — 71 47 75 0.220 0.009 
Variable Selection 28.86% 84 76 86 0.469 0.455 
PROM 
Original — 53 46 57 -0.025 -0.068 
Variable Selection 23.54% 77 75 79 0.406 0.377 
pre-Jaundice 
Original — 70 79 16 -0.089 -0.046 
Variable Selection 26.17% 78 45 84 0.117 0.254 
Respiratory 
depression 
Original — 84 71 85 0.147 0.052 
Variable Selection 27.88% 91 96 91 0.475 0.500 
Malformations 
Original — 81 1 83 -0.006 -0.319 
Variable Selection 25.56% 89 73 90 0.424 0.391 
M
at
er
n
al
 d
is
o
rd
er
 
GDM 
Original — 71 15 76 -0.042 -0.203 
Variable Selection 23.82% 82 73 83 0.394 0.401 
Mat thyroid disease 
Original — 84 51 85 0.149 -0.130 
Variable Selection 22.60% 89 88 89 0.458 0.374 
Mat hypertension 
Original — 85 37 86 -0.193 -0.005 
Variable Selection 23.54% 90 100 90 0.432 0.485 
Mat psychiatric 
disease 
Original — 86 0 87 0.149 -0.068 
Variable Selection 26.90% 91 96 90 0.474 0.549 
Mat respiratory 
disease 
Original — 83 54 84 0.120 -0.024 
Variable Selection 28.07% 87 84 87 0.427 0.457 
C
o
n
fo
u
n
d
in
g
 e
ff
ec
ts
 
Delivery mode 
Original — 64 52 71 0.039 0.130 
Variable Selection 25.92% 88 79 94 0.523 0.609 
Gender 
Original — 58 58 59 0.270 0.237 
Variable Selection 31.12% 76 75 76 0.474 0.515 
Day of life (Day 1 
vs. day 2) 
Original — 76 80 7 0.069 -0.197 
Variable Selection 23.96% 86 87 73 0.452 0.466 
GA: 37 vs. 38 g.w Original — 59 69 38 0.126 0.060 
 Variable Selection 31.08% 85 81 100 0.622 0.626 
GA: 38 vs. 39 g.w Original — 64 68 50 0.025 0.228 
 Variable Selection 28.50% 87 89 82 0.494 0.650 
GA: 39 vs. 40 g.w Original — 51 39 57 0.031 -0.211 
 Variable Selection 28.13% 78 74 82 0.526 0.525 
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Annex IV: Reproducibility of UPLC-MS experiments and model quality 
parameters 
Figure A-IV.1: PCA score plots of UPLC-MS data set for a) HSS/ESI+, b) HSS/ESI-, c)HILIC/ESI+ and 
c) HILIC/ESI- using UV (left), Pareto (center) scaling and Log transformation (right). Study ( ) and QC 
(●) samples.  
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Table A-IV.1: PLS-DA Q
2 
(predictive power)
 
and MCCV parameters obtained for pre-PTD vs. controls 
analyzed by UPLC-MS with HSS/ESI+, HSS/ESI-, HILIC/ESI+ and HILIC/ESI- using Log 
transformation, Pareto and UV scaling using the intersection variable selection method. CR: classification 
rate, Sens: sensitivity, Spec: specificity. 
Column/ 
Detection 
mode 
Scaling/ 
Transform
ation 
Initial 
no. of 
features 
No. features 
after variable 
selection 
CR 
(%) 
Sens 
(%) 
Spec 
(%) 
Q
2
 Q
2
median 
HSS/ESI+ 
Log 
42104 
7870 97 96 97 0.730 0.738 
Pareto 4413 95 92 99 0.602 0.753 
UV 12745 97 96 99 0.692 0.697 
HSS/ ESI- 
Log 
78149 
14039 96 96 96 0.643 0.662 
Pareto 8474 59 62 59 -0.140 0.211 
UV 24515 98 97 99 0.666 0.718 
HILIC/ESI+ 
Log 
22376 
4156 86 85 87 0.562 0.603 
Pareto 1894 91 92 90 0.417 0.651 
UV 6616 97 98 97 0.668 0.682 
HILIC/ESI- 
Log 
43223 
8087 84 84 84 0.586 0.566 
Pareto 2683 82 80 84 0.540 0.376 
UV 13171 93 91 95 0.607 0.628 
 
 
 
Table A-IV.2: PLS-DA Q
2 
(predictive power)
 
and MCCV parameters obtained for pre-PTD vs. controls 
analyzed by UPLC-MS with HSS/ESI+, HSS/ESI-, HILIC/ESI+ and HILIC/ESI- using Log 
transformation, Pareto and UV scaling. Best model is shown in bold. CR: classification rate, Sens: 
sensitivity, Spec: specificity. 
Column/ 
Detection mode 
Scaling/ 
Transformation 
No. 
features 
CR 
(%) 
Sens 
(%) 
Spec 
(%) 
Q
2
 Q
2
median 
HSS/ESI+ 
Log 
2850 
69 69 70 0.258 0.242 
Pareto 50 47 53 0.114 -0.051 
UV 54 57 52 0.298 -0.125 
HSS/ ESI- 
Log 
7755 
52 55 50 0.104 -0.084 
Pareto 53 56 49 0.114 -0.179 
UV 53 56 51 0.328 -0.031 
HILIC/ESI+ 
Log 
1995 
65 65 64 0.004 0.121 
Pareto 54 56 51 0.053 0.075 
UV 54 56 51 -0.016 0.039 
HILIC/ESI- 
Log 
4822 
47 50 44 0.321 -0.104 
Pareto 48 51 43 0.084 -0.203 
UV 51 54 48 0.121 -0.110 
 
